(Annual Report - 2020 - 21)



NOTICE OF 17TH ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that 17th Annual General Meeting of the Members of Global Health Limited will be held on Tuesday, 21st day of September, 2021 at 4:30 p.m. at shorter notice at the Registered Office of the Company, Medanta – Mediclinic, E-18, Defence Colony, New Delhi, Delhi-110024 for the transaction of following Businesses:

ORDINARY BUSINESSES

- 1. To receive, consider and adopt the audited Standalone Financial Statements of the Company for the Financial Year ended March 31, 2021, the Reports of the Auditors and Board of Directors thereon and the Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2021 and the Report of the Auditors thereon.
- 2. To appoint a Director in place of Mr. Sunil Sachdeva (DIN: 00012115), who retires by rotation and being eligible offers himself for re-appointment.

SPECIAL BUSINESSES

3. To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:

"RESOLVED THAT, pursuant to the provisions of Section 148 and all the other applicable provisions, if any, of the Companies Act, 2013 read with Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactments thereof for the time being in force), and any other applicable provision / statues as may be applicable from time to time, the Company hereby approve the remuneration of Rs. 8,10,000 (Rupees Eight Lakhs Ten Thousand only) per annum excluding GST and out of pocket expenses payable to M/s. Ramanath Iyer & Co., (Firm Registration number: 000019) who are appointed as Cost Auditors to conduct the audit of cost records for the financial year ending 31st March 2022.

RESOLVED FURTHER THAT, the Board of Directors of the Company, be and are hereby authorized to do all such acts, deeds and things as may be necessary, proper, expedient or incidental for giving effect to this resolution."

Certified True Copy













4. Approval of Initial Public Offer

To consider, and if thought fit, to pass, with or without modifications, the following resolution as Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 23, 62(1)(c) and all other applicable provisions, if any, of the Companies Act, 2013, and the rules made thereunder, including the Companies (Prospectus and Allotment of Securities) Rules, 2014, the Companies (Share Capital and Debentures) Rules, 2014 (collectively, the "Companies Act"), the Securities Contracts (Regulation) Act, 1956 (and the applicable rules thereunder), the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (the "SEBI ICDR Regulations"), the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Foreign Exchange Management Act, 1999 and the rules and regulations made thereunder, including the Foreign Exchange Management (Non-debt Instruments) Rules, 2019 (including any statutory modifications or re-enactment thereof, for the time being in force) and any other applicable laws, rules, regulations, guidelines, press notes, notifications, circulars and clarifications issued from time to time, in India or outside India (collectively, the "Applicable Laws"), and in accordance with the enabling provisions of the Memorandum of Association and the Articles of Association of the Company and the uniform listing agreement to be entered into between the Company and the respective recognized Stock Exchanges of India where the equity shares of face value of Rs. 2 each of the Company (the "Equity Shares") are proposed to be listed ("Stock Exchanges"), and subject to any approvals, consents, permissions or sanctions from the Government of India (the "GoI"), including the Department for Promotion of Industry and Internal Trade, the Department of Economic Affairs, Ministry of Finance, the Reserve Bank of India ("RBI"), the Securities and Exchange Board of India (the "SEBI"), the Registrar of Companies, National Capital Territory of Delhi & Haryana at New Delhi (the "RoC"), the Stock Exchanges, and/or any other appropriate government, statutory or regulatory authorities (collectively, the "Regulatory Authorities"), and subject to such conditions and modifications as may be prescribed, stipulated or imposed by any of them while granting such approvals, consents, permissions and/or sanctions, which may be agreed to by the Board of Directors of the Company (the "Board", which term shall be deemed to include any committee which the Board has duly constituted or may hereinafter duly constitute to exercise its powers including the powers conferred by this resolution), the consent, authority and approval of the shareholders of the Company is hereby granted for an initial public offering of Equity Shares (the "Offer"), and the Board be and is hereby authorized to create, issue, offer and allot such number of Equity Shares aggregating up to Rs. 5000 million, by way of a fresh issue of Equity Shares by the Company (the "Fresh Issue") and an offer for sale upto 4,84,40,000 Equity Shares of Rs. 2 each by certain shareholders of the Company (the "Selling Shareholders", and such offer for sale, the "Offer for Sale")















in the Offer, on such terms and conditions, in such manner and during such period, to such person or persons as may be permitted by and in accordance with Applicable Laws, who may or may not be shareholders of the Company, as the Board may decide. including to one or more of the members of the Company, eligible employees of the Company, Hindu undivided families, anchor investors (if any) or qualified institutional buyers, each as defined under the SEBI ICDR Regulations, foreign portfolio investors, registered foreign venture capital investors, registered alternate investment funds. public financial institutions as specified in Section 2(72) of the Companies Act, scheduled commercial banks, multilateral and bilateral financial institutions, state industrial development corporations, insurance companies registered with the Insurance Regulatory and Development Authority of India, provident funds, pension funds, the National Investment Fund set up by the GoI, insurance funds set up by the army, navy or air force of the Union of India, insurance funds set up by the Department of Posts, India, development financial institutions, systemically important non-banking financial companies, Indian mutual funds registered with the SEBI, non-resident Indians, Indian public, bodies corporate, companies (private or public) or other entities, authorities, and to such other persons eligible to invest in Equity Shares of the Company, including high net worth individuals, retail individual bidders or other entities, in one or more combinations thereof as may be permitted under Applicable Laws, in one or more tranches, at a price determined by the book building process in terms of the SEBI ICDR Regulations, for cash at such price or prices (at a discount, at par or at a premium) per Equity Share as may be fixed and determined by the Board, and subject to Applicable Laws, including, without limitation, through a prospectus, offering circular or an offering document, and in such manner and on such terms and conditions as may be finalized by the Board, in consultation with the book running lead managers to the Offer ("BRLMs") and/or underwriters and/or other advisors or such persons appointed for the Offer, and that the Board in consultation with the BRLMs may finalize all matters incidental thereto as it may in its absolute discretion thinks fit.

RESOLVED FURTHER THAT such of the Equity Shares to be issued under the Offer as are not subscribed may be disposed of by the Board to such persons and in such manner and on such terms as the Board in its absolute discretion think most beneficial to the Company, including offering or placing them with banks/financial institutions/investment institutions/mutual funds/bodies corporate/such other persons or otherwise as the Board may in its absolute discretion decide, subject to compliance with all Applicable Law.

RESOLVED FURTHER THAT the Equity Shares allotted and/or transferred in the Offer shall be subject to the memorandum of association and the articles of association of the Company and rank *pari passu* with the existing Equity Shares of the Company, in all respects, including rights in respect of dividend.















RESOLVED FURTHER THAT subject to Applicable Laws, oversubscription to the extent of 1% of the net Offer size, or such other extent as may be permitted under Applicable Laws may be retained by the Company for the purpose of rounding off to the nearest integer while finalizing the basis of allotment in relation to the Offer.

RESOLVED FURTHER THAT subject to Applicable Laws, the approval of the shareholders of the Company be and is hereby accorded to the listing and trading of the Equity Shares on BSE Limited and the National Stock Exchange of India Limited pursuant to the IPO.

RESOLVED FURTHER THAT the Board be and is hereby authorized to do such acts, deeds and things as the Board in its absolute discretion deems necessary or desirable in connection with the Offer and to delegate all or any of the powers herein conferred in such manner as it may deem fit, including, without limitation, the following:

- (i) To make applications to seek clarifications and obtain approvals from, where necessary, the SEBI, the RBI, and any other Regulatory Authorities as may be required in connection with the Offer and accept on behalf of the Board such conditions and modifications as may be prescribed or imposed by any of them while granting such approvals, permissions and sanctions as may be required:
- (ii) To take all actions as may be necessary in connection with the Offer, including extending the Bid/ Offer period, revision of the Price Band, in accordance with the Applicable Laws;
- (iii) To appoint and enter into arrangements with the BRLMs, underwriters to the Offer, syndicate members to the Offer, brokers to the Offer, sponsor bank to the Offer, advisors to the Offer, escrow collection banks to the Offer, sponsor bank to the Offer, registrars to the Offer, refund banks to the Offer, public Offer account banks to the Offer, advertising agencies, legal counsel and any other agencies or persons or intermediaries (including any replacements thereof) to the Offer and to negotiate and finalize and amend the terms of their appointment, including but not limited to execution of the BRLMs' mandate letter, negotiation, finalization, execution and, if required, the amendment of the Offer agreement with the BRLMs and the underwriting agreement with the underwriters;
- (iv) To negotiate, finalize, settle, execute and deliver or arrange the delivery of the draft red herring prospectus ("DRHP"), the red herring prospectus ("RHP"), the prospectus, Offer agreement, registrar agreement, syndicate agreement, underwriting agreement, advertising agency agreement, escrow and sponsor bank agreement, share escrow agreement and all other documents, deeds, agreements, memorandum of understanding and any notices, supplements and



corrigenda thereto, as may be required or desirable, and other instruments whatsoever with the registrar to the Offer, legal advisors, auditors, Stock Exchanges, BRLMs and any other agencies/intermediaries in connection with the Offer with the power to authorize one or more officers of the Company to negotiate, execute and deliver all or any of the aforementioned documents;

- (v) To decide the pricing, the terms of the Offer of the Equity Shares, all other related matters regarding the Pre-IPO Placement, if any, including the execution of the relevant documents with the investors, in consultation with the Selling Shareholders and the BRLMs, and rounding off, if any, in the event of oversubscription and in accordance with Applicable Laws;
- (vi) To decide in consultation with the Selling Shareholders and the BRLMs on the size, timing, pricing, discount, reservation and all the terms and conditions of the Offer, including the price band, bid period, Offer price, and to accept any amendments, modifications, variations or alterations thereto;
- (vii) To finalize, settle, approve and adopt and file in consultation with the Selling Shareholders and the BRLMs, where applicable, the DRHP with the SEBI, RHP with the RoC, the prospectus for the Offer together with any addenda, corrigenda or supplement thereto with the SEBI and RoC and take all such actions as may be necessary for filing of these documents including incorporating such alterations/corrections/modifications as may be required by and to submit undertaking/certificates or provide clarifications to the SEBI, the RoC or any other relevant Regulatory Authorities or in accordance with Applicable Laws;
- (viii) To seek, if required, the consent of the lenders of the Company, industry data providers, parties with whom the Company has entered into various commercial and other agreements, all concerned Regulatory Authorities in India or outside India, and any other consents that may be required in relation to the Offer or any actions connected therewith;
- (ix) To open and operate bank account(s) of the Company in terms of the escrow and sponsor bank agreement and to authorize one or more officers of the Company to execute all documents/deeds as may be necessary in this regard;
- (x) To authorize and approve incurring of expenditure and payment of fees, commissions, brokerage, remuneration and reimbursement of expenses in connection with the Offer;
- (xi) To approve code of conduct as may be considered necessary or as required under Applicable Laws for the Board, officers of the Company and other employees of the Company;















- (xii) To authorize any concerned person on behalf of the Company to give such declarations, affidavits, certificates, consents and authorities as may be required from time to time in relation to the Offer;
- (xiii) To approve suitable policies in relation to the Offer as may be required under Applicable Laws;
- (xiv) To approve any corporate governance requirement that may be considered necessary by the Board or as may be required under Applicable Laws, in connection with the Offer;
- (xv) To authorize and approve notices, advertisements in relation to the Offer in consultation with the relevant intermediaries appointed for the Offer;
- (xvi) To open and operate bank accounts of the Company in terms of Section 40(3) of the Companies Act, 2013 or as may be required by the regulations issued by the SEBI and to authorize one or more officers of the Company to execute all documents/deeds as may be necessary in this regard;
- (xvii) To approve the basis for allocation/allotment and confirm allocation/allotment of the Equity Shares to various categories of persons as disclosed in the DRHP, the RHP and the prospectus, in consultation with the Selling Shareholders and the BRLMs;
- (xviii) To issue receipts/allotment letters/confirmation of allocation notes either in physical or electronic mode representing the underlying Equity Shares in the capital of the Company with such features and attributes as may be required and to provide for the tradability and free transferability thereof as per market practices and regulations, including listing on the Stock Exchanges, with power to authorize one or more officers of the Company to sign all or any of the aforementioned documents;
- (xix) To withdraw the DRHP or the RHP or not to proceed with the Offer at any stage, if considered necessary and expedient, in accordance with Applicable Laws;
- (xx) To make applications for listing of Equity Shares on the Stock Exchanges and to execute and to deliver or arrange the delivery of necessary documentation to the Stock Exchanges and to take all such other actions as may be necessary in connection with obtaining such listing;
- (xxi) To do all such deeds and acts as may be required to dematerialize the Equity Shares and to sign and/or modify, as the case may be, agreements and/or such other documents as may be required with the National Securities Depository



Limited, Central Depository Services (India) Limited, registrar and transfer agents and such other agencies, as may be required in this regard with power to authorize one or more officers of the Company to execute all or any of the aforementioned documents;

- (xxii) To do all such acts, deeds, matters and things and execute all such other documents, etc., as it may, in its absolute discretion, deem necessary or desirable for the Offer, in consultation with the Selling Shareholders and the BRLMs, including without limitation, determining the anchor investor portion and allocation to Anchor Investors, finalizing the basis of allocation and allotment of Equity Shares to the successful allottees and credit of Equity Shares to the demat accounts of the successful allottees in accordance with Applicable Laws:
- (xxiii) To settle all questions, difficulties or doubts that may arise in regard to the Offer, including such issues or allotment and matters incidental thereto as it may deem fit and to delegate such of its powers as may be deemed necessary and permissible under Applicable Laws to the officials of the Company;
- (xxiv) To approve the expenditure in relation to the Offer;
- (xxv) To approve and adopt the relevant restated financial statements to be issued in connection with the Offer;
- (xxvi) To take such action, give such directions, as may be necessary or desirable as regards the Offer and to do all such acts, matters, deeds and things, including but not limited to the allotment of Equity Shares against the valid applications received in the Offer, as are in the best interests of the Company;
- (xxvii) To negotiate, finalize, settle, execute and deliver any and all other documents or instruments and doing or causing to be done any and all acts or things as it may deem necessary, appropriate or advisable in order to carry out the purposes and intent of the foregoing or in connection with the Offer and any documents or instruments so executed and delivered or acts and things done or caused to be done by it or any committee thereof shall be conclusive evidence of the authority of the Board in so doing; and
- (xxviii)To delegate any of the powers mentioned above to the following persons, namely Dr. Naresh Trehan, Chairman and Managing Director, Mr. Pankaj Salmi, Chief Executive Officer, Mr. Sanjeev Kumar, Group Chief Financial Officer and Mr. Rahul Ranjan, Company Secretary, severally, to do all such acts, deeds, matters and things as may be required to be done to give effect to the above resolution.















RESOLVED FURTHER THAT in relation to the Offer, any decision regarding the Offer may be made by the Company together with, or in consultation with the Selling Shareholders and the BRLMs as may be mutually agreed upon in terms of any agreement in connection with the Offer.

RESOLVED FURTHER THAT for the purpose of giving effect to the above resolution, Dr. Naresh Trehan, Chairman and Managing Director, Mr. Pankaj Sahni, Chief Executive Officer, Mr. Sanjeev Kumar, Group Chief Financial Officer and Mr. Rahul Ranjan, Company Secretary, severally, be and are hereby authorized to do all such acts, deeds, matters and things as they may, in their absolute discretion, deem necessary, proper or desirable for such purpose, including, without limitation, the issue. transfer and allotment of the Equity Shares pursuant to the Offer, and may, along with the Selling Shareholders and subject to the provisions of Applicable Laws, determine the terms of the Offer, including with respect to the class of investors to whom the Equity Shares are to be allotted and/or transferred, the number of Equity Shares to be allotted and/or transferred, the Offer price, premium amount, Discount (as allowed under Applicable Laws), appointment of the intermediaries, opening escrow accounts, finalizing the basis of allotment of the Equity Shares, to approve the incurring of expenditure and the payment of fees, commissions, brokerage, remuneration and reimbursement of expenses in connection with the Offer, to make any filings, furnish any returns or submit any other documents to any regulatory or governmental authorities as may be required, and to settle any question, difficulty or doubt, and further, to negotiate, finalize and execute all documents, agreements, papers, instruments and writings including arrangements with the Selling Shareholders, the BRLMs, underwriters, escrow agents, legal advisors, etc., as they may deem necessary, proper, desirable or expedient and to give such directions and/or instructions as they may from time to time decide and to accept and give effect to such modifications. changes, variations, alterations, deletions and/or additions as regards the terms and conditions of the Offer or the documentation in relation thereto as may be required; and any documents so executed and delivered or acts and things done shall be conclusive evidence of the authority of the Company in so doing and any document so executed and delivered or acts and things done prior to the date hereof are hereby ratified, confirmed and approved as the act and deed of the Company, as the case may be.

RESOLVED FURTHER THAT duly certified copies of the above resolutions be furnished to any government, statutory or regulatory authority as may be required from time to time."

By order of the Board of Directors For Global Health Limited

Date: 17th September, 2021

Place: Gurgaon

Rahul Ranjan Company Secretary















NOTES:

- (a) Explanatory Statement pursuant to Section 102(1) of the Companies Act, 2013 in relation to above items is annexed herewith and forms part of this Notice.
- (b) A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead of herself/himself and the proxy need not be a member of the company.
- (c) The meeting is convened at shorter notice subject to consent of members.
- (d) Corporate Members intending to send their authorized representatives are requested to send a duly certified copy of the Board Resolution authorizing the representatives to attend and vote at the AGM.
- (e) Members/ Proxies should fill the Attendance Slip for attending the Meeting and bring their Attendance Slips to the Meeting.
- (f) All relevant documents referred in this Notice and the Explanatory Statement shall be open for inspection by the Members at the Registered office of the Company at Medanta Mediclinic, E-18, Defence Colony, New Delhi, Delhi-110024 during the business hours on all working days upto the date of AGM.















EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013 FORMING PART OF NOTICE CONVENING ANNUAL GENERAL MEETING ON SEPTEMBER 21, 2021

Item No. 3:

Approval of Remuneration payable to the Cost Auditors for the Financial Year 2021-22

The Board, on the recommendations of Audit Committee, has approved the re-appointment of M/s. Ramanath Iyer & Co., Cost Accountants, as Cost Auditors for the Financial Year ending 31st March 2022, at a remuneration of Rs. 8,10,000 (Rupees Eight Lakhs Ten Thousand only) excluding GST and out of pocket expenses payable to the Cost Auditors.

In accordance with Section 148(3) of the Act read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014, the remuneration so payable to the Cost Auditors is required to be ratified by the members of the Company.

Accordingly, consent of the members is sought for passing an Ordinary Resolution as set out at Item No. 3 of the Notice of the AGM for ratification of remuneration payable to the Cost Auditors for the Financial Year ending 31st March 2022.

None of the Directors, Key Managerial Personnel and their relatives are in any way concerned or interested, financially or otherwise, either directly or indirectly in the proposed resolution.

Accordingly, the Board recommends passing of the Ordinary Resolution as set out at Item No. 3 of this Notice, for the approval of the Members.

Item No. 4:

Approval of Initial Public Offer

Considering the long term strategic growth plan and agreed position with key shareholders of the Company, the Board of Directors of the Company proposes to undertake an initial public offering of its equity shares of face value of Rs.2 each (the "Equity Shares" and such offering, the "Offer") in accordance with the enabling provisions of the memorandum of association and the articles of association of the Company, the uniform listing agreement to be entered into between the Company and the relevant stock exchanges where the Equity Shares are proposed to be listed (the "Stock Exchanges") and applicable laws, regulations, policies and guidelines, in India or outside India, including, without limitation, the Securities Contracts (Regulation)















Act, 1956 (and the applicable rules thereunder), the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, the Companies Act, 2013 and the applicable rules thereunder, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Foreign Exchange Management Act, 1999 and the regulations made thereunder, including the Foreign Exchange Management (Non-debt Instruments) Rules, 2019 and any other foreign investment law and the rules, regulations, guidelines, press notes, notifications, circulars and clarifications issued from time to time by the Government of India, including the Department for Promotion of Industry and Internal Trade, the Reserve Bank of India, the Securities and Exchange Board of India, the Registrar of Companies, National Capital Territory of Delhi & Haryana at New Delhi, the Stock Exchanges and/or any other competent authorities, in each case, as amended (collectively, "Applicable Laws").

The Offer structure, which may comprise a fresh issue of Equity Shares of up to Rs. 5000 million by the Company(the "Fresh Issue") and an offer for sale of up to 4,84,40,000 Equity Shares of Rs.2 each by certain shareholders of the Company (the "Selling Shareholders", and such offer for sale, the "Offer for Sale"), will be finalized at the absolute discretion of the board of directors of the Company (the "Board", which term shall be deemed to include any committee which the Board may constitute to exercise its powers including the powers conferred by this resolution).

The Company may further offer a discount to the price at which the Equity Shares are offered pursuant to the Offer, to any category or categories of persons as permitted under Applicable Laws.

In connection with the Offer, the Company is required, inter alia, to prepare various documents and execute various agreements, including, without limitation, engagement letters, the listing agreements to be entered into by the Company with the Stock Exchanges, the registrar's agreement, the offer agreement with the Selling Shareholders and the book running lead managers, the monitoring agency agreement, the share escrow agreement, the syndicate agreement, the cash escrow and sponsor bank agreement, the underwriting agreement and the service provider agreement with the advertising agency. Accordingly, it is proposed to authorize the members of the Board and certain officers of the Company to negotiate, finalize and execute such documents and agreements as may be required and to do all such acts, deeds, matters and things in this regard for and on behalf of the Company.















In view of the above and in terms of Section 62(1)(c), and other applicable provisions of the Companies Act, the approval of shareholders of the Company is required through a special resolution.

Except as and to the extent of the participation by directors or key managerial personnel in the Offer mentioned above, none of the directors or managers or key managerial personnel of the Company or the relatives of said persons are interested in the said resolution.

No change in control of the Company or its management of its business is intended or expected pursuant to the Offer.

In view of the above approval of shareholders of the Company is sought to issue Equity Shares under section 62(1)(c) and other applicable provisions of the Companies Act and the rules and regulations made thereunder, each, as amended. The Board recommends the resolution in Item 4 of the accompanying Notice for your approval as special resolution.

Date: 17th September, 2021

Place: Gurgaon

By order of the Board of Directors For Global Health Limited

> Rahul Ranjan Company Secretary (M. No. – A 17035)















GLOBAL HEALTH LIMITED

Registered Office: E-18, Defence Colony, New Delhi – 110024 CIN: U85110DL2004PLC128319

Telephone: (011) 4411 4411 * Fax: (011) 2433 1433* Website: www.medanta.org

ATTENDANCE SLIP

Members attending the Meeting in person or by Proxy are requested to complete the Attendance Slip and hand it over at the entrance of the meeting room.

I hereby record my presence at the Annual General Meeting of the Company at its Registered office at Medanta – Mediclinic, E-18, Defence Colony, New Delhi, Delhi-110024, to be held on Tucsday, 21³⁸ day of September, 2021 at 4:30 p.m. at shorter notice

•			Signature
Folio No.:*DP ID No.:*		ent ID No:*	
*Applicable for Members holding shares in e	lectronic form		A _g s.















GLOBAL HEALTH LIMITED

Registered Office: E-18, Defence Colony, New Delhi - 110024

CIN: U85110DL2004PLC128319

Telephone: (011) 4411 4411 * Fax: (011) 2433 1433 * Website: www.medanta.org

Form No. MGT - 11 PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: U85110DL2004PLC128319

Name 6	of the Memb	er(s):		
				··
E-mail	id:	DP ID No:*	Client ID No*	
Appli	cable for Me	embers holding shares in	Client ID No.:	
I/We, b appoint	eing the Me t:	mber(s) of	Shares of Global He	ealth Limited, he
1.	Name:	·		
				•
	Email id: _			
	Signature:	· · · · · · · · · · · · · · · · · · ·	or falling him/her	
<u>></u> .	Name:			
	Email id: _			
3.	Signature: Name:	A CAMADIA MINISTER CONTRACTOR CON	, or falling him/her	
	ر .	1 .		2















Email id:	
Signature:	, or falling him/her
as my / our proxy to attend and vote (on a pol	1) for me / us and on my / our behalf at the Annual General
	day, 21st day of September, 2021 at 4:30 p.m. at shorter
notice at its Registered Office at Medanta -	- Mediclinic, E-18, Defence Colony, New Delhi, Delhi-
110024 and at any adjournment thereof, in r	respect of the Resolutions set out in the Notice convening
the Meeting, as indicated below:	en e

S. NO.	RESOLUTIONS	FOR	AGAINST
Ordinar	y Business	:	
1 .5	To receive, consider and adopt the audited financial statements of the Company including the audited consolidated financial statements for the financial year ended 31st March 2021, together with the reports of the Board of Directors and the Auditors thereon.		
2	To re-appoint Mr. Sunil Sachdeva (DIN: 00012115) as Director		
Special I	Business		<u></u>
3	Ratification of remuneration payable to the Cost Auditors for the Financial Year 2021-22		
4.	Approval of Initial Public Offer		

Signed this [•] day of [•], 2021

Signature of Shareholder

Affix Revenue Stamp Signature

Signature of Proxy Holder(s)

Notes:

- 1. This form should be signed across the stamp as per specimen signature registered with the Company.
- 2. The Proxy, to be effective, should be deposited at the Registered Office of the Company.
- 3. A proxy need not be a member of the Company.
- 4. Please put a √ in the appropriate column against the resolutions indicated in the Box. If you leave the For or Against column blank against any or all the resolutions, your proxy will be entitled to vote in the manner as he/she thinks appropriate. This is only optional.
















ROUTE MAP OF REGISTERED OFFICE

















Directors' Report

for financial year ended March 31, 2021

Corporate Information

Board of Directors

Sr. No.	Name of Directors	me of Directors Designation	
1	Dr. Naresh Trehan	Chairman & Managing Director	
2	Mr. Hari Shanker Bhartia	Independent Director	
3	Mr. Neeraj Bhardwaj	Nominee Director	
4	Ms. Praveen Mahajan	Independent Director	
5	Mr. Rajan Bharti Mittal	Independent Director	
6	Dr. Ravi Gupta	Independent Director	
7	Mr. Ravi Kant Jaipuria	Nominee Director	
8	Mr. Sunil Sachdeva	Non-Executive Director	
9	Mr. Venkatesh R.	Nominee Director	
10	Mr. Vikram Singh Mehta	Independent Director	

Registered Office:

Medanta-Mediclinic E-18, Defence Colony New Delhi-110024

Registrar & Share Transfer Agent

ISIN - IN474Q01023 Kfin Technologies Private Limited Selenium Tower B, Plot 31-32, Gachibowli, Financial District, Hyderabad 500032

Corporate Office:

Medanta - The Medicity, Sector-31, Gurugram, 122001, Haryana

Company secretary

Rahul Ranjan

Auditors

M/s Walker Chandiok & Co. LLP. Chartered Accountants

Website:

www.mcdanta.org





Board's Report

Dear Members.

Your Directors are pleased to present the 17th Annual Report on business and operations together with the Audited Financial Statements for the financial year ended March 31, 2021.

Financial Performance

The standalone and Consolidated Financial results of your Company and its subsidiaries for the financial year ended March 31, 2021 are summarized below:

(Rupees in Lakhs)

Particulars:			Consolidated financial performance	
	31.3.2021	31,3,2020	31,3,2021	31,3,2020
Revenue from operations	1,22,739.81	1,47,208.62	1,44,674.32	150,042.20
Other Income	2,834.86	4353.89	3,141.53	4,384.50
Total Revenue	1,25,574.67	1,51,562.51	1,47,815.85	1,54,426.70
Total Expenditure	1,17,132.39	1,38,469.17	1,44,569.29	1,48,037.57
Profit before Taxation	8,442.28	13,093.34	3,246.56	6,386.96

Business Performance Overview

You Directors have pleasure to share with you that the during the financial year 2020-21, the Company has once again established itself as one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India, with key specialties of cardiology and cardiac science, neurosciences and urology. As at March 31, 2021, the Company provided healthcare services over 30 medical specialties and engaged over 1,100 doctors led by highly experienced department heads and, spanning an area of 3.2 million sq. ft. with operational hospitals have approximately 2,176 installed beds. Under the "Medanta" brand, the Group has a network of four hospitals currently in operation (Gurugram, Indore, Ranchi and Lucknow), a hospital which is under construction with an already-operational outpatient facility (Patna), and one hospital (Noida) planned for development. The Company has applied for various regulatory approvals from respective authorities for commencement of development of Noida Hospital project.

The Company's business has been affected due to the ongoing Covid-19 pandemic coupled with a weaker economy on hospitals and restrictions required as a result of Covid-19 resulted in, among other, things, lower patient volumes, deferred surgeries, decline in elective surgeries, higher operational costs, leading to lower profit as reflected in our Fiscal 2020 and Fiscal 2021 financial statements (as compared to Fiscal 2019). In April 2021, India witnessed a drastic surge in COVID-19 cases resulting in shortages of medical supplies and equipment and overwhelming the healthcare infrastructure. The Company is continuously calibrating its response to Covid-19 situation and its





business has demonstrated steady financial performance over the last three fiscal years and successfully weathered the challenges of Covid-19.

To reduce the impact of Covid-19 on Company's facilities, the Company has re-aligned infrastructure, patient flows and setup various protocols. In FY2021, your company and its subsidiary took the out-patient department pharmacies in-house at Gurugram, Lucknow and Indore hospitals, and launched home-care services at Gurugram. It scaled up its telemedicine and remote delivery of healthcare services, and the monthly average consultation via video and telephone witnessed visible growth in Gurugram unit. The home-care sample collection services ("Home Care Services") provide sample collection, preventive health checks, paediatric vaccinations and nursing services, all at the convenience of the patient's home.

As an organisation, the Company focus on quality tertiary and quaternary care, treatment of lifestyle diseases, provision of value-based treatments and work on a high number of critical, complex cases. It is continually looking for value-accretive opportunities while strengthening its presence in key growth markets.

Proposed Initial Public Offer

During the year your Board of Directors proposed to undertake an initial public offering of Company's equity shares (the "Equity Shares" and such offering, the "Offer") and authorised the management to take all necessary steps in this regard. Your Directors have pleasure to share with you that effective steps have been initiated, especially post the year under review in this regard and an initial public offering and consequential listing of shares of the Company is contemplated in near future, subject to necessary approvals. The formal proposal of Offer, forms part of agenda of ensuing Annual General Meeting of the Company, as recommended by your Beard of Directors.


The Company has adopted and implemented various requirements of Corporate Governance and mandatory corporate policies/code of conduct required under the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended, in its pursuit to get the shares listed and meet all the eligibility norms.

The status of the Company has been changed from Private Limited to Public Limited by a special resolution passed by the shareholder on July 31, 2021 and a new certificate of incorporation was issued by the Registrar of Companies NCT of Delhi and Haryana ("ROC") dated 11th August, 2021. On September 17th, 2021, the Memorandum of Association (MOA) and Articles of Association (AOA) of the Company, were changed pursuant to resolutions passed by the shareholders to align the contents thereof with the requirements of listing and agreed understanding of the Company with its key shareholders under Waiver, Amendment and Termination Agreement ("WATA"), approved by the shareholder. Under WATA it has been agreed that Dr. Naresh Trehan shall be the only promoter of the Company going forward.

Directors and Key Managerial Personnel

The composition of Board of Directors is well balanced with a view to manage the affairs of the Company efficiently and professionally. The Board is a balanced Board, comprising Executive and Non-Executive Directors and includes independent professionals and meets the composition









requirements of Companies Act as well as SEBI listing norms. During the financial year 2020-21 following changes in the Board of Directors took place:

- Mr. Udairam Thali Koattiath (DIN 08703201) who was appointed on 5th June 2020 as an additional - nominee director by the Board of Directors of the Company to represent M/s Dunearn Investments (Mauritius) Pte Ltd had resigned from the directorship of the Company with effect from 17th March, 2021. He was also a member of the Audit Committee.
- Ms. Prayeen Mahajan (DIN 07138514) was appointed as an Additional Independent Director on the Board of the Company on 10th July, 2020 for a period of 5 years. Her appointment was approved by the shareholder at last Annual General Meeting of the Company held on 29th October, 2020.
- Mr. Vikram Singh Mehta (DIN: 00041197) has been appointed as an Additional Independent Director by the Board w.e.f. 25th January, 2021 for a period of 5 year. His appointment was approved by the shareholders of the Company at the Extra Ordinary General Meeting held on 31st July, 2021.
- Mr. Venkatesh Ratnasami (DIN: 03433678) has been appointed as nominee director of Dunearn Investments (Mauritius) Pte Ltd. in place of Mr. Udairam Thali Koattiath on 23rd March, 2021 by the Board of Directors. His appointment was approved by the shareholders of the Company at the Extra Ordinary General Meeting held on 31st July, 2021.
- Mr. Hari Shanker Bhartia (DIN: 00010499) who was appointed as an Additional Independent Director by the Board w.e.f. 23rd March, 2021. His appointment was approved by the shareholders of the Company at the Extra Ordinary General Meeting held on 31st July, 2021.

During the current financial year following changes happened to the Board of Directors:

- Mr. Rajan Bhartí Mittal (DIN; 00028016) has been appointed as an Additional Independent Director of the Company with effect from 8th July, 2021 for a period of 5 years. His appointment was approved by the shareholders of the Company at the Extra Ordinary General Meeting held on 28th July, 2021.
- Dr. Ravi Gupta (DIN: 00023487) has been appointed as an Additional Independent Director of the Company with effect from 8th July, 2021 for a period of 5 years. His appointment was approved by the shareholders of the Company at the Extra Ordinary General Meeting held on 28th July, 2021.
- Further, Dr. Naresh Trehan was re-appointed as Chairman and Managing Director of the Company with effect from 1st August, 2021 by way of shareholders' approval accorded vide their special resolution dated 06th September, 2021. He is also associated with the Company in his professional capacity as Chairman-Heart Institute and Chief Cardiac Surgeon, the appointment to which was also approved by the shareholders of the Company.

Mr. Sunil Sachdeva (DIN-00012115), Director of the Company is liable to retire by rotation at ensuing Annual General Meeting of the Company and being eligible, has offered himself for re-appointment and the Board recommends his appointment as Director.

Your Company has appointed aforesaid Independent Directors as per the provisions of Section 149 of the Companies Act, 2013 and declarations of independence in compliance with Section 149(6) of the Companies Act, 2013, have been taken on record from all the Independent Directors of the Company. In the opinion of the Board, the Independent Directors fulfil the conditions prescribed under the Act and the Listing Regulations and are independent of the management of the Company.

The policy relating to Directors' Appointment, Remuneration and evaluation etc. was approved by the Board and is available on the Website of the Company, Further the terms of reference of all the committees are also available on the website. The Board on a yearly basis evaluates its performance





and performance of individual directors and committees of the Board. During the year such evaluation was carried out and found to be satisfactory.

Key Managerial Personnel

During the year there was no change in the Key Managerial Personnel of the Company. Mr. Rahul Ranjan was appointed as Company Secretary of the Company with effect from 08th July, 2021, in place of Mr. Sunil Bansal.

Committees of the Board

The Composition of committees of the Board as on date is as follows:

Audit Committee

Dr. Ravi Gupta	Chairperson
Mr. Neeraj Bharadwaj	Member
Ms. Praveen Mahajan	Member
Mr. Hari Shanker Bhartia	Member
Mr. Venkatesh Ratnasami	Member

Nomination & Remuneration Committee

Mr. Vikarm Singh Mehta	Chairperson
Ms. Praveen Mahajan	Member
Mr. Rajan Bhartí Mittal	Member
Dr. Naresh Treban	Member

Corporate Social Responsibility Committee

Dr. Naresh Trehan	Chairman
Mr. Sunil Sachdeva	Member
Mr. Rajan Bharti Mittal	Member
Mr. Vikram Singh Mehta	Member

Stakeholders' Relationship Committee

Chairperson
Member
Member
Member

Risk Management Committee

Dr. Ravi Gupta	Chairperson
Ms. Praveen Mahajan	Member
Mr. Pankaj Sahni	Member

Annual Return

In terms of Section 92(3) and Section 134(3)(a) of the Companies Act, 2013 and Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return of the Company is available on the website of the Company at the link https://www.medanta.org/inverstor-relation.

Page 5 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411

CIN: U85110DL2004PLC128319

www.medanta.orgc





Number of Meetings of the Board

In order to work most effectively and efficiently, to discuss on the business performance, policies, strategies and other significance matter, the Board meets on regular interval. We maintain tentative scheduled programme of meetings which is generally determined in the beginning of the year.

During the financial year under the review, the Board of Directors duly met six times in respect of which proper notices were given and the proceedings were properly recorded. The gap between two Board Meeting was within the prescribed limits.

Dividend

The Board of Directors of the Company has not recommended any dividend on its equity shares for the financial year ended March 31, 2021.

The dividend has been paid to the CCPS holders as per the terms of issuance.

Transfer of unpaid and unclaimed amount to IEPF

Pursuant to the provisions of Section 124(5) of the Companies Act, 2013, dividend and refund of share application money due for refund which remains unpaid or unclaimed for a period of seven years from the date of its transfer to unpaid dividend/unclaimed account is required to be transferred by the Company to Investor Education and Protection Fund (IEPF), established by the Central Government under the provisions of Section 125 of the Companies Act, 2013.

During the year under the review, no amount was due for transfer to IEPF.

Public Deposit

The Company has neither accepted nor renewed any deposits under section 73 -76 of Companies Act, 2013 to be read along with The Companies (Acceptance of Deposits) Rules, 2014, during the year. Also, there is no amount of principal or interest is outstanding on the date of the Balance Sheet.

Transfer to Reserve / Issue of Bonus Shares

During the year under review, Your company has proposed to transfer amounting Rs.5,976.44 Lakhs to the general reserves out of amount available for appropriation.

Share Capital

During the year under review, there was no change in the Authorised Share Capital of the Company. During the current financial year following changes happened to the Authorised Share Capital of the Company:-

- a. The Class A Equity Shares of Rs. 10 each of the Company was sub-divided into Class A Equity Shares of Rs. 2 each. Consequently, against 1 Class A Equity share of the Company, 5 Class A Equity Share of Rs. 2 each were credited to all shareholders holding Class A Equity shares. Further the ISIN No of the Company has changed to INE474Q01023.
- b. Class B Equity Shares of Rs. 10 each were re-classified as Class A Equity Shares of Rs. 2 each. Consequently 1000 Class B Equity shares of Rs. 10 each in the Authorised Capital were re-classified into 5000 Class A Equity shares of Rs. 2 each.
- c. Entire Class A Equity Shares were renamed as Equity Shares.

New Delly



Currently the Authorised Share Capital consist of 50,51,25,000 Equity shares of Rs. 2 each and 4,66,954 Class A Preference Shares of Rs. 696 each.

During the year under review, the Company has issued 2,40,815 Equity shares of Rs. 10 each to ESOP holders. Therefore, as on 31st March, 2021 the paid-up share capital of the Company is as under;-

Sr. No.	Class	No. of Shares	Face Value	Amount (Rs)
J.	Class A Equity Shares	4,95,85,818	10	49,58,58,180
	Class A Preference Shares	4,66,954	696	32,49,99,984
Total Paid	d up Share Capital			82,08,58,164

Employee Stock Option Plan (ESOP) 2014 and ESOP Plan 2016 of the Company

As at March 31, 2021, there were two ESOP Schemes in force named GHPL ESOP Plan 2014 and GHPL ESOP Plan 2016. The details of ESOP(s) available and allocated under both plans are as under:

Particulars	No. of options under ESOP Plan 2014	No. of options under ESOP Plan 2016
Number of total options	8,52,973	10,25,000
Total options granted as on 1st April 2020	8,44,824	9,55,000
Options lapsed, forfeited and added back to the pool during the year	19,839 (Options lapsed)	55,000 (options lapsed)
Options granted during the FY 2020- 21 (including Options lapsed, forfeited and added back to the pool during the year)	NA	NA
Total Options in force as on 31st March, 2021	7,89,258	8,09,000
Total options exercised as on 31st March, 2021	6,34,014	4,57,750
Total options vested but not yet exercised as on 31st March, 2021	1,55,244	1,72,750
Total option pending for allocation as on 31.3, 2021	63,715	2,16,000
The exercise price for each option	Rs.10 each	Rs.10 cach
Money realized by exercise of options	63,40,140	45,77,500
Employee-wise details of options granted to:- (i) Key managerial personnel	NITE	
(ii) Any other employee who receives	NIL	20,000

Page 7 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 CIN: U85110DL2004PLC128319 www.medanta.org.





a grant of options in any one year of option amounting to 5% or more of options granted during that year;	NIL	NIL
(iii) Identified employees who were granted option, during any one year, equal to or exceeding 1% of the issued capital (excluding outstanding warrants and conversions) of the company at the time of grant	NIL	NIL

- Each option has been granted at Rs 10 each convertible into one Equity share of Rs 10 each at par.
- The total options granted shall vest every year @ 20% / 25% / 33%, from date of grant over a period of 5/4/3 years as per terms of respective, Offer Letter(s).
- The vested options can be exercised within a period of 3 years from the date of vesting.

Allotment of Secured Non-Convertible Debentures (NCDs) for Rs.100 Crores to Asian Development Bank (ADB)

The Company has executed Debenture Subscription Agreement with Asian Development Bank (ADB) and Debenture Trust Deed with IDBI Trusteeship Services Limited, Security Trustee on 12th February, 2021 for borrowing Rs. 100 Crores (Rupees One Hundred Crore Only) from Asian Development Bank (ADB) by way of issuance of NCDs.

The Company has allotted 1000 secured, unlisted, redeemable, transferable and interest bearing Non-Convertible Debentures (NCDs) of the face value of Rs.10,00,000/- (Rupees Ten Lakhs Only) each aggregating to Rs. 1,00,00,00,000/- to ADB on 18th May 2021.

Issuance of 6,52,973 Equity Shares of Rs 10 each to Dr. Naresh Trehan in accordance with the provisions of Articles of Association of the Company and subject to approval of members, the Board has proposed to issue and allot, 6,52,973 Equity Shares of Rs 10 each to Dr. Naresh Trehan at a premium of Rs. 565 (Indian Rupees Five Hundred Sixty-Five) per equity share.

Whistle Blower Mechanism (Vigil Mechanism)

Pursuant to the provisions of Section 177 of the Companies Act, 2013 and Rules made there under, the Company has adopted a Whistle Blower Policy and has established the necessary vigil mechanism for Directors and employees to report genuine concerns about unethical behaviour, actual or suspected fraud or violation of the Company's code of conduct or policy.

Prevention of Sexual Harassment Policy

A policy on prevention of Sexual Harassment of Women at Workplace had been implemented in the Company and Internal Complaint Committee(s) have been constituted to handle / investigate the matters relating to Sexual Harassment at various locations. The Company had received 3 (Three)

Page 8 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411
CIN: U85110DL2004PLC128319
www.medanta.orgc





complaints under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 (POSH) & same had been disposed as per the terms of the policy of the Company. The company has complied with provisions relating to constitution of Internal Committee under POSH.

Subsidiaries, Associates and Joint Ventures

During the year under review, the subsidiaries of the Company are as follows:

- · Medanta Holdings Private Limited (MHPL),
- Global Health Patliputra Private Limited" (GHPPL) and
- · Medanta Duke Research Institute Private Limited (MDRI).

The Reports on the performance and financial position of MHPL, GHPPL and MDRI as per the Companies Act, 2013 are given below and also provided to the consolidated financial statement of the Company.

1. MHPL

MHPL is a 100% subsidiary of the Company.

During the Year the Company was issued 63,29,113 Equity Shares of Rs.10 each on conversion of Compulsority Convertible Preference Shares (CCPS) on 27th August 2020. Further 24,78,929 CCPS of Rs.10 each at a premium of Rs 90.85/- was allotted to the Company amounting to total investment of Rs. 24,99,99,989.70 during the financial year 2020-21. The Company holds 7,17,36,341 Equity shares and 24,78,929 CCPS of Rs 10/- each as on 31st March, 2021.

Medanta Lucknow commenced its operations on 05th November 2019 and is now offering state-of-the-art Patient Care Services in Cardiology and Cardiac-surgery, Neurosciences, Nephrology, Urology, Orthopedics & Joint Replacement, Digestive and Hepatobiliary Sciences, Internal Medicine, Pulmonary Medicine, Critical Care, Anesthesiology, Transfusion Medicine and Blood Bank, Radiology and Nuclear Medicine, Pathology and Laboratory Medicine and 24X7 Emergency Medicine and Trauma Care.


Spread over 12.58 acres, MEDANTA LUCKNOW – a 1000 bedded hospital – is an excellent combination of future generation healthcare services comprising of 350 critical care beds (ICUs), more than 30 super-specialties, 37 ultra-clean operation theaters, state of the art high-end Laboratory Services, 24X7 Blood Bank, Bone Densitometry, Mammography, Ultrasound, high-end MRI, CT, PET Scan, Gamma Camera, etc.

Its financial performance for the year ended March 31, 2021 is as under:

(Rupees in Lakhs)

T C	personal control of the following and the following the following the first of the following the first of the following the following the following the first of	A SOME AND SOME AND A SOUTH AND A SOUTH ASSOCIATION AND A SOUTH ASSOCIATION AS
Income from operations	21,963.17	2,849.08
Other Income	239.92	111.70
Total Revenue	22,203.09	2,960.78
Total Expenditure	25,763.81	8,413.30
Profit\(Loss) before Taxation	(3,560.72)	(5452.52)









2. GHPPL

GHPPL is a 100% subsidiary of the Company.

Global Health Patliputra Private Limited (GHPPL) has been in process of development of 500 beds Super Specialty Hospital (in 4 Phases) in Patna (Kankarbagh) over an area of 7 acres approx through PPP mode on a design, build, finance, operate and transfer basis.

GHPPL has already commenced its OPD operations with effect from 18th September, 2020

In order to provide necessary medical support to public during COVID pandemic, the Company has started COVID ward of approx. 40 beds in emergency and heart command area as per request of Government of Bihar during April 2021. Operations are gearing up for starting 330 IPD beds by 3rd quarter of current financial year. Core operation team is on board. As of now OPD and COVID isolation facilities are operational. The Company had subscribed an additional 10,00,00,000 Equity Shares of Rs. 10 each amounting to Rs. 100 Crores during FY-2020-21 and subsequently 6,00,00,000 Equity Shares of Rs.10 each amounting to Rs. 60,00,00,000.The total amount invested by the Company in GHPPL till date is Rs. 255 Crores.

GHPPL's financial performance for the year ended March 31, 2021 is as under:

Particulars	(Rs: 11			
	2021	2020		
Revenue from operation	22.65	00.00		
Other Income	66.75	2.48		
Total Revenue	89.40	2.48		
Total Expenditure	1724.35	1,256.34		
Loss before Tax	(1634.95)	(1,253.87)		

3. MDRI

MDRI, a subsidiary of Global Health Private Ltd. (GHPL / Company) wherein GHPL was holing 10,001 (50.01%) equity shares and Duke Medicine Asia Pte. Ltd. ("Duke") is holding 10,000 (49.99%) equity shares.

MDRI is in the process of voluntary liquidation under Section 59 of the Insolvency and Bankruptcy Code, 2016 (IBC Code 2016). The share capital has been returned to shareholders by Insolvency Professional/Liquidator and the matter is pending with NCLT for winding up orders.

The Company does not have any Associates Company and Joint Venture.



Consolidated Financial Statement

In accordance with the provisions of the Companies Act, 2013 and Accounting Standard (AS) - 21, the audited consolidated financial statement form part of the Annual Report. Further the salient features of financials of the subsidiaries for the financial year 2020-21 is provided in the prescribed form AOC-1 as Annexure-II which forms a part of the Annual Report.

Directors' Responsibility Statement

Pursuant to the requirement of the Companies Act, 2013, the Board of Directors confirms that:

- (a) In the preparation of the annual accounts for the year ended 31st March, 2021, the applicable accounting standards had been followed along with proper explanation relating to material departures.
- (b) the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year 2021 and of the profit of the company for that period.
- (c) the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities.
- (d) the directors had prepared the annual accounts on a going concern basis; and
- (e) the directors, had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
- (f) the directors had devised proper systems to ensure compliance with the provision of all applicable laws and that such systems were adequate and operating effectively.

Internal Financial Controls and Risk Management

The Company has in place adequate internal financial controls for preparation of financial statements. During the year, such controls were tested and no reportable material weakness in the design or operation was observed.

Report on the Internal Financial Controls over Financial Reporting under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 formed part of Audit Report. In addition, the Company has adequate Risk Management Controls in place considering the nature and size of operation. The Risks attributable to the business are evaluated regularly and remedial measures are ensured.

Significant and Material Orders passed by the Regulators or Courts

There are no significant material orders passed by the Regulators / Courts except the matter pending before the National Green Tribunal ("NGT") regarding 'Iharsa bundh' land.

Sarv Jan Kalyan Samiti filed a case before Hon'ble National Green Tribunal (NGT) seeking direction for removal of concrete wall constructed by the Company in Gurgaon on bundh area (Protected Forest) and restoration of encroached bundli/forest land.



GHL has submitted before the Hon'ble NGT that it is a bona fide allottee and were allotted the said land on an "as is" basis by Haryana Urban Development Authority. As suggested by the Hon'ble NGT, the State authorities discussed the matter and offered that the Company may apply for conversion of the land. GHL has initiated the process of conversion and has made the payment of requisite fee, GHL has also got Stage — 1 approval and final approval is awaited.

Particulars of loans given, Investment made, Guarantees given, and Securities provided

Your Company has made an investment for an amount aggregating to Rs. 100.00 Crores in the shares of GHPPL and Rs.25.00 Crores in the shares of MHPL during the financial year 2020-21.

Details of Loans, Advances, Investments, guarantees given and outstanding during the FY 2020-21 forms part of the Notes to the Financial Statements.

Particulars of contracts or arrangements with related parties

All the Contracts / arrangements / transactions entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis. The Company has obtained all necessary approvals as and when required and applicable under the provision of law, while entering into contracts or arrangements with related parties.

Particulars of contracts or arrangements with related parties referred to in Section 188 (1) of the Companies Act, 2013, in prescribed form AOC-2 is appended as Annexure-III to the Board's report.

Your Directors draw your attention to Note No(s) 38 to the standalone financial statement which sets out related party Disclosures.

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo

The information on conservation of energy, technology absorption and foreign exchange earnings and outgo stipulated under Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014 is detailed in Annexure-IV.

Auditors and Auditors' Report

A. Statutory Auditors

M/s Walker Chandiok & Co. LLP, Chartered Accountants were appointed as Statutory Auditors of the Company for a period of 5 consecutive years at the Annual General Meeting held on 15th September, 2017.

M/s Walker Chandiok & Co. LLP, Statutory Auditors of the Company have submitted their report for the financial year 2020-21. The Notes on financial statement referred to in the Auditors' Report are self- explanatory and do not call for any further comments. The Auditors' Report does not contain any qualification, reservation or adverse remark.

B. Cost Auditors

M/s. Ramanath lyer & Co., retiring Cost Auditors were eligible for re-appointment. They had confirmed their eligibility to the effect that their re-appointment, if made, for the financial year 2021-22 would be within the prescribed limits under the Act and that they were not disqualified for reappointment.





The Cost Auditors have submitted their Report and it does not contain any qualification, reservation or adverse remark.

C. Internal Auditors

M/s Pricewaterhousecoopers, Services LLP, Chartered Accountants, (PwC) has been appointed as Internal Auditors of the Company.

M/s Pricewaterhousecoopers, Services LLP, Chartered Accountants, (PwC) have submitted their Report and it does not contain any qualification, reservation or adverse remark. No Fraud was reported during the Financial Year under review.

D. Secretarial Auditors

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, with the consent of the Board in their meeting held on 23rd March, 2021, the Company has appointed M/s VAPN & Associates, Practicing Company Secretaries as Secretarial Auditors of the Company for the Financial Year 2020-21.

The Secretarial Audit Report submitted by M/s VAPN & Associates for the Financial Year 2020-21 is annexed as Annexure – V and forms part of this report. Further, there has been no qualification, reservation, adverse remarks or disclaimer made by the Secretarial Auditors in their report for the financial year ended 31st March, 2021.

Secretarial Standards

During the financial year under review, your Company has complied with applicable Scoretarial Standards issued by the Institute of Company Scoretaries of India.

Acknowledgements:

Your Directors place on record their sincere appreciation for significant contribution made by your Company's employees at all levels and look forward to their continued support.

Your directors also take this opportunity to express sincere thanks to the medical professionals / fraternity and patients for their continued co-operation, patronage and trust reposed in the Company and its services.

Your Directors also wish to place on record their appreciation and acknowledge with gratitude the support and co-operation extended by State Governments, our bankers, consultants, customers, vendors, affiliated hospitals, shareholders and other business associates for their confidence reposed in the Company and its management.

For and on behalf of the Board Global Health Limited

Place: Gurugram

Date: 17th September, 2021

Chairman and Managing Director

New Delhi

(DIN No.: 00012148)

Page 13 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011-44114411 CIN: U85110DL2004PLC128319

www.medanta.orge



ANNEXURE-I TO DIRECTORS' REPORT

ANNUAL REPORT ON CORPORATE SOCIAL RESPONSIBILITY ("CSR") ACTIVITIES [Pursuant to the Companies (Corporate Social Responsibility Policy) Rules, 2014]

1. Brief outline of the Company's CSR policy:

The Company (Global Health Limited / Medanta) is committed to incorporating policies, systems and approaches to achieve its positive impact growth objectives. Deeply inherent in our vision statement are the principles of sustainability. The CSR approach stems from our vision statement focusing on "continuously enhancing stakeholder value", which includes the larger society and environment in which the Company operates.

Medanta aims to be committed to social causes and relevance for its inclusive growth and to contribute to society by supporting causes on the health and other well-being platform. Through CSR, the Medanta intends to proactively engage with the society by working with communities to improve their well being in an empathetic manner. The core areas for Medanta CSR programs are Healthcare, Education, Sustainable Livelihood, Infrastructure Development and Social Change as all of these areas are vital preconditions for promoting social good. Concern for the environment is in line with our belief that this

global cause demands our attention to ensure a sustainable and productive planet. These themes are established centrally for adoption or adaptation across all geographies. Our Corporate Social Responsibility policy conforms to the Corporate Social Responsibility as stipulated in Section 135 of the Act and the CSR Rules

2. Composition of CSR Committee as on 31st March 2021:

S. No.	Name of Director	Designation / Nature of Directorship	No. of meetings of CSR Committee
,			held during attended during the the year
1.	Dr. Naresh Trehan Chairman of Co Chairman & N Director		2 2
2.	Mr. Sunil Sachdeva	Member of Committee, Non- Executive Director	2 2
3.	Ms, Praveen Mahajan	Member of Committee, Independent Director	2 2
4	Mr. Vikram Singh Mehta	Member of Committee, Independent Director	1 1

3.	Web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed.	
4.	Details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of Rule 8 of Companies (Corporate Social Responsibility Policy Policy) Rules, 2014	

Page 14 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 CIN: U85110DL2004PLC128319 <u>www.medanta.org</u>





5.	Details of the amount available for set off in pursuance of sub-rule (3) of rule 7 of the Companies (Corporate Social Responsibility Policy) Rules, 2014 and amount required for set off for the financial year.	Not Applicable
----	--	----------------

6.	Average net profit of the Company as per section 135(5)	Rs. 9,727.00 Lakhs

7.	(a) Two percent of Average net profit of the Company as per section 135(5)	Rs. 194.54 Laklis
	(b) Surplus arising out of the CSR projects/ programmes or activities of the previous financial year	NII
	(c) Amount required to be set off for the financial year, if any	Nil
	(d) Total CSR obligation for the financial year (7a+7b -7c)	Rs. 194.54 Lakhs

8 (a) CSR amount spent / unspent for the financial year: As under: -

Total		Air	nount Unspent (ii	3 ₹)	
Amount Spent for the	Total Amount Unspent CSR section 135(6)	transferred to Account as per	Amount transfe Schedule VII a 135(5)	erred to any fur s per second p	nd specified under proviso to section
Financial Year (in ₹)	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
Rs. 42.72 Lakhs	Rs. 151.82 Lakhs	28 th April, 2021	Not applicable	Not applicable	Not applicable

(b) Details of CSR amount spent against ongoing projects for the financial year:

No.	Nam e of the Proje ct	Item from the list of activiti es in Sched ule VII to the Act	Loca i area (Yes /No)	Locatio n of the project (State & Districts)	Proje ct Dura tion	Amou nt allocat ed for the project (in ₹)	Amount spent in the current financial Year (m	Amount transferr ed to Unspent CSR Account for the project as per Section	Mod c of Impl emen tatio n - Direc t (Yes/ No)	tation Thro	emen ugh emen
-----	--------------------------------------	---	-----------------------------------	---	-----------------------------	---	---	--	--	----------------	---------------------

Page 15 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011-44114411 CIN: U85110DL2004PLC128319 www.medanta.orga



								135(6) (in ₹)			on Nu mb er
1.	Preventive Heal th Care Prog	Preve ntive Healt hcare (Item 1)	Yes	Haryana , Delhi, Uttar Pradesh, Rajastha n (Mathur a, Gorakhp ur, Souipat, Sirsa, Jhajjar, Karnal and Panipat)	years with effec t from 13th July, 2018	Rs. 10 Crores	Rs. 12.65 Lakhs	Rs. 151.82 Lakhs	Yes(Direc t)	NA	NA

(c) Details of CSR amount spent against other than ongoing projects for the financial year:

S. No.	Name of the Project	Item from the list of activities in schedule	Local Area (Yes/ No)	Location of the Project	Amount Spent for the project	Mode of Implemen tation Direct (Yes/No)	Mode of Implementation Through Implementing Agency	
		VII to the Act		State District			Name	CSR registrat ion number
1.	Mission TB-Free Haryana	Preventive Healthcare	Yes	Bhiwani Fatchabad & Hissar districts of Haryana	Rs. 28,03 Lakhs	Yes (Direct)	NA	NA

- (d) Amount spent in Administrative Overheads: Rs. 2.03
- (e) Amount spent on Impact Assessment, if applicable: Not Applicable
- (f) Total amount spent for the Financial Year (8b+8c+8d+8e): ₹ 42.72 Lakhs
- (g) Excess amount for set off, if any: Nil

S. No.	Particular	Amount (in ₹)
i	Two percent of average net profit of the Company as	Rs. 194,54 Lakhs
1	per section 135(5)	
ii,	Total amount spent for the Financial Year	Rs. 42.72 Lakhs
ii i .	Excess amount spent for the financial year [(ii)-(i)]	NA .

Page 16 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411
CIN: U85110DL2004PLC128319

www.medanta.org.





iv.	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	NA
V.	Amount available for set off in succeeding financial years [(iii)-(iv)]	NA

9 (a) Details of Unspent CSR amount for the preceding three financial years:

Preceding Financial Year	Amount transferred to Unspent CSR Account	Financial	Amount trans CSR Fund a proviso to Secany	remaining	
	under section 135 (6)	Year (in ₹)	Amount (in ₹)	Date of Transfer	financial years
2017-18	NIL.	NIL	NIL	NA	NIL ·
2018-19	NIL	NIL	NIL	NA	NIL
2020-21	Rs. 151.82 Lakhs	Rs. 42.72 Lakhs	NIL	NA	NIL

(b) Details of CSR amount spent in the financial year for ongoing projects of the preceding financial year(s):

S. No	Project ID	Name of the Project	Financial Year in which the project was commence d	Project Duration	Total amount allocate d for the project (in ₹)	Amount spent on the project in the reporting Financial Year (in ?)	Cumulative Amount spent at the end of reporting Financial Year (in ?)	Status of the project - Completed Ongoing
1	Preventi ve Healthc are	Preventive Health Care	2018	5 years	Rs. 10 Crores	Rs. 12.65 Lakhs	Rs. 101.79	Ongoing

- 10 In case of creation or acquisition of capital asset, furnish the details relating to the asset so created or acquired through CSR spent in the financial year: Nii (asset-wise details).
- (a) Date of creation or acquisition of the capital asset(s).; Not Applicable
- (b) Amount of CSR spent for creation or acquisition of capital asset.: Not Applicable
- (c) Details of the entity or public authority or beneficiary under whose name such capital asset is registered, their address etc.: Not Applicable
- (d) Provide details of the capital asset(s) created or acquired (including complete address and location of the capital asset).: Not Applicable





11 Specify the reason(s), if the Company has failed to spend two per sent of the average net profit as per section 135(5).:

The CSR activities were affected due to COVID Pandemic, travel restrictions and lock down imposed by Centre / State Governments and Company could not organise camps for CSR activities. The activities were resumed from month of October 2020 however the beneficiaries have shown less interest in participating in camps due to COVID issues.

On behalf of the Board of Directors

Mr. Pankaj Kumar Sahn Chief Executive Officer On behalf of the Board of Directors

Dr. Naresh Kumar Trehan Chairman CSR Committee

(DIN No.: 00012148)



Annexure-II to Directors' Report

Form AQC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries/associate companies/joint ventures

Part "A": Subsidiaries

(Information in respect of each subsidiary to be presented with amounts in Rs.)

No.	Particulars	Detnils		
	Name of the subsidiary	Medanta Duke	Global Heath	Medant
		Research Institute	Patliputra Private	Holdings Pvi
		Private Limited	Limited	Ltd(MHPL
		(MDRI)*	(GHPPL)	
	Reporting period for the	31st March, 2021	31 st March, 2021	31st March, 202
	subsidiary concerned, if	,		
	different from the holding		·	,
	company's reporting period			
•	Reporting currency and	INR(Rs) in Lakh	INR(Rs) in Lakh	INR(Rs) in Lak
	Exchange rate as on the last	.		, ,
	date of the relevant Financial			
	year in the case of foreign			
	subsidiaries			
	Share capital		19,500.00	7,173.63
	Reserves & surplus		(4588.92)	21,155.97
	Total assets		41.504.51	0.5
-	1864 N. C.		41,524.51	81,985.94
	Total Liabilities	-	26,413.43	53,208.46
	Investments		00.00	00.00
	Turnover		22,65	21,963.17
:	Profit (Loss) before taxation		(1634.95)	(3560.74
	Provision for taxation -			
	Deferred Tax (credit)			
	expenses	Realth	0.44	(2348,40

Page 19 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011-44114411

CIN: U85110DL2004PLC128319

www.medanta.orga.

... ســه إلي



Profit (Loss) after taxation	(1635.39)	(1212.34)
Proposed Dividend	NII.	NIL
% of shareholding	100	100

*MDRI is under liquidation

- Notes: The following information shall be furnished at the end of the statement:
- 1. Names of subsidiaries which are yet to commence operations- GHPPL has commenced its OPD operations from 18th September, 2020.
- 2. Names of subsidiaries which have been liquidated or sold during the year-MDRI is in process of liquidation.

Part "B": Associates and Joint Ventures

Statement pursuant to Section 129 (3) of the Companies Act, 2013 related to Associate Companies and Joint Ventures:

Not Applicable

hairman and Managing

Director

CEO Group CFO

Company Secretary

Note: This Form is to be certified in the same manner in which the Balance Sheet is to be certified,





Annexure-III to Directors' Report

FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the .

Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub-section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis:

There were no contracts or arrangements, or transactions entered into during the year ended March 31, 2021, which are not on arm's length basis.

2. Details of contracts or arrangements or transactions at Arm's length basis:

related party	Nature of contracts/arran genients/transa ction	Duration of the contracts /arrange ments/tra nsaction	Salient ferms of the contincts or arrangements of transaction including the value, if any	approval by	Amount paid as advance s, if any
IFAN Global India Private Limited	Agreement for Human Resource Services (Nursing)	Three years	The Company has availed Recruitment services from IFAN and paid a fee of Rs.95.85 Lakhs during the year.	22.12.2017	Nil
Mr. Naveen Trehan, CEO of IFAN is the brother of Dr. Naresh Trehan, CMD of the Company.					
Law Chamber of Kapur and Trehan Ms. Shyel Trehan, Partner of the firm, is the daughter of Dr. Naresh	Retainership Agreement	One year	Retainership and Appearance fees before Courts/ competent forum in India on behalf of the Company in relation to legal cases and any other cases as the case may be. (Transaction during the year was Rs 26.46 Lakhs)	28.09.2020	Nil

Page 21 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411
CIN: U85110DL2004PLC128319
www.medanta.orgc





Vidyanta Skill Institute Private Limited (VSIPL) Mr. Naveen Trehan, director and member of VSIPL is the brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company during the year was as under: Particulars Amount in Lakhs Particulars Amount in Trehan, CMD of the Company during the year was as under: Particulars Amount in Lakhs	7.1. 0.45	1	1	,		*	
Vidyanta Skill Institute Private Agreement Agreement Agreement Years VSIPL Identifies training 05.11.2018 Nil Nil Nil Naveen Trehan, director and member of VSIPL. is the brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA TPA Agreement Openended Private Limited Private Li	Trehan, CMD						
Institute Private Limited (VSIPL) Mr. Naveen Trehan, director and member of VSIPL, is the brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Trehan, CMD of the Company Bread and member of Trehan, CMD Of the Company Trehan, CMD of the Company Bread and member of Trehan, CMD Of the Company Trehan, CMD of the Company Bread and member of Trehan, CMD Of the Company Trehan, CMD Of the Company Bread and member of Trehan, CMD Of the Company Trehan, CMD Of the Company Bread avails the medical of 1.09.2010 Nil Trehan, CMD Of the Company Bread avails the medical services for Raksha TPA Members at Medanta Hospital (GHPL) for IPD Services. Trehan, CMD Of the Company Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Rs 213.62	of me-Company						
Limited (VSIPL) Mr. Naveen Trehan, director and member of VSIPL. is the brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahni, CMD of the Company during the year was as under: Particulars Amount in Lakhs Nil Naring Personnel of the Company. (Transaction during the year was Rs. 14.84 Lakhs) Nil	Vidyanta Skill	Service	Three	VSIPL Identifie	s training	05.11.2018	Nil
Mr. Naveen Trehan, director and member of VSIPL, is the brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD Of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Company. (Transaction during the medical services for Raksha TPA Members at Medanta Hospital (GHPL) for IPD services. (Transaction during the year was Rs.2065.18 Lukhs) Total amount paid to Mr. Pankaj Sahni, Cheo, is the son in law of Dr. Naresh Trehan, CMD of the Company during the year was as under: Particulars Amount in Lakhs Remuneration Rs 213.62	Institute Private	Agreement	years	requirements/ i	needs of		
Mr. Naveen Trehan, director and member of VSIPL. is the brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahmi Mr. Pankaj Sahmi, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. (Transaction during the year was Rs. 2065.18 Lakhs) Nil (Transaction during the year was Rs. 2065.18 Lakhs) Nil (Transaction during the year was Rs. 2065.18 Lakhs) Nil (Transaction during the year was Rs. 2065.18 Lakhs) Total amount paid to Mr. Pankaj Sahmi, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount in Lakhs Remuneration Rs 213.62	Limited			Nursing Personn	el of the		
Mr. Naveen Trehan, director and member of VSIPL, is the brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company Dr. Naresh Trehan, CMD of the Company Brivate Limited TPA Agreement Openended Raksha avails the medical services for Raksha TPA Members at Medanta Hospital (GHPL) for IPD services. (Transaction during the year was Rs.2065.18 Lakhs) Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company Total amount paid to Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company Raksha TPA Private Limited Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company Raksha TPA Private Limited Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company Raksha PPA Members at Medanta Hospital (GHPL) for IPD services. Pankaj Sahni, Chref Executive Officer (CEO) of the Company during the year was as under: Particulars Amount in Lakhs Remuneration Rs 213.62	(VSIPL)			Company.			
Mr. Naveen Trehan, director and member of VSIPL, is the brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company Dr. Naresh Trehan, CMD of the Company Brivate Limited TPA Agreement Openended Raksha avails the medical services for Raksha TPA Members at Medanta Hospital (GHPL) for IPD services. (Transaction during the year was Rs.2065.18 Lakhs) Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company Total amount paid to Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company Raksha TPA Private Limited Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company Raksha TPA Private Limited Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company Raksha PPA Members at Medanta Hospital (GHPL) for IPD services. Pankaj Sahni, Chref Executive Officer (CEO) of the Company during the year was as under: Particulars Amount in Lakhs Remuneration Rs 213.62				(Thursday)			
Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company during the year was as under: Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company during the year was as under: Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company.				1	-		Nil
and member of VSIPL, is the brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. A members at Medanta Hospital (GHPL) for IPD services. Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Rs 213.62	Mr. Naveen			year was RS. 14.6	4 Lakiis)		
VSIPL. is the brother of Dr. Naresh Trelan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company during the year was as under: Particulars Amount in Lakhs Remuneration Rs 213.62	Trehan, director		i				
brother of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. British TPA Private Limited Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount in Lakhs Remuneration Rs 213.62							
Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahmi Mr. Pankaj Sahmi Mr. Pankaj Sahmi, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahmi, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Raksha TPA Private Limited Mr. Pankaj Sahmi, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Rs 213.62							
CMD of the Company. Raksha TPA Private Limited TPA Agreement Private Limited Transaction during the year was Rs.2065.18 Lakhs) Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: TPA Agreement Private Limited Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: TPA Agreement Private Limited Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: TPA Agreement Private Limited							
Company. Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Canpany. Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Raksha avails the medical services for Raksha TPA Members at Medanta Hospital (GHPL) for IPD services. Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Rs 213.62							
Raksha TPA Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Raksha avails the medical services for Raksha TPA Members at Medanta Hospital (GHPL) for IPD services. (Transaction during the year was Rs.2065.18 Lakhs) Nor. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Remuneration Rs 213.62							
Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. ended services for Raksha TPA Members at Medanta Hospital (GHPL) for IPD services. (Transaction during the year was Rs.2065.18 Lakhs) Den Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Rs 213.62	Company,						
Private Limited Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. ended services for Raksha TPA Members at Medanta Hospital (GHPL) for IPD services. (Transaction during the year was Rs.2065.18 Lakhs) Den Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Rs 213.62	Raksha TPA	TPA Agreement	Open-	Raksha avails th	e medical	01.09.2010	Nii
Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Members at Medanta Hospital (GHPL) for IPD services. (Transaction during the year was Rs.2065.18 Lakhs) Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Rs 213.62	1	J	ł ·	}		01,02,010	'''
Dr. Naresh Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Services. (Transaction during the year was Rs.2065.18 Lakhs) Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Rs 213.62				3			
Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Employment Open ended Mr. Pankaj Sahni Chief Executive Officer (CEO) of the Company during the year was as under: Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount in Lakhs Trehan, CMD of the Company. Remuneration Rs 213.62				Hospital (GHPL)	for IPD		
Trehan, CMD of the Company is director in Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount in Lakhs Remuneration Rs 213.62	Dr. Naresh			services.			
is director in Raksha TPA Private Limited Mr. Pankaj Employment Open ended Total amount paid to Mr. 28.09.2020 Nil Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Particulars Amount Lakhs Remuneration Rs 213.62							
Raksha TPA Private Limited Mr. Pankaj Sahni Mr. Pankaj Sahni Mr. Pankaj Sahni Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Raksha TPA Private Limited Den Total amount paid to Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Remuneration Rs 213.62	of the Company						
Private Limited Mr. Pankaj Employment Open ended Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Particulars Remuneration Rs 213.62	is director in			(Transaction du	ring the		
Mr. Pankaj Employment Open Total amount paid to Mr. 28.09.2020 Nil Sahni Chief Executive Officer (CEO) of the Company during the year was as under: Mr. Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount in Lakhs Trehan, CMD of the Company. Remuneration Rs 213.62	i :			year was F	Rs.2065.18		1
Sahni ended Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Particulars Remuneration Rs 213.62	Private Limited			Lakhs)			
Sahni ended Pankaj Sahni, Chief Executive Officer (CEO) of the Company during the year was as under: Particulars Amount Lakhs Particulars Remuneration Rs 213.62	Mr Danksi	Employment	Onen	Total pursuant as	24 40 860	20.00.2020	
Executive Officer (CEO) of the Company during the year was as under: Particulars Amount in Lakhs Trehan, CMD of the Company. Remuneration Rs 213.62		cmproyment				28.09.2020	NII
Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. the Company during the year was as under: Particulars Amount in Lakhs Remuneration Rs 213.62	· • • • • • • • • • • • • • • • • • • •		ciraca				
Mr. Pankaj Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Particulars Amount in Lakhs Remuneration Rs 213.62							
Sahni, CEO, is the son in law of Dr. Naresh Trehan, CMD of the Company. Particulars Amount in Lakhs Remuneration Rs 213.62	New Domini				_		
the son in law of Dr. Naresh Trehan, CMD of the Company. Remuneration Rs 213.62							
of Dr. Naresh Trehan, CMD of the Company. Remuneration Rs 213.62				Particulars		in	
Trehan, CMD of the Company. Remuneration Rs 213.62					Lakhs		
of the Company. Remuneration Rs 213.62							
	-						
· Sealth?	Company,			Remuneration	Rs 213.62		
. Sealtha							
· \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \							
l sealth?							
i anth				L	ļ		
							Part (V)

Page 22 of 34

O Now Delh

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 CIN: U85110DL2004PLC128319



	·		· · · · · · · · · · · · · · · · · · ·			<u></u>
			ESOP Perquisites Total Further, 4,000 equ of Rs.10/- ear allotted to Mr. Par during the year	ch were	22.07.2019 25.01.2021	
Medanta Institute of Education & Research (MIER) Dr. Naresh Trehan, CMD of the Company is trustee of MIER.	Contract for providing services	Open ended	The Company ha space of 250 so MIER and provide services to MIER. (Transaction du year was 10.17 La	p. feet to es Clinical ring the	21.12.2012	Nil
Global Health Patliputra Private Limited (GHPPL)	Board Resolution for investment in shares of GHPPL Bank guarantee dated——for	Open ended Two years	Rs.10,000 Lakhs	GHPPL car was	10.07.2020 25.01.2021	Nil
Subsidiary Company	providing bank guarantee as Performance Guarantee to the Health Department, Government of Bihar, investment on behalf of GHPPL Board	w.e.f 15 th Sep, 2020		of Guarantee ompany	28.09.2020	
·]	Board					

Page 23 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 CIN: U85110DL2004PLC128319 www.medanta.orgc





	sale of equipment/asset s and providing Lab Services to GHPPL		Sale of equipment/assets and providing Lab Services to GHPPL The Company has received Rs.78.52 Lakhs on account of sale of assets/equipments. The Company has paid the expenses of Rs.8.86 Lakhs and Tax amount of Rs.2.33 Lakhs on behalf of GHPPL during the year	27.08.2020	
Devyani International Ltd (DIL) Mr. Ravi Kant Jaipuria, Director of the Company is Director of DIL.	Agreement for serving food and beverages at Food Court of Medanta	15 years, effective from Feb 9,2013	The Company has provided space to DIL for serving food and beverages at Food Court of Medanta. (Transaction during the year was Rs. 112.46 Lakhs)	06.01.2016	Nil
Diagno Labs Private Limited (DPL) for Indore Hospital* Mr. Ravi Kant Jaipuria, Director of the Company is Director of DPL	Agreement for providing tests to patients	27th Dec., 2019 to 31st July, 2021	The Company has provided space to DPL for providing clinical diagnostic services to the Patients visiting the Hospital or Referred Patients at Medanta, Indore. The Agreement has been terminated with effect from March 31,2021 (Transaction during the year was Rs. 286.06 Lakhs)	13.05.2017 01.03.2019 05.06.2020 23.03.2021	

Page 24 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411 CIN: U85110DL2004PLC128319 www.medanta.orgc





Medanta Holdings Private Limited	Board Resolution (s) for making investment in share capital of MHPL, providing guarantee to Customs Authority on behalf of MHPL and sale of equipments & providing Lab Services to MHPL	Open ended	The Company has made investment in MHPL during the year was Rs. 2,500 Lakhs. The Company has given guarantee on behalf of MHPL for Rs.15.68 Lakhs during the year. The Company has sold assets/ equipments for Rs 33.72 Lakhs during the year. The Company has paid expenses of Rs.108.59 Lakhs on behalf of MHPL	10.07,2020 19.12.2019 27.08,2020	
S.A.S. Infotech Private Limited ("SAS") Mr. Sunil Sachdeva, Director of the Company is director of SAS	Re-imbursement of electricity charges	Open ended	Company has supplied electricity during the financial year 20120-21 to SAS for consumption of electricity in SAS Tower. (Transaction during the year was Rs. 265.23 Lakhs)	29.03.2019	

Note: In addition to above, some relatives of directors/employees have availed medical treatment at hospital of the Company which are in ordinary course of business as mentioned at note no.37 of standalone financial statement.

*These contracts were entered when these were not related party transactions.

On behalf of the Board of Directors

Dr. Naresh Kumar Trehan Chairman & Managing Director

(DIN No.: 00012148)

Red (New Delly)



Annexure-IV- to Directors' Report

INFORMATION AS PER SECTION 134(3)(M) READ WITH RULE 8 (3) OF THE COMPANIES (ACCOUNTS) RULES, 2014 AND FORMING PART OF THE DIRECTORS' REPORT FOR THE YEAR ENDED 31ST MARCH, 2021

CONSERVATION OF ENERGY

Steps taken or Impact on Conservation of Energy

The operations of the Company are not energy intensive. However, significant measures are being taken to reduce the energy consumption by using energy-efficient equipments. The Company has planned for the following additional Energy Conservation Measures during the Financial Year 2020-21.

DG Set fuel conversation kit installation for HSD and PNG both in 30:70 ratio. The plan to convert the DG sets with duel fuel kit which was likely to save RS 52 Lacs per year depending on load (65 % to 80%) and fuel sharing (50% to 70%) during the Financial Year 2020-21. Project cost was Rs.25.28 Lacs for DG Set.

However, due to Covid Pandemic, the Company will implement the above in due course of time.

TECHNOLOGY ABSORPTION

In its continuous endeavour to serve the patients better and to bring healthcare of international standards within the reach of every individual, your company has introduced the latest technologies in its hospitals as under:

Upgrade of Cath Labs for Invasive Cardiology and Neurology

Artis zee Cath labs - Upgraded to the level of Artis zee pure

We have upgraded five cath labs from Artis zee to Artis zee pure level, now these cath labs are equipped with industry-leading imaging technology, unique dose management tools, and the latest clinical applications based on the innovative PURE® platform. With addition of new software and hardware equipment life got enhanced till 2027.

Cost involved for Cath Lab upgradation was approx. Rs 4.25 Crore.

Upgrade of Syngo via & syngo dynamics

PACS software version was upgraded from VB10 to VB40 which is even more intuitive & helps clinicians to read and complete reports more easily and quickly with greater accuracy. It enables fast, secure, and consistent access to critical information and images, necessary to improve outcomes. Added new software for Cinemat VRT, Breast Care package, ALPHA technologies as per need of radiologist. Up gradation of system will enhance the Life of equipment till 2027. Integration of Radiology PACS with Lucknow HIS SHAL help radiologist of Medanta Gurgaon to report Medanta Lucknow scans.

Also, we have added ordering message integration from modality to HIS to prevent revenue leakage. Cost involved for upgrading Syngo via & syngo dynamics was approx. Rs 2.76 Crore.

Page 26 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No.011- 44114411
CIN: U85110DL2004PLC128319
www.medanta.org.





Upgrade of Elekta linear accelerator platform

Elekta Linear accelerators platform Synergy S upgraded from Beam Modulator to Agility and Linear accelerators Infinity from MLCi to Agility

Agility is the next generation, high resolution beam shaping solution from Elekta. Built on a strong understanding of the factors that are critical to patient plan optimization and treatment delivery, Agility is designed to meet the needs of modern radiotherapy facilities. Agility offers excellent clinical flexibility and efficiency, while ensuring that patient safety and comfort remain a priority. Agility reduce unwanted dose to healthy tissue or organs-at-risk is critical, the Agility leaf bank provides extremely low transmission (< 0.5%).

Upgradation of system will enhance the Life of equipment till 2027.

Cost involved there in for Elekta linear accelerator platform up gradation is approx. Rs 10 Crore,

Samsung DR system for Radiology

Premium mobile digital radiography system AccE GM85 provides advanced driving experience and advanced applications to support enhanced usability and high image quality. AccE Detector is a new introduction to the Samsung DR prestige line-up to accelerate connection and promote synergy between the systems. Its user-centric design of the detector support patient positioning and alleviate daily burdens.

Software SimGridTM streamlines the workflow by guarantee in image quality without the use of a conventional grid. This allows the omission of grid installation and removal step from the conventional workflow leading to 28% reduction in total exam time.

Cost involved there in for EECP Therapy SR System is approx. Rs 55 lacs.

Thopaz+ Digital Chest Drainage system for Thoracic Surgery

Medela's Thopaz+ takes chest drainage therapy to a new level of care. Thopaz+ allows the optimal pressure to be applied for post-operative chest drainage management, And as a result, patient's length of hospital stay can be shortened and can help reduction in cost of hospital. Cost involved there in for Medela's Thopaz+ takes chest drainage is approx. Rs 69 lacs.

FT10 Energy plateform for Thoracic Surgery

The Valleylab FT10 energy devices helps in fast sealing & cutting and can reduce upto 50% time of procedure. Valleylab FT10 energy platform delivers precise amount of energy where and when it is needed most.

FT10 energy devices is best in class advanced energy and electrosurgery devices and are powered by smart generators that manage energy delivery with precision enabling algorithms.



Cost involved there in for FT10 energy platform is approx. Rs 27 lacs.

ERBE APC 2 for Thoracic Surgery

APC is an electrosurgical technique for the management of bleeding and the devitalization of tissue abnormalities. During the procedure, the electrosurgical current is transferred to the tissue via ionized argon gas. Creating effective hemostasis and homogenous surface coagulation with limited penetration depth. Since transmission of the electrosurgical current is by a non-contact technique, (the instruments do not come into direct contact with tissue), and the instruments never stick to the tissue. Simplified Control — Reduces the need for constant foot pedal interaction, allowing you to focus more on target tissue areas.

Cost involved there in for ERBE APC 2 energy platform is approx. Rs 16 lacs.

1688 Advanced Imaging Modalities (AIM) 4K Platform for Thoracic Surgery

Stryker's 1688 AIM 4K Platform is the first system to 4K fluorescence. This system gives elinicians seamless connectivity to images and surgical teams can see in greater detail than ever with superior image clarity, more accurate color reproduction, and enhanced light quality. With the added benefit of 4K fluorescence, this system has truly taken visualization beyond the limits of any previous technology.

The system has SPY Portable Handheld Imager (SPY-PHI) and utilizes SPY Fluorescence Imaging Technology and allows surgeons to visualize blood flow in vessels and related tissue perfusion during plastic, microsurgical, reconstructive and gastrointestinal procedures.

Cost involved there in for 1688 AIM 4K Platform is approx. Rs 50 lacs.

FOREIGN EXCHANGE EARNINGS AND OUTGO:

	Rs. in Crore Current year	Previous year
Foreign Exchange Earnings	34.48	118.49
Foreign Exchange outgo (remittance)	<i>8</i> ∙ 3 <i>8</i>	9.03

For and on behalf of the Board

Place: Gurgaon

Date: 17th September, 2021

Dr. Naresh Kumar Trehan Chairman & Managing Director

(DIN No.: 00012148)

New Delhi

Page 28 of 34

Regd. Office: E-18, Defence Colony, New Delhi 110024, Ph No. 21 CIN: U85110DL2004PLC128319

www.medanta.orga



COMPANY SECRETARIES

FORM NO. MR - 3

SECRETARIAL AUDIT REPORT

FOR THE FINANCIAL YEAR ENDED 31st MARCH, 2021

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Renumeration of Managerial Personnel) Rules, 2014]

To.

The Members

Global Health Limited.

(Formerly known as: Global Health Private Limited)

CIN: U85110DL2004PLC128319

Registered Office: Medanta-Mediclinic E-18,

Defence Colony New Delhi 110024

Corporate Office: "Medanta The Medicity",

Sector 38, Gurgaon 122001 Haryana

We have conducted Secretarial Audit of compliance with the applicable statutory provisions and adherence to good corporate practices by Global Health Limited (hereinafter called 'the Company') for the Financial Year ended on 31st March, 2021. Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts / statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, We hereby report that in our opinion, the Company has, during the audit period covering the Financial Year ended on 31st March, 2021 ('Audit Period') complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We report that, we have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on 31st March, 2021 according to the provisions of (as amended):

Office - E18, Ground Floor, Guru Namakgura Janakpuri, Delhi-110058, India



COMPANY SECRETARIES

- The Companies Act, 2013 ('the Act') and the Rules made there under read with notifications, exemptions and clarifications thereto;
- 2. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- The Depositories Act, 1996 and the Regulations and bye-laws framed there under;
- Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment, External Commercial Borrowings;
- The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'): -
 - (a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011–[Not Applicable to the Company during the Audit Period under review];
 - (b) The Securities and Exchange Board of India (Prohibitions of Insider Trading) Regulations, 2015- [Not Applicable to the Company during the Audit Period under review];
 - (c) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018- [Not Applicable to the Company during the Audit Period under review];
 - (d) The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014- [Not Applicable to the Company during the Audit Period under review];
 - (e) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008- [Not Applicable to the Company during the Audit Period under review];
 - (f) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and



COMPANY SECRETARIES

dealing with client- [Not Applicable to the Company during the Audit Period under review];

- (g) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009- [Not Applicable to the Company during the Audit Period under review];
- (h) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018- [Not Applicable to the Company during the Audit Period under review];
- (i) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015- [Not Applicable to the Company thring the Audit Period under review];

We further report that, we have also examined, on test-check basis, the relevant documents and records maintained by the Company according to the following laws applicable specifically to the Company:

- (i) The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013;
- (ii) The Employer's Provident fund & Miscellaneous Provisions Act, 1952;
- (iii) The Employee's State Insurance Act, 1948
- (iv) The Maternity Benefit Act, 1961;
- (v) The Payment of Bonus Act, 1965;
- (vi) The Contract Labour (Regulation and Abolition) Act, 1970
- (vii) The Payment of Wages Act, 1936
- (viii) The Minimum Wages, Act 1948;

Office - E18, Ground Floor, Guru Wariakbura, Janakpuri, Delhi-110058,India



COMPANY SECRETARIES

Based on such examination and having regard to the compliance system prevailing in the Company, the Company has complied with the provisions of the above laws during the audit period.

We have also examined compliance with the applicable clauses of the following:

- Secretarial Standards issued by the Institute of Company Secretaries of India-Complied with.
- 2. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015- [Not Applicable to the Company during the Audit Period under review].

During the Financial Year under report, the Company has generally complied with the provisions of the applicable Acts, Rules, Regulations, Guidelines, Secretarial Standards etc. as mentioned above.

We further report that during the audit period under review:

- The Board of Directors of the Company is duly constituted with proper balance
 of executive directors and non-executive directors. The changes in the
 composition of the Board of Directors that took place during the period under
 review were carried out in compliance with the provisions of the Act.
- 2. Except in case of meetings convened at a shorter notice, adequate Notice was given to all Directors to schedule the Board meetings and the agenda and detailed notes on agenda was sent at least seven days in advance. However, a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.
- 3. All the decisions made in the Board/Committee meeting(s) were carried out with unanimous consent of all the Directors/Members present during the meeting and dissent, if any, have been duly incorporated in the Minutes.





COMPANY SECRETARIES

- 4. There seems to be adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliances with applicable laws, rules, regulations and guidelines.
- 5. No specific events / actions having a major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines, standards, etc. referred to above has occurred in the Company other than mentioned above.

For VAPN & Associates

Practicing Company Secretaries Firm Registration No.: P2015DE045500 Peer Review Certificate No. 975/2020

PASSOCIATION OF THE PROPERTY O

\Prabhakar Kumar

Partner

Membership No.: F5781

CP. No.: 10630

UDIN: F005781C000959041

Place: New Delhi Date: 17/09/2021

Note: This report is to be read with letter of even date by the secretarial auditor, which is annexed as 'Annexure A' and forms an integral part of this report.



COMPANY SECRETARIES

'Annexure A'

To,
The Members
Global Health Limited
(Formerly known as: Global Health Private Limited)
CIN: U85110DL2004PLC128319
Registered Office: Medanta-Mediclinic E-18,
Defence Colony New Delhi 110024

Corporate Office: "Medanta The Medicity", Sector 38, Gurgaon 122001 Haryana

Our Secretarial Audit Report of even date is to be read along with this letter.

Management's Responsibility:

It is the responsibility of the management of the Company to maintain the secretarial records, and to devise proper systems, to ensure compliance with the provisions of all applicable laws and regulations and to ensure that the systems are adequate and operate effectively.

Auditor's Responsibility:

- Our responsibility is to express an opinion on these secretarial records, standards and procedures followed by the Company with respects to Secretarial Compliances.
- 3. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. Verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
- 4. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.

Office - E16, Ground Floor, Guru Nanakpista Janakpuri; Delhi-110058,India



COMPANY SECRETARIES

- 5. Wherever required, we have obtained the Management representations about the compliance of laws, rules and regulations & happening of events etc.
- 6. Our examination was limited to the verification of procedures on test basis.

Disclaimer

The Secretarial Audit Report is neither an assurance as to the future viability of the company nor of the efficacy or effectiveness with which the management has conducted the affairs of the company.

For VAPN & Associates

Practicing Company Secretaries Firm Registration No.: P2015DE045500 Peer Review Certificate No. 975/2020

PRINTER OF THE PRINTE

rabhakar Kumar

Partner

Membership No.: F5781

CP. No.: 10630

UDIN: F005781C000959041

Place: New Delhi Date: 17/09/2021

Walker Chandlok & Co LLP (Formerly Walker, Chandlok & Cos 21st Floor, DLF Square Jacaranda Marg, DLF Phase II Gurgaon 122002 India

T +91 124 462 8000 F +91 124 462 8001

Independent Auditor's Report

To the Members of Global Health Limited (formerly known as Global Health Private Limited)

Report on the Audit of the Consolidated Financial Statements

Opinion

- 1. We have audited the accompanying consolidated financial statements of Global Health Limited (formerly known as Global Health Private Limited) ('the Holding Company'), and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), as listed in Annexure I, which comprise the Consolidated Balance Sheet as at 31 March 2021, the Consolidated Statement of Profit and Loss (including Other Comprehensive Income), the Consolidated Cash Flow Statement and the Consolidated Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information.
- 2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Indian Accounting Standards ('Ind AS') specified under section 133 of the Act, of the consolidated state of affairs of the Group, as at 31 March 2021, and their consolidated profit (including other comprehensive income), consolidated cash flows and the consolidated changes in equity for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) rogether with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Independent Auditor's Report to the members of Global Health Limited (formerly known as Global Health Private Limited) on the consolidated financial statements for the year ended 31 March 2021 (cont'd)

Information other than the Consolidated Financial Statements and Auditor's Report thereon

4. The Holding Company's Board of Directors are responsible for the other information. The other information comprises the information included in the Director's Report but does not include the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

- The accompanying consolidated financial statements have been approved by the Holding Company's Board of Directors. The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these consolidated financial statements that give a true and fair view of the consolidated financial position, consolidated financial performance including other comprehensive income, consolidated changes in equity and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act. The respective Board of Directors/management of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.
- 6. In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intend to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
- Those Board of Directors are also responsible for overseeing the financial reporting process of the companies
 included in the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

8. Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the

Chartered Accountants Chartered Accountants

Independent Auditor's Report to the members of Global Health Limited (formerly known as Global Health Private Limited) on the consolidated financial statements for the year ended 31 March 2021 (cont'd)

aggiegate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

- 9. As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the consolidated financial statements, whether
 due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit
 evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting
 a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may
 involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures
 that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for
 expressing our opinion on whether the Holding Company has adequate internal financial controls with
 reference to financial statements in place and the operating effectiveness of such controls;
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
 - Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern; and
 - Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

- 11. Based on our audit, we report that the provisions of section 197 read with Schedule V to the Act are not applicable to the Holding Company and its subsidiary companies, since none of such companies is a public company as at 31 March 2021, as defined under section 2(71) of the Act. Accordingly, reporting under section 197(16) is not applicable.
- 12. As required by Section 143 (3) of the Act, we report, to the extent applicable, that:
 - a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid consolidated financial statements;
- b) in our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those pooks;

Independent Auditor's Report to the members of Global Health Limited (formerly known as Global Health Private Limited) on the consolidated financial statements for the year ended 31 March 2021 (cont'd)

- c) the consolidated financial statements dealt with by this report are in agreement with the relevant books
 of account maintained for the purpose of preparation of the consolidated financial statements;
- d) in our opinion, the aforesaid consolidated financial statements comply with Ind AS specified under section 133 of the Acr;
- e) on the basis of the written representations received from the directors of the Holding Company and subsidiary companies and taken on record by the Board of Directors of the respective companies, none of the directors of the group companies, are disqualified as on 31 March 2021 from being appointed as a director in terms of Section 164(2) of the Act;
- f) with respect to the adequacy of the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies, and the operating effectiveness of such controls, refer to our separate report in 'Annexure II'; and
- g) with respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
 - i. the consolidated financial statements disclose the impact of pending litigations on the consolidated financial position of the Group as detailed in Note 40 to the consolidated financial statements;
 - the Group did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2021;
 - there were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company and its subsidiary companies, during the year ended 31 March 2021; and
- iv. the disclosure requirements relating to holdings as well as dealings in specified bank notes were applicable for the period from 8 November 2016 to 30 December 2016, which are not relevant to these consolidated financial statements. Hence, reporting under this clause is not applicable.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Partner

Membership No.: 058644

UDIN: 21058644AAAAFG8636

Place: New Delhi

Date: 17 September 2021

Independent Auditor's Report to the members of Global Health Limited (formerly known as Global Health Private Limited) on the consolidated financial statements for the year ended 31 March 2021 (cont'd)

Annexure I

List of subsidiary companies included in the Consolidated Financial Statements:

- 1. Medanta Holdings Private Limited; and
- Global Health Pathiputra Private Limited



Annexure II to the Independent Auditor's Report of even date to the members of Global Health Limited (formerly known as Global Health Private Limited) on the consolidated financial statements for the year ended 31 March 2021 (cont'd)

Annexure II

Independent Auditor's Report on the internal financial controls with reference to the consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

1. In conjunction with our audit of the consolidated financial statements of Global Health Limited (formerly known as Global Health Private Limited) ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group') as at and for the year ended 31 March 2021, we have audited the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies which are companies covered under the Act, as at that date.

Responsibilities of Management and Those Charged with Governance for Internal Financial Controls

2. The respective Board of Directors of the Holding Company and its subsidiary companies, which are companies covered under the Act, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the 'Guidance Note') issued by the Institute of Chartered Accountants of India (TCAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility for the Audit of the Internal Financial Controls with Reference to Financial Statements

- 3. Our responsibility is to express an opinion on the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies, as aforesaid, based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the ICAI prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.
- 4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
- 5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls with reference to financial statements of the Holding Company and its subsidiary companies as aforesaid.

Meaning of Internal Financial Controls with Reference to Financial Statements

reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for extendal purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain

Annexure II to the Independent Auditor's Report of even date to the members of Global Health Limited (formerly known as Global Health Private Limited) on the consolidated financial statements for the year ended 31 March 2021 (cont'd)

to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

8. In our opinion, the Holding Company and its subsidiary companies, which are companies covered under the Act, have in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2021, based on the internal control over financial reporting criteria established by the respective companies considering the essential components of internal control stated in the Guidance Note issued by the ICAL.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

PED ACCO

Rajni Mundra

Partner

Membership No.: 058644

UDIN: 21058644AAAAFG8636

Place: New Delhi

Date: 17 September 2021

	Notes	As at 31 March 2021	As at 31 March 2020
ASSETS		(E in takha)	(Fin lakhs)
Non-current assets			
Property, plant and equipment	6 A .		
Capital work an progress		123,949.50	132,033.49
Right Olasse assets	6-11	36,381.77. 34,893.05	38,172.91
Intanguide assets	7	254'25 24'952'03	37,408.86
investments accounted for using the equity method	8 A	124.02	848.14
Futancial assets		•	•
Investments Leans	8 13	5.00	,
Other financial assets	9 A	817.73	789.81
Deferred as asset; (net)	v 01	1,880.58	2,384,30
fucometax asset (net)	H A	2,573.99	2,364.30
Odier usus-current assets	12	4,712.90	6,595.75
Total non-current assets	13 A	1,258.23	515.82
1 Old Harvet at tell 1 map 512		219,197,27	218,769.08
Current assets			2201/07:00
Inventories			
Pinancial assets	14	3,975.92	3,851.90
Trade receivables			-,
Cash and eash equivalents	1\$	13,362.63	14,915.00
Other bank balances	16	6,946.67	14,757.12
langes -	17	21,983.47	. 10,355.17
Other financial assets	9. 13	38.41	9.79
Other current assets	10 B	3,139.30	3,409.74
Total current assets	13 8	766.73	660.75
Total assess		50,213.32	47,859.56
•		269,410.59	266,628.64
EQUITY AND LIABILITIES Equity			
Equity share capital	18 A		•
Instruments controlly equity in nature	18 13	4,958.58	4,934.50
Other equity	19	3,250.00	3,250.00
Total equity	•7	130,025.79	136,769.20
		138,234,37	134,953.70
Liabilities			
Non-corrent liabilities			
Unsucial habitues			
Bostowings	20	57,770.29	
Lease liabilities .	21 A	25,072.07	60,551,35
. Provisions.	22-A	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	27,028.63
Deferred tax liabilities (net)	11 8	aparpidi	\$,608:89
Other non-current habilines	23 A	3,634.16	811 37
Total non-current liabilities		90,709.92	3,908.28
Proceedings of the Control of the Co			95,968.71
Current Habilities Financial habilities			
Lowe trainings	21 B	3,605.86	
Trade payables	-	3,000.00	3,668.13
wild mustanding dury of micro enterprises and small enterprises	24 A	3,012.44	4 844
total outstanding thus of eceditors other than micro outerprises and small euterprises	34 B	10,142.77	1,794.58
Officer imanesal liabilities	25	15,717.50	11,279.46
Other current liabilities	23 B	5,216.15	12,806,06
Provisions Transformer United States	22 D	3,771.58	4,325.45
Total current liabilities		40,466,30	1,892.55
Total equity and liabilities	•	269,410.59	35,766,23
		-0.1470.03	266,628.64

The accompanying summary of significant accounting policies and other explanatory information are an integeral part of these consolidated financial statements.

This is the consolidated balance sheet referred to in our report of even date.

For Walker Chandisk & Co LLP

Chartered Accountants

Fron's Registration No.: 0:1076N/N500013

Rajni Mandra Parroce

Membership No.: 058644

Place: New Dello Date: 17 September 2021 For and on behalf of the Board of Directors

Dr. Nuresh Trehan Chairman and Managing Director

IDIN:00012348}

Placer Gunigram Date: 17 September 2021

Sarijeev Kumar Group Chief Financial Officer

Place: Gurugeam Data: 17 September 2021 Chief Executive Officer

Place: Gurugeam Date: 17 September 2021

Rahul Adajar Company Secretary

Place: Guargram Date: 17 September 2021

	Notes	Por the year ended 31 March 2021	For the year ended 31 March 2020
		(f.in.lakhs)	(Lin laldıs)
Income			
Revenue from operations	26	144,674.32	150,042,20
Other meome	27	3,141.53	4,384.50
		147,815.85	154,426.70
Expenses			
Cost of materials consumed		A 25 No.	
Employee bonelits expense	28	34,855.73	32,482.74
Finance costs	29	46,633.55	53,878.05
	30	6,717.44	5,154.75
Depreciation and amortisation expense	3!	12,321.43	11,503.98
Impairment losses on financial assers	12	625.95	1,111.61
Other expenses	3.3	43,415.19	43,906.43
		144,569.29	148,037.56
Profit before tax and share of loss in joint yearure		3,246.56	6,389.14
Share of loss in cont venture	46	5,040.50	
Profit before tax	74,	2 244 54	(2.18)
Tax expenses		3,246.56	6,386.96
•	. 34		
Current tax - for the year		3,677.20	4,971.83
Current tax - eather years		72.97	
Deferred ax coda '		(3,384.34)	(2,217.76)
Profit after tax		2,880.73	3,632.89
Other comprehensive income			
tems that will not be reclassified to statement of profit and loss		<i>'</i>	
Re-measurement loss on defined benefit plans		(4.04)	(233.02)
Income rax relating to items that will not be reclassified statement of profit and loss		1.02	58.68
Other comprehensive income for the year	•	(3.02)	(174,34)
Lord comprehensive income for the year			
rous complemental mediate sof the year		2,877.71	3,458,55
Net profit attributable to:			
Owners of the Holding Company		2,886.73	3,632.89
Non-controlling interests	•	-	3,032.69
•		2,880.73	3,632.89
Other comprehensive income autibutable to:		2,000.73	3,032.89
Owners of the Holding Company		# Fe03	
Non-controlling interests		(3.02)	(174.34)
1101 Continues interests		(3.02)	(174.34)
l'otal comprehensive income attributable to:			(174,34)
Owners of the Holding Company		2,877.71	\$ 450 CE
Non-controlling interests		2,377.71	3,458.55
£2.		2,877.71	3,458.55
•			
Essnings per equity share	35	WINLAST	3,458.55
Easnings per equity share Basic (?)	35	5.15	3,438.55

The accompanying summary of significant accounting policies and other explanatory information are so integral part of these consolidated financial statements.

This is the consolidated statement of profit and loss referred to in our report of even date.

For Walker Chandiele & Co LLP

Characted Accountains

Firm's Registration No.: 001076N/N50000

Rajni@lundra

Paciner Membership No.: 058644

Pince: New Delhi Date: 17 September 2021 For and on behalf of the Board of Directors

Dr. Natorn Trehan Chairman and Managing Director

[DIN:00012148] Place: Gurugram

Place: Gurugram Date: 17 September 2021

Sanjeev Kumas Group Chief Financial Officer

Place: Gurugram

Date: 17 September 2021

Chief Executive Officer

Place: Gurugram

Date: 17 September 2021

Dank

Company Secretary
Place: Gurugean

Date: 17 September 2021

A CASH FLOWS PROM OPERATING ACTIVITIES	For the year ended 31 harch 2021	For the year coded 31 March 2020	
Profit before our and shore of loss in joint venture	(f ip faklis)	(t in lather)	
Adjustracqui for:	3,246.56	6,389.14	
Department of process, almit and equipment			
Digiteration of eight of use of angle	(9,581.8)	2,569.27	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
base absolute to antangable about	1,527.84	1,799,49	
Productions on sale of purposes, plant and equipments (acc)	208 70	135.22	
interest that the transfer and linearity states and linearity and linearity at an according to the	(66.30) {1,546.24]	9.63	
attracted informs are televisided in recolution in a	[227.64]	(1,964.49)	
Convergences general inclusive	(1,559.32)	(1,630.63)	
Recently in the value of investments	(-1,		
United foreign exchange - loss fairl	202.20	(2.18) 135 6 1	3
finisciple on house highlightes	3,107.76	1,396,80	
faterest on deserted payment haldrest and other boscowing conte	3,013.68	3,158.48	
Impairment lesies on (insectal assets	595.98	619.46	
Receivables under expent beseefe scheme winner off	625.95	1,111.61	
Arters written ou	674.43		
Limpinger there based payment expense	125.76	-	
Province for couplinger benefits free)	378.62	956.97	
Provided for contageness (not)	690.75	397.70	
Gain on descongulation of level habilities and right of use users	57.305	844.99	
Верт сопсехного from lesson	[B3.35]		
Operating grafit before working capital changes	[128 32]		
Name of the second seco	22,457,17	22,917.20	
Mountain marking explisi			
Content and non-content loans Inventones	(56.54)	(79.8E)	
Other cutters Gazacial assess	(124 02)	(1,522.04)	
Other current assets	(454.96)	(846.66)	
Feddy securialism	(105.97)	399.13	
Chiles mon-traisent agents	1.026.65	480.25	
Other stepene habilites and current financial habilities	36.55	(143,76)	
Other with content fastglings	1,969.50	586.53	
Triele psychics	1,265.21	966.73	
Cash flower from operations	21.17	<u>+28.04</u>	
Income-tax past (not or retinads)	25,816.76	23,124.51	
Net exclusions operating activities (A)	(1,639.67)	(5,617,61)	
	24,177.69	\$7,\$06.9d	
B CASH PLOWS PROM INVESTING ACTIVITIES			•
Practice of property plant and equipments, capital work-in-progress and intragible assets (including capital advances,	(14,57),89)		
colours are any as well are letter by student transferings	(14,113,50)	(18,626.73)	
Escaped strong disposed on progress, plant and equipments	379.61	45	
Movement in order trans between facti	(11,728.36)	53-11 10,3-44-51	
Marcount in teach separate larguig meaning period more than 12 months (net)	563.72	(2,224,67)	
	1,503-40	1,946 89	
Net cath used in increasing activities (B)	(23,915,24)	(6,706.79)	
C CASH FLOWS FROM FINANCING ACTIVITIES			
Parket di finni macci al repuig distre capital			
Proxects from ston-custom barrowings	34.08	21.22	
Replayment of inde-current borowings	•	11,230.00	
present buy ou possimalis	(302.39)	(1,632,42)	
Other Hugging Comp paid	(3,727.98)	(5,196.41)	
Inverses pant on lease habiture	(7.27)	(56.25)	
Payanter of lease hybridges	(2,303.02)	(2,449.18)	
Net cash used in financing activities (C)	(1,552.93)	(1,603.32)	•
	(6,073.30)	(65.36)	
(Decremolythic use in Custi and Costs equations (A+ B+C)			
Carle and each equivalents at the Ingertaine of the ceae	(7,516.45)	8,711.75	
Cash and each equivalents at the end of the year (refee aute below)	14.757.12	5,045.57	
	6.946.67	14,757.12	
Note: Accordination of coch and cash equivalents as per cash flow statement (refer note 16)		•	
Bulantines with history in extremy processing. Chapters are transf	0,374.22	4,619,79	
Cash on hand	5.13	4'012'10	
tents deposits with engage maratay loss than fluce months	193.47	162.42	
	373.85	2,973.54	
•	6,946.67	14,757.12	
		TOTAL PROPERTY AND ADDRESS OF	

The accumpanting areamony of agoinform accomming policies and other explanatory information are an integral part of these complicated florweist materials. This is the constituted cash three transform referred in in our tepon of even date.

For Walker Chandlok & Co LEP Chanced Accounting Finite Regardation No.: 000076N/NS00013

Roymi Rajai Mandra

Cancer Mendocatop No. 058644

Place: New Delin Date: (7 Squenther 202) Por and on bebeif of the Board of Directors

Dr. North Prelizo Chairman nod Managing Discour (DINEXXI2148)

Place: Guengron Base: 17 September 2021

Sanjrev Russiar Group Ovel Financial Otlicer

Place: Gungram Dace: 17 September 2021

ealth New Delhi Penkaj Sabai Chilef Bacquive Offices

Place: Guengeins Date: 37 September 2021

Rabut It pja Company Secretary

Place: Garagesen Date: 17 September 2021

*****	uity share capital*					(₹ in lakhs)	1
Pan	riculars	balance as at	Changes in equity share capital	Belance of at 31 Murch 2020	Changes in equity share capital during	Balance as at 31 Murch 2021	<u></u>
		- 1 ubin enix	during the year	~ 41	the year		J
tiqu	ny share capital	4,913.28	21.2 2	4,934.50	24.08	4,958.58	4

B Instruments entirely equity in nature** Particulars	Opening balance as at 1 April 2019	Changes during the year	Balance as at 31 March 2020	Changes during the year	(V in takha) Bolance as at 31 March 2021
Compulsorily convertible preference shares	3,250.00		3,250.00	· ·	3,250.00

Particulars			(₹ in lakha Total		
	Securities premium	Share options outstanding account	Retained carnings	Capital reserve	7.7111
Opening balance se at 1 April 2019	45,519,15	5,368.20	70,273.60	1,192.74	122,353,69
Profit for the year		-	3,632.89		3,632.89
Other comprehensive income	i				,,,032.0)
Re-measurement luss on defined benefit plans (net of tax)	-	•	(174.35)	•	(174.35
Employee share based payment expense	.	256.97			FF. 34
Stock options lapsed during the year	1				956.93
Issue of equity shares (on account of exercise of stock options)	1,481.72	(1,481.72)			•
Balance as at 31 March 2020	47,000.87	4,843,45	73,732,14	1,192.74	104 767 0
Profit for the year			2,860.73	2,22017	126,769.20
Other comprehensive income	ļ		2,4100.75	.	2,880.73
Re-measurement loss on defined benefit plans (not of tax)			(3.02)		(3.02
Employee share based payment expense		378.88			
Stock options lapsed during the year		(286.47)	288.47	-	378.88
Issue of equity shares (on account of exercise of stock options)	1,701.44	(1,701.44)		-	•
Balance as at 31 March 2021	48,702,31	3,232,42	76,898.32	1,192,74	130,025.79

The accompanying summary of significant accounting policies and other explanatory information are an integral past of these consolidated financial statements.

This is the consolidated statement of changes in equity referred to in our report of even date.

For Walker Chandiok & Co LLP

Chartered Accountants

Fign's Registration No.: 001076N/N500013

Rajni Mundra

Pactoer

Membership No.: 058644

Place: New Deffu

Date: 17 September 202)

For and on behalf of the Board of Directors

Dr. Naresh Trehan

Chairman and Manuging Director

[DIN:00012148]

Place: Gurugram

Date: 17 September 2021

Sanjeev Kumar

Group Chief Pinancial Officer

Place: Gurugram

Date: 17 September 2021

Chief Executive Officer

Place: Gurugram Date: 17 September 2021

Rahul Ranjan · Company Secretary

Рівосі Бигиргаев Date: 17 September 2021

[&]quot;Refer note 18B

[&]quot;"Refer note 19

I. Background

Global Health Private Limited ('GHPL') was incorporated on 13 August 2004 and is engaged in the business of providing healthcare services. Subsequent to the year-end, GHPL has been converted to a public company namely 'Global Health Limited' ('the Company') as mentioned in 'Certificate of Incorporation consequent upon conversion from private company to public company' dated 11 August 2021 as issued by the Ministry of Corporate Affairs ('MCA'). The Company is domiciled in India and its registered office is situated at E – 18, Defence Colony, New Delhi – 110024.

2. General information and statement of compliance with Ind AS

The consolidated financial statements include the financial statements of the Holding Company and its undermentioned subsidiaries (hereinafter referred to as the 'Group'):

(i) Medanta Holdings Private Limited, 100% subsidiary with effect from 20 March 2018.

(ii) Global Health Patliputra Private Limited, 100% subsidiary with effect from 11 August 2015.

Upto 31 March 2020, the consolidated financial statements also included the financial information of a Joint venture (refer note 46(b)).

The consolidated financial statements comply in all material aspects with Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified by Ministry of Corporate Affairs under Section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules 2015, as amended and other relevant provisions of the Act.

The consolidated financial statements for the year ended 31 March 2021 were authorized and approved for issue by the Board of Directors on 14 September 2021. The revision to consolidated financial statements is permitted by Board of Directors of the Holding Company after obtaining necessary approvals or at the instance of regulatory authorities as per provisions of the Act.

3. Basis of preparation

The consolidated financial statements have been prepared on going concern basis in accordance with accounting principles generally accepted in India. Further, the consolidated financial statements have been prepared on historical cost basis except for share based payments and certain financial assets and financial liabilities which are measured at fair value.

4. Recent accounting pronouncement

Amendments to Schedule III of the Act

On 24 March 2021, the Ministry of Corporate Affairs ("MCA") through a notification, amended Schedule III of the Act. The amendments revise Division I, II and III of Schedule III and are applicable from 1 April 2021. The revised Division II which relate to companies whose financial statements are required to comply with Companies (Indian Accounting Standards) Rules 2015, as amended, prescribes amendments for various additional disclosures. The Group is evaluating the requirements of these amendments and their impact on the consolidated financial statements.

Amendment to Ind AS 116, Leases

On 18 June 2021, Ministry of Corporate Affairs ('MCA') has issued an updated amendment to Ind AS 116 in respect of rent concessions occurring as a direct consequence of the Covid-19 pandemic. The effective date of these amendments is 1 April 2021. However, in case an entity (lessee) has not yet approved the financial statements before the issuance of this amendment, then the same may be applied for annual reporting periods beginning on or after 1 April 2020 as well. The Group is evaluating the requirements of these amendments and their invitate on the financial statements.

New Delhi

Amendments to Ind AS 107, Financial Instruments: Disclosures

New disclosures requirements are added in the standard to enable the users to understand the effect of interest rate benchmark reforms on entity's risk management strategy. The related amendments are also made in the other accounting standard as applicable. The Group is evaluating the requirements of these amendments and their impact on the financial statements.

Amendments to Ind AS 105, Non-current Assets Held for Sale and Discontinued Operations and Ind AS 16, Property, Plant and Equipment

There is change in definition of recoverable amount from 'fair value less costs to sell' to 'fair value less costs of disposal'. The Group is evaluating the requirements of these amendments and their impact on the financial statements.

5. Summary of significant accounting policies

The consolidated financial statements have been prepared using the significant accounting policies and measurement bases summarised below. These policies have been consistently applied to all the years presented, unless otherwise stated.

5.1 Principles of consolidation

Subsidiaries

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity. The Group has power over the investee even if it owns less than majority voting rights i.e. rights arising from other contractual arrangements. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases. Statement of profit and loss (including other comprehensive income (OCI)) of subsidiaries acquired or disposed of during the period are recognised from the effective date of acquisition, or up to the effective date of disposal, as applicable. All the consolidated subsidiaries have a consistent reporting date of 31 March 2021. The Group combines the financial statements of the Holding Company and its subsidiaries line by line adding together like items of assets, liabilities, equity, income and expenses. Inter group transactions, balances and unrealised gains on transactions between group companies are eliminated. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Non-controlling interests, presented as part of equity, represent the portion of a subsidiary's statement of profit and loss and net assets that is not held by the Group. Statement of profit and loss balance (including other comprehensive income ('OCI') is attributed to the equity holders of the Holding Company and to the non-controlling interests, basis the respective ownership interests and such balance is attributed even if this results in controlling interests having a deficit balance.

The Group treats transactions with non-controlling interests that do not result in a loss of control as transactions with equity owners of the Group. Such a change in ownership interest results in an adjustment between the carrying amounts of the controlling and non-controlling interests to reflect their relative interests in the subsidiary. Any difference between the amount of the adjustment to non-controlling interests and any consideration paid or received is recognized within equity.

Joint ventures

Investments in joint arrangements are classified as either Joint operations or Joint ventures. The classification depends on the contractual rights and obligations of each investor, rather than the legal structure of the Joint arrangement. The Group has classified its investment in joint arrangement as joint ventures.

Interest in joint venture is accounted for using the equity method, after initially being recognised at cost. The carrying amount of the investment is adjusted thereafter for the post acquisition change in the share of net assets of the investee or impairment, if any, adjusted where necessary to ensure consistency with the accounting policies



of the Group. The consolidated statement of profit and loss (including the other comprehensive income) includes the Group's share of the results of the operations of the investee. Dividends received or receivable from joint ventures are recognised as a reduction in the carrying amount of the investment.

5.2 Business combinations

The Group applies the acquisition method in accounting for business combinations. The consideration transferred by the Group to obtain control of a entity is calculated as the sum of the acquisition-date fair values of assets transferred and liabilities incurred. Acquisition costs are expensed as incurred.

Identifiable assets acquired and liabilities and contingent liabilities assumed in a business combination are measured initially at their acquisition-date fair values. Goodwill is measured as excess of the aggregate of the fair value of the consideration transferred, the amount recognized for non-controlling interests and fair value of any previous interest held, over the fair value of the net of identifiable assets acquired and liabilities assumed. If the fair value of the net of identifiable assets acquired and liabilities assumed is in excess of the aggregate mentioned above, the resulting gain on bargain purchase is recognized in other comprehensive income and accumulated in equity as capital reserve. However, if there is no clear evidence of bargain purchase, the entity recognizes the gain directly in equity as capital reserve, without routing the same through other comprehensive income.

5.3 Current versus non-current classification

All assets and liabilities have been classified as current or non-current as per the operating cycle and other criteria set out in Division II of Schedule III of the Act. Based on the nature of the operations and the time between the acquisition of assets for processing/servicing and their realisation in cash or cash equivalents, the Group has ascertained its operating cycle as twelve months for the purpose of current/non-current classification of assets and liabilities.

5.4 Property, plant and equipment

Recognition and initial measurement

Property, plant and equipment are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discount and rebates are deducted in arriving at the purchase price. Property, plant and equipment purchased on deferred payment basis are recorded at equivalent cash price. The difference between the cash price equivalent and the total payment is recognised as interest expense over the period until payment is made.

Subsequent costs and disposal

Subsequent costs are included in the asser's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repair and maintenance costs are recognised in statement of profit and loss as incurred.

Items such as space parts, stand-by equipment and servicing equipment are recognised as property, plant and equipment when they meet the definition of property, plant and equipment. Otherwise, such items are classified as inventory.

An item of property, plant and equipment initially recognised is de-recognised upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognised in statement of profit and loss when the asset is derecognised.

Capital work-in-progress includes property, plant and equipment under construction and not ready for intended use as on the balance sheet date.

Subsequent measurement (depreciation and useful lives)

Freehold land is carried at historical cost. All other items of property, plant and equipment are subsequently measured at cost less accumulated depreciation and impairment losses. Depreciation on property, plant and



equipment is provided on a straight-line basis, computed on the basis of useful lives (as set out below) prescribed in Schedule II to the Act.

Asset class	Useful life
Building	30 years
Medical equipments	5 to 15 years
Medical and surgical instruments	3 years
Other plant and equipment	15 years
Furniture and fixtures	10 years
IT equipment	3 to 6 years
Office equipment	5 years
Electrical installation	10 years
Vehicles	6 to 8 years

Leasehold improvements are amortised over the lower of useful life and the lease term.

The residual values, useful lives and method of depreciation of are reviewed at the end of each financial year.

5.5 Intangible assets

Recognition and initial measurement

Intangible assets (software) are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attribumble cost of bringing the asset to its working condition for the intended use.

Subsequent measurement

The cost of capitalized software is amortized over a period of five years from the date of its acquisition.

De-revogmnon

Intangible asset is de-recognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognized in the statement of profit and loss, when the asset is derecognised.

5.6 Inventories

Inventories are valued at cost or net realisable value, whichever is lower. Cost is calculated on weighted average basis. Cost of these inventories comprises of all cost of purchase, taxes (except where credit is allowed) and other costs incurred in bringing the inventories to their present location and condition. Cost of purchased inventory is determined after deducting rebates and discounts.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

5.7 Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized upon transfer of control of promised products or services to customers/patients in an amount that reflects the consideration the Group expects to receive in exchange for those products or services. Revenue is measured net of rebates, discounts and taxes. The Group applies the revenue recognition criteria to each component of the revenue transaction as set out below.

Income from bealthcare services

Revenue from healthcare services is recognized as and when related services are rendered and include services for patients undergoing treatment and pending for discharge, which is shown as unbilled revenue under other current



financial assets. The Group considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Group expects to be entitled in exchange for the services, excluding amounts collected on behalf of third parties (for example, indirect taxes).

A receivable is recognised by the Group when the control is transferred as this is the case of point in time recognition where consideration is unconditional because only the passage of time is required. When either party to a contract has performed, an entity shall present the contract in the balance sheet as a contract asset or a contract liability, depending on the relationship between the entity's performance and the payment.

Income from out-patient pharmacy

Revenue from pharmacy products is recognized as and when the control of products is transferred to the customer. The Group considers its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Group expects to be entitled in exchange for the products, excluding amounts collected on behalf of third parties (for example, indirect taxes).

Clinical research

Clinical research income is recognized over time basis percentage completion method which is determined based on achievement of milestones.

Interest income

Interest income is recorded on accrual basis using the effective interest rate (EIR) method.

Sponsorship income

Sponsorship income is recognised in the accounting year in which the services are rendered as per the agreed terms with the customers.

Other income

Revenue arising from revenue sharing agreements is recognized as per the terms of the arrangement.

Rental income is recognised on a straight-line basis over the lease term, except for contingent rental income which is recognised when it arises.

5.8 Borrowing cost

Borrowing cost includes interest expense as per effective interest rate (EIR). Borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset are capitalized during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for its intended use or sale. All other borrowing costs are expensed in the period they occur.

5.9 Leases

Group as a lessee - Right of use assets and lease liabilities

A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'.

Classification of leases

The Group enters into leasing arrangements for various assets. The assessment of the lease is based on several factors, including, but not limited to, transfer of ownership of leased asset at end of lease term, lessee's option to extend/purchase etc.

Recognition and initial measurement of right of use assets

At lease commencement date, the Group recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Group, an estimate of any costs to dismantle and remove the asset at the end of

the lease (if any), and any lease payments made in advance of the lease commencement date (net of any incentives received).

Subsequent measurement of right of use assets

The Group depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Group also assesses the right-of-use asset for impairment when such indicators exist.

Lease liabilities

At lease commencement date, the Group measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Group's incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed payments) and variable payments based on an index or rate. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is re-measured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is re-measured, the corresponding adjustment is reflected in the right-of-use asset.

The Group has elected to account for short-term leases using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these short-term leases are recognised as an expense in statement of profit and loss on a straight-line basis over the lease term.

Further, the Group has also elected to apply another practical expedient whereby it has assessed all the rent concessions occurring as a direct consequence of the COVID-19 pandemic, basis the following conditions prescribed under the standard:

- a) the change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change;
- b) any reduction in lease payments affects only payments originally due on or before the 30 June 2021; and
- c) there is no substantive change to other terms and conditions of the lease.

If all the rent concessions meet the above conditions, then, the related rent concession has been recognised in statement of profit and loss.

Group as a lessor

Leases in which the Group does not transfer substantially all the risks and rewards of ownership of an asset are classified as operating leases. The respective leased assets are included in the balance sheet based on their nature. Rental income is recognized on straight-line basis over the lease-term.

5.10 Impairment of non-financial assets

Assessment is done at each balance sheet date as to whether there is any indication that an asset may be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Assets whose carrying value exceeds their recoverable amount are written down to the recoverable amount. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each balance sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased.

5.11 Foreign currency

Functional and presentation currency

The consolidated financial statements have been prepared and presented in Indian Rupees (INR), which is the Holding Company's functional and presentation currency.



Transactions and balances

Foreign currency transactions are recorded in the functional currency, by applying to the exchange rate between the functional currency and the foreign currency at the date of the transaction.

Foreign currency monetary items outstanding at the balance sheet date are converted to functional currency using the closing rate. Non-monetary items denominated in a foreign currency which are carried at historical cost are reported using the exchange rate at the date of the transaction.

Exchange differences arising on monetary items on settlement, or restatement as at reporting date, at rates different from those at which they were initially recorded, are recognized in the statement of profit and loss in the year in which they arise.

5.12 Financial instruments

Recognition and initial measurement

Financial assets and financial liabilities are recognised when the Group becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted for transaction costs, except for those carried at fair value through profit or loss which are measured initially at fair value.

The classification depends on the Group's business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in the statement of profit and loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI).

Non-derivative financial assets

Subsequent measurement

Financial assets carried at amortised cost - A 'financial asset' is measured at the amortised cost if both the following conditions are met:

- The asser is held within a business model whose objective is to hold assets for collecting contractual cash flows;
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective interest rate (EIR) method.

Investments in equity instruments of others - These are measured at fair value through other comprehensive income.

De-recognition of financial assets

A financial asset is de-recognised when the contractual rights to receive cash flows from the asset have expired or the Group has transferred its rights to receive cash flows from the asset.

Non-derivative financial liabilities

Subsequent measurement

Subsequent to initial recognition, all non-derivative financial liabilities are measured at amortised cost using the effective interest method.

De-recognition of financial liabilities



A financial liability is de-recognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Group or the counterparty.

5.13 Impairment of financial assets

The Group assesses on a forward looking basis the expected credit losses associated with its financial assets and the impairment methodology depends on whether there has been a significant increase in credit risk.

Trade receivables

In respect of trade receivables, the Group applies the simplified approach of Ind AS 109, which requires measurement of loss allowance at an amount equal to lifetime expected credit losses. Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument.

Other financial assets

In respect of its other financial assets, the Group assesses if the credit risk on those financial assets has increased significantly since initial recognition. If the credit risk has not increased significantly since initial recognition, the Group measures the loss allowance at an amount equal to 12-month expected credit losses, else at an amount equal to the lifetime expected credit losses.

When making this assessment, the Group uses the change in the risk of a default occurring over the expected life of the financial asset. To make that assessment, the Group compares the risk of a default occurring on the financial asset as at the balance sheet date with the risk of a default occurring on the financial asset as at the date of initial recognition and considers reasonable and supportable information, that is available without undue cost or effort, that is indicative of significant increases in credit risk since initial recognition. The Group assumes that the credit risk on a financial asset has not increased significantly since initial recognition if the financial asset is determined to have low credit risk at the balance sheet date.

5.14 Taxes

Tax expense comprises current and deferred tax. Current and deferred tax is recognised in statement of profit and loss except to the extent that it relates to items recognised directly in equity or other comprehensive income.

The current income-tax charge is calculated on the basis of the tax laws enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax is provided in full, on temporary differences arising between the tax base of assets and liabilities and their carrying amounts in the consolidated financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred tax asset is realised or the deferred tax liability is settled. Deferred tax assets are recognised for all deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. Deferred tax assets and



liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same raxation authority.

5.15 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits with the banks, other short-term highly liquid investments with original maturity of three months and less.

5.16 Employee benefits

Short-term employee bonefits

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are classified as short-term employee benefits. These benefits include salaries and wages, short-term bonus, incentives etc. These are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

Defined contribution plan

Contribution towards provident fund is made to the regulatory authorities, where the Group has no further obligations. Such benefits are classified as defined contribution plan as the Group does not carry any further obligations, apart from the contributions made on a monthly basis. In addition, contributions are made to employees' state insurance schemes and labour welfare fund, which are also defined contribution plans recognized and administered by the Government of India and Haryana respectively. The Group's contributions to these schemes are expensed in the statement of profit and loss.

Defined benefit plan

The Group has unfunded gravity as defined benefit plan where the amount that an employee will receive on retirement is defined by reference to the employee's length of service and final salary. The gravity plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment. The Group's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. This is based on standard rates of inflation, salary growth rate and mortality.

Discount factors are determined close to each year-end by reference to market yields on government bonds that have terms to maturity approximating the terms of the related liability. Service cost and net interest expense on the Group's defined benefit plan is included in employee benefits expense.

Actuarial gains/losses resulting from re-measurements of the defined benefit obligation are included in other comprehensive income.

Other long-term employee benefits

The Group also provides benefit of compensated absences to its employees which are in the nature of long-term employee benefit plan. Liability in respect of compensated absences becoming due and expected to be availed more than one year after the balance sheet date is estimated on the basis of an actuarial valuation performed by an independent actuary using the projected unit credit method as on the reporting date. Service cost and net interest expense on the Group's other long-term employee benefits plan is included in employee benefits expense. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are recorded in the statement of profit and loss in the year in which such gains or losses arise.

5.17 Government grants.

Grants from the government are recognised at their fair value when there is reasonable assurance that the grant will be received and the Group will comply with all attached conditions. When the grant relates to a revenue item, it is recognized in statement of profit and loss on a systematic basis over the periods in which the related costs are expensed. The grant can either be presented separately or can deduct from related reported expense. Government grant relating to capital assets are recognised initially as deferred income and are credited to statement of profit and



loss on a straight line basis over the expected lives of the related asset and presented within other operating income. This accounting policy is to be read with note 44.

5.18 Share based payment expense

The fair value of options granted under Global Health Employee Stock Option Scheme 2014 and 2016 is recognized as an employee benefit expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:

- Including any market performance conditions (e.g., the entity's share price)
- Excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales
 growth targets and remaining an employee of the entity over a specified time period), and
- Including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holding shares for a specified period of time).

Total expense is recognized over the vesting period, which is the period over which all the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to be vest based on the non-market vesting and service conditions. It recognizes the impact of revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.

5.19 Provisious, contingent liabilities and contingent assets

Provisions are recognized when the Group has a present (legal or constructive) obligation as a result of past events, for which it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate of the amount can be made. Provisions required to settle are reviewed regularly and are adjusted where necessary to reflect the current best estimates of the obligation. Provisions are discounted to their present values, where the time value of money is material.

Contingent liability is disclosed unless the likelihood of an outflow of resources is remote and there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources.

Contingent assets are disclosed only when inflow of economic benefits therefrom is probable and recognized only when realization of income is virtually certain.

5.20 Earnings per share

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events including a bonus issue or share split.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

5.21 Rounding of amounts

All amounts disclosed in the consolidated financial statements and notes have been rounded off to the nearest lakhs as per the requirement of Division II of Schedule III, unless otherwise stated.

5.22 Critical estimates and judgements

The preparation of consolidated financial statements requires the use of accounting estimates which, by definition, will seldom equal the actual results. Management also needs to exercise judgement in applying the Group's accounting policies. This note provides an overview of the areas that involved a higher degree of judgement or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning



Global Health Limited (formerly known as Global Health Private Limited)
Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

out to be different than those originally assessed. Detailed information about each of these estimates and judgements is included in relevant notes together with information about the basis of calculation for each affected line trem in the consolidated financial statements.

- a) Recognition of deferred tax assets The extent to which deferred tax assets can be recognized is based on an assessment of the probability of the future taxable income (supported by reliable evidence) against which the deferred tax assets can be utilized.
- b) Evaluation of indicators for impairment of assets The evaluation of applicability of indicators of impairment of assets requires assessment of several external and internal factors which could result in deterioration of recoverable amount of the assets.
- c) Contingent liabilities At each balance sheer date basis the management judgment, changes in facts and legal aspects, the Group assesses the requirement of provisions against the outstanding contingent liabilities. However, the actual future outcome may be different from this judgement.
- d) Impairment of financial assets At each balance sheet date, based on historical default rates observed over expected life, existing market conditions as well as forward looking estimates, the management assesses the expected credit losses on outstanding receivables. Further, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with industry and country in which the customer operates.
- e) Defined benefit obligation (DBO) Management's estimate of the DBO is based on a number of underlying assumptions such as standard rates of inflation, mortality, discount rate and anticipation of future salary increases. Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.
- f) Useful lives of depreciable/amortisable assets Management reviews its estimate of the useful lives of depreciable/amortisable assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical and economic obsolescence that may change the utilisation of assets.
- g) Leases The Group evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgment. The Group uses significant judgment in assessing the lease term (including anticipated renewals) and the applicable discount rate. The Group determines the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the Group is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Group is reasonably certain not to exercise that option. In assessing whether the Group is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Group to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The Group revises the lease term if there is a change in the non-cancellable period of a lease.
- h) Government grant Grants receivables are based on estimates for utilization of the grant as per the regulations as well as analysing actual outcomes on a regular basis and compliance with stipulated conditions. Changes in estimates or non-compliance of stipulated conditions could lead to significant changes in grant income and are accounted for prospectively over the balance life of the asset.
- i) Fair value measurements Management applies valuation techniques to determine fair value of equity shares (where active market quotes are not available) and stock options. This involves developing estimates and assumptions around volatility, dividend yield which may affect the value of equity shares or stock options.

Estimates and judgements are continuously evaluated. They are based on historical experience and other factors including expectation of future events that may have a financial impact on the Group and that are believed to be reasonable under the circumstances.



Consolidated summary of ingnificant accounting politices and other explanatory information for the year ended 31 March 2023 Global Health Limited (formedy known as Global Health Private Limited)

64 Property, plant and equipment and expiral work-in-propress

Property, plant and equipment and expited work-in-propress	decipies leaders b	rogress												1000
Particulars						Owned assets						Leasted assets	10.50	Caning and
	Freshold fand	gnistin I	Medical equipment#	Medical and surgical	Other plant and equipment	1_	II equipment	Office equipment#	Electrical insculation	Lessthold	Vehicles	Leasehold land	· · · ·	in-progress
Grass block								:						
Balance as at 1 April 2019	22,427.01	31,387,63	39,582.40	1,467.26	12,604.51	2,452.75	1,643.96	385.53	3,085,46	2,532,20	459.19	17.622.00	135,640 96	64 605 53
Additions		31,022,03	12,480.13	571.53	\$,163,66	(HC.33	1,502.00	123.06	3,721.85	67.55	135.03		100 15	1
Osquesals/adjastments			(9.44)	٠	(0.23)	(6.50)		(1,38)			0260		168 22	
Transfer to right of use meet		,	•	٠								\$17,622.000	000	
Rabnee as at M March 2020	22,427.01	62,409.66	52,053,13	2,038.79	12,767.92	3,098.73	3,546.05	507.21	6,807.31	2,590.69	512.67		175.754.17	38,572.93
Ackhires		1,252.48	1,928,76	139,50	316.16	12,083	328.56	38.06	258.36	639	157.95	,	1 500 1	L
Disposats/adjustments	,	,	(425.65)	(8.14)	(22.19)	(22.34)	(40,78)	(16.09)		(20225)	66.150		(A)	
Balance 25 21 31 March 2021	22,427,01	63,661.14	53,5\$6.24	2,470.64	\$8,061.89	3,256.26	3,817.83	527.18	7,065.09	2,395.40	518.71		177,855.99	46.381.77
														L
Accumulated depreciation													~	
Batance as at 1 April 2019	-	5,048.16	14,023.06	1,214.79	4.585.41	1,713.08	1,226.54	272.24	2,507.06	1,505.10	6243	6577.9	32,734,76	·
Charge for the year		1,716.50	1,304.82	219.00	1,355.32	52,237	341.00	63,59	552.81	603.57	25.33		936127	
Deposabladjasimonis		•	(5.13)		(1) (1) (1) (1) (1) (1) (1) (1) (1) (1)	(821)	٠	(CT)			(14.60)	,	27	
Transfer to right of use assets.		,	,	•	1					•	÷	(626.83)	8	,
Batanee as at 31 March 2020	-	6,754,56	15,324.77	1,434.39	5,940.68	2,058,39	1,507.54	334.54	3,059,87	2,108.67	112.17		41,705.68	
Charge for the year		2,343,86	4,871.96	3008	£,588.30	174.07	55%53	59,51	413.81	191,28	75.66	•	10,584.83	
Disposable/adjustments		,	(171.54)	(4.8.4)	(10.05)	(9.71)	(121)	(15.22)		(26.23)	(42.63)		(380,02	•
Balance as at 31 March 2621	,	9,108.52	23,024.69	1,737.40	7,518,93	2,222,75	2,076.76	378.B3	3,473.68	2,22,73	195.00		51,910.49	ļ .
Net block as at 31 March 2020	22,427.08	55,645.00	33,728.36	604.40	11,827.34	1,040.34	15-31-6-31	172.63	3,747.44	452.02	400.50	,	132,053,49	38,172.91
Net block as at 31 March 2021	22,427.01	54,552.62	30,531,35	733.25	10,542%	15.660.1	1,741.07	150.35	3,592.01	171.67	#1.00p		175,949,50	46,381,77

Dure so thangs in secounting policy, previous year numbers have been received. For details, refer note \$4,

During the year ended \$1 March 2021 and \$1 March 2021, following expenses has been expended as part of expension oracless progress.

On the best

		112 14 15 14
Paeticulars	31 March 2021	31 March 2020
Borrowing costs	2524.34	21,823,5
Employee benefits expense	84.78	762.66
Other expenses	261.86	52.00
Depreciation empense	251.40	
Total	3,127.34	4,991.67

(i) Convacual abligations (contractual commentments for the acquisition of property, plant and equipment. Refer note 40lb for disclosure of contractual commentments for the acquisition of property, plant and equipment.

(ii) Property, plant and equipment photograd as accounty in one of the labding Company, all manable property, plant and equipment have been piedigied as accurity against the bostowing figurities. In one of the subsidiary companies, exclusive/pus passe of property, plant and equipment for bostowing facilities. Refet right 20(4)(3) and 24(4)(3) for denith.



(This spain has here intermently tell black)

Global Health Limited (formerly known as Global Health Private Limited)

Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Right of use assets					(26.1
Particulars .	Building	Other plant and	Vehicle lease	Lessehold land#	(₹ in laklis Total
Gross block		- d h		ащот	******
Balance as at 1 April 2019 - recognised on transition to lad AS 116	9,871.68	127,59	138.34	7,429.73	43.543.5
Balance as at 1 April 2019 - transferred from property, plant and equipment*	.,		130.34	, [17,567.34
Additions	4,623,29	22.61	•	16,995.11	16,995.11
Balance as at 31 March 2020	14,494.97	, 150.20	170.31	71.46.14.1	4,645.90
Additions	. *********	, , , , , , , , , , , , , , , , , , , ,	138,34	24,424.84	39,208.35
Disposals/adjustments#	(937.66)	• ,	(79.42)	-	(1,017.08
Balance as at 31 March 2021	13,557.31	150.20	58.92	24,424.84	38,191.27
Accumulated depreciation	•	·	, -		
Balance as at 1 April 2019	_			i	
Charge for the year	1,258.20	7,71	7C Cu		•
Balance as at 31 March 2020	1,258.20	7,71	75.58	458.00	1,799.49
Charge for the year\$	1,263.71	9.85	75.58	458.00	1,799.49
Disposals/adjustments	•	7.85	50.68	458.00	1,782.24
Balance as at 31 March 2021	(204.09)		(79.42)		(283.51
And the second s	2,317.82	17.56	46.84	916.00	3,298.22
Net block as at 31 March 2020	13,236.77	142,49	62.76	23,966.84	37,408.86
Net block as at 31 March 2021	11,239,49	132.64	12.08	23,508.84	34,893.05

^{*} The March 2019, leasehold land and related liabilities were recognised as 'finance leases' under Ind AS 17 'Leases'. Leasehold land was presented as part of property, plant and equipment and the liabilities as deferred payment liabilities as part of the Group's borrowings. However, under Ind AS 116, these have been transferred to right of use assets and lease liabilities.

(This space has been insentionally left blank)

[#] Change of $\stackrel{<}{\cdot}$ 45.12 lakhs on account of lease modifications during the year.

S During the year ended 31 March 2021 depreciation of ₹ 254.40 lakin has been capitalised as part of capital work-in-progress.

Global Health Limited (formerly known as Global Flealth Private Limited) Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Intangible assets	(₹ in lakhs)
	Software
Balance as at 01 April 2019	275.82
Additions	846.36
Balance as at 31 March 2020	1,122.18
Additions	85.14
Balance as at 31 March 2021	1,207.32
Accumulated amortisation	
Balance as at 01 April 2019	138.82
Charge for the year	135.22
Balance as at 31 March 2020	274.04
Charge for the year	208.76
Balance as at 31 March 2021	482.80
Net block as at 31 March 2020	848.14
Net block as at 31 March 2021	724.52



(This space has been intentionally left blank).

Consolidated summary of significant accounting policies and other explanatory information for the year ended 34 March 2021

Man. 6	As at 31 March 2031 (F in laking)	As at 31 Adarch 2028 (8 in labble)
Note - 8 A-Investments accounted for using the equity method		(11111)
Joint venture an anguoted		
Mediana Dake Research Institute Private Limnedte	·	
[Nil equity shares (3) March 2020; 10,000 capity shares) of ₹ 10 each}		+79.25
Less : Impairment in the value of investments - joint venture	•	479.25
		(479.25)
Aggregate book value of unquoted investments		
Aggregate amount of impairment in value of investments		•
WThe Board of Directors (the Board) of Medana Duke Research Institute Private Limited (a joint venture) in its ence the aforementioned entity and subsequently, they have indicated the process of voluntary liquidation of the said entity in read with Insolvency and Bankupics (Voluntary Liquidation Process) Regulations, 2017. This has also been affirmed Research Institute Private Limited held on 24 September 2019. During the year, on 25 February 2021, the official liquidation National Company Law Tribonal (NGLT). However, the final order from the NCLT is awaited.	accordance with the provisions of the Insolvency	and Bankrupter Code, 2016
B Investment in equity instruments		
Others - unquoted 5		
(Measured at fair value through other comprehensive income) Swash Digital Health Foundation		
5,000 copiny shares (3) March 2020; Mil) of \$ 100 cach	5.00	•
, , , , , , , , , , , , , , , , , , ,		
	5.00	
Aggregate back value of unquosed investments	5.60	
Aggregate acrount of impairment in value of investments		-
S Aleasured at fair value through other comprehensive income. The underlying objective of this investment is not to earn	,	•
Note - 9 A Lyans - non currents (Unsecured considered good) Seconty deposits	a Jacoma and Bened, this obes not early any piece list	
,	\$17.73	789.81
	817.73	789.81
B Loans - current*		
(Unsecuted considered good)		The second secon
Security deposits	38,41	6.70
	WA!	9.79
"The Group does not have any loads which are either could impaired or where there is significant increase in credit risk.		5/13
Note - 10		
A Other financial assets - non-current		
(Unsecured considered good)	•	
Bank deposits with musicity of more than 12 months (refer note below)		
The state of the s	- 1,880.58	2,384.30
Notes:	1,880.58	2,364,30
 (i) Bank deposits (excluding interest accound) of ₹ 128.40 lakhs (31 March 2020; ₹ 48.30 lakhs) have been lien marked as a see (ii) Bank deposits (excluding interest accound) of ₹ 653.14 lakhs (31 March 2020; ₹ 652.45 lakhs) are kept under lien with ban government authorities and letter of credit issued by respective banks. 8 Other financial assess - current (Unsecured considered good, unless otherwise stated) 1 Recoverable from related parties (refer note 38) 	ik as mazgio munuy against the brok guazzoteus issoi	
Unbilled revenue	262.52	249.84
Receivables under export benefit schemen	1,417,50	618.41
Other secentibles*	934.01	1,834.13
Considered good	523.27	717.37
Considered doubtful	232,39	
Less: Allowance for expected credit ioss		136.60
	3,139,30	(136.60)
5 Other recentables are primarily on account of revenue sharing atrangements.	95134.20	3,409.74
Movement of receivables under export benefit scheme		
Opening balance	1,824.12	702.38
Add: grants incorred during the year	934.01	1,149.48
Lass r grants with/transferred during the year	(1,149.69)	1,143/119
Less grants expered/winten during the year	(674.43)	'
Less unlisted for purchase of property, plant and equipment/consumables	•	(27.84)
	934.01 20	3117
	(%)	whole 3
	(S(Ne	w Delhi)

Note 1.2467 1.2		As at 31 March 2021 (#.in.lakhe)	As at 31 Murch 2020
1,7240 1	Non-13	(S. D. ISERLY)	(Z-tn/tekhs)
April Apri	A Other non-current usuest	•	
Propose (groupes 1346 1356 13	Capital advances	1 224.02	
Propriet cerebrables 1,280,25	Advances other than expiral advances:	1,220,01	447.12
B Other current selests 1,585.25 515.52 Pregulal expenses. 617.98 426.74 Advance or unatural/service providers 104.55 212.37 Advance or unatural/service providers 9.41 196.64 Bissers with government authorities 9.41 196.67 Note - 14 1.00 15.18 Invasion Servit 30.03.33 3,214.40 Plannacy, modified and lighoratory consumables related to mepatient services 3,083.33 3,214.40 Plannacy, modified and lighoratory consumables related to mepatient services 378.07 227.30 Plannacy and modified consumables related to make a fighter stage products to one patients 344.32 378.70 227.30 ** valued at cost or not established value, whichever is lower. 378.07 227.30 388.30 ** Fortile receivablishes 15.280.15 16.455.46 16.455.46 16.455.46 Trade receivablishes 15.280.15 16.455.46 16.455.46 16.455.46 16.455.46 16.455.46 16.455.46 16.455.46 16.455.46 16.455.46 16.455.46 16.455.46 16.455.46 <td< td=""><td>Prepaid expanses</td><td>*41/</td><td></td></td<>	Prepaid expanses	*41/	
Proper of propers 1728 426.74 1726.75			
Proposed agreement 17.00	B. Other current assets	1,600,60	515.82
Advance to anabount/scoree previolers		1 4505	
2009 2009	·	·	
Parameter and proteins and proteins 15,48	·	•	
Note - 14 Investoring ### Inve			19.64
Note - 14		*	
Investorates File Plantmen, medical and fisheratory consumables related to in-patient services 3,03,33 3,614.00 Plantmen, medical consumables related to sale of pharmacy products to out patients 504.52 378.07 277.30 3,705.02 3,851.70		768.12	660.75
Investorates File Plantmen, medical and fisheratory consumables related to in-patient services 3,03,33 3,614.00 Plantmen, medical consumables related to sale of pharmacy products to out patients 504.52 378.07 277.30 3,705.02 3,851.70	Now . 14		
Plantmacy; medical and ighomatory consumables related to mispatient services 1,093,33 3,614,100 Pharmacy and medical consumables related as sake of pharmacy products to out-patients 304,82 327,300 338,070 327,300 338,070 327,300 338,070 327,300 338,070 327,300 338,070 327,300 338,070 327,300 338,070 327,300 338,070 338,0			
Passangery nod madical consensables related to sale of pharmacy products to out patients 304.52 378.07 277.30 277.30			
Ceneral stores			3,614.40
* valued at cost or not realisable value, whichever is lower. # First pain passu charge on inventories, both present and future. **Note - 15 **Trade receivables** Trade receivables - considered good, unsecured# 15,289.15 16,455.48 17.00 technology (1,950.41 19,565.48 19,105.41 19,565.48 19,105.41 19,565.48 19,105.48 19,1	Consert stores		. •
* valued at cors or not realisable value, whichever is lower. **Note - 15 **Note - 15 **Trade receivables** **Trade receivables** **Trade receivables** **Trade receivables** **Trade receivables**- considered good, unsecured#* **Trade receivables*- considered good, unsecured** **Trade receivables*- considered good, unsecured** **Trade receivables*- considered good, unsecured** **Trade receivables*- eredic impaired** **Trade receivables*- eredic impaired** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables, both present and future** **First pair passu charge on trade receivables from related parties (teler note 18). **Note - 16 **Cash and cash equivalents **Balances with original materity less than three months **Af17.26	Change of States	· · · · · · · · · · · · · · · · · · ·	·
### Pirst pan in passu charge on interesting, both present and future. Note - 15	Furthered as a most and another the control of the	3,975.92	3,851.90
Note - 15 Trade receivables = 15,280,15 16,465,48 16,465			
Trade receivables № 15,289.15 16,465.48 Trade receivables - considered good, unsecured# 4,671.26 4,571.03 Least Afflowance for expected credit loss 19,660.41 20,825.51 Trade receivables - considered good, unsecured (1,925.32) (3,550.39) Trade receivables - credit impaired (1,925.32) (4,571.26) (4,571.26) Trade receivables - credit impaired 13,362.83 84,915.69 * First pan passes charge on trade receivables, both present and future 13,362.83 84,915.69 # instrador, includes ₹ 296.81 labbis (31 March 2020 ₹ 273.55 labbis) receivables from related parties (refer note 38). 84,915.69 84,915.69 Note - 16 Cash and cash equivalents 6,374.22 4,619.79 84,915.69 Cash and cash equivalents 5,15 1,137 1,619.75 1,619.75 Cash on band 5,15 1,937 162.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75	o the par passi charge on mechanics, both present and luthre.		
Trade receivables № 15,289.15 16,465.48 Trade receivables - considered good, unsecured# 4,671.26 4,571.03 Least Afflowance for expected credit loss 19,660.41 20,825.51 Trade receivables - considered good, unsecured (1,925.32) (3,550.39) Trade receivables - credit impaired (1,925.32) (4,571.26) (4,571.26) Trade receivables - credit impaired 13,362.83 84,915.69 * First pan passes charge on trade receivables, both present and future 13,362.83 84,915.69 # instrador, includes ₹ 296.81 labbis (31 March 2020 ₹ 273.55 labbis) receivables from related parties (refer note 38). 84,915.69 84,915.69 Note - 16 Cash and cash equivalents 6,374.22 4,619.79 84,915.69 Cash and cash equivalents 5,15 1,137 1,619.75 1,619.75 Cash on band 5,15 1,937 162.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75 1,62.42 1,619.75	Nois-15		
Tende receivables - considered good, unsecured# 15,289.15 16,465.46 Tende receivables - crecks impriced 4,671.26 4,511.03 Less: Allowance for expected credit loss 19,960.41 20,982.51 Tende receivables - considered good, unsecured (1,926.32) (2,553.39) Tende receivables - considered good, unsecured (4,671.26) (4,571.03) Tende receivables - considered good, unsecured (4,671.26) (4,571.03) Tende receivables - considered good, unsecured (4,671.26) (4,571.03) Tende receivables - considered good, unsecured (3,362.83) \$4,915.69 * First part passes charge on land terecivables, both present and future 13,362.83 \$4,915.69 Note - 16 Cash and cash equivalents 5.15 1,37 Charges on load 5.13 1,37 1,642.42 Bank deposits with original maturity less than three months 373.85 9,973.54 Note - 17 Other bank butances 5.06,946.67 14,757.12 Note - 17 Other bank butances 21,983.47 10,255.17 Bank deposits with maturity of more than three months and upto twelve months (refer notes below			
Trade receivables - credit impaired 4,671.26 4,517.05 1,960.41 20,982.51			
1. 1. 1. 1. 1. 1. 1. 1.		•	16,465.46
Prade receivables - considered good, unsetured (1,926.52) (3,503.9) Trade receivables - credit impaired (4,671.26) (4,511.03) First part passus charge on trade receivables, both present and future (1,502.83) (4,671.26) First part passus charge on trade receivables, both present and future (1,502.83) (4,671.26) First part passus charge on trade receivables, both present and future (1,502.83) (4,671.26) First part passus charge on trade receivables, both present and future Individue, includes \(\) 296.81 labbs (31 March 2020; \(\) 273.35 labbs) receivables from related parties (select note 38). Note - 16	Code receivables - cream imparted		4,517.05
Trade receivables - considered good, unsetured (1,926.52) (3,503.9) Trade receivables - credit impaired (4,671.26) (4,517.03) * First pair passes charge on trade receivables, both present and future 13,362.83 \$4,915.60 # Initiriates, includes \$2,96.81 lakins (31 March 2000; \$2.75.35 lakins) receivables from related parties (refer note \$8). \$4,619.75 Note - 16 \$4,619.75 \$4,619.75 Cash and cosh equivalents \$4,574.22 \$4,619.75 Cheques on loand \$5,15 \$1,37 Cash on load \$193.47 \$162.42 Bank deposits with original maturity less than three months \$373.85 \$9,973.54 Note - 17 Other bank betweeness \$4,767.12 \$4,767.12 Other bank betweenes \$2,983.47 \$10,255.17 Bank deposits with maturity of more than three months and upto twelve months (refer notes below) \$21,983.47 \$10,255.17	Losse Affirmance for consecret reads less	19,960.41	20,982.51
1,253,303,303,303,303,303,303,303,303,303,3			
* Fans pan passe charge on trade receivables, both present and future # intricator, includes \(\frac{7}{206.81} \) labbis (31 March 2020, \(\frac{7}{275.35} \) labbis proceivables from related parties (sefer note 38). Note - 16 Cash and cash equivalents # balances with banks in current accounts Cash on hand Cash on hand Sans and posits with original maturity less than three months **Note - 17** Other bank bulances Bank deposits with maturity of more than three months and upto receive months (refer notes below) 21,983.47 10,255.17 21,983.47 10,255.17	" '	(1,926.32)	(3,550,39)
First part passes charge on tende receivables, both present and future ### individue	Traffic receivables electrimbares	(4,671.26)	(4,517.03)
### Instruction, includes \$\circ 296.81 lakins (31 March 2020; \$\circ 275.35 lakins) receivables from related parties (sefer note 38). Note - 16 Cash and cash equivalents Balances with banks in current accounts Cheques on hand Cash on hand 5.15 1.37 Cash on hand 8 Jank deposits with original maturity less than three months 7 Janks 102.42 Note - 17 Other bank balances Bank deposits with maturity of more than three months and upto receive months (refer notes below) 21,983.47 10,255.17		13,362.83	14,915.09
Note - 16 Cash and cash equivalents Balances with banks in current accounts Cheques on hand Cash on hand 5.15 193.47 Bank deposits with original maturity less than three months 7.37 Note - 17 Other bank balances Bank deposits with maturity of more than three months and upto receive months (refer notes below) 21,983.47 10,255.17	* First part passes charge on trade receivables, both present and future		·····
Cash and cash equivalents 4,374.22 4,619.79 Balances with banks in current accounts 5.15 1,37 Cheques on hand 5.15 193.47 162.42 Bank deposits with original maturity less than three months 373.85 9,973.54 Note - 17 5.17 5.17 5.18 5.19 Other bank balances 5.18 10,255.17 10,255.17 Bank deposits with maturity of more than three months and upto welve months (refer notes below) 21,983.47 10,255.17	Winter atter, includes ₹ 296.81 lakhs (31 March 2020; ₹ 275.35 lakhs) receivables from related parties (refer note 38).	1114,000	
Cash and cash equivalents 4,374.22 4,619.79 Balances with banks in current accounts 5.15 1,37 Cheques on hand 5.15 193.47 162.42 Bank deposits with original maturity less than three months 373.85 9,973.54 Note - 17 5.17 5.17 5.18 5.19 Other bank balances 5.18 10,255.17 10,255.17 Bank deposits with maturity of more than three months and upto welve months (refer notes below) 21,983.47 10,255.17	hi ac	•	
Balances with banks in current accounts			
Cheques on hand 5,13 1,37 162,42	·		
Cash on head 19.47 162.42		6,374.22	4,619.79
193.47 162.42 373.85 9,973.54	•	5.15	. 1.37
Bank deposits with original maturity less than three months 373,85 9,973.54		193.47	
6,946.67 14,757.12	Bank deposits with original matterty less than three months	373.85	
Note - 17 Other bank balances Bank deposits with maturity of more than three months and upto excive months (refer notes below) 21,983.47 10,255.17	•	6,946.67	
Other bank balances . Bank deposits with maturity of more than three months and upto ovelve months (refer notes below) 21,983.47 10,235.17			
Bank deposits with manurity of more than three months and upto ovelve months (refer notes below) 21,983.47 10,235.17 24,983.47 10,235.17			
21,983.47 10,255.17	Other bank bulances		
21,983.47 10,255.17	Bank deposits with maturity of more than three months and upto twelve months (refer notes below)	21 983.47	311 07 4 4 5
			
	Notes:		10,633.17

(a) Bank deposits of ₹ 2,793.52 lakhs (31 March 2020. ₹ 1,043.91 lakhs) are kept under lice with bank as margin money against the bank guarantees in favour of various government authorities and lener of credit associal.

(ii) Bank deposits of ₹ 488.57 likhts (31 March 2020; ₹ 488.57 likhts) are pledged against debt service reserve account (DSRA).



(This stones has been intentionally left blanks



Note - 18

A Equity share capital

As at 31 March 2021

As 21 31 March 2020

\$ A	~~····································	Amount		
Authorised*	Number	(Cin lakhe)	Number	(₹ in lakhs)
Class A liquity shares of \$ 10 each	101,024,000	10,102.40	101,024,000	
Class B Equity shares of € 16 each		-		10,102.40
	1,000	0.10	0000,1	0.10
		10,102.50	-	10,102.50
•	•	***************************************	-	
ii Issued, subscribed and paid upo				
Class A Equity shares of ₹ 10 each				
1 /	49,585,818	4,958.58	49,345,003	n > 1.60 T
•	.,	4,958.58		4,934.50 4,934.58
	. **		_	4,734.80

^{*} Subsequent to the year-ond, the Board of Directors of the Holding Company have approved share spit of Class A equity shares from * 10 per share to * 2 per share and the same has been duly approved by the shareholders of the Holding Company. Accordingly, the number of Class A equity shares in authorised share capital and issued, subscribed and fully paid up have increased from 101,024,600 shares to \$0.5,120,000 shares and from 49,585,818 shares to 247,929,000 shares respectively. In addition, the Board of Directors have also approved conversion of Class B equity shares of Rs. 2 each shall be increased to Class A equity shares of 8.2 each shall be increased to Class A equity shares of \$0.5,120,000 of Rs. 2 each shall be increased to Class A equity shares.

iii Reconciliation of number of equity shares outstanding at the beginning and at the end of the year

anice shares

Balance at the beginning of the year	49,343,003	4,934.50	49,132,778	4,913.28
Add: Issued during the year (on account of exercise of stock option) Balance at the end of the year	240,815	24.08	212,225	21.22
white it sie the of the year	49,585,818	4,958.58	49,345,003	4,934.50

iv Rights, preferences and restrictions attached to equity shares

The Holding Company has two class of equity shares with face value of \$ 10 per share. In case of class A equity share, each holder of equity is entitled to one vote per share. In case of class B shares, each holder of equity is entitled to one vote per share. In case of class B shares,

The dividend proposed by the Beard of Directors is subject to the approval of the shareholders in the country Annual General Meeting, except in case of interim dividend.

v Details of shatcholder holding more than 5% of equity share capital

Name of the equity shareholder Dr. Namsh Tiglan	Number	%	Number	Number
Mr. Small Sachdera jointly with Mrs. Suman Sachdera		20.57%	10,200,600	20.67%
· · · · · · · · · · · · · · · · · · ·	6,800,000	13.71%	6,860,000	13.78%
Dr. Natesh Trehan jointly with hirs. Madhu Tzehan Duneam Investments [Mauritius] PTE led.	4,893,075	13,90%	6,892,075	13.97%
Adam Investments (watering) 1/1/5 ag.	8,601,979	17.35%	8,601,979	17.43%
MINIST HIS COUNTY !	13,000,000	26.22%	13,000,000	26.35%

vi Aggregate number and class of shares allotted as fully paid up pursuant to contract(s) without payment being received in cash, by way of bonus shares and shares bought back for the period of 5 years immediately preceding the halance sheet date

The Holding Company slid not issue any shares pursuant to contract(s) without payment being seceived in each

The Holding Company did not issue bonus shares in preceding 5 years

The Holding Company has not undertaken any buy back of shares.

vil Shares reserved for issue under options

For details of shares reserved for issue under the Employee Stock Option Plan (ESOP) of the Holding Company, refer note 43.



(This space has been intentionally tell blank)



B. Instruments entirely equity in nature .

As at

Às at

	31 Maich 202	ł‡	31 March 20	020
s Authorised	Nunbag	Antonst	Иппреу-	Amount (Cin lakks)
Compulsarily converible preference shares (Class A) of \$ 696 each	466,954	3,250.(x)	466,954	3,25(800)
	466,954	3,250.60	466,954	3,250.00
ii lasued, subscribed and futly paid up				
Compulsionly conversible preference shares (Class A) of 7 696 each	466,954	3,250.00	466,954	3,250.00
	466,954	3,250.00	466,954	3,250.00

iii Rights, proferences and restrictions attached to Compulsurily Convertible Preference Shares ('CCPS' or 'perference share') These shares are non-cumulative Class A compulsorily convertible preference shares having no voting rights and not entitled to vote together with the holders of equity shares of the Holding Company and mandatorily entitled to dividend @ 0.09001% of the face value per annum. The shares are convertible into Class A Equity Shares as per the events and conditions stated below:

	Conversion even(*	Conversion ratio
ш	Nameseenth aumiversary of the issuance of the Class A preference share	
1	The date on which the Anant Investments (holder of the aforementioned CCPS) owns fewer than 6,630,000 Class A equity shares.	
	convertible Securities in the Group should be converted into equity shares in order for the Qualified IPO to be permitted under Indian Law.	One Class A equity shares for every 466,954 Class A prefesence shares
1	or me use take by which all convertible securities in the Holding Company should be converted into Equity shares as permitted under applicable law.	Each Class A preference share shall convenients the lower of (f) One Class A equity share; or (f) The following number of Class A equity shares = {[(932 * X)/Y} - X)/466,954 Where X = Total number of equity shares owned by the holder of the Class A CCPS immediately before conversion Y = Actual IPO Price

*CCPS is classified as equity as the Holding Company expects to issue fixed number of equity shares on the occurrence of conversion ovent, the nature of which is controlled by the Holding Company.

Subsequent to the year-end, owing to the shares aplit enumerated in note 18A(i) and (ii), the aforententioned conversion event and convention ratio has been updated and tabulated below

L	Conversion event	Conversion ratio
1	Nineteenth anniversary of the issuance of the Class A preference share	
2	The date on which the Anant Investments (holder of the aforementioned CCPS) owns fewer than 53,150,000 equity shares.	·
	The occurrence of a Qualified Initial Public Offer or the last date by which all convertible securities in the Holding Company should be converted into equity shares in order for the Qualified Initial Public Offer to be permitted under Indian Law.	Pive equity shares of Rs. 2 each for every 466,954 Class A CCPS
	The accustence of an IPO which is not a Qualified IPO or the last date by which all convertible Securities in the Holding Company should be converted into Equity Shares in order for the IPO which is not a Qualified IPO to be permitted under applicable law.	Each Class A Preference Shate shall convert into the lower of (1) Five equity shares of Rs. 2 each; or (11) The following number of equity shares of Rs. 3 each = {\(\frac{1}{1}(186.46^4\text{X})/Y\\) - \(\text{X}\) / \(\frac{4}{6}6.954\) Where X = Total number of equity shares of Rs. 2 each owned by the holder of the Class A preference share immediately before conversion Y = Indicative IPO Price

	As at 31 March 2		As a 31 March	
	Number	Antount (₹ in lakhs)	Number	Amount (₹ in lakin)
Balance at the beginning and at the end of the year	466,954	3,250.00	466,954	3,250.0
Details of shareholder holding more than 5% of CCPS				
Name of the shareholder	Number	% .	Number	%
Anant Investments	466,934	100.00%	466,954	100.00%
Nose - 19			As at 31 March 2021	As at 31 March 2020
Other equity			(E in lakhs)	(K in lakine)
Securities premium Share optimis passanding account	•		48,702 31	47,000.80
Retuned garming			3,232.42	4,843-45
Laparat resource Control of the Cont			76,898 32	73,732.14
		-	1,192.74	1,192.74
			130,025.79	ealt A126,769.20
	•		(4	

Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Nature and purpose of other reserves

Securities premium

Securities premium is used to record the premium on issue of shares. This balance can be utilised in accordance with provisions of the Companies Act, 2013.

Share options outstanding account

This account is used to recognise the grant date fair value of the options usued to employees under the Holding Company's employee stock option plan.

Remained carnings

Retained earnings is used to record babase of statement of profit and loss and other equity adjustments

Capital reserve

Capital seserve represents difference between these capital of transferor entity and share expiral issued to essewhile shareholders of transferor entity.

Note - 20	As at	As at 31 March 2020
Borrowings non-corrent	(E in takhs)	(7 in takks)
Secured loans		
Tem logus		
From banks (refer note (a) below)	56,724,96	55,045.79
Loss: current manuties of long-term borrowings	(1,629.77)	(1,068.13)
	55,005.19	53,977.66
Vehicle loans		
From financial institution (roles note (b) below)	96.33	140.02
Less: corrent maximum of long-term borrowings	(48.62)	(43.69)
	47.70	96.33
Deferred payment liabilities (refer note (c) below)	7,638.50	7,008.00
Less: Cursent maturities of deferred payment liabilities	(5,011.10)	(530,44)
•	2,627.40	6,477.56
	57,770.29	. 60,551.55
•		

(a) Repayment terms (including current maturities) and accurity details for term loan from banks:

(1) One of the subsidiary companies have availed a loan facility from Yes Bank Limited (YBL) amounting to \$ 50,000.00 lakhs out of which YBL has novated \$ 5,000.00 lakhs to State Bank of India (SBI). During the year, the said subsidiary company has availed monatorium facility given by YBL in late with goldelines from Reserve Bank of India (RBI) at a result of which interests fincluding microst on interest) the during the prescribed monatorium period amounting \$ 1,732.37 lakhs was converted into loan. YBL has also revised the repayment schedule accordingly. The amount outstanding as on 31 March 2021 is payable in 28 quarterly instalments. The rate of interest as on 31 March 2021 is 8-40% per amount and interest is payable monthly. The outstanding balance as at 31 March 2021 is \$ 35,696.16 lakhs (31 March 2020; \$ 34,144.07 lakhs).

The loan is secured by way of first chasge on -

- equitable mortgage on Medania Hospital in Lucknow (hereinafter referred to as the Project in this note) land admeasting 12.50 erres and building
- all current assets and movable property, plant and equipment of the Project;
- · Project's book delns, operating cash flows, receivables, commission and intangible assets (excluding goodwill) pertaining to the Project; and
- all Project's bank accounts.

The horrower shall maintain a debts service reserve account (DSRA) for one month's principal and interest repayment, principal DSRA to be maintained one quarter prior to commencement of repayment, laterest DSRA to be created upfront at the time of each disbursement.

- (2) One of the subsidiary companies have avalled a total facility from State Bank of India (SBI) amounting to ₹ 5,000.00 takhs. During the year, the said subsidiary company has availed moratorium facility given by SBI in line with guidelines from Reserve Bank of India (RBI) as a result of which interests fineliding interest on interest) due during prescribed moratorium period amounting ₹ 205.41 takhs were converted into loan. SBI has also revised the repayment schedule accordingly. The amount containing as on 31 March 2021 is payable in 28 quarterly instalments. The rate of microst as on 31 March 2021 is 8 40% p.a. and unerest is payable monthly. The outstanding balance as at 31 March 2021 is ₹ 5,098,80 takhs (31 March 2020; ₹ 4,971,72 bakhs).

 The loan is secured by way of first page passes charge on .
 - espanible mortgage on Mechana Hospital in Lucknow Cheroinafter referred to as the Project in this note) land admeasuring 12.50 acres and building
 - all current assets and movable property, plant and equipment of the Project;
 - Project's book debis, operating cash flows, receivables, commission and intangible assets (excluding goodwill) pertaining to the Project; and
 - all Project's bank accounts

The borrower shall maintain a debts service reserve account (DSRA) for one quarter principal and one month interest repayment, principal DSRA to be maintained one quarter prior to commencement of repayment, laterest DSRA to be created upfron at the time of each disbursement.

- (3) (a) One of the subsidiary companies have availed a loan facility from Ratnakae Bank Limited (RBL) amounting to ₹ 36,500.00 lakits.
 - (ii) The line is secured by way of by way of hypothecation of property, where hyphotecated property means all prosent and finite current and movable property, plant and equipments of the bottower, including without limitation, the stocks, buok debts, plant and machinery, receivables, bills of exchange, movable fittings, equipments, computer inclusive, computer software, machinery sparses, such and accessores and other anerables, both present and future whether now hying loose, or in cases or which are now lying or recred in or about or slith thereafter from time to time during the continuousty of the security of the loan be brought into or upon be stored or be in or all the borrower's premises, watchouses, stockyards, godowns, but not limited to those movable assets of the borrower.
 - (ii) The ban is exparable in quarterly installments starting from October 2022. Interest is charged at the rate of bank's six month marginal cost of funds based leading and (MCLR)+th05% per annum payable monthly.
 - (iv) The amount nontanding as at 31 March 2021 is \$ 15,930.00 lables (31 March 2020; \$ 15,930.00 lables).
- (b) The Floking Company has availed vehicle loan of ₹ 211.75 likbs from Damier Financial Services India Private Limited which carries an interest at 10.75% per annum, secured by way of hypothecation of vehicle purchased vide the said loan. The loan is repayable in 48 monthly installments and repayment has commenced from 14 May 2018.
- (a) This represents fishility for medical equipment purchased on deferred payment terms to be repaid between April 2021 to May 2025.



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2921

	s follows	Finance custif	Total
Particulars	Botrowings	•	10(2)
		rrent	
April 2019	45,761.13		45,76E1
ich Bown	11,230.00		11,230 0
Proceeds from non-current horrowings Repayment of non-current horrowings	(1,632.42)		(1,832.4
receeds from current borrowings (net)		•	
You-each adjustments	27.10	. (27.10)	
nterest paid		. (5,198.41)	(5,196.4
aterest expense (meloding interest capitalised)		- 5,225.51	5,225.5
March 2020	55,185.81	•	55,185.8
ish flows:			
Repayment of non-current borrowings	(302.29)		(2023
nterest paid	•	(3,727.98)	(3,727)
interest expense (including interest capitalised)		5,665.75	5,665.
interest of monitorium period converted into borrowings	1,937.77	(1,937.77)	-,
March 2021	56,621.29		56,821.
		M	
This includes current maturines of non-current borrowings. Opening and closing balances represent interest accorded (excluding interest accorde	and the former of the body in the body of the body	inner des secretaire message	
Obesitud and closing parameter achiescon interest secured fexchange interest secures	on deserted payment intentions outstand		4
		As at 31 March 2021	As at 31 March 2020
	_		~~~
	•	(* in fakhs)	(₹ in lakhs)
ose - 21	•		
ease liabilities - non-current			
ease traditions (sefer note 41)		25,072.07	27,028
	•	25,072.07	27,028
case liubilities - current			
ease liabilities (refer note 41)		3,60\$.86	3,668
		3,605.86	3,668
		•	/E ! . I. I
he changes in the Group's lease liabilities arising from financing activities can be ch	issified as follows:		(₹in lak
prisculars			เสเอบก(
case tiabilities as at 1 April 2019 (cutrent and non-current)			27,32
dultsone			4,489
nieresi on leave liabilities			3,13
aymear of lease liabilities			(4,25)
case liabilities as at 31 March 2020 (current and non-current)			30,696
			{-6.
hange on account of lease modifications			(60
Deletions/adjustments on account of early termination			
nterest on lease liabilities			3,01
ayment of lease liabilities			(4,05)
lent contessions from lessor			(12
ease fiabilities as at 31 March 2021 (current and non-current)			28,67
			<u></u>
Aore - 22			
rovisions - non-current			
torition for employee benefits:		A 20 A 40	4.44
Grating (refer note 42)		2,690.39	2,37
Compensated absences	•	1,543.11	1,53
		4,233.40	3,60
Providing a greens		•	
Provisions - current			
rovision for employee benefits:	•	2 N. S.	
Gratumy (refer now 42)	•	580.48	57
Compensated absences -		367.26	30
Provision for contingeneurs! (refer note below)		1,823.84	1,01
		2,771.58	1,89
#Movement of provision for contingencies		***************************************	
Opening balance		1,015.08	17
• •		608.76	н.
Add: additional provision made during the year			D+
Less - smoons utilised during the year		1 1 2 2 4 4	
		1,823.84	10,1
			



Name		As at 31 March 2021	Ar at 31 March 2020
Policy	Note - 23	(₹ in lakhs)	(₹ in lakhs)
িব্ৰুল্য বুলানাকৰ grant'		· · · · · · · · · · · · · · · · · · ·	
Perferred growments grants			
1			
Case Recivered in streichers of profes and loss	Descried government grant	3,634,16	3,908.28
Class Clas	" E		
Case Ruberred to nationand of profit and lose 1,762.57 1,7	Grants seceived throng the year		
Classified into Classified	" '		
Note of the Note of Supering Profession (1998) 1998	·		
Current person	Classified into	, 4 ₁ 277.01	4,585.67
### Date or change or accounting policy, previous year numbers have been restated. For details, sefer note 4-4 ### Date or change or accounting policy, previous year numbers have been restated. For details, sefer note 4-4 ### Date or change or accounting policy, previous year numbers have been restated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy, previous year numbers have been extated. For details, refer pose 4-4 ### Date or change or accounting policy or change	Non exercit portion	7,674.44	
### Dute or change in accounting policy, previous year numbers have been restrated For details, sefer were 4. Possible or stratumery submines	Current portor	- ·	• •
# Define commany pulsary in accounting policy, previous year numbers have been restated For details, sefer new 4. # Payah in a restaurory valdencies Paya			
Description of Stationary suddenines 1,551.47 1,516.17 1,5	# Due to change to accounting policy, previous year numbers have been restated. For details, teler note 44.	4,277.02	4,505.67
Page			
1,511,11	9 Other current liabilities		
Advance frame reasonance 2915 Ag 2,11160 1,11160	Payable to standory authorities	3 521 50	
Performance	Advance from customers		
Chief infabilities 13.5.5 10.28 13.5.5 10.28 13.5.5 10.28 13.5.5 10.28 13.5.5 10.28 13.5.5 10.28 13.5.5 10.28 13.5.5 10.28 13.5.5	Deferred government grants#		•
# Due to change in accounting policy, pravious year numbers have been estanted. For details, refer nose 44. Note - 24 Trade pupablier - current A Torst outstanding dues of micro cuterprises and small enterprises Particular	Other liabilities		
# Due to change in accounting policy, previous year numbers have been estated. For details, refer once 4. Note - 24			
Note - 24 Trade psyables - current 3,02.44 1,794.58 1,79	# Due to change in accounting policy, previous year numbers have been restated. For details, refer note 44.	A32010	4,343.43
Trade payables - current 3,02.44 1,794.56 1,794			
A Total outrasseling dues of micro enterprises and small enterprises? ***Positionary and enterprises and small enterprises Development Act, 2006 ("MSMED Act, 2006") as at 31 March 2021 and 31 March 2021. **Positionary and enterprises and Medium Enterprises Development Act, 2006 ("MSMED Act, 2006") as at 31 March 2021 and 31 March 2021. **Positionary and enterprises and the interest due thereon remaining unpaid to any suppliers at 1 the end of each accounting year. **Positionary and an accounting and the interest due thereon remaining unpaid to any suppliers at 1 the end of each accounting year. **Positionary and the interest due thereon remaining unpaid to any suppliers at 1 the end of each accounting year. **Positionary and the interest due thereon remaining unpaid to any suppliers at 1 the end of each accounting year. **Positionary and the interest due thereon remaining unpaid to any suppliers at 1 the end of each accounting year. **Positionary and the interest due and parable for the parable of delay in making payment (which have been paid but beyond the appointed day during each accounting year power and admitted the MSMED Act; **Positionary and the interest accord and remaining unpaid at the end of each accounting year; and the date when the interest dues as above are a contract of further interest remaining due and payable even in the situate enterprises and architecture of the further interest remaining due and payable even in the situate enterprises and architecture separate the MSMED Act; **Positionary and the interest accord and remaining unpaid at the end of each accounting year; and such date when the interest dues as above are a contract to the small enterprises. **Positionary and the interest accord and remaining unpaid at the end of each accounting year; and such date when the interest dues as above are a deductible expenditure under accord 2.24 10, 22.19 **Positionary and the interest accord and remaining unpaid at the end of each accounting year; and such date when the interest due	Nate - 24		
**Disclosure under the Micro, Small and Medium Enterprises Development Act, 2006 ("MSMED Act, 2000") as at 31 March 2020 Particular	Trade payables - custem		
*Disclosure under the Micro, Small and Medium Enterprises Development Act, 2006 ("MSMED Act, 2006") as at 31 March 2021 and 31 March 2020 Particular	A. Total containing dues of micro enterprises and small enterprises.	300244	4.70.50
Particular Partic	- Carlotte in the Carlotte in		
Particulars Particulars Particulars Pa			1,774.50
Particulars Particulars Particulars Pa	*Disclosure under the Micro, Small and Medium Enterprices Development Act, 2006 ("MSMED Act, 2006") as at 31 March 2021 and 31 March 2	020	
the principal amount and the interest due thereon tensaining unpaid to any supplier as at the end of each accounting year; the amount of interests paid by the buyer-in-terms of section 16, along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year; the amount of interest are and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act; the amount of interest are and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act; the amount of interest accound and remaining unpaid at the end of each accounting year; and the amount of further interest remaining during and payable even in the succeeding year, with such date when the interest dues as above are actually paid to the small enterprise. The the purpose of deallowance as a deductible expenditure under section 23. B Total constanting dues of creditors other than nucco enterprises and small enterprises Due to others Pour to related parties (refer note 38) Due to others Other financial liabilities - current Current maturities of moneurem borrowings 1,029.77 1,068.13 According to the state of the payment liabilities Current maturities of deferred payment liabilities Current maturities of deferred payment liabilities Security deposit received 5,001.00 5,004.00 5	Particular		31 March 2020
spinometed day during tech becoming year; if the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during tech becoming year; if the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act; if the amount of interest due and payable for the period of each accounting year; and		(₹ in lakhs)	
spinned and young acts Accounting year; ib the amount of interest due and pagable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act; iv) the amount of interest accord and remaining unpaid at the end of each accounting year; and 6.77 56.25 it is amount of further interest remaining due and payable even in the interesting year, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23. B. Total currountility dues of creditors other than nucro enterprises and small enterprises. Due to related paties (refer note 38) Due to others Note - 23 Other financial liabilities - current Current maturities of non-current borrowings Current maturities of non-current borrowings Current maturities of vehicle loan 48.62 43.69 Current maturities of deferred payment liabilities Capital cectuors Security deposit received Capital cectuors Security deposit received Employee related payables Other liabilities 5.512.71 4.115.33 Other liabilities	O integrational and the interest due thereon ternaming unpaid to any supplier as at the end of each accounting year;	3,012.44	1,794.58
the amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under the MSMED Act; the amount of interest accreed and remaining unpaid at the end of each accounting year; and 6.77 56.25 the amount of interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 25. B. Total constanting dues of creditors other than nucco enterprises and small enterprises. Due to related paxies (refer note 38) 274.17 221.99 Due to others 9,918.60 11,627.97 11,279.46	any or arrown to day drive each section to the control of the control of the payment made to the supplier beyond the		
during the year) but without adding the interest specified under the MSMID Act			
y) the annount of further interest renaming due and payable oven in the succeeding years, until such date when the interest dues as above are actually paid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 25. B. Total constantibility dues of creditors other than nucro enterprises and small enterprises. Due to others Due to others Pure to related parties (refer note 3R) Due to others Note - 25 Other financial liabilities - current Current maturities of vehicle loan Current maturities of vehicle loan Current maturities of deferred payment habilities futerest accroed Capital creditors Security deposit received Enterprise of the payment habilities of t	during the year) but without adding the interest specified under the MSMED Act;	.	•
Security part to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23. B Total contrastibility dues of creditors other than nucro enterprises and small enterprises Due to related practics (refer note 38) 224.17 221.99 Due to others 9,918.60 11,657.47 10,142.77 11,279.46 Note - 25 Other financial liabilities - current	iv) the amount of interest accord and remaining unpaid at the end of each accounting year; and	6.77	56.25
Part	v) the anseam of further interest remaining due and payable even in the succeeding years, until such date when the interest dues as above are	-	
Due to others 1,057.47 221.99 224.17 221.99 221.17 221.99 221.00 2	pectary part to my small enterprise, for the purpose of disansystates as a deductible expenditing under section 23.		
Due to others 1,057.47 221.99 224.17 221.99 221.17 221.99 221.00 2	B. Sand many affair days of continuous to the same of		
Due to others 9,918.60 11,657.47 10,657.47 10,657.47 10,657.47 11,279.46			
Note - 25 Note - 25		234.17	221.99
Note - 25 Other financial liabilities - current Current maturities of mon-current borrowings Current maturities of vehicle loan Current maturities of deferred payment liabilities futerest accroed Capital creditors Security deposit received Security deposit received Supployee related payables Supployee related payables Other liabilities Supployee related payables Supployee felated payables Supployee related payables	Due to due to	····	11,057.47
Other financial liabilities - current 1,629.77 1,608.13 Current maturities of mon-current borrowings 1,629.77 1,608.13 Current maturities of vehicle loan 48.62 43.69 Current maturities of deferred payment liabilities 5,011.10 530.44 Interest accroed 3,84.58 472.94 Capital creditors 3,357.40 6,570.03 Security deposit received 5.50 5.50 Employee related payables 5,128.71 4,115.33 Other liabilities 151.82		10,142.77	11,279.46
Other financial liabilities - current 1,629.77 1,608.13 Current maturities of mon-current borrowings 1,629.77 1,608.13 Current maturities of vehicle loan 48.62 43.69 Current maturities of deferred payment liabilities 5,011.10 530.44 Interest accroed 3,84.58 472.94 Capital creditors 3,357.40 6,570.03 Security deposit received 5.50 5.50 Employee related payables 5,128.71 4,115.33 Other liabilities 151.82	Nove 25		
Current maturities of non-current borrowings 1,629.77 1,008.18 Current maturities of vehicle loan 48.62 43.69 Current maturities of deferred payment liabilities 5,011.10 530.44 Interest accroed 3,84.58 472.94 Capital creditors 3,357.40 6,570.03 Security deposit received 5,50 5,50 Employee related payables 5,128.71 4,115.33 Other liabilities 151.82			
Current materities of vehicle loan			
Current maturities of deferred payment liabilities 5,011.40 530.44 Interest accross 384.58 472.94 Capital creditors 3,557.40 6,570.03 Security deposit received 5,50 5,50 Employee related payables 5,128.71 4,115.33 Other liabilities 151.82	·		1,068.13
Interest accroed 384.58 472.94 Capital creditors 3,57.40 6,570.03 Security deposit received 5.50 5.50 Employee related payables 5,128.71 4,135.33 Other liabilities 151.82		· ·	43.69
Capital creditors 3,357,40 4,294 Security deposit received 5,50 5,50 Employee related payables 5,128,71 4,115,33 Other liabilities 151,82	•		530.44
Security deposit received 5,50 5,50			472.94
5.50 5.50	•		6,570.03
Other liabilities 151.82	···		5.50
			4,115.33
15,717.50 12,806.06	SARING TORONSON		-
	· · · · · · · · · · · · · · · · · · ·	15,717.50	12,806.06

(This space has been intentionally left think)



•	As at 31 March 2021 (₹ in lakhs)	As at 31 March 2020
Note - 11	(z iti taitus)	(f in laktis)
A Defected tax assets (net)	•	
Deferred tax assets atising on account of		
Unabsorbed Insuress know and dejineration	3,295.85	653.30
timplace benefits	1,303,08	20.7?
Fax impact of expenses which will be allowed to payment basis	400.64	274.17
Expected credit loss on trade and other receivables	1,718.97	
Right of use assets and lease highlines	1,673.84	
Others	192.29	
	8,591.57	674.02
Deferred tax liabilities prising on account of:		
Property, plant and equipment and mangable assets	(6,917,58)	(674.52)
	(6,017,58)	(674.62)
	4	-
Deferred can assem (net)	. 2,573.99	*
3 Deferred tax liabilities (not)	•	
Deferred tax liabilities arising on account of:		
Property, plant and equipment and unaughte assets		1.063
	•	4,753.64
Defended tax assets arising on account of:		
Employee benefits		(1,106.33)
Expected credit loss on trade and other receivables	•	(1,561.43)
luiciesi cust and luxse payments related to leasohold land		(1,146.26)
Odies		(168.45)
		811,37

(i) Subsidisty companies have madesurbed business losses (including madesubed depreciation) of \$\vec{t}\$ 15,017.41 lakhs (3). March 2020: \$\vec{t}\$ 7,829.49 lakhs). Deferred tax assets on unabsorbed business losses (including unabsorbed depreciation) are recognised to the extent that it is probable that it will be utilised against future taxable income. Further, the madesurbed business losses are available for utilisation for a maximum period of eight years.

(ii) _	Caption wise movement in deferred tax assets as folio)(V\$;						(Tim lakhs)
	Particulues	1 April 2019	Recognised in statement of profit and loss	Recognised in other comprehensive income	31 March 2020	Recognised in statement of profit and loss	Recognised in other comprehensive income	31 March 2021
	Vercia							
	Unabsorbed business Insses and depreciation	31.13	622.17		653.30	2,642.55		3,295.85
	Employee tienefits	2.74	18.27	(0.29)	20.72	46.68	(12.61)	54.79
	Tax unpact of expenses which will be allowed on payment basis	٠	-	ſ		406.64		406.64
	Expected credit loss on trade and other receivables	-				1.23		1.25.
	Others	0.48	(0.48)	•	,	57.85		57.85
- t	Right of use assets and lease liabilities Liabilities		, '	•		38.59	-	38.59
	Property, plant and equipment and manightle assets	(0.0.0)	(673.96)		(674.02)	(815.17)		(1,\$19.19)
- 1	Sub-total	34,29	(34.00)	(0.29)	· ·	2,348,39	(12,61)	2,335.78
	Almanum afteenase tax credit emittersent	0.33	(0.13)	`. `]			, , , , ,	PJ355170
	Net deferred tax assets	34.62	(34,33)	(0.29)	-	2,348.39	(12.61)	2,335.78

Preticulars	1 April 2019	Recognised in scatement of profit and lose	Recognised in other comprehensive income	31 March 2026	Recognised in statement of profit and loss	Recognised in other comprehensive income	(R in lakhs) 31 March 2021
Arsety	•	, , , ,					
Improment so value of investments	112.15	(112.13)		.]			, ,
Employee benefits	1,343.62	(296.26)	58.97	1,106.33	129.23	13.63	1,249.19
Expected credit loss on trade and other receivables	1,731.76	(170.33)	,	1,561.43	156.29		1,717.72
Right of use assets and lease liabilities	816.17	330.09		1,146.26	488.90		1,635.25
Oilicis	210.27	(41.82)	. 1	168.45	(34.01)		134 64
12abitities							i
Property, plans and equipment and intaughte assets	(7,336.39)	2,5 (2.55		(4,793.84)	295.45		(4,498.39)
Net deferred tax assets/(lishilities)	(3,122.42)	2,252.08	58.97	(811.37)	1,035.95	13.63	238.21

Note - 12

Income-tox assets (act)

Advance sax (net of provision for tax amounting to ₹ 41,836.73 lakhs (31 March 2020; ₹ 58,087.00 laldis)

1,712.90	6,595.75
4,712.90	6,595,75

No. 11 to the term of the term			
Movement is income tax assets (net)			(K in lakhs)
l'articulars	,	Aε 81	Asat
		31 March 2021	31 March 2026
Opening balance		6,595.75	5,950.50
Add: Taxes paid		1,867.32	5,617.08
Less. Current an provided for		(3,750:17)	(4,971.83)
Glosing balance		4,712.90	6,595.75



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Income from sale of pharmacy products Sale of pharmacy products Other operating revolues Covernment grant ancounc# Climical research income 1,559.32 1,620.62 Other operating revolue 129.01 186.82 The ro-change in accounting policy, previous year number has been restand. For details, refer note 44. Note - 27 Other income Interest income on bank deposit Interest income on other financial assets measured at amortised cost 1,503.42 1,946.89	•	For the year ended 31 March 2021	For the year ended 31 March 2020
Inspirent Insp	Note - 26	(? in lakhs)	(₹ in takhs)
Pagestriet 18,655.00 18,645.00 18,	Reseaue from operations.		
Displacem 18,655.00 19,0	Income from healthcare services		
2,145.00 2,145.00	In protein	**************************************	
Contest of phoneners products to only planeters of phoneners products of phoneners p			119,412.03
Section Processing processing 1,165,02 1,000,00	Income from sale of pharmacy products to out-patients	23,130,50	28,645.08
1,59,22	Sale of pharmacy products		
1,50,202 1,50,202		1,148.32	
1200 1200			
1.00			-
144.674.33 180.181.35	Other operating revenue		
Note - 27		33.57 364 674 32	
Distance in formation 1,503.42 1,144.84 1,140	44 Due to change in accounting pality, previous year anadus has been restated. For details, refer note 44.		150,042.20
1,503.42 1,046.89 1,050.44 1,046.89	Note - 27		
1948 1948			,
1948 1948	Interest income on bank deposit		
Part	interest income on other financial assets measured at amortised cost		1,246.89
Part And disposed of property, pinus and equipment (aut)	Interest income on refund of income-tax		17.60
Spansers			•
Spansership incomes	Profit on disposal of property, plant and equipment (act)		138.33
Revenue share from find our 14696 250,	Spankorship income	<u>.</u>	
Revenue share from food cour 26,000	Reversal of impairment in the value of investments	103.45	733.55
Caim on de-recognision of lesses inhibities and right of use assets* 266.38 778.39 Rent concessions from lesses 126.32 126.32 Rent concessions from lesses 126.32 126.32 Rent concessions from lesses 126.32 126.32 Aftilia 126.32 126.32 126.32 Rent concessions from lesses 126.32 126.32 Antilia 126.32 126.32 126.32 Antilia 126.32 126.32 126.32 Adtilia 126.32 126.32 Adtilia 126.32 126.32 126.32 Adtilia 126.32 126.32 126.32 Adtilia 12	Revenue share from food court		2.18
Rest concessions from leators 1823 1825 182	Revenue share from pharmacy		265.04
Rest concessions from leators 1823 1825 182	Gain on de-recognition of lease liabilities and right of use assets*		778.39
Parametr of early lensimation of least Parametr of early lensimation of early lensing stock 2003-333 26,514-60	Rent concessions from lessors		-
on account of early tennications of learly 3,64,50 4,584,50 Note - 28 Cost of materials consumed	Miscellaneous income	,	•
Note - 28 Cast of materials consumed Pharmacy, medical and laburatory consumables related to in-patient services Copening stock 3,614.60 2,212.31 Add: Parchases (includes government assistance of X.nili (3). March 2020: ₹ 27.85 labbs)) 3,598.60 33,599.50 33,5093.35 Less: Closing stock (3,093.35) (3,614.40) 33,599.50 31,900.81 General stores Copening stock 227.50 116.65 Add: Purchases (a,093.35) (3,614.40) 116.65 Add: Purchases (a,093.35) (3,614.40) 116.65 Add: Purchases (a,093.35) (3,780.77) (2,793.50) Add: Purchases (3,780.77) (2,793.77) Add: Purchases (3		***************************************	
Plantmacy, medical and laboratory consumables related to in-patient services Copening stock 3,614.40 2,212.31 Adult Purchases (includes government assistance of X.nili.(31.March 2020; Z 27.85 lakhs)) 33,078.49 33,078.49 33,078.49 33,078.49 33,078.49 33,078.49 33,078.49 33,078.49 33,078.49 33,579.56 31,900.24 Meterials consumed (3,093.33) (3,614.40) (3,093.33) (3,614.40) Meterials consumed 297.50 116.65 Adult Purchases 297.50 116.65 Adult Purchases 297.50 116.65 Adult Purchases 297.50 116.65 Adult Purchases 277.50 207.50 Adult Purchases 277.50 207.50 Adult Purchases 277.50 207.50 Adult Purchases 277.50 207.50 Adult Purchases 1,270.66 Loss: Clossing stock (904.52) Adult Purchases 1,270.66 Loss: Clossing stock (904.52) Adult Purchases 1,270.66 Loss: Clossing stock (904.52) Adult Purchases 1,270.66	on acoust of early termination of lease	3,444.73	4,384.50
Pharmacy, medical and laboratory consumables related to in-patient services Opening stock	Note - 28		
Pharmacy, medical and laboratory consumables related to in-patient services Opening stock	Cost of materials consumed		
Copering stock	Pharmacy, medical and laboratory consumables related to in-patient services		
Last Classing stock Gameral stores		3 614 ¢n	
Materials consumed (3,093.33) (3,044.40) (3,093.33) (3,044.40) (3,093.33) (3,093.44) (3,093.33) (3,093.44) (3,093.33) (3,093.44) (3,093.33) (3,093.44) (3,093.33) (3,093.44) (3,093.33) (3,093.33) (3,093.44) (3,093.33) (3,093.33) (3,093.44) (3,093.33) (3,093.33) (3,093.33) (3,093.44) (3,093.33) (3,093.33) (3,093.44) (3,093.33) (3,093.33) (3,093.44) (3,093.33) (3,093.33) (3,093.44) (3,093.33) (3,093.33) (3,093.44) (3,093.33) (3,093.33) (3,093.44) (3,093.33) (3,093.33) (3,093.44) (3,093.33) (3,093.3	Add: Purchases (includes government assistance of Enil (3) March 2020: 2 27.85 lakhs))		·
Substitution Subs		· · · · · · · · · · · · · · · · · · ·	
Commissiones	Materials consumed		
Commission	Control of the contro		71,700.24
Add: Purchases 237.50 116.65 Less: Closing stock 631.20 703.35 Materials consumed 490.63 582.50 Pharmacy and medical consumables related to sale of phurmacy products to out-patients Opening stock 1,270.06 490.63 582.50 Add: Purchases 1,270.06 490.53 32,482.74 Materials consumed 1,270.06 490.53 32,482.74 Materials consumed 1,270.06 490.53 32,482.74 Note - 29 Employee benefits expense 58.758.65 58.758.65 Salanes and wages*8 44,391.76 58,758.65 Countibution to provident fauid and other funds 44,391.76 58,758.65 Staff welface expenses 1,858.32 2,029.00 Staff welface expenses 4.59 1,314.88 Employee share based payment expense (refer note 43) 3.78.88 956.97			•
Acta Purchases Acta Classing stock Acta A	- "	237.50	116.60
Materials consumed 378.07 (237.50)			
Pharmacy and medical consumables related to sale of pharmacy products to out-patients			
Pharmacy and medical consumables related to sale of pharmacy products to out-patients Opening stock	traterials consumed		
Commission Com	Pharmacy and medical grassumables related to rate of the		302.30
Adds Purchases 1,270.06 Loss: Cloxing stock (504.52) Materials consumed 765.54 34,855.73 32,482.74 Note - 29 Employee benefits expense Salaries and wages**8 44,391.76 58,758.60 Countibution to provident fund and other funds 44,391.76 58,758.60 Staff welfare expenses 1,858.32 2,029.00 Employee share based payment expense (refer note 43) 4.59 133.48 Employee share based payment expense (refer note 43) 956.97	Operation stock		
1,270.06		•	
Materials consumed (504.52)		1,270.06	_
Note - 29 Employee benefits expense Salaries and wages** 44,391.76 59,758.60	· ·	(504.52)	
Note - 29 Employee benefits expense Salanes and wages*# 44,391.76 56,758.60 Countibution to provident finid and other funds 1,858.32 2,029.00 Staff welfare expenses 4.59 133.48 Employee share based payment expense (refer note 43) 378.88 956.97	,	765,54	
Note - 29 Employee benefits expense Salanes and wages*# 44,391.76 56,758.60 Countibution to provident finid and other funds 1,858.32 2,029.00 Staff welfare expenses 4.59 133.48 Employee share based payment expense (refer note 43) 378.88 956.97			
Employee benefits expense 44,391.76 56,758.60 Salanes and wages*# 44,391.76 56,758.60 Countibution to provident fund and other funds 1,858.32 2,029.00 Staff welface expenses 4.59 133.48 Employee share based payment expense (refer note 43) 378.88 956.97		34,855.73	32,482.74
Salaries and wages*# 44,391.76 58,758.60 Countibution to provident find and other funds 1,858.32 2,029.00 Staff welface expenses 4.39 133.48 Employee share based payment expense (refer note 43) 378.88 956.97			
Countibution to provident fund and other funds 44,391.76 56,758.60 Staff welface expenses 1,858.32 2,029.00 Employee share based payment expense (refer note 43) 4.39 133.48 378.88 956.97			
Staff welfare espenses 1,858.32 2,029.00		44 301 27	
Employee share based payment expense (refer note 43) 4.59 133.48 956.97		-	
378.88 956.97			
	Employer share based payment expense (refer note 43)		
53,878.65			
		- CC-12-24-24-7	\$3,878.05

⁻ During the year ended 31 March 2021, employee benefit expenses of \$86.66 lakks (31 March 2020: \$762.66 lakks) has been capitalised as a part of capital work in-progress.

[#] This intrivalia, includes salary expense of employees working for research and development amounting to ₹ 78.36 laklis (3) March 2020; ₹ 99.29 laklis).



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

•	Por the year ended 31 March 2021	For the year end 31 March 2020	
	(₹ in lakhs)	(₹ in lakJrs)	
Note - 30			
Finance costs			
Interest on term loans*	3,053.09	1,379	
hiterest on working capital toans	41.74		
Interest on vehicle loan	12.94		
Interest on lease liabilities	3,013.68	3,13	
Interest on defected payment liabilities	588.72	56	
Other barrowing costs	7.27		
	6,717.44	5,15	
* During the year ended 31 March 2021, borrowing cost of ₹ 2,524.34 lakins (31 March 2020: ₹ 3,828.72 lakhs) has been capitalised as part of capital work in-pr	ogress.	
Note - 31	•		
Depreciation and amortisation expense			
Depreciation of property, plant and equipment#	10,584.83	9,54	
Depreciation on right of use assets*	5,527.84	1,75	
Amortisation of introgible assets	268.76	13	
	12,321.43	11,50	
·	d. Par details, refer note 44. ₹ 254.40 lakhs (31 March 2020 : 2 nil) has been capitalised as a part of capital work	-in-progress.	
Note - 32 Impairment losses on financial assets			
Expected credit loss on trade receivables	530.16	1,11	
Expected credit loss on other receivables	95.79	1911	
•	625.95	Į,1	
	- UZ5.73	·	
Note - 33			
Other expenses#			
Power and fuel	3,655.69	3,45	
Lease root:	0,102107	· dan	
Promises	135.67		
Vehicles	44.35	13	
Equipments	3,469.35		
Repairs and maintenance:	3,402.73	3,80	
Yquipments	3,810.90	7.61	
Office	362,57	3,93	
Building	224.92	38	
Rates and taxes	1,346.98	22	
Recruitment expenses	239.61	1,41	
Insurance		34	
Travelling and conveyance	227.33	i -	
Communication expenses	286.79	7:	
Auditor's remaneration	259,82	28	
Statutory audit fees (including taxes)	2/24		
Reimbursement of expenses (including taxes)	74.75	•	
Pantry expenses	2.35		
	1,640.27	1,5	
Loundry expenses Security expenses	508.95	40	
	1,166.25	1,10	
Findity management expenses	4,853.61	4,53	
Advectisement and sales promotion	238.79	41	
Research and development expense*	2.72		
Outsourced services	898.64	90	
Retainer and consultant fee - medical	13,717.95	11,3	
Facilitation fee	876.35	3,00	
Legal and professional fee	2,142.71	2,75	
Printing and stationery	484.37	59	
Subscription and membership charges	104.28	j.	
Corporate social responsibility expenses	194.54	21	
Directors' sitting fees	12.98		
Bank charges	546.71	\$6	
Foreign exchange - less (not)	208.09	1.7	
	125.76		
Assets written off		•	
Assets written off 14.88 on disposal of property plant and equipment (net)	,		
Assets written off	123,23	5.9	
Assets written off 14.88 on disposal of property plant and equipment (net)		58	
Assets written off Loss on disposal of property plant and equipment (net) Travel, boarding and other related expenses for conferences	123.23	34	

[#] During the year ended 31 March 2021, other expenses of ₹ 261.86 lakhs (31 March 2020) ₹ 400.29 lakhs) has been capitalised as a part of capital work-in-propers.



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

	For the year ended 31 Murch 2021	For the year ended 3I March 2020
Note - 34	(₹ io lakhs)	(t in lakhs)
Tox expenses		
Current tox - for the year		
Current tax - earlier years	3,677.20	4,971.83
Deferred tax esedit	72.97	
Tax expense recognised in the statement of profit and loss	(3,384.34)	(2,217.76)
, , , , , , , , , , , , , , , , , , , ,	365.83	2,754.07
The major companents of account tax expense and the reconciliation of expected tax expense based on the domest expense in profit or loss are as follows:	tic offective tax rate of the Group at 25	5.168% and the reported tax
Accounting profit before income tax		
Add: Losses incurred by subsidiaries and joint venture on which no deferred tax asset is created	3,246.56	6,386.96
Accounting profit before income tax (gross)	1,634,95	6,708.54
At India's statutory income tax rate of 25.168% (31 March 2020: 25.168%)	4,881.51	13,095.50
·	1,228.58	3,295.87
Tax effect of amounts which are not deductible (taxable) in calculating taxable income:	•	
13x impact of statutory deduction allowed as per income-tax Act, 1961 under the head income from Element Reported		
Tax impact of deferred tax on impairment in value of investments	(31.77)	(69.98)
Pax impact of expenses which will never be allowed under Income-tax Act, 1961		112.15
Tax impact on account of change in income tax rate	563.36	327.42
Tax impact of unabsorbed business fosses		(909.29)
Yax impact in respect of earlier years	(1,601.12)	•
Others	72.97	•
Tax expenses	139.81	17.90
	365.83	2,754.07
Nate - 35	•	
Eurnings per share (EPS)		
Earnings per share (RPS) is determined based on the net profet preclamation of the absolute to the	a de la companya de	
outstanding during the year. Diluted earnings per share is computed using the weighted average number of common a except where the result would be anti-dilutive.	r snare is computed using the weighter	average number of shares
except where the result would be anti-dilutive.	ing omitte commun editariest spaces	outeranding during the year,

Profit attributable to equity shareholders for basic and diluted EPS

Weighted average number of equity shares for basic EPS*

251,408,994

250,255,111

Effect of dilution - weightage average number of potential equity shares on account of employee stock options*

647,391

1,304,783

Weighted average number of equity shares adjusted for the effect of dilution

252,056,385

251,559,894

Earnings per equity share Basic

Diluted E.15 1.45 1.45 1.44 1.44

"The Holding Company had issued compulsorily convertible preference shares which are expected to be converted into equity shares and the same has been duly considered in calculation of basic carning per share, considering maximum number of equity shares to be issued upon conversion.

"Share options (unvested) under the ESOP Plan 2014 and ESOP Plan 2016 are considered to be potential equity shares. They have been included in the determination of diluted curnings per share to the extent to which they are dilutive.

Subsequent to the year-end, the Board of Directors of the Holding Company has approved there split of Class A equity shares from \$10 per share to \$2 per share and the same has subsequently been duly approved by the shareholders of the Holding Company. As prescribed under find AS 33, 'Barnings per Share', the Group has presented basic and diluted earnings per share on considering the aforementioned share split for the current as well as previous year.



(Vhis space bus been intentionally left blank)



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Note - 36

Fair value disclosuces

(l) Fair value hierarchy

The following explains the judgements and estimates under in determining the fair values of the financial instruments that are recognised and measured at lair value. To provide on indication about the reliability of the inputs used in eletermining fair value, the Group has classified its financial instruments into the titree levels prescribed under the accounting standard.

Level Is quoted prices (unadjussed) in active markets for financial instruments.

Level 2; inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly

Level 3: unobservable inputs for the asset or liability.

Valuation techniques used to determine fair value

The fair value of the futancial assets and fiabilities are included at the amount that would be received to sell an asset and paid to transfer a liability in an orderly transaction between market participants. The following methods were used to estimate the fair values:-

- Frade receivables, each and each equivalents, other bank balances, loans, other current financial assets, under payables and other current financial flabilities: Approximate their carrying amounts largely due to the short-term materities of these instruments.

Borrowings taken by the Group are as per the Group's credit and liquidity risk assessment and there is no comparable instrument having the similar terms and conditions with related security heing pledged and hence the carrying value of the borrowings represents the best estimate of fair value.

(ii) Pair value of assets and liabilities which are measured at amortised cost for which fair value are disclosed

Particulars	As at 31 M	As at 31 Murch 2021		(₹ in lakhs As at 31 March 2020	
Pistancial apports	Carrying value	Poic value	Carrying value	Pair value	
lians Frativ recovables	856.15	836,15	799.61	799.6	
Cash and cash equivalents	13,362.83	13,362.83	14,915.09	14,915.0	
Other bank balances	6,946,67 21,983,47	6,946.67	14,757.12	14,757.1	
Other furancial assets	5,019.88	21,983,47 5,019,88	10,255,17 5,794,04	10,255.1	
Total financial assets	48,169.00	48,169.00	46,521.03	5,794.0 46,521.0	
Borrowings (including current manufaces of long-term borrowings) Lade payables	64,459.78	64,459.78	62,193.80	62,193,8	
Other financial liabilities (excluding current maturities of long-term borrowings)	13,155.21	13,155.21	13,074.04	13,074,0	
Forst financial liabilities	9,028.00 86,642,99	9,028.00	11,163,81	11,163.8	
	90,042,79	80,692.99	86,431.65	86,431.6	

Pair velues

5.00

31 Merch 2020

As at 31 March 2021

Note - 37

Particulars

Financial assets Investments Loans Emda receivables Cash and cash equivalents Other bank balances Other figuratial assets Total Emancial assets

Financial liabilides

Lease habilities

Trade payables

Borrowings (including current maturities of non-current horrowings)

Other funncial liabilities (excluding current maturities of non-current borrowings)

Pinancial risk management

(i) Financial instruments by category

	(₹ io laklıs)
Amortised	cast
As 21 31 Murch 2021	As at 31 March 2020
,	
856.15	. 79961
13,362.63	14,915.09
6,946.67	14,757.12
21,983.47	10,255.17
5,019.88	5,794.04
48,169.00	46,521,03
64,459.78	62 193 80

30,696.76

13.074.04

11,163.81

117,128.41

28,677.93

13,555.21

9,028.00

115.320.92

Total financial liabilities If This investment is measured at fair value through other comprehensive income and is categorised as level 5 in fair value hierarchy

(ii) Hisk management

The Group's activities expose it to market risk (foreign exchange and interest risk), liquidity risk and credit risk. The respective board of directors of the Holding Company and entities considered into the Group have averall responsibility for the establishment and oversight of the risk management framework. This note explains the sources of risk which the entity is exposed to and how the entity manages the risk and the related impact in the financial statements.

Risk	Exposure arising from	leasurement	Management
Geedи нsk	Leans, trade receivables, cash and each equivalents, As other bank balances and other financial assets measured at amortised cost	gring sanlysis	Diversification of bank deposits and creations and regular monitoring and followers
Liquidity risk	Bostowings, trade payables and other financial Co		Availability of committed credit lines an borrowing facilities
Market risk – foreign exchange	Future commercial resusactions, recognised financial Consistency and liabilities not denominated in Indianana rupee	osle flow forcessing sens palysis	stivity Forward foreign exchange contracts
darket risk – atterest rare	Long-term borrowings at variable rates Se	ensitivity analysis	Diversification of bucrowings



Global Health Limited (themesty toower as Global Health Private Limited) Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 Macci 2021

(a) Credit risk

Credet risk management

Credit risk is the fisk of financial loss to the Group if a customer or counterparty to a financial asset fails to nicer his contactual diligations. The Listoup's exposure to credit six is stillusticed mainly—by the individual characteristics of each financial asset. The carrying amounts of financial assets represent the maximum credit risk exposure.

A default on a linaucial asset is when the counterparty fails to make contractual payments as per agreed terms. This definition of default is determined by considering the business environment in which entity operates and other matro-economic factors.

The Group has a credit risk management policy in place to limit credit losses due to non-performance of counterparties. The Group monitors its exposure to credit risk on an ongoing basis. Assets are written off when there is no reasonable exponention of recovery. Where loans and receivables are written off, the Group continues to cogage in enforcement activity to attempt to recover the dues.

Teade receivables

The Group closely monitors the credit-worthiness of the receivables through internal systems that are configured to define credit families of customers, thereby, limiting the credit risk to precalculated amounts. The Group uses a simplified approach difference expected credit loss modely for the purpose of computation of expected credit loss for tade receivables. Expected credit losses are measured on collective basis for each of the following categories:

Category	Inputs for measurement of expected credit	Assumptions
Covenment	Information on deductions made by government agencies in past years	Trade receivables outstanding for more than two years are considered irrecoverable. Allowance for expected credit loss on receivables outstanding for less than two years is recognised based on expected deductions by government agencies.
Non-gryesument		
Individuals	Individual customer wise trade receivables and information obtained through sales recovery follow ups	Trade receivables outstanding for more than two years are considered irrecoverable. Other receivables are considered good due to ongoing communication with customers.
Corpurates	years	Trend of collections made by the Group over a period of six years preceding balance sheet date and considering default to have occurred if receivables are not collected for more than two years.
Third party administrature of insurance companies	Collection against outstanding receivables in past years	Trade receivables outstanding for more than two years are considered irrecoverable. Allowance for expected credit loss on receivables outstanding for less than two years is recognised based on expected deductions by third party administrators.
Orliers	Customer wise scade receivables and information obtained through sales recovery follow ups	Specific allowance is made by assessing party wise outstanding receivables based on communication between sales team and customers.

Cash and each equivalents and other bank bulinees

Credit risk related to eash and each equivalents and bank deposits is managed by only investing in deposits with highly rated banks and financial institutions and diversifying bank deposits and accounts in different banks. Credit risk is considered low because the Group deals with highly rated banks and financial institution.

Loans and other financial asset

Lamis and other financial assets measured at amortized cost includes received deposits and other receivables. Credit risk related to these financial assets is managed by monitoring the recoverability of such amounts continuously, while at the same time internal control system are in place ensure the amounts are within defined limits. Credit risk is considered low because the Group is in possession of the underlying asset (in case of security deposit) or as per trade experience (in case of unbilled revenue from patient and other receivables from revenue sharing aroung orients). Further, the Group creates provision by assessing individual financial asset for expectation of any credit loss basis 12 month expected credit loss model.

(This space has been intentionally left blank)



(h) Credit risk exposure

i) Expected credit loss for trade receivables under simplified approach i.e. provision matrix approach using historical trends.

	Ar ar 31 March 2021		<u> </u>			······································	***************************************
~	Particulars		, digital and the same and the		*************		(₹ in lakhs)
	PRICUISIS	Government*	Non-government				
			Individuals	Corporates	Third party	Others	Total
					administrators of		
	ļ				insurance	i	
		i		•	compunies		ŀ
	Gross carrying value	11,879,83	1,142,15	1,295.33	4,810.31	832,79	19,960.40
	Less: Expected credit loss (impairment)	3,223.53	757.01		1 '' ' 1	***********	- 1
				1,185.61	941.57	489.85	6,597.57
1	Carrying amount (net of impairment)	8,656.39	385.14	109,72	3,868.74	342.94	13,362.83
	* Inter util including puretonling belongs from partial and of apparent and	Att Inner of all all all a		the second		4/143.444	

et of expected credit loss of similar economic characteristics i.e., Central Government Health Schotte (CGHS) amounts to \$3,392.68 labbs and Ex-serviceman Contributory Health Scheme (ECHS) amounts to \$1,477.96 lakhs.

As at 31 March 2020							(¥ in latchs)
Particulars .		Government*			Non-governme	int .	
			Individuals	Corporates	Third parry	Others	Total
·					#dministrators of		
	÷				insurance		
					companies		
Gross carrying value		12,625.89	993.99	1,714.37	+,319.51	1,328.75	20,982.51
Less: Hapecred credit loss (impairment)		3,067.15	641.01	794.48	777.80	786.98	6.062.42

Carrying amount (net of insparement) 9,558.74 352.98 919.89 3,541.71 541.77 342.7500 * India including outstanding balance from parties net of expected credit loss of similar economic characteristics i.e., Contral Government Health Scheme (CGHS) amounts to \$ 3,496.24 jables

ii) Expected credit losses for other financial assets (measured at an amount equal to 12 months expected credit losses)

As at 31 March 2021			(C in lokhs)
Particulors	. Celimated gross	Expected credit	Carrying amount net of impairment
	corrying amount at default	losses	provision
Loans	856.15	+	856.15
Costs and cash equivalents	6,946.67		6,946.67
Other bank halances	21,983.47		21,983.47
Other Bijancial assets	5,252.37	232.39	5.019.48
			7,777.15

As in 31 March 2020			(V in takhs)
Particulars	Essimated gross carrying amount at default	Expected credit losses	Carrying amount net of impairment provision
zaro.i	799.61		799.61
Cash and cash equivalents	14,757.12		14,757.12
Other bank balances	10,255.17		10,255.17
Other farancial assets	5,930.64	136.60	

iu)	Reconciliation of expected credit toes for other financials asset and trade receivables		(₹ in ialdes)
	Reconciliation of loss allowance	Other financial assets	
	Loss allowance on 1 April 2019		receivables
	Allowance for expected credit loss	136.60	4,955.61
		Ţ.	1,111.61
	Loss ultowance on 31 Murch 2020	136,60	6,067.42
	Allowance for expected credit loss	95.79	530.16
	Loss allowance on 31 March 2021	232,39	6,597,58
	The loss allowance in respect of trade excelebles has changed due to increase in eross carrying amount and change in expected occurrent rates	d	

(b) Liquidity risk

Liquidity risk is the risk that the Group will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cosh or another financial asset. The Group's approach to managing liquidity is to ensure, that it will have sufficient liquidity to meet its liabilities when they are due.

The Group maintains flexibility in funding by maintaining availability under committed credit lines. Management atomitors the Group's liquidity purition (comprising the undrawn borrowing facilities below) and cash and cash equivalents on the basis of expected cash flows.

The Group takes into account the liquidity of the market in which the entity operates.

Maturities of financial liabilities

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include contractual interest payments and exclusion the impact of neiting agreements.

As at 31 March 2021	Less than 1 year	1 - 3 years	More than 3 years	(7 in lak)(s) Total
Non-derivatives		- "		
Borowings	7,106.19	18,719.48	39,298,36	65,124.03
Leose habities	4,042.99	7,270.39		290,945.20
Trade payable	13,J55.3E		-	13,155.21
Other financial liabilities	9,028.00			9,028,03
Total	33,332,39	25,989,87	318,930.18	378,252.45





	·			(₹ in lakhs)
As at 31 Murch 2020	Less than I year	1 - 3 years	More than 3 years	Total
Non-derivatives	***************************************			
Boncovings	1,410.13	14.330.06	46.845.86	62,576.05
Lease habilities	4,289,14	8,346,81	283,679,11	296,315.06
Trade pagable	13,074,04		200,017.11	15,074.04
Other financial liabilities	11,163.81	,		11,163,81
Total	29,937,12	22,666.87	330,524,97	383,128.96
\$,	22,200.01	339,324,31	303,128,90

The Group also has access to the following undrawn horrowing from banks at the end of the reporting period.

		(₹ in lakhs)
Panicolars	As at	As at
	31 March 2021	31 March 2020
Cadrawa honowing facilities	30,344,40	21,286.32

(c) Market risk

(i) Foreign exchange risk

The Group has international transactions and is exposed to foreign exchange risk arising from foreign currency (massections (imports and exports). Foreign exchange risk arises from future commercial transactions and recognised assets and habilities denominated in a currency that is not the Group's functional currency. The Group has not hedged its foreign exchange receivables and payables as at 31 March 2021.

Foreign currency risk exposure:

	As at 31 h	iarch 2021	As at 31 March 2020	
Particulars	Foreign currency	INR (€ in lakhs)	Foreign currency	INR (* in laklis)
Assets				· · · · · · · · · · · · · · · · · · ·
Trade receivables (gross)	USD	287.27	USD	686.90
Liabilities		287.27		686.90
Trade payables	EURO	0.16	EURO	19.55
Tracke payables	USD	0.01	USD	17.08
Timde payables	GBP	62.74	GBI	232.36
Deferred payment liabilities -	USD	406.74	USD	380.68
Defenced payment liabilities	EURO	5,646.18	EURO	4,385.36
		6,115.83		5,035.03

Sensitivity

The sensitivity of profit or loss to changes in the exchange rates arises from foreign currency denominated financial instruments. 31 March 2021					(f in takhs)		
, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Сиятепсу	Exchange rate increase by 3%	Exchange rate decrease by 3%	31 March Exchange rate increase by 6%	Exchange rate decrease by 6%		
Assets Finde receivables (gross)	USD	8.62	(8.62)	41.21	(43.21)		
Liabilities Trade payables	EURO	0.00	(0.03)	1.17	(1.17		
Tinde payables Tinde payables	USD GBP	00.0 88.1	(0.00) (1.88)	1. 02 1 3 .94	(1.02 (13.94)		
Deferred payment hibilities Deferred payment hibilities	USD EURO	12.20 169.39	(13.20)	22.84 263.12	(22.84) (263.13)		

(ii) Interest rate risk

The exposure of the Group's borrowings to interest rate changes at the end of reporting period are as follows.

The Group's variable rate borrowing is subject to interest rate. Below is the overall exposure of the borrowing		(₹ in lakhe)
Particulars	31 March 2021	31 March 2020
Variable (ale Distroying	1 56,724,96 [55,045.79
Total borrowings	56,724.96	55,045.79

Sensitivity

***************************************		,
Profit or loss is sensitive to higher/lower interest expense from borrowings as a result of changes in interest rates.		(₹ in lakhs)
Particulars	31 March 2021	31 March 2020
Interest rates - increase by 100 basis points	(567.25)	(550.44)
Interest rates - decrease by 100 basis points	567.25	\$50.46

Finance lease obligation, vehicle loan and deferred payment liabilities are at fixed rate.



Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Note - 38

Related party transactions

In accordance with the requirements of Ind AS 24, Related party disclosures, the names of the related parties, transactions and year-end balances with them as identified and certified by the management are given below:

i) Entities where control/joint control exists

Joint venture

(i) Medanta Duke Research Institute Private Limited (refer note below)

The Board of Directors (the Board') of Medanta Duke Research Institute Private Limited (a joint venture) in its meeting held on 19 June 2019 had resolved to initiate the process of winding up of the aforementioned entity and subsequently, they have initiated the process of voluntary liquidation of the said entity in accordance with the provisions of the Insolvency and Bankruptey Code, 2016 read with Insolvency and Bankruptey (Voluntary Liquidation Process) Regulations, 2017. This has also been affirmed by the shareholders in the Annual General Meeting ('AGM') of Medanta Duke Research Institute Private Limited held on 24 September 2019. During the year, on 25 February 2021, the official liquidator has submitted final application for liquidation/winding up of the said entity with National Company Law Tribunal ('NCLT'). Flowever, the final order from the NCLT' is availed.

ii) Individual who exercise control over the Holding Company

31 March 2021	31 March 2020
(i) Dr. Naresh Trehan*	(i) Dr. Naresh Trehan

^{*} Basis the rights available as per Articles of Association, Dr. Naresh Treban exercises control over the holding Company.

iii) Key management personnel (KMP)

31 March 2021	31 March 2020
(i) Dr. Naresh Trehan - Chairman and Managing Director	(i) Dr. Naresh Trehan - Chairman and Managing Director
(ii) Mr. Simil Sachdeva	(ii) Mr. Sunil Sachdeva
(iii) Mr. Ravi Kant Jaipuria	(iii) Mr. Ravi Kant Jaipuria
(iv) Mr. Neesaj Bharadwaj	(iv) Mr. Robit Sipahimalani (upto 26 September 2019)
(v) Mr. Sanjeev Kumar	(v) Mr. Necraj Bharadwaj
(vi) Mr. Pankaj Sahni	(vi) Ms. Shayama Chana (upto 24 February 2020)
(vii) Mr. Udairam Thali Koatiiath (from 05 June 2020 upto 21 February 2021)	(vii) Mr. Sanjoes Kumar
(viii) Mr. Bari Shanker Bhartia (from 23 March 2021)	(viii) Mr. Pankaj Salmi
(ix) Mr. Vikram Singh Mehta (from 25 January 2021)	
(x) Mr. Venkotesh Ratousami (from 23 March 2021)	
(xi) Mr. Praveen Mahajan (from 10 July 2020)	

iv) Relatives of KMP

31 March 2021 and 31 March 2020

Name of Relatives	Relationship with KMP
Mr. R.L. Sachdeva	Pather of Mr. Sunil Sachdeva
Mrs. Savitri Sachdova	Mother of Mr. Sunil Sachdeva
Mrs. Shonan Troban	Daughter of Dr. Nacesh Trehan
Mrs. Shyel Trehan	Daughter of Dr. Naresh Trehan
Mrs. Madhu Techan	Wife of Dr. Narosh Trehan
Mr. Navgen Treban	Brother of Dr. Nacesh Trehan

v) Enterprises under the control joint control of KMPs and their relatives or where the individual exercising control over the Holding Company is exercising significant influence or is a KMP, with whom transactions have been undertaken or whose balances are outstanding:

31 March 2021	31 March 2020
MFAN Global India Private Limited	(i)IFAN Global India Private Limited
(ii)Law Chamber of Kapur & Trehan	(ii)Law Chamber of Kapur & Trehan
iii)Raksha TPA Private Limited	(iii)Roksha TPA Private Limited
iv)Sharak Healtheure Private Limited	(iv)Sharak Fleatthcare Private Limited
(v)Language Architecture Body (LAB)	(v)Language Architecture Body (LAB)
(vi)Vidyama Skill Institute Private Limited	(vi) Vidyania Skill Institute Private Limited
(vii)Medanta Institute of Education & Research (Trust)	(vii) Medanto Institute of Education & Research (Urust)
(viii)R) Corp Limited	(viii)RJ Corp Limited
(x)Devyani International Limited	(ix)Devyani International Limited
(x)Diagno Labs Private Limited	(x)Diagno Labs Private Limited
(a)S.A.S Inforech Private Limited	(xi)S.A.S Inforech Private Limited
(sii)Varen Beyerages Limitéd	(sii)Vanin Beverages Limited 28811/

(n) Transac	tions with related parties capited out in the ordinary course of business	:					(f in lakhe)
		1	Related parties]
S No.	Particular	Year	individuals who exercises consuct) pilot Yenture	Key management personnel and their	Emerprises under the control of KMPs and their	
1		<u>-</u>	greather tolung		relandes	scialives of whose Kaip's	Total
1	Rental income		Company			utc.common	
		31 March 2021					,
	Medania Dake Research Institute Private Laured	31 March 2020	****** **** **** *	101		1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	Medianta furnishe of Education & Research (Trust)	31 Slarch 2021				10.17	4.01 10.17
2	Revenue share from food court	31 March 2020				10.17	10.57
1		31 Muncia 2021			ر ماه الماه الم		
	Devyani International familied	31 March 2026			**************************************	144.65	144.65
3	Recumment expenses					203.53	265,53
	IFAN Global India Private Japaned	33 March 2013				147.02	147.02
ļ		3) March 2020				292.02	292.02
[<u>1</u>	Rent expenses	31 Magch 2021					
	Medanta Duke Research Institute Pressae Limited	31 Alarch 2020		6.96			<u>:</u>
5	Professional charges					—	8.98
	Lase Chamber of Kapour and Trehan	51 March 2021				26.46	26,46
J	to state to the annual contract programme of the state of	31 March 2020		re toll manuscus as a second		34.35	31,35
	Training expenses	31 March 2021					
	Vidyanua Shills Institute Provate Limited	31 March 2021				149,57	149.57
7	Reimbursement of expenses					121.30	121.30
	Desygne International Luminal	31 Alaich 2021	-			4.94	4.94
	Purchase of property, plant and equipment	31 March 2020					
		31 March 2021		- 1-5m+ 4mm a - ran - 141-1 r 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1			
	Median Dake Research Institute Private Limited	31 March 2020	**************************************	57.51	<u></u>		
	Hevenue from patients covered under tie-ups				A-181.		57.51
	Rakulai TPA Drivite Limited	33 March 2023				2,090.46	2,090,46
	The second secon	31 March 2020 31 March 2023	···	***************************************		1,850.76	1,850.76
	Sharak Hashheare Private Limited	31 March 2020					
10	Rendering of healtheare services					0.24	0.24
	R.L. Socialeva	31 March 2021			1.97		1.97
1		M March 2020			3.16		3.16
	Mrs. Saeun Sagluleva	31 March 2021 31 March 2020	··				-
	The state of the s	31 March 2021			0.30		0.30
	RJ Corp Lanuest	31 Atrech 2020				1.61	1.61
	Vision Beeringes Limited	31 March 2021			**************************************	1 L-65	11,88
1		5) March 2020				0.85	0.85
	Devium International Lumited	31 March 2021 31 March 2030				0.16	0.16
	A CONTRACTOR OF THE PROPERTY O	31 March 2021	···· - · · · · · · · · · · · · · · · ·			0.62	0.62
	Pankay Sohna	31 March 2020			0.76		0.76
	S.A.S Inforects Driving Diagnost	31 March 2021			*	22.10	22.10
111		31 March 2020			**1	5.05	5.95
ļ	Outsourced lab services	31 March 2021	#1.d	***************************************		17-17-17-17-18-1-1-18-18-18-18-18-18-18-18-18-18-18	
İ	Dague Lifes Preste Limited	31 Alarch 2021 31 March 2020		1880 (46 40)(1-11, 140 / 11-1, 12 k 11-1		286.06	286.06
12	Expenses paid on behalf of	V1 1784 SH 8050				327.48	327.48
1	S.A.S. Inferent Private Limited	31 March 2021	-	W-872-11-11-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1		265.23	265.23
		31 March 2020	*		-	311.99	311.99
13	being of share cupital (including seconities premium)	31 March 2021					
}	Panka Sahui	31 March 2021 31 March 2020	<u>.</u>		25.05 30.23		25.05
14	Director's strong fees (including GST)	- mary 11 2029	······································	···	30.23		39.23
1	Prayern Managen	3t March 2021			9.44		9.44
1	Vikeum Saugh Mehta	31 Moreli 2020				**************************************	+
]	a success smith mitally	31 March 2021 31 March 2020			236	16 -6	2.36
	Han Straker Bhartis	31 March 2021	***************************************				
1	Shayama Chuaa	31 March 2020				************************	4.18
]	puspuna Clines	31 March 2021				1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
	Salaries and other benefits	11 March 2020	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		1.18	*****	1.16
	Dr. Naresh Trehangi	31 March 2021	1,042.28		····		4 0 0 4 4 -
-	The state of the s	31 March 2020	1,825.03				1,842.28 1,825.05
	Sangeev Kumasti	31 March 2021			[46.8]	** ***********************************	146.81
		31 March 2020 31 March 2021		•	170.05		170.05
	Pyrokaj Saluri	31 March 2020		· · · · · · · · · · · · · · · · · ·	213.62 260.66		213,62
	* Net of theated	1	······		460.66	<u></u>	260.86

Net of shedard

We of shedard

There are no post complayarem insteller, other long-teem employee benefits and share based payment payable to Dr. Naiesh Techan, if There are no share based payment payable to Soncev Kunar.



(b) Closing balance with related parties in the ordinary course of business: Kin lakha). Related parties Individuals who loint venture Enterprises under the Perticulars exercises control over the Holding Year personnel and their coursel of KMPs and their Tent relatives relatives or whose KatPs Company are common Equity there capital 31 March 2021 Or. Noresh Treban jointly with Mrr. Madha Techan 689.20 689.21 31 March 2020 689.21 689.21 Dr. Narrah Trelian 31 Murch 2021 1,020.00 1,020.60 31 March 2020 1,020.60 1,020,00 31 March 2021 660.00 Mr. Soud Sachdera Jointly with Mrs. Summi Sachdeea 580.00 31 March 2020 660.00 Pankag Salim 680.00 31 Murch 2021 0.60 0.80 31 March 2020 0.40 9.40 31 March 2021 RJ Cosp Limited 200,00 260.00 31 March 2020 280.00 200.00 Trade payables Dr. Noresh Trebon 31 March 202) 30.54 30.54 31 March 2020 30.54 30.54 Sund Sarlideva 3t March 2021 10.51 50.54 31 March 2020 30.54 30.54 31 March 2021 IFAN Global India Private Limited 29.78 29.78 31 March 2020 15.08 15.06 31 March 2021 Law Chamber of Ropur & Trehan 6.36 6.36 31 March 2020 5.01 5.01 31 March 2021 Volyoma Stall Institute Private Limited 14.84 14.84 31 Murch 2020 12.59 12.57 34 March 2021 Language Architecture Body 0.17 0,17 31 March 2020 0.17 0.17 31 March 2021 Diagno Labs Private Limited 111.94 111.94 31 March 2020 128.09 128.09 Other receivables 31 March 2021 Mediana Institute of Education & Research (Trust) 7.77 7.77 31 March 2020 7.77 7.72 31 Nacch 2021 Deepari International Lorence F13.25 113.25 31 March 2020 136.63 136.63 31 March 2021 S.A.S Inforech Private Limnort 141.50 141.50 31 March 2020 105,44 105.44 Trade receivables 3t March 2021 Rabiba TPA Private Limited 259.21 259.21 31 March 2020 254.30 254.30 31 March 2021 Sharak Healtheare Presate Lenited 31 March 2020 0.93 0.95 31 March 2021 IIJ Corp Linuted 8.60 8.60 31 March 2020 13.16 13.16 31 March 2021 Varun Beverages Limited 0.17 0.17 31 March 2020 0.39 0.39 31 March 2021 Devyani International Lamited 0.78 0.78 31 March 2020 0.62 0.62 31 March 2021 S.A.S Inforecti Private Lamited 26.05

This is the ner investment balance at the holding company has recorded impairment for entire balance in eather years.

31 March 2020

31 March 2021

31 March 2020

(This space has been intentionally life blank)



Medania Duke Research Intrinue Private (Invaed (gross)"

Investment in joint venture



5.95

5.95

Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Note - 39

Capital management

The Circup's objectives when managing capital accres-

To ensure Group's ability to continue as a going concern, and

- To maintain optimum capital structure and so reduce cost of capital

Management assesses the capital requirements in order to maintain an efficient overall financing structure. The Group manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. The Group is not subject to externally imposed capital requirements. The Group has complied with debt covenants as per the terms of the borrowing facility arrangements, except in case of one of the subsidiary, whereby, it is in process of seeling waiver. The Group manages its capital requirements by overseeing the gening ratio:

		(₹ in talchs)
Particulars	As at 31 March 2021	As at 31 March 2020
Total borrowings (excluding interest account)	64,459.78	62,193,80
Linal celuité.	138,234.37	134,953,70
Net debt to equity ratio	47%	46%

Note - 40

Contingent liabilities and commitments

A	Contingent liabilities		(₹ in lakbs)
	Particulars	As at 31 March 2021	As at 31 March 2020
	The order of the management of the order of	1,081.38	1,081.38
	Other cases (refer note (iii) below)	208.36	132,05

- (i) It is not practicable for the Group to estimate the timings of each outflows, if any, in respect of the above pending resolution of the respective proceedings.
- (ii) The amounts disclosed above represent the best possible estimates arrived at on the basis of available information and do not include any penalty payable.
- (ii) The Group is contesting employee related cases in various forums. Based on the internal analysis, the Group is of the view that the likelihood of any outflow of the resources is tempte, except as mentioned above.
- (iv) The Group is contesting various medical related logal cases in various forums. Based on the legal opinion from external consultant and internal analysis, the Group is of the view that the likelihood of any outflow of the resources is remote.

B Commitment

(i)	Capital commissioner		(₹ in lakhs)
	Particulars	As at 31 March 2021	As at 31 March 2020
	Property, plant and equipment	12,496,33	11,015.71

(ii) Other commitment

Part	culars	As at 31 March 2021.	As at 31 March 2020
Dani		231.73	474.53
	zmance bank guarantee \$	1,500.00	1,500.00

*This includes bank guarantees given for capital goods imported under the Export Promotion Capital Goods, of the Government of India, at concessional rates of duty on an undertaking to fulfill quantified exports within stipulated period of time.

S The Holding Company has issued a performance bank guarantee of ₹ 1,500.00 lakhs to Government of Bihar on behalf of Global Flealth Pathiputta Private Limited (a wholly owned subsidiary).



(This space has been intentionally left blank)



Giobal Health Limited (furmerly known as Global Health Private Limited) Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Note - 42 Employee benefits obligations

4	Defined contribution plan		(* to lakha)
	Particulars	For the year ended 31 March 2021	For the year ended 31 March 2020
	Employer's contribution to provident fund charged to statement of profit and loss	1,640.46	1,821.37
	Contribution to employee state insurance scheme charged to statement of profit and loss Contribution to labour welfare fund charged to statement of profit and loss	194.17	184.77
	Total	23.81	22,86
	The Group also has certain defined contributions plans. Contributions are made in contributions.	1,858,44	2,029.00

The Group also has certain defined contributions plans. Contributions are made to recognised provident fund administrated by the Government of India for employees at the rate of 12% of basic salary as per regulations. The obligation of the Group is limited to the amount contributed and it has no further contractual or constructive obligation.

B Gratuity

The Group provides for gratuity for employees in India as pee the Payment of Gratuity Act, 1972. Employees who are in continuous service for a period of 5 years are eligible for gratuity. The amount of gratuity payable on retirement/termination is the employees last drawn basic salary per month computed proportionately for 15 days salary multiplied for the number of years of service

(i) Amounts recognized in the balance sheet

Present value of the obligation at end
Unfunded liability/provision in Balance Sheet

(* in takks)

Present value of the obligation at end
Unfunded liability/provision in Balance Sheet

(* in takks)

As at 31 March 2021 As at 31 March 2020

3,270.77 2,847.96

(2,847.96)

Bifurcation of present value of obligation at the end of the year - Corrent and Non Current

Particulars Current liability	As at 31 March 2021	As at 31 March 2020
Nun-current liability	580.48	575.10
Total	2,690.29 3,270,77	2,272.86 2,847.96
	3,2,70,77	2,847.9

(ii) Expenses recognized in other comprehensive income (₹ in lakhs) For the year ended For the year ended **Particulars** 31 March 2021 31 March 2020 Actuarial loss/(gains) -Changes in demographic assumptions (46.34) (1.71)·Changes in financial assumptions 301.27 177.38 -Changes in experience adjustment (206.22) 57.35 Expenses recognized in other comprehensive income 48.71 233.02

(iii) Expenses recognized in statement of profit and loss (₹ in lakbs) **Particulars** For the year ended For the year ouded 31 March 2021 31 March 2020 Corrent service cost 512.58 467,07 Interest cost 195.61 183.74 Cost recognized during the year 708.19 650.81

(iv) Movement in the liability recognized in the balance sheet is as under (₹ ín takiss) For the year ended For the year ended 31 March 2021 31 March 2020 Present value of defined benefit obligation at the beginning of the year 2,847.97 2,399.05 Currein service cost 512.58 467.07 Interest cost 195.61 163,74 A cruarial loss 48.71 233.02 Benefits paid (334.11)(434.91) Present value of defined benefit obligation at the end of the year 3,270.76 2,847.97

(v) For determination of the liability, the following actuarial assumptions were used:

Particulars	For the year ended 31 March 2021	For the year ended 31 March 2020
Discount rate	6.76%	6.76% to 6.87
Salary escalation rate	5% to 6%	
Rotiromoni age (years)	i I	2.017
Average past service	60 years	···) · · ·
Average age	0.57 to 3.74 years	
Average ternaining working life	29 to 32.88 years	28,43 to 31,53 yes
	27.12 to 31 years	
Wishdeawal rate	ļ '	
Up to 30 years	4% to 13.4%;	
From 31 to 44 years	I 1	· · · · · ·
Above 44 years	3% to 3.6%	3.00
Marialize cause inclusive of paradicina for disability, 100% of 133331 (2012), 435	2% to 0.4%	2.00

Mortality rates inclusive of provision for disability -100% of IALM (2012 - 14)



(vi)	Maturity profile	of def	fined ben	efit oblig	ation

i) į	Maturity profile of defined benef	it obligation		(₹ in lakhs)
	Year 31 March 2021	Year 31 March 2020	As at 31 March 2021	As at 31 March 2020.
	April 2021 March 2022	April 2020: March 2021	599.78	589.31
- 1	April 2022- March 2023	April 2021 - March 2022	140.50	115.80
-	April 2023- March 2024	April 2022- March 2023	204,61	183.35
1	April 2024 - March 2025	April 2023 - March 2024	130.76	165.17
Ì	April 2025- March 2026	April 2024- March 2025	176.42	116.64
-	April 2026- March 2027	April 2025: March 2026	369.65	266.02
ı	April 2027 onwards	April 2026 onwards	4,193.82	3,769.48
ŧ	Gross Total		5,815.54	5,205.77

sensitivity analysis for gramity		₹ in lakhs
Particulars	31 March 2021	31 March 2020
a) Impact of the change in discount rate		······································
Present value of obligation at the end of the year	3,270.76	2,847,9
Impact due to increase of 0.50 %	(152.02)	(119.78
impact the to decrease of 0.50 %	165.93	130.4
b) Impact of the change in salary increase		
Present value of obligation at the end of the year	3,270.76	2,847.9
Impact due to increase of 0.50 %	166.42	132.19
Impact due to decrease of 0.50 %	(153.81)	(122.38

and withdrawals are not material. Hence impact of change is not calculated above.

Sensitivities as to rate of inflation, rate of increase of pensions in payment, rate of increase of pensions before retirement and life expectancy are not applicable being a lump sum benefit on retirement

The above sensitivity analysis are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in sum of the assumptions may be correlated. When calculating the sensitivity of defined benefit obligation to significant actuarial assumptions the same method (present value of defined benefit obligations calculated with the projected unit credit method at the end of the repozing period) has been applied as when calculating the defined benefit liability

(viii) Risk

Salacy increases	Actual salary increases will increase the plan's liability. Increase in salary increase rate assumption in future valuations will also increase the hability.
	Reduction in discount rate in subsequent valuations can increase the plan's liability.
Mortality and disability	Actual deaths and disability cases proving lower or higher than assumed in the valuation can impact the liabilities.
Wighdrowsls	Actual withdrawals proving higher or lower than assumed withdrawals and change of withdrawal rates at subsequent valuations can impact plan's liability.

Note - 43

Share based payments

GHPL ESOP Plan 2014

The Holding Company vide General Meeting resolution dated 25 September 2014 approved "Global Health Employee Stock Option Scheme 2014" for granting employee stuck uptions in the form of equity shares linked to the completion of a minimum period of continued employment to the eligible employees of the Holding Company. The plan was modified on 11 May 2016 where in the folding Company increased the number of available options from 740,628 to 852,973 to sligible employees and the vesting period was revised from 5 years from the date of grant to graded vesting of 25% each year starting with effect from 30 April 2016. The Holding Company had granted 740,628 options to chigible employees on 25 September 2014. The eligible employees, including directors, for the purpose of this scheme will be determined by the Remuneration Committee from time to time. Each stock options entitle the eligible employee to avail one share at the end of the vesting period. The vested options can be exercised within a period of 3 years from the date of vesting.

Movement in number of options:

Particulars	As at 31 March 2021	As at 31 March 2020
Opening balance	260,648	354,123
15surgised during the year	85,565	93,475
Lapsed during the year	19,839	
Closing balance	155,244	260,648



Particulars	Grant I	Grant II	Grant [1]	Grant IV
Outstanding options (unvested and vested but not exercised) as at 31	50,244			105.000
March 2021				11,2,0,87
Outstanding options (unvested and vested but not exercised) as at 31 March 2020	40,972	26,451	19,838	173,387
Grant date Verting period	25 September 2014 Graded vesting (25% options to vest every year from the date of grant)		Graded vesting (25% options to vest every year	Graderi vertino 125%
Exercise price Expiry date Expiry date Fair value of option on the date of Remaining contractual life (weighted months) as at 31 March 2021 Remaining contractual life (weighted months) as at 31 March 2020	10.00 29 April 2022 691.95 13.13 25.30	10.00 12 July 2023 742.28 0.00 39.93	10.06 08 November 2023 755.29 0.00 43.90	09 December 2023 755.24

*The fair value of the options has been determined using the Black Scholes model, as certified by an independent valuer with the following assumptions:

			en me tonemanif unsettibild	415.
Particulars	Grant F	Grant II	Grant III	Grant IV
Weighted average share price (Rs.)	698.65	749.78	762.95	762,95
Unorcise price (Rs.)	10.00	10.00	10.00	10,00
Expected volatility (%)	37%	37%	37%	
Expected life of the option (years)	3-7	17	1-7	5-7
Risk-free interest rate	8,70%	7.18%	6.67%	6.51%
Weighted average fair value as on the grant date (Rs.)	691.95	742.28	755.29	755.24

GHPL ESOP Plan 2016

The Holding Company vide General Meeting resolution dated 13 July 2016 approved "Global Health Employee Stock Option Scheme 2016" for granting employee stock options in the form of equity shares linked to the completion of a minimum period of continued employment to the eligible employees of the Holding Company. The eligible employees, including directors, for the purpose of this scheme will be determined by the Remuneration Committee from time to time. Each stock options entitle the eligible employee to avail one share at the end of the vesting period. The authorized share capital of the Holding Company was also increased by creation of 1,025,000 Class A equity shares on 13 July 2016 with a view to allot the shares under the PSOP Plan 2016. Each stock options entitle the eligible employee to avail one share at the end of the vesting period. The vested options can be exercised within a period of 3 years from the date of vesting.

Movement in number of options:

iculars	As at 31 March 2021	As at 31 March 2020
ning balance		***************************************
cised during the year	561,500	771,250
used duting the year	155,250	118,750
ed during the year	' 1	· ,
ing balance	55,000	91,000
ing stance	351,250	561,500

Particulars Particulars	Grant I	Grapt II	Grant III	Great IV	Grant V
Outstanding options (unvested and vested but not exercised) as at 31 March 2021	116,250	25,000	17,000	17,000	176,000
Outstanding options (unvested and vested but not exercised) as at 31 March 2020	157,590	80,000	. 50,000	50,000	224,000
Grant date	10 December 2016	19 March 2018	37 April 2018	25 April 2018	12 1-1- 000
Vesting period	Graded vesting (25% options to vest every year from the date of grant)	options to vest every year	Graded vesting (33.33% options to vest every year	Graded vesting (33,33% options to vest every year	Graded vesting (20% options to yest every wa
Exercise price	10.00	10.00	10.00	10.00	
Expiry date	09 December 2023		16 April 2024	24 April 2024	10.00
Fide market value of option on the date of grant*	755.24	626.01	626.03	626.16	13 July 2020 626.11
Reasoning contractual life (weighted months) as at 31 March 2021	32.77	48.30	37.07	37.33	64.33
Remaining contractual life (weighted months) as at 31 March 2020	44.93	60.47	49,23	49.50	76.50





Consulidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

"The fair value of the options has been determined using the black Scholes model, as certified by an independent valuer with the following assumptions

Particulars Particulars		Geant II	Crant III	Grant IV	Caner
Weighted average share price (Rs.)	762.95	623.44	633:44		
Exercise price (Rs.)	10.00	10.00	10.00	035,44	633.44
Isspected volatility (%)	36%			10.00	
Expected life of the option (rears)	3076	37%	38%	38%	37%
<u> </u>	1-7	1.7	1-6	1-6	1.8
Risk-free interest rate	6.51%	7.44%	8.09%	7.82%	8.22%
Weighted average fair value as on the	755.24	626.61	626.03	626.16	626.17
grant date (Rs.)					

During the year ended on 31 March 2021 and 31 March 2028, the Holding Company has recorded an employee stock compensation expense of ₹ 378.67 laklis and ₹ 956.97 laklis respectively.

During the year ended on 31 March 2021, the total number of options vested but not exercised is 3,28,092 (31 March 2020 : 392,195).

The weighted average share price on the date of exercise is ₹ 574.02 (31 March 2020 : ₹ 505.88)

Note - 44

Change in accounting policy on government grants

- 1 During the year, the Group has voluntarily changed its accounting policy related to government grants whereby, grants relating to capital assets are recognised as deferred income on initial recognition and are credited to statement of profit and loss on a straight line basis over the expected useful life of the related asset and presented within 'other operating income'.
- II The application of new accounting policy will depict the actual cost of the capital assets and provides more relevant information to the users of financial statements.
- III In case of the Holding Company and one of the subsidiary companies, the impact of accounting policy change is not material on the preceding period and in the balance sheet as at the beginning of preceding period. However, the impact on the relevant financial statement line items for all periods pertaining to another subsidiary and impact for the current period for the Group has been tabulated below:

	Particulars			(₹ in lakhs)
^	Paraculary	As at 31 March 2021	As at 31 March 2020	As at 01 April 2010
	Balance sheer	·————		
	Increase in property, plant and equipment (net block)	2,189.69	1,999.70	}
	Increase in capital work-in-progress			1,035,76
	Increase in other non-current liabilities	1,954.21	1,815.78	1,002.56
	Increase in other current liabilities	235.48	183.92	33.20
	The state of the s		Ve 10 2 a Augustine	

В	Particulars		(₹ in lakhs)
D	rusticulars	For the year ended	For the year ended
		31 March 2021	31 March 2020
	Increase in other operating income	207.66	62.62
	Increase in depreciation and amortisation expense	207,66	62.62

C. There is no impact on basic and diluted earnings per share in the respective years on account of the above.

Note - 45

Previous period/year numbers have been regrouped/reclassified wherever considered necessary.

Balance slieet	31 March 2020 (Reported)	Adjustments	31 March 2020 (Reclassified)
Liabilities			
Non-current provisions	4,623.97	(1,015.08)	3,608.89
Current provisions	877.47	1,015.08	-
Asseis		1,012.00	1,892.55
Other corrent financial assets	3,386.13	23.61	3,409.74
Other current assets	684.37	(23.62)	660.75
		(2.5.02)	000.73
Cash and eash equivalents	14,915.18	(158.06)	1478746
Other bank balances	10.097.11	, , ,	14,757.13
	10,077.113	156.06	10,2 5 5.17

Statement of profit and loss	31 March 2020 (Reported)	Adjustments	31 March 2020 (Rechassified)	Adjustments due to change in accounting policy*	31 March 2020 (Restated)
Revenue from operations	148,421.58	1,558.00	149,979.58	62.62	150,042,20
Other income	5,942.51	(1,588.01)	4,384.50		4,384,50
"Refer unte 12 for details					1,504.50

(This space has been intentionally left blank)



Global Health Limited (formerly known as Global Health Private Limited) Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Note - 46 Interest in subsidiaries and joint venture

A Collegian Day

Nume of entity	Place of business	Ownership interest	held by the Group	Ownership intere- controlling i		Principal activities
•	Place of Business	As 2t 31 March 2021	As at 31 March 2020	As at 31 March 2021	As at 31 March 2020	
Global Fleaith Pathputra Private Limited	India	100	100	,	-	Floalthcare services
Medanta Holdings Private Limited	India	100	100	-	-	Healthcare services

(b) Joint venture (equity method)\$

5 The Board of Directors ('the Board') of Modanta Duke Research Institute Private Limited (a joint venture) in its meeting held on 19 June 2019 had resolved to initiate the process of winding up of the aforementioned entity and subsequently, they have initiated the process of voluntary liquidation of the said entity in accordance with the provisions of the Insolvency and Bankruptcy Code, 2016 read with Insolvency and Bankruptcy (Voluntary Liquidation Process) Regulations, 2017. This has also been affirmed by the shareholders in the Annual General Meeting ('AGM') of I 'edanta Duke Research Institute Private Limited field on 24 September 2019. During the year, on 25 February 2021, the official liquidator has submitted final application for liquidation/winding up of the said entity with National Company Law Tolbural (NCLT'). However, the final order from the NCLT is awaited. The disclosures pertaining to previous year ended i.e., 31 March 2020 are us below:

						(f in lukhs)
(i)	Name of entity	Place of business	% of ownership	Accounting method		g amount opsirment)
	, water 52 cavary	X 144.0 01 M 404114113	interest	/xccommag menou	As at 31 March 2021	As at 31 March 2020
	Medanta Duke Research Institute Private Limited	India	50.01%	Equity method	-	-

(ii) There were no commitments and contingent liabilities in joint venture company.

(iii) Summarised financial information for joint venture\$

Summarised balance sheer	As at 31 March 2020		
Currom assets			
Cash and cash equivalents	58.80		
Total current assets (A)	58.80		
Total non-current assets (B)	30.00		
Assets held for sale (C)			
Total assets (D = A+B+C)	58.81		
Current liabilities			
Financial liabilities (excluding trade payables)	1.05		
Total current liabilities (E)	1.05		
Total non-current habitities (P)			
Total liabilities (G = E+P)	1.05		
Net assets (D-G)	57,75		

Reconciliation to carrying amount of investment

Summarised balance sheet	As at 31 March 2020
Opening retained carnings	(840,61)
Loss for the year	(4.36)
Other comprehensive income	
Closing net assets	(844.97)
Circup's share in %	50.01%
Group's share in ?	(422.57)
Gross value of investment	901.80
Carrying value of investment	479,25
Less: Impairment in the value of investment	(479.25)
Net carrying value of investment	(477.60)





Chobal Health Limited (Interesty known as Global Health Privote Limited)
Convolidated summary of significant accounting policies and other explanatory information for the year coded 31 March 2021

Name of the equity	total lia	tal acaets minus bilities	Share in pa-	ofic and loss	Share in other of inco-		Share in total coince	
	As % of Consolidated Bel 255616	Ajagiigi (V in lakhe)	As Va of Consolidated profit	Augunt (f in iakha)	Consolidated other comprehensive income	Amount (₹ io laklis)	As % of Convolidated total comprehensive income	Amson (f in laklis)
Holding Compray						<u></u>		<u></u>
Global Health Lemiest (tornerly known as Global Health Privace Lemies)	108.18%	149,535,51	201.37%	5,800.97	1340.4064	(40.53)	200.12%	5,760
Subsidiaries	Υ			~~~				
IIIdlan					···			
Global Realth Padipules Private Lumted	(3.32%)	(4,586.90)	(59,29%)	(1,707.92)	0.00%		(59.35%)	0.700.0
Medania Holdings Paware Limited	(4.80%)	(6,712.24)	(42.09W)	(1,212.33)	(12÷0.40%)	37.51	(+0.83%)	0,707.92 (1,174.8
foint reature (investment accounted for using the equity method)								
Indian					······			
Medianti Duko Research Institute Private Limited	0.00%		0.00%		0.00%	·		
Total	100.06%	138,234,37	100.00%	2,880.73	100.00%	(3.02)	0.00%	2,877.7



(This space has been intentionally left blank)

Note - 48

Revenue related disclosures

-1 Disaggregation of revenue

Revenue recognised mainly comprises of healthcare services. Set out below is the disaggregation of the Group's sevenue from contracts with customers:

		(V in lakhs)
Description	For the year ended 31 March 2021	For the year ended 31 March 2020
(A) Operating revenue		
income from healthcare services		
In patient	118,653.60	119,412.03
Out patient	23,130.50	28,645.08
Sub-total (A)	141,784.10	146,057,11
(B) Income from sale of pharmacy products to out-patients		
Salu of pharmacy products	1,148.32	- 1
Sub-votal (B)	1,148.32	-
(B) Other operating revenue]	
Clinical research income	129.01	186.82
Other operating revenue	53.57	177.65
Sub-total (C)	182.58	364.47
Total revenue under Ind AS 115	143,115.00	148,421.58

Description	For the year ended 31 March 2021	For the year ended 31 March 2020
(A) Operating revenue		
Income from healthcare services		
Gavernmen	12,019.35	16,677.25
Non-government	129,764.75	131,379.86
Total operating revenue	141,784.10	148,057.11

ii Contract balances

The following table provides information about receivables and contract liabilities from contract with customers:

		(K in laichs)
Particulars	As at 31 Moreh 2021	As at 31 March 2020
Contract liabilities		
Advance from customers	2,915.46	2,110.61
Total contract liabilities	2,915,46	2,110.61
•		
Contract assets		
Unbilled revenue	1,417.50	618.41
Total contract assets	1,417.50	618.41

Contract asset is the right to consideration in exchange for goods or services transferred to the customer. Contract liability is the entity's obligation to transfer goods or services to a customer for which the entity has received consideration from the customer in advance. Contract assets (unbilled receivables) are transferred to receivables when the rights become unconditional and contract liabilities are derecognised as and when the performance obligation is satisfied.

111	Significant changes in the contract liabilities balances during the year are as follows:		(₹ in lakhs)
	Contract liabilities - advance from customers	As at 31 March 2021	As at 31 Murch 2020
	Opening balance of contract liabilities - advance from customers	2,110.61	1,609.61
	Less: Amount of revenue recognised during the year	(141,784.10)	148,057.11)
	Add: Addition during the year	142,588.95	148,558.11
	Closing balance of contract liabilities - advance from customers	2,915,46	2,110.61

IV The aggregate amount of transaction price allocated to the performance obligations (yet to complete) as at 31 March 2021 is ₹ 2,915.46 lakhs (31 March 2020; ₹ 2,110.61 lakhs). This balance represents the advance received from outtomers (gross) against healthcare services. The management expects to further bill and collect the remaining balance of total consideration in the coming period. These balances will be recognised as revenue in subsequent period as per the policy of the Group.

V Reconciliation of revenue:

<u> </u>		(₹ in faldes)
Particulars	For the year ended 31 March 2023	For the year ended 31 March 2020
Revenue from operations	147,645.08	193,679,40
Adjustment for:	Į į	-
Discounts and rebates	(4,712.66)	
Income from healthcare services and sale of pharmacy products to out-patients	142,932.42	148,057.12

(New Deih)

Global Health Limited (formerly known as Global Health Private Limited) Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Note - 49

The chief aperating decision maker (CODM) examines due Group's performance from a service perspective and has identified the Healtheane services as single business segment. The GODM reviews internal management reports to assess the performance of the segment Healtheare services.

The revenues from external costemers attributed to an individual is not material and there are no transactions with a single external customer which would amount to rea percent or more of the Group's revenues.

Note - 50

Research and development expenditure includes consultant's and specialist honoration amounting to ₹ 2.72 lakbs (31 March 2020; ₹ 1.23 lakbs) and saluries of employees amounting to ₹ 78.36 lakbs (31 March 2020; ₹ 99.29 Lakbs).

Note - 51

Raman Sharma (Complainant) filed a First Information Report (FIR) dated 6 June 2020 against, inter alia, the Holding Company and certain directors and other office beaters, under various provisions of the Indian Penal Code, the Prevention of Money Laundering Act, 2002 and the Prevention of Corruption Act, 1988. The Complainant has alleged that the Haryana Urban Development Authority (HUDA) had illegally allotted hospital land parcel, resulting in unfair pseumiary advantage. The said matter was investigated and the investigation agencies concluded the matter in the favour of the Holding Company. Accordingly, the investigation agencies filed a Cancellation Report with respect to the PIR before the Additional Sessions Court, Gurugram ("the Court"). The Complainant filed a protest petition challenging the above Cancellation Report. Vide its order dated 12 March 2021, the Caust accepted the Cancellation Report and the FIR stood cancelled. Prior to closing of the FIR, the Enforcement Directorate, New Delhi in its letter dated 22 December 2020 (Notice") has also sought certain information from the Holding Company regarding, inter alia, the capital investment made in and by the Holding Company in India and oveness, detaits of bank accounts of the directors of the Holding Company, and details of fixed assets created in the Holding Company has requested the Enforcement Directorate to close this matter in light of cancellation of the FIR. The Holding Company has not received any further communication from the Enforcement Directorate in this matter.

Note - 52

In the board meeting dated 25 January 2021, the Board of Directors of the Holding Company has approved capital raising comprising of fresh issue and offer for sale of equity shares by the existing shareholders through an Initial Public Offering (IPO). Further, subsequent to the year-end, the Holding Company has allotted 652,973 Class A equity shares to Dr. Natesh Trehan at face value of \$\frac{1}{2}\$ to each at a premium of \$\frac{1}{2}\$ 565 per share on preferential allottment basis as per provisions of the Articles of Association (IAOA) of the Holding Company and the shareholders agreement dated 12 January 2015.

Note - \$3

The trade receivables as at 31 March 2021 interedia include receivables in foreign currency which have been outstanding aggregating to ₹ 287.27 lakhs (31 March 2020 : ₹ 686.90 lakhs) beyond the timeline stipulated by the applicable provisions of Reserve Bank of India read with foreign exchange management regulations. The Holding Company has filed necessary applications with the appropriate authority in this regard as per regulations. The management does not envisage any additional financial impact of the same at this stage.

Note - 54

The Code on Social Security, 2020 ("the Code") relating to employee benefits during employment and post-employment received Presidential assent in September 2020. Subsequently, the Ministry of Labour and Employment had released the draft rules on the aforementioned Code. However, the same is yet to be notified. The Group will evaluate the impact and make necessary adjustments to the financial statements in the period when the Code will be notified and will come into effect.

(This space but been intentionally left blank)



Global Health Limited (formerly known as Global Health Private Limited) Consolidated summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Note - 55

The outbreak of Goronavirus Disease 2019 (COVID-19), declared as a pandemic by the World Health Organisation, severely impacted the businesses and economic activities around the world including India: Doring the year ended 31 March 2021; both Central and State Governments of India lind imposed took down and other emergency restrictions which had led to the discuption of all regular business operations. Purther, the recent second wave of COVID-19 has again resulted in partial lockdown/restrictions in various states. The Group is closely monitoring the impact of the aforementioned pandemic and has made a detailed assessment and considered possible effects, if any, on its liquidity position, including recoverability of its assets as at the balance sheet date and currently believes that there will not be any adverse impact on the long term operations, financial position and performance of the Group.

This is the consolidated summary of significant accounting policies and other explanatory information referred to in our report of even date.

For Walker Chandiak & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013.

Rajni Mundra

Paciner

Membership No.: 058644

Place: New Delhi

Date: 17 September 2021

For and on behalf of the Board of Directors

Dr. Naresh Trehan

Chairman and Munaging Director

[DIN:00012148]

Place: Gurugram

Date: 17 September 2021

Saniecy Kumar

Group Chief Financial Officer

Place: Gurugram

Date: 17 September 2021

(Company of the comp

Chief Excounte Officer

Place: Gunigram

Date: 17 September 2021

Rahus Rahjan Company Secretary

Place: Gutugram

Date: 17 September 2021

والمعادية والمعادية والمنافق و

Walker Chandiok & Co LLP (Formerly Walker, Chandiok & Co) 6th Floor, Plot No. 19A, Sector 16A, Noida 201361 India

T +91 120 710 9001 F +91 120 710 9002

Independent Auditor's Report

To the Members of Global Health Limited (formerly known as Global Health Private Limited)

Report on the Audit of the Standalone Financial Statements

Opinion

- 1. We have audited the accompanying standalone financial statements of Global Health Limited formerly known as Global Health Private Limited) ('the Company'), which comprise the Balance Sheet as at 31 March 2021, the Statement of Profit and Loss (including Other Comprehensive Income), the Cash Flow Statement and the Statement of Changes in Equity for the year then ended, and a summary of the significant accounting policies and other explanatory information.
- 2. In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India including Indian Accounting Standards ('Ind AS') specified under section 133 of the Act, of the state of affairs of the Company as at 31 March 2021, and its profit (including other comprehensive income), its cash flows and the changes in equity for the year ended on that date.

Basis for Opinion

3. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Information other than the Standalone Financial Statements and Auditor's Report thereon

4. The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Director's Report, but does not include the standalone financial statements and our applicar's report thereon.

CAGO VOOR

Independent Auditor's Report to the members of Global Health Limited (formerly known as Global Health Private Limited), on the standalone financial statements for the year ended 31 March 2021 (cont'd)

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

- 5. The accompanying standalone financial statements have been approved by the Company's Board of Directors. The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Ind AS specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.
- 6. In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.
- 7. Those Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

- 8. Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.
- As part of an audit in accordance with Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a tradecrial misstatement resulting from fraud is higher than for one resulting from error, as fraud may havelve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

PEDVECE

Independent Auditor's Report to the members of Global Health Limited (formerly known as Global Health Private Limited), on the standalone financial statements for the year ended 31 March 2021 (cont'd)

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
 are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for
 expressing our opinion on whether the Company has adequate internal financial controls with reference
 to financial statements in place and the operating effectiveness of such controls;
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management;
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern; and
- Evaluate the overall presentation, structure and content of the standalone financial statements, including
 the disclosures, and whether the standalone financial statements represent the underlying transactions
 and events in a manner that achieves fair presentation.
- 10. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Report on Other Legal and Regulatory Requirements

- 11. Based on our audit, we report that the provisions of section 197 read with Schedule V to the Act was not applicable to the Company since the Company was not a public company as at 31 March 2021, as defined under section 2(71) of the Act. Accordingly, reporting under section 197(16) is not applicable.
- 12. As required by the Companies (Auditor's Report) Order, 2016 ('the Order') issued by the Central Government of India in terms of section 143(11) of the Act, we give in the Annexure A, a statement on the matters specified in paragraphs 3 and 4 of the Order.
- 13. Further to our comments in Annexure A, as required by section 143(3) of the Act, based on our audit, we report, to the extent applicable, that:
 - a) we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the accompanying standalone financial statements:
 - b) in our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;
 - c) the standalone financial statements dealt with by this report are in agreement with the books of account;

in our opinion, the aforesaid standalone financial statements comply with Ind AS specified under section of the Act;

Independent Auditor's Report to the members of Global Health Limited (formerly known as Global Health Private Limited), on the standalone financial statements for the year ended 31 March 2021 (cont'd)

- on the basis of the written representations received from the directors and taken on record by the Board
 of Directors, none of the directors is disqualified as on 31 March 2021 from being appointed as a director
 in terms of section 164(2) of the Act;
- f) we have also audited the internal financial controls with reference to financial statements of the Company as on 31 March 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date and our report dated 17 September 2021 as per Annexure B expressed unmodified opinion; and
- g) with respect to the other matters to be included in the Auditor's Report in accordance with rule 11 of the Companies (Audit and Auditors) Rules, 2014 (as amended), in our opinion and to the best of our information and according to the explanations given to us:
 - i. the Company, as detailed in note 40 to the standalone financial statements, has disclosed the impact of pending litigations on its financial position as at 31 March 2021;
 - ii. the Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses as at 31 March 2021;
 - iii. there were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended 31 March 2021; and
 - iv. the disclosure requirements relating to holdings as well as dealings in specified bank notes were applicable for the period from 8 November 2016 to 30 December 2016, which are not relevant to these standalone financial statements. Hence, reporting under this clause is not applicable.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Partner

Membership No.: 058644

UDIN: 21058644AAAAFF4992

Place: New Delhi-

Date: 17 September 2021

Annexure A to the Independent Auditor's Report of even date to the members of Global Health Limited (Iormerly known as Global Health Private Limited), on the standalone financial statements for the year ended 31 March 2021 (cont'd)

Annexure A

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, and to the best of our knowledge and belief, we report that:

- (i) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of property, plant and equipment, capital work-in-progress, right of use assets and intangible assets.
 - (b) The Company has a regular program of physical verification of its property, plant and equipment under which property, plant and equipment are verified in a phased manner over a period of two years, which, in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. In accordance with this program, certain property, plant and equipment were verified during the year and no material discrepancies were noticed on such verification.
 - (c) The title/lease deeds of all the immovable properties (which are included under the head 'property, plant and equipment' and 'right of use assets') are held in the name of the Company.
- (ii) In our opinion, the management has conducted physical verification of inventory at reasonable intervals during the year and no material discrepancies between physical inventory and book records were noticed on physical verification.
- (iii) The Company has not granted any loan, secured or unsecured to companies, firms, Limited Liability Partnerships (LLPs) or other parties covered in the register maintained under Section 189 of the Act. Accordingly, the provisions of clauses 3(iii)(a), 3(iii)(b) and 3(iii)(c) of the Order are not applicable.
- (iv) In our opinion, the Company has complied with the provisions of Section 186 in respect of investments and guarantees. Further, in our opinion, the Company has not entered into any transaction covered under Section 185 and Section 186 of the Act in respect of loans and security.
- (v) In our opinion, the Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of clause 3(v) of the Order are not applicable.
- (vi) We have broadly reviewed the books of account maintained by the Company pursuant to the Rules made by the Central Government for the maintenance of cost records under sub-section (1) of Section 148 of the Act in respect of Company's products/services and are of the opinion that, prima facie, the prescribed accounts and records have been made and maintained. However, we have not made a detailed examination of the cost records with a view to determine whether they are accurate or complete.

(vii)(a) The Company is generally regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, goods and services tax, cess and other material statutory dues, as applicable, to the appropriate authorities. Further, no undisputed amounts payable in respect thereof were outstanding at the year-end for a period of more than six months from the date they become payable.

Annexure A to the Independent Auditor's Report of even date to the members of Global Health Limited (formerly known as Global Health Private Limited), on the standalone financial statements for the year ended 31 March 2021 (cont'd)

(b) The dues outstanding in respect of income-tax, sales tax, service-tax, duty of customs, duty of excise, value added tax and goods and services tax on account of any dispute, are as follows:

Statement of Disputed Dues

Name of the statute	Nature of ducs	Amount (₹ in lakhs)	Amount paid under protest (₹ in lakhs)	Period to which the amount relates	Forum where dispute is pending
Income-tax Act, 1961	Disallowance of certain expenses	30.55	-	Assessment Year 2016-17	Commissioner of Income-tax (Appeals)
Income-tax Act, 1961	Disallowance of share based payment expense and certain other expenses	1,050.83	_	Assessment Year 2017-18	Commissioner of Income-tax (Appeals)

- (viii) The Company has not defaulted in repayment of loans or borrowings to any financial institution or bank during the year. The Company does not have any loans or borrowings payable to government and no dues payable to debenture-holders during the year.
- (ix) In our opinion, the Company has applied moneys raised by way of the term loans for the purposes for which these were raised. The Company did not raise moneys by way of initial public offer or further public offer (including debt instruments).
- (x) No final by the Company or on the Company by its officers or employees has been noticed or reported during the period covered by our audit.
- (xi) The provisions of Section 197 of the Act read with Schedule V to the Act was not applicable to the Company since the Company was not a public company as at 31 March 2021, as defined under Section 2(71) of the Act. Accordingly, provisions of clause 3(xi) of the Order are not applicable.
- (xii) In our opinion, the Company is not a Nidhi Company. Accordingly, provisions of clause 3(xii) of the Order are not applicable.
- (xiii) In our opinion, all transactions with the related parties are in compliance with Section 188 of the Act, where applicable, and the requisite details have been disclosed in the financial statements, as required by the applicable Ind AS. Further, in our opinion, the Company was not required to constitute audit committee under Section 177 of the Act as at 31 March 2021.
- (xiv) During the year, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures.
- (xv) In our opinion, the Company has not entered into any non-cash transactions with the directors or persons connected with them covered under Section 192 of the Act.



Annexure A to the Independent Auditor's Report of even date to the members of Global Health Limited (formerly known as Global Health Private Limited), on the standalone financial statements for the year ended 31 March 2021 (cont'd)

xvi) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Partner

Membership No.: 058644

UDIN: 21058644AAAAFF4992

Place: New Delhi

Date: 17 September 2021

Annexure B to the Independent Auditor's Report of even date to the members of Global Health Limited (formerly known as Global Health Private Limited) on the standalone financial statements for the year ended 31 March 2021 (cont'd)

Annexure B

Independent Auditor's Report on the internal financial controls with reference to the standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ('the Act')

1. In conjunction with our audit of the standalone financial statements of Global Health Limited (formerly known as Global Health Private Limited) ('the Company') as at and for the year ended 31 March 2021, we have audited the internal financial controls with reference to financial statements of the Company as at that date.

Responsibilities of Management and Those Charged with Governance for Internal Financial Controls

2. The Company's Board of Directors is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the 'Guidance Note') issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of the Company's business, including adherence to the Company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility for the Audit of the Internal Financial Controls with Reference to Financial Statements

- 3. Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Standards on Auditing issued by the ICAI prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements, and the Guidance Note issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.
- 4. Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements includes obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.
- 5. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial Controls with Reference to Financial Statements

6. A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements

Annexure B to the Independent Auditor's Report of even date to the members of Global Health Limited (formerly known as Global Health Private Limited) on the standalone financial statements for the year ended 31 March 2021 (cont'd)

for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

7. Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion .

8. In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such controls were operating effectively as at 31 March 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note issued by the ICAI.

For Walker Chandiok & Co LLP

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Partner

Membership No.: 058644

UDIN: 21058644AAAAFF4992

Place: New Delhi

Date: 17 September 2021

	· ·· Notes · · · · · · ·	Av at 31 March 2021	As as 33 March 2020
ASSETS		(7 in inlde)	(f in lakha)
Non-correst assets			••
Property, plant and equipment	_		
Capital weak-in-progress	6 A	\$7,171.94	62,653,80
Toghi of use asser	6 A	416.86	347.13
latangible assess	6 13	27,663.34	39,869.50
Financial assess	7	305.21	263.60
Incusations			20.504
Longia	8	62,555,00	\$6,030.00
Other ferminal assets	9 ለ	613.18	
Deferred (as assets (net)	10 A	t_£00.07	596.13
	II A	238.21	1,672.11
Inchere due august (net)	12	4,525.30	
Other non-current assets	13 A	94.62	0,584.03
Total non-current assets		\$54,683.00	76.62
	•	\$34,683,00	152,213,12
Current #55es6			
Inventories	14		
Consucral assets	14	3,166.RK	3,225.62
Finde receivables	1.6	•	
Cash and eath regionalents	15	12,983.69	14,042.48
Other hank balances	16	4,530.65	13,155.36
Loans	17	20,946.76	8,721.39
Other brancal assets	9 I)	37.51	9.70
Other current wreets	10 B	3,241.17	3,005,46
Total current appells	13 B	620.15	
Cotal aspets		45,52A.B1	617.14
CONTAINER	•	200,211.81	43,576.84
EQUITY AND LIABILITIES Equity Equity share expusi			195,789.96
	18 A	4,958.58	
Insuraneurs aprincly equity in mature	1H 15	3,230.00	4,934.60
Other equity	Ð	140,154.60	3,250.00
Total equity		148,363.18	134,087.75
		110,103,10	142,272.25
LiabiBries			,
Non-current Babilities			
Patoncial billibries			
Burrowage	20		
Lease Subdings	-•	1,934.52	1,807.64
Provisions	21 A	17,290.99	19,439.64
Deferred tax Infalities (act)	22 A	4,031.22	3,527.53
Other non-corrent hubitizes	11 9		KI1.37
Total non-current liabilities	23 A	1,271.55	1,666.47
The state of the s		25,028.28	27,472.85
Current Babilities			47,472.05
Productat fabilities			
	the second contract of		
Lear Chabitities	21 B	2.156.04	
Trade payables	2, 2	3,155.00	3,282.38
- total nutstanding dues of intere enterprises and small enterprises	24 A	**	
 total outstanding does of creditors other than micso engerprises and small 	24 13	2,313.37	1,613.35
enterprise	44 TI	6,607.79	10,160.25
Other financial habituge	•		
Other current labilities	25	6.324.04	5,596.60
Provissons	23 B	4,314.31	3,899.40
Total correct limitities	22 B	2,705.84	1,552.70
Total equity and liabilities		26,820.35	26,044,86
	A STATE OF THE PARTY OF THE PAR	200,211.81	
10 mars - 1 m	•	No.	195,780,98

The accompanying summary of significant accounting policies and other explanatory information are an integral part of these simulatone financial statements,

This is the standalone balance slices referred to an our report of even date.

ED ACCC

For Walker Chandick & Co LLP

Chartered Accountants
Fam's Regulation No.: 001076N/N\$00013

Rajoi Muudea

Parsier Membership No.: 058644

Place: New Della Date: 17 September 2021 For and on behalf of the Bourd of Directors

Dr. Marcall Tremen Chairman and Managing Director [DIN:00012148]

Pince: Gurogram Date: 17 September 2021

Sonjeev Rumer Group Chief Financial Officer

Place: Garagram Date: 17 September 2021 Piaces Guruguan Date: 17 September 2021

Chief Brecutive O

New Delhi

Ramus Handan Company Secretary

Place: (ionigram Date: 17 September 2021

	Notes	For the year unded 31 March 2021	For the year ended 31 March 2020
Income		(₹ in laklıs)	(₹ in laklis)
Revenue from operations			
Other meonse	26	122,739.81	147,208.62
	27	2,834.86	4,353.89
		125,574.67	151,562.51
Expenses			
Cost of materials consumed			
Employee benefits expense	28	30,173.41	31,920.66
Finance costs	29	41,590.53	52,230.13
Depreciation and amortisation expense	30	2,472.55	2,765.45
Impairment losses on financial assets	31	8,763.82	9,856.82
Other expenses	32	621.00	1,111,61
	33	33,511.08	40,584.50
		117,132.39	138,469,17
Profit before tax			<u> </u>
Tax expenses		8,442,28	13,093.34
Current tax - for the year	34		•
Current tax - endier years		3,677,20	4,971.83
Deferred as credit		72.53	
Profit after tax		(3,035.95)	(2,154.15)
		5,728.50	10,275.66
Other comprehensive income			
Items that will not be reclassified to statement of profit and loss			
Re-measurement loss on defined benefit plans			
Information relation to improve the will asset to the control of t		(54.16)	(234.29)
Income tax relating to items that will not be reclassified to statement of profit and loss. Other comprehensive income for the year.		13.63	58.97
s and sompromote fittenic for the year		(40.53)	(175.32)
Total comprehensive income for the year			
2 other complications of the year		5,687.97	10,100.34
Earnings per equity share		··· ··································	
Basic (2)	35		
Diluted (₹)		2.28	4.11
		2.27	4.08

The accompanying summary of significant accounting policies and other explanatory information are an integral part of these standalone financial statements.

This is the standalone statement of profit and loss referred to in our report of even date.

For Walker Chandiok & Corl. P.

Chartered Accountants

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Parmer

Membership No.: 058644

Place: New Delhi ..

Date: 17 September 2021

For and on behalf of the Board of Directors

Dr. Nuresh Treban

Chairman and Managing Director

[DIN:00012148]

Place: Gurugram

Date: 17 September 2021

Sanjeev Kumar

Group Chief Financial Officer

Place: Gurugram

Date: 17 September 2021

Place: Gurugram

Date: 17 September 2021

00 . ×

Company Secretary

Place: Gorugram

Date: 17 September 2021

Continued the section of the year anded 33 March 2021	For the year ended 31 March 2023	For the year ended If March 2020
A CASH PLOWS FROM OPERATING ACTIVITIES Profit before the	(7 in takhç)	(č ia izkhe)
	R,442 28	15,093.54
Petrocustion of property, plant and equipment		
Debicemen on ablt of nee agests	7,189.31	A,262.73
Amunication of mininghis acres	1,472.59	1,499.53
(Probalisors on sale of property, plane and equipments (nec)	101,92	94.57
interest income on Bank depoint and other financials assert incomered at amornised core	(86.3 6) (1,407.63)	9.65
Interest income on refund of income tax: Convenient genus income	(227.64)	(10.538.1)
Unrealised fineign exchange goin (net)	(1,355.91)	(1.551.44)
lotter is on borrowings	16.31	(89.04)
Increase on lease liabilities	\$4.67	110.20
Interest on defected payment bubilines and other burrowing costs	2,258.45	2,415.16
Impairment losses de finançal marci	159 44 631.00	240.09
Receivables unifer expan basely scheme written off Assess worken all	302.35	1,112.61
Employee shate tizaed payment expense	125.76	•
Personal for employer benefits (net)	378.88	956.97
Province for contingencies tirei	513.47	316 42
Gain on devectorymissis of time liabilities and rights of one society	\$89.21	681.44
Real elateration from history	(85.15)	
Operating profit before working capital changes	18,936,48	21.0/2.0
Movement in working capital	10,777.80	23,247,21
Current and non-custom loxin		
Inventoca	(44.76)	(68.88)
Other current finances orions	\$6.74	(\$96.65)
Other current assess	(569.03)	(\$74.43)
Franke seccionables	(A.01)	143.91
Other non-carry	1,316 ±8 36.56	553.24
Other cutrery lishifices and current linancial lishifities Other nan-current lishifities	1,485.53	25.91
Trade (sassably)	1,340,99	276.61 973.85
Cuth flows from operations	(682.41)	
Income car paid (net of refunds)	21,551.57	24,812,14
Net cash hower from operating activities (A)	(1,463.45)	(5,616.36)
B CASH FLOWS FROM INVESTING ACTIVITIES	20,088.14	19,255,96
Positions of property glast and experiments, capath work in progress and intengible asters (metading capital advances, capital exeditors and deferred payment liabilities)	(2,636.84)	(1,730.32)
Proceeds from disposal of progeny, glant and equipments		(
histories in other hook balances med	378.18	53.11
Movement in bank deposits having maturity period more than 12 months	(12.225.37)	11,246.18
luteters received	572.03 1,362.64	(1,072.11)
Investment in others	(12,500.0h)	1,869.41
Net cash used in investing activities (B)	(5.03)	(\$4,300.00)
	[25,046.16]	(4,533,73)
C Cash plows from Pinancing activities		
Deocteds from usua of equity share capital	34.0k	
Repayment of non-custons borrowings Interest paid on borrowings	(43.67)	21.53
Other horreswing come poid	(34.67)	(1,632.54) (63.16)
Interest pand on lease habitates	(5.87)	(34.41)
Payment of teate liabilities	(2,057,15)	(2,236.96)
Not east used in financing activities (C)	{1,529,33}	(1,564.70)
	(3,666.69)	(5,564.49)
(Decemb) Indicated Capital Cap	(8,624.71)	A = 2.5 = -
Cish and easts equivalents at the beginning of the year Cash and easts equivalents at the end of the year (refer note below)	13,155-36	9,157,74 3,992,63
	4,530.65	13,145.34
Notel Reconciliation of cash and cash equivalents as pat cash flow statement (orfer note 16)		
therences with banks in current secounce Chaques on hand	3,993.64	3,040.69
thitances with banks in current accounts Chaques on hand Carh on hand	5.13	3,649.69 1.37
thistoness with banks on cursons accounts Chaques on hand	5.13 155-83	1.37 110.76
Halances with Banks on current accounts Chaques on hand Carlt on hand	5.13	1.37

Chanced Accommons
Funds Registration No.: 001026N/N500015

Rajni Madra

Stemberdup Stud 0586 t4

Place: New Delhi Date: 17 Septembre 2021

Dr. Naresh Prelian Chabrian and Managing Director fi2fN:00013148

Place: Goragiani Date: 17 September 2011

Sanjbev Kumar Group Chief Pinancial Offices

Place: Guingram Date: 17 September 2021

New Delhi

Company Secretary Place: Guengeam Dace: 17 September 2021

Equity chare capital* Particulars	Opening balance se at I April 2019	those capital during		Changes in equity share capital during the year	
Equity sliare capital	4,913,28	21.22	4,934.50	34.08	4,956.58

B Instruments entirely equity in nature **					• • • • • • • • • • • • • • • • • • • •
Particulars	Opening balance	Changes during the	Balance as as	Characteristics	(V in laklus)
	as at 1 April 2019	усыг	31 March 2020	Changes during the year	Balance as ut 31 Murch 2021
Compulsorily convenible preference shares	3,250.00		3,250.00		3,250.00
		~			3,230,00

Pardeulass .		(₹ in lakhe)			
	Securities premium	Share options outstanding account	and surplus Retained carnings	Capital reserve	Total
Balance as at 01 April 2019	45,519.15	5,368.20	72,123,09	50.60	····
Profit for the year		······································	·	20.00	123,030.44
Other comprehensive income		'	10,275.66	- 1	10,275.66
Re-invaringment loss on defined benefit plans (net of tax)	•	-	(175.32)		(175.32)
Employee thate based payment expense		014.07	į	ļ	
issue of equity shares (on account of exercise stock uptions)	1,481.72	956.97 (1,481.72)	:	: [956.97
Bolance as at 31 March 2026			1		•
rula for the year	47,000.87	4,843.45	82,223.43	20,60	134,087.75
Other comprehensive income	•		3,728.50	,	5,728.50
Re-measurement loss on dofined benefit plans (net- of tax)	•		(40.53)	.]	(40.53)
imployee share based payment expense		378.88			
took options lapsed during the year		(288.47)		·	378.88
one of equity states (on account of exercise stock	1,701.44	(1,701.44)	288.47	-	
infance as at 31 March 2021	48,702.31				
Refer note 18A	10,702.31	3,232.42	68,199.87	20.00	148,154.60

[&]quot;Refer note 188

The accompanying surrouter of significant accounting pulicles and other explanatory information are an integral part of these standalone financial statements.

This is the standalone seatement of changes in equity referred to in our report of even date.

For	Walker	Chandink	ě,	Co LLP	

Chartered Accountants

Firm's Registration No.: 001076N/N300013:

Rajni Mlandra

Partner

Membership No.: 058644

Place: New Della Date: 17 September 2021 For and on behalf of the Board of Directors

Dr. Naresh Trehan

Chairman and Managing Director

[DIN:00012148]

Place: Guengram Date: 17 September 2021

Date: 17 September 20

Sanjaev Kumar Group Chief Pinancial Officer

Place: Gurugram Date: 17 September 2021 Chief Executive Of

Pankaj Sahal

Place: Gurugram Date: 17 September 2021 New Delhi

Rahul Ranjork Company Secretary

Place: Gurageam Date: 17 September 2021

^{***}Refer note 188

1. Background

Global Health Private Limited ('GHPL') was incorporated on 13 August 2004 and is engaged in the business of providing healthcare services. Subsequent to the year-end, GHPL has been converted to a public company namely 'Global Health Limited' ('the Company') vide revised 'Certificate of Incorporation consequent upon conversion from private company to public company' dated 11 August 2021 as issued by the Ministry of Corporate Affairs ('MCA'). The Company is domiciled in India and its registered office is situated at E – 18, Defence Colony, New Delhi – 110024.

2. General information and statement of compliance with Ind AS

The standalone financial statements ('financial statements') comply in all material aspects with Indian Accounting Standards (hereinafter referred to as the 'Ind AS') as notified by Ministry of Corporate Affairs under Section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules 2015, as amended and other relevant provisions of the Act.

The financial statements for the year ended 31 March 2021 were authorized and approved for issue by the Board of Directors on 17 September 2021. The revision to financial statements is permitted by Board of Directors after obtaining necessary approvals or at the instance of regulatory authorities as per provisions of the Act.

3. Basis of preparation

The financial statements have been prepared on going concern basis in accordance with accounting principles generally accepted in India. Further, the financial statements have been prepared on historical cost basis except for share based payments and certain financial assets and financial liabilities which are measured at fair value.

4. Recent accounting pronouncement

Amendments to Schedule III of the Act

On 24 March 2021, the Ministry of Corporate Affairs ("MCA") through a notification, amended Schedule III of the Act. The amendments revise Division I, II and III of Schedule III and are applicable from 1 April 2021. The revised Division II which relate to companies whose financial statements are required to comply with Companies (Indian Accounting Standards) Rules 2015, as amended, prescribes amendments for various additional disclosures. The Company is evaluating the requirements of these amendments and their impact on the financial statements.

Amendment to Ind AS 116, Leases

On 18 June 2021, Ministry of Corporate Affairs (MCA) has issued an updated amendment to Ind AS 116 in respect of rent concessions occurring as a direct consequence of the Covid-19 pandemic. The effective date of these amendments is 1 April 2021. However, in case an entity (lessee) has not yet approved the financial statements before the issuance of this amendment, then the same may be applied for annual reporting periods beginning on or after 1 April 2020 as well. The Company is evaluating the requirements of these amendments and their impact on the financial statements.

Amendments to Ind AS 107, Financial Instruments: Disclosures

New disclosures requirements are added in the standard to enable the users to understand the effect of interest rate benchmark reforms on entity's risk management strategy. The related amendments are also made in the other accounting standard as applicable. The Company is evaluating the requirements of these amendments and their impact on the financial statements.





Amendments to Ind AS 105, Non-current Assets Held for Sale and Discontinued Operations and Ind AS 16, Property, Plant and Equipment

There is change in definition of recoverable amount from 'fair value less costs to sell' to 'fair value less costs of disposal'. The Company is evaluating the requirements of these amendments and their impact on the financial statement.

5. Summary of significant accounting policies

The financial statements have been prepared using the significant accounting policies and measurement bases summarised below. These policies have been consistently applied to all the years presented, unless otherwise stated.

5.1 Current versus non-current classification

All assets and liabilities have been classified as current or non-current as per the Company's operating cycle and other criteria set out in Division II of Schedule III of the Act. Based on the nature of the operations and the time between the acquisition of assets for processing/servicing and their realisation in cash or cash equivalents, the Company has ascertained its operating cycle as twelve months for the purpose of current/non-current classification of assets and liabilities.

5.2 Property, plant and equipment

Recognition and initial measurement

Property, plant and equipment are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use. Any trade discount and rebates are deducted in arriving at the purchase price. Property, plant and equipment purchased on deferred payment basis are recorded at equivalent cash price. The difference between the cash price equivalent and the total payment is recognised as interest expense over the period until payment is made.

Subsequent costs and disposal

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is de-recognised when replaced. All other repair and maintenance costs are recognised in statement of profit and loss as incurred.

Items such as spare parts, stand-by equipment and servicing equipment are recognised as property, plant and equipment when they meet the definition of property, plant and equipment. Otherwise, such items are classified as inventory.

An item of property, plant and equipment initially recognised is de-recognised upon disposal or when no future economic benefits are expected from its use. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognised in statement of profit and loss when the asset is derecognised.

Capital work-in-progress includes property, plant and equipment under construction and not ready for intended use-as-on-the balance sheet date.

Subsequent measurement (depreciation and useful lives)

Freehold land is carried at historical cost. All other items of property, plant and equipment are subsequently measured at cost less accumulated depreciation and impairment losses. Depreciation on property, plant and equipment is provided on a straight-line basis, computed on the basis of useful lives (as set out below) prescribed in Schedule II to the Act.

Asset class	Useful life
Building	30 years
Medical equipments	5 to 15 years



Medical and surgical instruments	3 years
Other plant and equipment	15 years
Furniture and fixtures	10 years
IT equipment	3 to 6 years
Office equipment	5 years
Electrical installation	10 years
Vehícles	6 to 8 years

Leasehold improvements are amortised over the lower of useful life and the lease term available to the Company.

The residual values, useful lives and method of depreciation of are reviewed at the end of each financial year.

5.3 Intangible assets

Recognition and initial measurement

Intangible assets (software) are stated at their cost of acquisition. The cost comprises purchase price, borrowing cost if capitalization criteria are met and directly attributable cost of bringing the asset to its working condition for the intended use.

Subsequent measurement

The cost of capitalized software is amortized over a period of five years from the date of its acquisition.

De-recognition

Intangible asset is de-recognised upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss arising on de-recognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is recognized in the statement of profit and loss, when the asset is derecognised.

5.4 Inventories

Inventories are valued at cost or net realisable value, whichever is lower. Cost is calculated on weighted average basis. Cost of these inventories comprises of all cost of purchase, taxes (except where credit is allowed) and other costs incurred in bringing the inventories to their present location and condition. Cost of purchased inventory is determined after deducting rebates and discounts.

Net realisable value is the estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

5.5 Revenue recognition

Revenue is measured at the fair value of the consideration received or receivable. Revenue is recognized upon transfer of control of promised products or services to customers/patients in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. Revenue is measured net of rebates, discounts and taxes. The Company applies the revenue recognition criteria to each component of the revenue transaction as set out below.

Income from healthcare services

Revenue from healthcare services is recognized as and when related services are rendered and include services for patients undergoing treatment and pending for discharge, which is shown as unbilled revenue under other current financial assets. The Company considers the terms of the contract and its customary business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for the services, excluding amounts collected on behalf of third parties (for example, indirect taxes).



A receivable is recognised by the Company when the control is transferred as this is the case of point in time recognition where consideration is unconditional because only the passage of time is required. When either party to a contract has performed, an entity shall present the contract in the balance sheet as a contract asset or a contract liability, depending on the relationship between the entity's performance and the payment.

Income from sale of pharmacy products to out-patients

Revenue from pharmacy products is recognized as and when the control of products is transferred to the customer. The Company considers its customery business practices to determine the transaction price. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for the products, excluding amounts collected on behalf of third parties (for example, indirect taxes).

Clinical research

Clinical research income is recognized over time basis percentage completion method which is determined based on achievement of milestones.

Interest income

Interest income is recorded on accrual basis using the effective interest rate (EIR) method.

Sponsorship income

Sponsorship income is recognised in the accounting year in which the services are rendered as per the agreed terms with the customers.

Other income

Revenue arising from revenue sharing agreements is recognized as per the terms of the arrangement. Rental income is recognised on a straight-line basis over the lease term, except for contingent rental income which is recognised when it arises.

5.6 Borrowing cost

Borrowing cost includes interest expense as per effective interest rate (EIR). Borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset are capitalized during the period of time that is required to complete and prepare the asset for its intended use or sale. Qualifying assets are assets that necessarily take a substantial period of time to get ready for its intended use or sale. All other borrowing costs are expensed in the period they occur.

5.7 Leases

Company as a lessee - Right of use assets and lease liabilities

A lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration'.

Classification of leases

The Company enters into leasing arrangements for various assets. The assessment of the lease is based on several factors, including, but not limited to, transfer of ownership of leased asset at end of lease term, lessee's option to extend/purchase etc.

Recognition and initial measurement of right of use assets

At lease commencement date, the Company recognises a right-of-use asset and a lease liability on the balance sheet. The right-of-use asset is measured at cost, which is made up of the initial measurement of the lease liability, any initial direct costs incurred by the Company, an estimate of any costs to dismantle and remove the asset at the end of the lease (if any), and any lease payments made in advance of the lease commencement date (net of any incentives received).

Subsequent measurement of right of use assets

The Company depreciates the right-of-use assets on a straight-line basis from the lease commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The Company also assesses the right-of-use asset for impairment when such indicators exist.

Lease habilities

At lease commencement date, the Company measures the lease liability at the present value of the lease payments unpaid at that date, discounted using the interest rate implicit in the lease if that rate is readily available or the Company's incremental borrowing rate. Lease payments included in the measurement of the lease liability are made up of fixed payments (including in substance fixed payments) and variable payments based on an index or rate. Subsequent to initial measurement, the liability will be reduced for payments made and increased for interest. It is re-measured to reflect any reassessment or modification, or if there are changes in in-substance fixed payments. When the lease liability is re-measured, the corresponding adjustment is reflected in the right-of-use asset.

The Company has elected to account for short-term leases using the practical expedients. Instead of recognising a right-of-use asset and lease liability, the payments in relation to these short-term leases are recognised as an expense in statement of profit and loss on a straight-line basis over the lease term.

Further, the Company has also elected to apply another practical expedient whereby it has assessed all the rent concessions occurring as a direct consequence of the COVID-19 pandemic, basis the following conditions prescribed under the standard:

- a) the change in lease payments results in revised consideration for the lease that is substantially the same as, or less than, the consideration for the lease immediately preceding the change;
- b) any reduction in lease payments affects only payments originally due on or before the 30 June 2021; and
- c) there is no substantive change to other terms and conditions of the lease.

If all the rent concessions meet the above conditions, then, the related rent concession has been recognised in statement of profit and loss.

Company as a lessor

Leases in which the Company does not transfer substantially all the risks and rewards of ownership of an asser are classified as operating leases. The respective leased assets are included in the balance sheet based on their nature. Rental income is recognized on straight-line basis over the lease-term.

5.8 Impairment of non-financial assets

Assessment is done at each balance sheet date as to whether there is any indication that an asset may be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets, is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of the asset/cash generating unit is made. Assets whose carrying value exceeds their recoverable amount are written down to the recoverable amount. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each balance sheet date as to whether their is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased.

5.9 Foreign cutrency

Functional and presentation currency

Items included in the financial statement of the Company are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The financial statements have been prepared and presented in Iudian Rupees (INR), which is the Company's functional and presentation currency.

Transactions and balances





Foreign currency transactions are recorded in the functional currency, by applying to the exchange rate between the functional currency and the foreign currency at the date of the transaction.

Foreign currency monetary items outstanding at the balance sheet date are converted to functional currency using the closing rate. Non-monetary items denominated in a foreign currency which are carried at historical cost are reported using the exchange rate at the date of the transaction.

Exchange differences arising on monetary items on settlement, or restatement as at reporting date, at rates different from those at which they were initially recorded, are recognized in the statement of profit and loss in the year in which they arise.

5.10 Financial instruments

Recognition and initial measurement

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the financial instrument and are measured initially at fair value adjusted for transaction costs, except for those carried at fair value through profit or loss which are measured initially at fair value.

The classification depends on the Company's business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in the statement of profit and loss or other comprehensive income. For investments in debt instruments, this will depend on the business model in which the investment is held. For investments in equity instruments, this will depend on whether the Company has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI).

Non-derivative financial assets

Subsequent measurement

Financial assets carried at amortised cost - A 'financial asset' is measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows; and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal
 and interest (SPPI) on the principal amount outstanding.

After initial measurement, such financial assets are subsequently measured at amortised cost using the effective

Investments in equity instruments of subsidiaries and joint ventures - These are measured at cost in accordance with Ind AS 27 Separate Financial Statements'.

Investments in equity instruments of others - These are measured at fair value through other comprehensive income.

Desterognition of financial assets

A financial asset is de-recognised when the contractual rights to receive cash flows from the asset have expired or the Company has transferred its rights to receive cash flows from the asset.

Non-derivative financial liabilities

Subsequent measurement

Subsequent to initial recognition, all non-derivative financial liabilities are measured at amortised cost using the effective interest method.

De-recognition of financial habilities



A financial liability is de-recognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit and loss.

Offsetting of financial instruments

Financial assets and financial liabilities are offset and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously. The legally enforceable right must not be contingent on future events and must be enforceable in the normal course of business and in the event of default, insolvency or bankruptcy of the Company or the counterparty.

5.11 Impairment of financial assets

The Company assesses on a forward looking basis the expected credit losses associated with its financial assets and the impairment methodology depends on whether there has been a significant increase in credit risk.

Trade receivables

In respect of trade receivables, the Company applies the simplified approach of Ind AS 109, which requires measurement of loss allowance at an amount equal to lifetime expected credit losses. Lifetime expected credit losses are the expected credit losses that result from all possible default events over the expected life of a financial instrument.

Other financial assets

In respect of its other financial assets, the Company assesses if the credit risk on those financial assets has increased significantly since initial recognition. If the credit risk has not increased significantly since initial recognition, the Company measures the loss allowance at an amount equal to 12-month expected credit losses, else at an amount equal to the lifetime expected credit losses.

When making this assessment, the Company uses the change in the risk of a default occurring over the expected life of the financial asset. To make that assessment, the Company compares the risk of a default occurring on the financial asset as at the balance sheet date with the risk of a default occurring on the financial asset as at the date of initial recognition and considers reasonable and supportable information, that is available without undue cost or effort, that is indicative of significant increases in credit risk since initial recognition. The Company assumes that the credit risk on a financial asset has not increased significantly since initial recognition if the financial asset is determined to have low credit risk as the balance where date.

5.12 Taxes

Tax expense comprises current and deferred tax. Current and deferred tax is recognised in statement of profit and loss except to the extent that it relates to items recognised directly in equity or other comprehensive income.

The current income-tax charge is calculated on the basis of the tax laws enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax-regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

Deferred tax is provided in full, on temporary differences arising between the tax base of assets and liabilities and their carrying amounts in the financial statements. Deferred tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred tax liability is settled. Deferred tax assets are recognised for all deductible temporary differences and unused tax losses only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.



Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously. Deferred tax assets and liabilities are offset when there is a legally enforceable right to offset current tax assets and liabilities and when the deferred tax balances relate to the same taxation authority.

5.13 Cash and cash equivalents

Cash and cash equivalents include cash in hand, demand deposits with the banks, other short-term highly liquid investments with original maturity of three months and less.

5.14 Employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are classified as short-term employee benefits. These benefits include salaries and wages, short-term bonus, incentives etc. These are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

Defined contribution plan

Contribution towards provident fund is made to the regulatory authorities, where the Company has no further obligations. Such benefits are classified as defined contribution plan as the Company does not carry any further obligations, apart from the contributions made on a monthly basis. In addition, contributions are made to employees' state insurance schemes and labour welfare fund, which are also defined contribution plans recognized and administered by the Government of India and Haryana respectively. The Company's contributions to these schemes are expensed in the statement of profit and loss.

Defined benefit plan

The Company has unfunded gratuity as defined benefit plan where the amount that an employee will receive on retirement is defined by reference to the employee's length of service and final salary. The gratuity plan provides a lump sum payment to vested employees at retirement, death, incapacitation or termination of employment, of an amount based on the respective employee's salary and the tenure of employment. The Company's liability is actuarially determined (using the Projected Unit Credit method) at the end of each year. This is based on standard rates of inflation, salary growth rate and mortality.

Discount factors are determined close to each year-end by reference to market yields on government bonds that have terms to maturity approximating the terms of the related liability. Service cost and net interest expense on the Company's defined benefit plan is included in employee benefits expense.

Actuarial gains/losses resulting from re-measurements of the defined benefit obligation are included in other comprehensive income.

Other long-term employee benefits

The Company also provides benefit of compensated absences to its employees which are in the nature of long-term employee benefit plan. Liability in respect of compensated absences becoming due and expected to be availed more than one year after the balance sheet date is estimated on the basis of an actuarial valuation performed by an independent actuary using the projected unit credit method as on the reporting date. Service cost and net interest expense on the Company's other long-term employee benefits plan is included in employee benefits expense. Actuarial gains and losses arising from experience adjustments and changes in actuarial assumptions are also recorded in the statement of profit and loss in the year in which such gains or losses arise.

5.15 Government grants

Grants from the government are recognised at their fair value when there is reasonable assurance that the grant will be received and the Company will comply with all attached conditions. When the grant relates to a revenue item, it is recognized in statement of profit and loss on a systematic basis over the periods in which the related





costs are expensed. The grant can either be presented separately or can deduct from related reported expense. Government grant relating to capital assets are recognised initially as deferred income and are credited to statement of profit and loss on a straight line basis over the expected lives of the related asset and presented within other operating income. This accounting policy is to be read with note 47.

5.16 Share based payment expense

The fair value of options granted under Global Health Employee Stock Option Scheme 2014 and 2016 is recognized as an employee benefit expense with a corresponding increase in equity. The total amount to be expensed is determined by reference to the fair value of the options granted:

- Including any market performance conditions (e.g., the entity's share price)
- Excluding the impact of any service and non-market performance vesting conditions (e.g. profitability, sales growth targets and remaining an employee of the entity over a specified time period), and
- Including the impact of any non-vesting conditions (e.g. the requirement for employees to save or holding shares for a specified period of time).

Total expense is recognized over the vesting period, which is the period over which all the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognizes the impact of revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.

5.17 Provisions, contingent liabilities and contingent assets

Provisions are recognized when the Company has a present (legal or constructive) obligation as a result of past events, for which it is probable that an outflow of resources will be required to settle the obligation and a reliable estimate of the amount can be made. Provisions required to settle are reviewed regularly and are adjusted where necessary to reflect the current best estimates of the obligation. Provisions are discounted to their present values, where the time value of money is material.

Contingent liability is disclosed unless the likelihood of an outflow of resources is remote and there is a possible obligation or a present obligation that may, but probably will not, require an outflow of resources.

Contingent assets are disclosed only when inflow of economic benefits therefrom is probable and recognize only when realization of income is virtually certain.

5.18 Exmings per share

Basic earnings per share is calculated by dividing the net profit or loss for the period attributable to equity shareholders (after deducting attributable taxes) by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period is adjusted for events including a bonus issue or share split.

For the purpose of calculating diluted earnings per share, the net profit or loss for the period attributable to equity shareholders and the weighted average-number of shares-outstanding during the period are adjusted for the effects of all dilutive potential equity shares.

5.19 Rounding of amounts

All amounts disclosed in the financial statements and notes have been rounded off to the nearest lakhs as per the requirement of Division II of Schedule III, unless otherwise stated.

5.20 Critical estimates and judgements

The preparation of financial statements requires the use of accounting estimates which, by definition, will seldom equal-the actual results. Management also needs to exercise judgement in applying the Company's accounting

Bally

policies. This note provides an overview of the areas that involved a higher degree of judgement or complexity, and of items which are more likely to be materially adjusted due to estimates and assumptions turning out to be different than those originally assessed. Detailed information about each of these estimates and judgements is included in relevant notes together with information about the basis of calculation for each affected line item in the financial statements.

- a) Recognition of deferred tax assets The extent to which deferred tax assets can be recognized is based on an assessment of the probability of the Company's future taxable income (supported by reliable evidence) against which the deferred tax assets can be utilized.
- b) Evaluation of indicators for impairment of assets The evaluation of applicability of indicators of impairment of assets requires assessment of several external and internal factors which could result in deterioration of recoverable amount of the assets.
- c) Contingent liabilities At each balance sheet date basis the management judgment, changes in facts and legal aspects, the Company assesses the requirement of provisions against the outstanding contingent liabilities. However, the actual future outcome may be different from this judgement.
- d) Impairment of financial assets At each balance sheet date, based on historical default rates observed over expected life, existing market conditions as well as forward looking estimates, the management assesses the expected credit losses on outstanding receivables. Further, management also considers the factors that may influence the credit risk of its customer base, including the default risk associated with industry and country in which the customer operates.
- e) Defined benefit obligation (DBO) Management's estimate of the DBO is based on a number of underlying assumptions such as standard rates of inflation, mortality, discount rate and anticipation of future salary increases. Variation in these assumptions may significantly impact the DBO amount and the annual defined benefit expenses.
- f) Useful lives of depreciable/amortisable assets Management reviews its estimate of the useful lives of depreciable/amortisable assets at each reporting date, based on the expected utility of the assets. Uncertainties in these estimates relate to technical and economic obsolescence that may change the utilisation of assets.
- g) Leases The Company evaluates if an arrangement qualifies to be a lease as per the requirements of Ind AS 116. Identification of a lease requires significant judgment. The Company uses significant judgement in assessing the lease term (including anticipated renewals) and the applicable discount rate. The Company option to extend the lease if the Company is reasonably certain to exercise that option; and periods covered by an option to terminate the lease if the Company is reasonably certain not to exercise that option. In assessing whether the Company is reasonably certain to exercise an option to extend a lease, or not to exercise an option to terminate a lease, it considers all relevant facts and circumstances that create an economic incentive for the Company to exercise the option to extend the lease, or not to exercise the option to terminate the lease. The Company revises the lease term if there is a change in the non-cancellable period of a lease.
- h) Government grant Grants receivables are based on estimates for utilization of the grant as per the regulations as well as analysing actual outcomes on a regular basis and compliance wide stipulated conditions. Changes in estimates or non-compliance of stipulated conditions could lead to significant changes in grant income and are accounted for prospectively over the balance life of the asset.
- Fair value measurements Management applies valuation techniques to determine fair value of equity shares (where active market quotes are not available) and stock option. This involves developing estimates and assumptions around volatility, dividend yield which may affect the value of equity shares or stock options.

Estimates and judgements are continuously evaluated. They are based on historical experience and other factors including expectation of future events that may have a financial impact on the Company and that are believed to be reasonable under the circumstances.



Chebal Heath Limited (finance): From as Global Heath Pipale Limited) Standalone summasy of significant accounting policies and fibed; explanatory information for the year edded 31 March 2021

64 Property, plant and equipment and expired very section and the	pital moderin-progra						٠							
Paraculars		Ш			0	Owned assets						Leaced secons	1,000	(in tiches)
	Freehold land	Portsing.		Medical and	Olives plant and	Furniture and	IT cquipmen	Office	Electrical	Lexichold	Vehicles	Leatehole land		Capital moral
			equipments	Surgical Metruments	cquipment	Brancs		comparent	п	ingrovement	1			
Gross block	1:=:	-			Carrier or transfer and the same of the sa					***************************************				
Saturce as 21 03 April 2019	6,300.09	1,387.63	39,582.46	1,467.26	15709721	2,453.19	1,637.15	364 08	30.746	2 577 70	00 937	********	807.40	
Addenone		15.72	626.53	20.0	2545	44.55	24.76	6.1	Ģ.	6 5	72.07	200	777-00-00-0	5,00,05
25 (pouds/adusensens	-	·	69.40	·.	(8.35)	(6.53)	٠.	**			5		W. W. L.	, i
Teamsfer to eaght oil use ussets	***				· , '						(0,000)	MO 167 CB7	() () () () () () () () () ()	(T8 9KL)
Balance as at 31 March 2020	63000	31,401.95	40,199.55	1,554.96	12,898.00	2,494.95	1,729.11	393.90	3,085.96	2,590,69	(2) 33		601 94R DO	11.02
:3ddinoas	-,-	2	1,456.13	12:44:27	50.03	11.15	-8.0%	30%	7.33	66.9	3.5		31360	the st
Disposals/adjustments			(425.65)	(3.14)	(22.39)	(23.24)	(40,73)	(36.09)		CO1 36	(51.06)		3 6	. 6
Balance as at 31 March 2021	\$ 30.05	5 33,409.29	41,230,03	1 L793.03	12,636,54	2,505.85	1,960,72	398 29	3,093.73	2,395,72	473.81		104 375 53	916 (36
Accumulated depreciation		(Loon)												
Balance as at 81 April 2019	7	5,048.56	14,023,86	1,214.79	4,585.44	1,722.46	1,722.69	271.78	2507.06	1.565.10	62.43	63 763	1802.0	
Charge for the vene	na.	1,287.30	3,956.64	18033	Dt eec.	13051	198.30	57.53	398.23	25 109	59.33		25.0%	
Disposals/adjustments	74,71	, Listain	(\$11)		(S)	(12.0)	•	(673)		-	03:00	,	\$ 0	٠ ,
Transfer to night of use assets		•		,					,	•	•	(636.89)	62.89	
Batance as at 31 March 2020		6.335.75	77.85.59	1 1,395,11	\$5,007,86	2,033.12	1,459.59	328.18	2,965.33	2,164.67	107.20		87 TAC 84	
Charge for the rear	···	8	3,939.74	7,501	1,254.11	94.39	134.91	80'55	38,11	191.28	61.73		7.189.31	Ţ,
Disposals/adjestiments	-	•	(321.26)	(9.84)	(10,05)	(1.71)	ម្	(15,23)		(76.21)	(42.83)		626.625	
Balance as at M March 2021	200	7,62213	21,772.49	1,497.83	7,051.92	2,122.20	\$3.5¥5.13	348.04	2943.44	223.74	0.321		67,203.59	
		_									-			
Net block as at \$! March 2020	€769.¢3	_	22,244.96	659.79	7,000,74	461.83	310,12	63.72	130.63	482.02	330.13		62,633.80	M7.13
Ner block as at 31 March 2021	6,355,00	23,786.01	19,503.54	2522	25,487,2	343,65	335.04	50.15	H9.83	171.78	17.75	,	57,771.94	416,06
(3) Contractual obligations	***************************************	EEE Shoon 4												

Neter Note 408 for disciouse of consequent communents for the acquisition of property, plant and equipment (ii) Property, plant and equipment photoged as a recursity.

All moretise property, plant and equipment,

19,15741 16,995.11 4,234.30 31,349.62 (1,017,00) 30,361,94 1,499.52 1,472.59 (289.51) 1,663.60 29,169,50 27,56,334 15,503,21 16,975.11 305.60 Leasebook land 16,395.11 16,995.11 195.80 195.80 53.92 138.34 13.57 12.53 13.57 13.57 13.53 13.53 13.53 12.09 Vehicles Other plant and cquipment 121.74 126.38 65.020 . 18 18 18 18 18 18 127.59 . Z 9,871.64 14,167.98 73769 LL 170.32 1,222,30 1,220,33 1,220,33 7,238,96 12.05.68 10.931.36 Suiding remises Balance as at 1 April 2019 - recognization transmiss no Ind. AS 116. Balance as at 1 April 2019 - transferred from property, plant and systement Accumulated depreciation

Balance as at April 2019
Chage for the year

Balance as at 30 March 2020

Chage for the year Net block as at 31 March 2020 Net block as at 34 March 2021 Additions
Balance as at 31 March 2020
Additions Digocals/achtsmust" Bringer as at 31 March 2021 Disposals/advisements Ralance as at 35 March 2021 68 Right of use assets Paraculans

ned 21 Januar Roses under had AS 17 Haves. Learthood hand mas presented as gont of preparity, phant and equipment and the hisbolisher as defenced payment labilities as pay at the Company's bomonowings. However, walter has AS 116, these bases have been define the year. " Thi March 2918, lessehold hand and returned listshiness were people instituted by public of by mystic of bases and insec hashedres." George of Feb. 12 Disks. on secount of team modifications for the second of team of the second of the sec



intangible assets	(₹ in lakihs
Gross black	Software
Balance as at 01 April 2019	
Additions	275.82
Balance as at 31 March 2020	321.17
Additions	596.99
Balance as at 31 March 2021	43.53
	640.52
Accumulated amortisation	, , , , , , , , , , , , , , , , , , , ,
Balance as at 01 April 2019	
Clearge for the year	138.82
Balance as at 31 March 2020	94.57
Charge for the year	233,39
Balance as at 31 March 2021	101.92
	335.31
Net block as at 31 March 2020	
Net block as at 31 March 2021	363.60
	305.21



(This space has been intentionally left blank)



Global Health Limited (formerly known as Global Health Private Limited)

Standatone swinners of significant accounting policies and other explanatory information for the year ended 11 Murch 2021 Az et

	31 Merch 2021	32 March 2020
Note · &	(f in Jokhe)	(? in lakte)
Investments - non-curem		
(i) Investments in equity shares		
Subsidiary - unquoted		
Glubal Realth Padipusta Private Limited		
1995/00/00 equity thates (3) March 2020, 93,000/000 equity thates) of \$ (6 each)	\$9,700.00	9,760.00
pledities i tradest spares fronted,		
	40,350cG	35,359.00
191.736.341 equity shares (31 Morch 2020, 65,487.228 equity shares) of Extrescing from venture - unquoted		
Mediara Dake Responsib Innamic Private Limitedia		•
		98.109
(NA equity Aluto) (31 March 2018: 10,001 equity shares) of £ 10 early Others - unquoteds	•	
	•	
Swarth Digital Realth Foundation	500	
15.000 equity strates (31 Muselin 2020) thin of \$ 100 eachy		
	40,055.00	45,951.60
Less: Impaiement in the value of investments: joint venture		(901.60)
Sub-rocal (A)	60,053.90	45,030.00
(ii) In compulsority convertible preference shares		
Subtidiary - unqueted		
Modeum Holdings Universe Limited		
19.278,020 shares (5) historic 2020-6,329,113 shaces) of € 10 cich and 0.0000146 coupon rate)	2,500.00	\$,000.00
Sub-teral (9)		
	2,500,00	5,000.00
Grand rotal (A+13)		
	62,555.00	50,650,60
Aggregate amount of unquarril investments (net)	10.000	
Aggregate emound of improment in the value of investments	62,555.00	\$0,030.00
		901.80

*Investment relative, includes § 200.00 likhs, recognised on account of tennifer of literate obtained under Served From India Scheme for such of the subsidiary.

30 The Board of Directors (the Bored) of Medicina Duke Research Institute Private Limited (a joint vectory) in its receiving held on 19 June 2019 and resolved to initiate the process of winding up of the abstractmented county and subsequently, they have initiated the process of coloriesty liquidation of the last only in incoording with the provisions of the Insolvency and Bankupper (Volume Limited Insolvency and Linited Private Limited Limited Head with Insolvency and Discharge (Volume) Proceed Regulations, 2017. This has also been affined by the distribution of the Annual General Meeting (AGM) of Medicine Duke Research Institute Private Limited held on 24 September 2019. During the year, on 25 February 1024, the official liquidates they substituted from application for liquidation wholling up of the stid entity with National Company Law Taburat (NCLT). However, the final order from the NCLT is awaited.

\$ Meximed at his value drough other compulsionive income. The underlying objective of this investment is not to early profits and hence, this does not every my price tips

1 000 31 140	ten 2020			
belonehip	Ownership in	nacenta	Principal place of	Accounted an
			Uninest	
	Ji hierch 2021	31 March 2020		
nt venture	-	50.0044	1	1300
	460.534		!	Measured ar con as per find
	100,00%	100.00%	i india	A\$ 27 Separate Financial
	100.00%	100.00%	and e	Statemenu
		at venture ubsidiary 100,004 ubsidiary 100,094	### Downstrhip intecests 31 h/sech 2021 \$1 Mesch 2020	Ownership Ownership intecests Principal place of Use inex

Note - 9

A Loren - nen cament (Unsecuted considered good)

Зесыну дервыя

613.18 596.13 596.13

5 Losas - current" (Unrecured considered good) Security deposits

37.51 * The Company dues not have any thans which are either credit impaired or where there is aignificant instease in circlis sisk.

A Other linancial assets - non-corren-

Chose maneral moved supplied the 13 mounts.

1,100,07 1,672,11 1,100.07

9.29

" Dank deposits of \$ 1000 laths (3) March 2000; Will are kept under lien with bank as margin muster against brack governness and better of credi-



ealth New Delhi

			A 41 31 31 31 31 31 31 31	At at	
1) Other Grance-lessor and			(Circletia)	(Cin lakha)	-
1 Other financial percit - current (Unsecured considered good, unless otherwise reged)				A PRIMATELY	
the conclude from sepred france beceletings bet					
Unitedical recognic			196 %	250.10	
Receivables under exposs bestelle sebences			1,350.97	\$96.69	
Other reconsister			934 63	1,452.03	
Coundred good					
Considered doubtful			459 53	701.55	
1- 10- 10-			232.39	136.60	
Lera Aflowance for expected coedit lass			(233.39)	41=	
			3,241.17	1136.60	
 Other receiveliles are premarily an account of covering sharing arrangements. 			7,397-13	3,005.40	-
Whileverness of accessivelyles under export benefit settings					
Opening balings					
yeld. Besult received going the here			1,453.03	530.20	
Less a greate audit transferred duping the very			934.00	1,149,68	
inter			(3.149.68)	(280000)	
here a milited the purchase of property, plant and equipment/communities			(302.56)	. •	
, ,			A3184	(27.65)	
			934.00		
Note - II					
A Dolcored on spects (see)					
Deferred sociates arising on account of:					
imployee benefits			1,249.39		
Hermored cardie has an made and eather recognition			1,717.72		
િલ્ફોલ અન્યાન કરવાર કહેલ સ્ટિક્ટ કરોડી સહક સ્ટિલિક્ટ			1,635.25	•	
VALUE			134.44		
Deferred to v Tiskellisten a deren and			6,756,60		
Deferred tax liabilities origing on account of:			-14.04		
Property, plant and equipment and intangible state			(4,498.39)		
			(4,498.39)		
Delemed inc neere (not)				·····	
The state of the s			238,21	***************************************	
onicolar,					
	A4 03	Recognised is	Recognised in other	At at	
	1 April 2020	absement of	comprehensive income	31 March 2021	
	(4)	profit and loss	(4)	(9+b-c)	
Facily	·	(6)	L		
mploped benefits		i		ļ	
• ·• · · · · · · · · · · · · · ·	1,166.33	129.23	1363	5,249.19	
AROCCES CLOSE fore too stade and artist constitution					
Aposted Crodit fore on stade and order receivables If the use secons and ferry lightlines	1,561.43	156 29	,	1,717.72	
aght of use secon and force lightings	1,56\$.43 1,146.26	+&\$ 99			
elin es All est describand fesse fixigillines	1,561.43			1,635.25	
nglii wi war aaron and foesy fishiiinga elises aabiililios	1,56\$.43 1,146.26	+&\$ 99			
ugh of wer secons and lease liabilities. Abilities Abilities Apilities Ap	1,56\$.43 1,146.26	+&\$ 99		1,635.25 154,44	
ugh of wer secons and legar liabilities. Abilities Abilities Apilities Ap	1,569.43 1,146.26 148.46	[3-1 02) +&‡ 99		1,635.25 134,44 (4,8839,	
ught of use secons and lease labilities. Labilities Opinity, plans and equipment and interpublic essess	1,569.43 1,146.26 168.46 (4,793.85)	195.46 295.46		1,635.25 154,44	
ught of use exects and least labilities a black of nativities replicity, pitch and equipment and intropolity assets utal	1,569.43 1,146.26 168.46 (4,793.85)	195.46 295.46		1,635.25 134,44 (4,8839,	
such to the executional lease liabilities below to substitutives beginning plants and equipment and intemplok assets total 18 Deferred and liabilities footh	1,569.43 1,146.26 168.46 (4,793.85)	195.46 295.46		1,635.25 134,44 (4,8839,	
ingly of one exert and least fabilities statistics requestly, plant and equipment and intemplote assets oral Deferred case the biblistics (ner) Deferred case the biblistics arising on account of:	1,569.43 1,146.26 168.46 (4,793.85)	195.46 295.46		1,635.25 134,44 (4,8839,	
such to the executional lease liabilities below to substitutives beginning plants and equipment and intemplok assets total 18 Deferred and liabilities footh	1,569.43 1,146.26 168.46 (4,793.85)	195.46 295.46		1,635.25 134,4 (4,458.35) 238.21	
ingle of the enter and feets liabilities Anatolities Populity pitter and equipment and intemplate assets Until Deferred can inabilities (net) Deferred can inabilities anatog on account of: 1 to pears, plant and equipment and unangifite aarcis	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46		1,635.25 134,44 (4,8839,	
ust in the exert and least labilities about the control of the con	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46		1,635.25 134,4 (4,458.35) 238.21	
upting the enters and least labilities a claim of the company of t	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46		1,635.25 134,4 (4,456.35) 238.21 4,793.45	
upling the enters and lease labilities and intemplate essent total and interplate essent total and interplate essent esse	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46		1,635.25 134,44 (4,4%8.30) 238.21 4,793.45	
abilities abilities opinity, pittin and equipment and intemplote assets self Deferred can liabilities (ner) Deferred tan liabilities (ner) Deferred tan liabilities anising on account oft licencesy, plant and equipment and unangifite ancis Deferred ton assets anising on account of: Simplyop benefit bispected exists on on stade and other accessibilities lights of one amon and dear liabilities.	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46		1,635.25 134,4 (4,478,30) 238.21 4,793.45 (1,106.35) (1,561.43)	
afting the secretarial lease labilities and intemplate essent and interplate essent essen	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46		1,635.25 134,44 (4,4%,30) 238.21 4,793.85 (1,106.35) (3,561.43) (1,146.26)	
abilities abilities operity, piton and equipment and intemplate assets tall Deferred and liabilities (nex) Deferred and liabilities anxiety on occount of: l'expecty, plant and equipment and unamplific assets Deferred to assets anxiety on occount of: Simplyon benefits bispected excist loss, on trade and other accessobles Right of one assets are not read and other accessobles Right of one assets are not fast shiblings.	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46		1,635.25 134,44 (4,4%3.39) 238.21 4,793.45 (1,366.35) (1,561.43) (1,146.26) (1,644.26)	
get us are encer and best liabilities lists abstitice opicity, piton and equipment and intemplate assets tall Deferred can inabilities (nes) Deferred tax liabilities anising on account ofs I concery, pitent and equipment and unampited assets Deferred tax assets arising on account of: Bimpluyor benefits Inspected recoil loss on trade and other receivables Hight of one assets and trace liabilities Cather	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46	13.63	1,635.25 134,44 (4,4%,30) 238.21 4,793.85 (1,106.35) (3,561.43) (1,146.26)	
the street series and lease liabilities has been series and intemplate assets to liabilities (next). Deferred can timbiblises (next) Deferred can timbiblises (next) Deferred tan timbiblises anising on account of: Irrepersy, plant and equipment and unangifile axicle Deferred tan assets arising on account of: Risuplayer being for the product of the proceeding of the process of the process and lease liabilities. Cancer.	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46	13.63	1,635.25 134,44 (4,4%3.39) 238.21 4,793.45 (1,366.35) (1,561.43) (1,146.26) (1,644.26)	
ashiffice operity, plant and equipment and intemplok assets tell Deferred can liabilities (net) Deferred an liabilities anxiety on account of: l'especy, plant and equipment and unanglific arcis Deferred can sasets arising on account of: himploype lieuefer highs of one assets arising on account of: Clinece Perform the measure and lease liabilities Connect	1,569.43 1,146.26 168.46 (4,793.85)	195.46 (3-1 02) 195.46	13.63	1,635.25 134,44 (4,498.30) 238.21 4,793.45 (1,106.33) (1,561.33) (1,146.20) (1,64.40) 811,37	CATALOGIC
ashiffice operity, plant and equipment and intemplok assets tell Deferred can liabilities (net) Deferred an liabilities anxiety on account of: l'especy, plant and equipment and unanglific arcis Deferred can sasets arising on account of: himploype lieuefer highs of one assets arising on account of: Clinece Perform the measure and lease liabilities Connect	1,565.43 1,146.26 168.46 (4,293.85) 4864.37)	148 99 [24 02] 295 46 E,035,05	13.63	1,635.25 134,44 (4,498.30) 238.21 4,793.45 (1,106.35) (1,561.43) (1,146.26) (1,146.26) (1,146.26)	
agin of our access and least labilities abilities abilities additivities Deferred can timbiblises (net) Deferred can timbiblises ansing on occount of: I'repeary, plean and equipment and unangolide acrets Deferred can small religious ansing on occount of: Simpleyed benefits Abspected eccol for on trade and other receivables Right of one acrets and least finishines Concer Processes the manufacture of the control of	1,561.45 1,146.25 168.46 (4,293.83) 4861.37)	148 99 [34 82] 29546 1,035.65	13.63	1,635.25 134,44 (4,428.39) 238.21 4,793.85 (1,366.35) (1,561.43) (1,46.26) (168.46) 811.37	
agin of our access and least labilities abilities abilities additivities Deferred can timbiblises (net) Deferred can timbiblises ansing on occount of: I'repeary, plean and equipment and unangolide acrets Deferred can small religious ansing on occount of: Simpleyed benefits Abspected eccol for on trade and other receivables Right of one acrets and least finishines Concer Processes the manufacture of the control of	1,565.43 1,146.26 168.46 (4,293.85) 4864.37)	148 99 [24 02] 295 46 E,035,05	Recognised in other tumpelseaster income	1,635.25 134,44 (4,458.30) 238.21 4,793.85 (1,106.35) (1,561.43) (1,146.20) (1(68.40) 811.37	
infinity of the access and least liabilities abilities positive, pation and equipment and intemplote assets total Deferred case the biblioses (ners) Deferred case the biblioses and ing on account off l'respectly, plant and equipment and unanightic assets Deferred last assets arising on account off: limply, one bous fers limply, one bous fers limply of one assets arising on account off: Chinese Chinese Transportation assets and trace instrument overnous in deferred tox limbilities (nest) titiculars	1,565.43 1,146.25 168.46 (4,293.83) 4861.37)	148 99 [34 02] 29546 1,035,05 Recognised in assessment of	13.63	1,635.25 134,44 (4,428.39) 238.21 4,793.85 (1,366.35) (1,561.43) (1,46.26) (168.46) 811.37	
ingly of the enters and least labilities. Antificies Antificies Togicity, patent and equipment and intemplok assets Unal B. Deferred can indifficies anxiety on occount of: I'reperty, plant and equipment and unangible assets Deferred lost assets arising on occount of: Himployed benefits Despected enter incorner and only gifted assets Light of one assets arising on occount of: Himployed benefits Despected enter incorner and other receivables Right of one assets and first himblines Chines Terretor is of the assets and other receivables India of one assets and least lightines Others Terretor is deferred tox lightines (mg) and offerred tox lightines (mg)	1,565.43 1,146.25 168.46 (4,293.83) 4861.37)	148 99 [34 02] 29546 L035.55 L035.55	Recognised in other tumpelseaster income	1,635.25 134,44 (4,458.30) 238.21 4,793.85 (1,106.35) (1,561.43) (1,146.20) (1(68.40) 811.37	
inglist of the entertaint least liabilities ashibities beginning pates and equipment and intemplote assets total B. Deferred case timbibities (nex) Deferred case timbibities ansing on account of: l'opeciny, plant and equipment and unangifite assets Deferred lost assets arising on account of: implayed benefits bispected executions on trade and other excellently light of one assets and least entitles highlines Cathers Cathers Deferred the assets and least highlines Cathers Comment in deferred tox liabilities (next) poems, plant and equipment and intemplify assets pherry, plant and equipment and intemplify assets	1,561.45 1,146.25 168.46 (4,293.85) (861.37)	Recognised in sustement of profit and less (b)	Recognised in other tumprelensise income (c)	1,635.25 134,44 (4,498.30) 238.21 4,793.85 (1,106.35) (3,561.43) (1,146.20) (168.40) 811.37 611.37	
sught of one sector and feest fabilities Analytics Analytics Politics, pasent and equipment and intemplote assets Cotal B. Deferred case imbibities (ner) Deferred case imbibities and equipment and unangities and to Property, plant and equipment and unangities and to Birophesty lost assets anising on account of: Birophest lost assets anising on account of: Birophest descriptions on account of: Birophest descriptions on trade and other receivables Right of one assets anising these highlines Chines Transport asset literature passet forements in deferred tox limitatives (ner) anticulars	1,565.43 1,146.25 168.46 (4,293.85) 4866.37)	148 99 [34 02] 29546 L035.55 L035.55	Recognised in other tumpelseaster income	1,635.25 134,44 (4,458.30) 238.21 4,793.85 (1,106.35) (1,561.43) (1,146.20) (1(68.40) 811.37	
sught of one sector and least labilities and intemplate assets beginning, patent and equipment and intemplate assets best Deferred case timbibities (nex) Deferred case timbibities ansisting on account of: Incorpery, plant and equipment and unangible assets Deferred lose assets anishing on account of: Hisplayor benefits Expected exists has on trade and other accessables light of one assets and first bibibities Chines: Terretar time like the action and timbibities Chines: Terretar time like the action of the action of the accessables Included the action and first bibibities (ag) Anticulars Sphilities appearance in white of securities and entangible assets appearance in value of securities of securities.	1,561.45 1,146.25 168.46 (4,293.85) (861.37)	Recognised in automotion for fire and less (b)	Recognised in other tumprelensise income (c)	1,635.25 134,44 (4,498.30) 238.21 4,793.85 (1,106.35) (3,561.43) (1,146.20) (168.40) 811.37 611.37	
such as are seen and lease liabilities. John of Joseph State and equipment and intemplate assets Deferred and liabilities (ner) Deferred and liabilities ansisting on occount of: Venery, plant and equipment and unanglist assets Deferred and unaness arising on account of: Simplayor brusefer Properted teach lost on trade and other receivables Right of one assets and lease liabilities. Cathers Terrestation the misses and lease liabilities. Southers of the assets and lease liabilities. Additional and defensed too liabilities (mg) articulars	1,561-46-25 168-46 (4,293-85) 4861-37) Ab Pi L Apoll 2019 (4) (7,336-4e) 22948	Recognised in statement of profit and less (b) 2,542.55 (210.03)	Recognised in other cumple least recome	1,635.25 134,44 (4,458.30) 238.21 4,793.85 (1,106.35) (1,561.43) (1,146.20) (1(68.40) 811.37 AF 81 31 March 2020 (a+b-c)	
sught of one exert and feest fabilities Antificies A	1,561.45 1,146.25 168.46 (4,793.85) (48/4.37) (48/4.37) (49/4.20) (4) (7,336.40) (29.94) 1,341.63	Recognised in attachment of profit and loss (b) 3,542.55 (210.03) (296.25)	Recognised in other tumprelensise income (c)	1,635.25 134,44 (4,478.30) 238.21 4,793.45 (1,106.35) (1,561.43) (1,146.26) (1,646.26) (1,646.27) 811.37 Ar st 31 March 2020 (a+b-c) (4,793.55)	
Incorporate, phen) and equipment and unanighte care is Deferred los essets arising on account of: Bitiphytoe broader Bisphytoe broader Bisphytoe broader Bisphytoe broader Bisphytoe under and other excellente Crince Crince Therefore is a server and first highlines Crince Therefore is a server and first highlines Crince Therefore is a server and bishibitive (mg) and critical aris is biblides unperty, plant and equipment and interrigible assets dects presented in value of socretiments inplayer besentin presented crick loss on rarde and induce (excessible a gire of use a server and every labelative	1,561-46-25 168-46 (4,293-85) 4861-37) Ab Pi L Apoll 2019 (4) (7,336-4e) 22948	Recognised in statement of profit and less (b) 2,542.55 (210.03)	Recognised in other cumple least recome	1,635.25 134,44 (4,4%35) 238.21 4,793.85 (1,106.35) (3,561.43) (1,146.26) (168.46) 811,37 511.37 4.793.85 (4,793.85)	
inglist of the entert and least liabilities and intemplote assets beginning patent and equipment and intemplote assets beginning patent and equipment and intemplote assets before and individual control of the period of the	Ab Pi L April 2019 (4) 77,556 441 21913, 1,731,76	Recognised in assessment of profit and less (b) (296.25) (296.25) (296.25) (370.2) 330.00	Recognised in other cumple least recome	1,635.25 134,44 (4,498.30) 238.21 4,793.85 (1,106.35) (1,561.43) (1,146.26) (168.40) 811.37 631.37 631.37 631.37	
authities Deferred can timbilities (net) Deferred can timbilities (net) Deferred can timbilities (net) Deferred can timbilities (net) Deferred can timbilities anising on account of: I'reperry, pheni and equipment and unangifile ancis Deferred can annote arising on account of: Simpleyed loss nearth anising on account of: Simpleyed terroit on on trade and other acceivabler Right of one amon and trade and other acceivabler Right of one amon and trade and other acceivabler Right of one amon and trade individues Cthese Deferred to the amon and trade and other acceivabler Right of one amon and interesting (net) riculars abilities species, plant and equipment and accentible ancis acce presented in acceptance of sexestments proced credit loss on reade and induce receivable.	1,561-43 1,146-26 168-46 (4,293-85) 4861-37) (4,293-85) 4861-37) (7,356-44) 2191-2 1,343-63 1,343-63 1,343-63	Recognized in attachment of profit and less (b) (210.03) (270.35) (270.35) (270.35)	Recognised in other cumple least recome	1,635.25 134,44 (4,4%35) 238.21 4,793.85 (1,106.35) (3,561.43) (1,146.26) (168.46) 811,37 511.37 4.793.85 (4,793.85)	





THE REPORT OF THE PARTY OF THE

Mr. III	At 01 34 March 2021	As ai St March 262
Note - 12	(t in takha)	(tin lakha)
Incorrespy, Escale (net)		•
Advence use face of processor for the emounting to \$ 41,836.73 likes (it March 2020. \$ 18,087.004km)	4,525.37	6,5
	4,525.37	6,5
histomen in income tex assets (net)		
Perticular	Ac et	ALAS
	31 March 2021	31 Nipreh 202
Openity balance	6.5B4.03	5.9
Alfor Times pand	1,691.07	5,6
Loss Concent as provided for	(3.749.73)	(4.5
Crasing balance	4,525.37	6,5
Note - 13		
Other don-current pasers		
Cristal advances		
Advances other data capital advances -	42.46	
Perpid express:		
salan alkan	32.16	
	94.62	
Other corrept pegets		
Prepaid expenses		
Advance to material/service providers	495.35	51
Advance to employees	117.32	3
	7.50	
	620.13	6
None - 14		
Processories ##		
Planemany, moderal and faboratory communication colored to in-passing services		
Plantage, and methods consumables related to aske of plantage; produces to comparients	2,540.68	3,0
Concret stores are produced to the or presented to the or presented our panents	344.63	
	386.17	15
valued access or net realisable value, whichever is lower	3,168.88	3,22
Print properties of the avenuation both presented forces		
and have been county, our graduaters' both bectom rad 1940%.		
Note + 15		
Travie receivable § *		
Trade receivables - considered good, unsecured#		
Tiede seceinbles - creat impared	14,786.27	16,39
	4,789.54	4,51
AND Allowance for expected coedit loss	19,576,31	20,96
Frafic recentables - consistency good, unrecured		
Frede receivables a cicilis imperient	(1,803.0%)	(1,55
• • • • • • • • • • • • • • • • • • •	(4,789,54)	(4,51
	12,983.69	14,84
Fusi part pasts clumps on to be receivables, both guescons and future Financian, includes 3 31.97 light (31 Merch 2020: \$ 283.51 lights) receivables from related parties (refer note 38).		
fore-16		
Selvend casts equivalente		
specer neith proget in zonsove occounts was now contact of meetings the		
greates and market in stateout recoluted	3,995.84	3,06
4th can famile	5.15	
ank deposits with original maturity less than direo months	155.63	\$1
	373.R5	9,97
	4,530.65	23,35
1012 - 17		
Rher bank belances		
and the province much make mineral designs about the second of the secon		
my quincing must meature of more than three months and moto marks months.	20,946.76	5,72
	20,946.76	8,721
termatypenne of the market the market market 175.08 tolding see kept underthen and their term symmotics agreement		

(Violetto V

(This space has been leterisenally left block)



Global Beauth Limited (formedy known as Global Health Private Limited)

Standatone summary of significant accounting policies and other suplanetory information for the year ended 51 March 2021

Nace . 18

An at 31 March 2021

A6 44 31 March 2020

A Equity chare conists

Ĺ	Authorized* Class A Equip clases of \$ 10 cach	Numbe:	Amoun) (E (n lakhy)	Number	Amount (Fin labby)
	Class It liquity theres of \$ 10 each	101,054,000	10,100.40	101,624,050	10.302.46
		1,033	0.10	1,000	6.10
			10,382.50		10,102.50
	Jeaned, subscribed and paid up? Class & Equip shares of C Reeach	49,585,61 <u>2</u>	4,938,58 4,936,58	49,345,005	4,934,50 4,934,50

Subsequent to the year end, the Board of Directors of the Company have approved thate apth of Class A equity shares from \$18 per share to \$2 per share and the same its uccordingly, the number of Class A equity shares in surhorized start capital and found, subscribed and fully paid up have uncessed from 111,021,000 there and from 45,856,818 there to 247,929,000 starts respectively. In addition, the Hord of Directors have also approved conversion of Class II there is Class A equity shares of \$1, 10 each list been conversed into \$5,000 Class A equity shares of \$1. It is a third that a equity share of \$1. It is the conversed into \$5,000 Class A equity shares of \$1. It is the conversed into \$5,000 Class A equity shares of \$1. It is the conversed into \$5,000 Class A equity shares of \$1. It is the conversed into \$5,000 Class A equity shares of \$1. It is the conversed into \$5,000 Class A equity shares of \$1. It is the \$1. It is the conversed into \$5,000 Class A equity shares of \$1. It is the \$1. It is the conversed into \$5,000 Class A equity shares of \$1. It is the \$1. It

iii Reconcilision of number of equity theres ourstanding at the beginning and at the end of the year

Equity shales Balance as the beginning of the year

19,345,003 Add Intest during the year for second of exercise of stock options!
Balance at the end of the year 4,934.50 49,132,778 4,913.38 2(0,415 49,585,818 34.08 217,723 49,343,663 31,22 4,938.68 4,934,50

iv Rights, preferences and restrictions another to equity shares. The Company has two class of equity shares with face value of t 10 per abare. In case of class A aliane, each studies of equity is emitted to one vote per aliane. In case of class B share, and holder of equity is emitted to one vote per aliane. In case of class B share, and holder of each studies of each share shall have voting power equivalent to one class A equity share and the class of the entire of equity shares shall have voting power equivalent to one class A equity share.

The dividend proposed by the Board of Onceton is subject to the approval of the shareholders in the entaing Assess General Meeting, except in case of meaning dividend.

v Details of shareholder holding more than 5% of equity strate capital

Name of the control o				
Name of the copity shareholder Dr. Name Tuchan	Number	7/4	Number	%
Mr. Sund Sachders jordby with Mrs. Samen Lichders	10,200,000	36.57%	10,240,600	20.67%
Dr. Naresh Techan jointly with Mrs. Madho Trehan	0 ,600,00 0	13.71%	6,860,000	13.76%
Dunrara Investments (Managues) PTE led	6,592,075	13.99%	6,892,075	15.97%
Assast Investments	8,601,979	17.35%	6,641,979	17.23%
	13,000,000	26 23%	13.000.000	26 1466

vi Aggregate number and class of charce allossed on fully paid up pursuant to contract(s) without payment being received in each, by way of bonus chares and charce bought back for the period of 5 years intotediately preceding the beinge office that

The Company did not notice any theree processed to contractife without payment being account in cash.

the Company did not have been interestin preceding 5 years. The Company has not analogished any buy back of above.

uti Shares reserved for issue under options

For details of states reserved for usua under the Employee Stock Option Plan (ESOP) of the Company, refer note 43.

\$ Instruments endictly equity in nature

	•	at March		Ar oc 31 Ninsen i	2020
i	Authorised	Number	Ameum (Kin lakka)	Number	Amount (f in lakks)
	Compalionly convertible preference thates (Class A) of C 896 each	465,954	3,250.00	466,934	3,250.00
		466,954	3,250.00	466,934	7,250,00
ä	lesued, subscribed and fully paid up				
	Compabath convertible preference states (Class A) of \$ 696 each	466,954	5,230.00	466,954	3,250,00
		466,954	3,250.00	466,954	3,230.00

(This spar but been encurredly by block)



Global Health Limited (farmerly known as Global Health Private Limited)

Standatene cummary of significant accounting policies and other explanatory information for the year ended 31 hisrob 2021

iii Rights, preference, and restrictions attached to Compulsority Convenible Preference Shares ("CCPS" or "perference shares").
These states are consecutative Class A computerally conversible preference above inviting no voting rights and any entitled to vote tagether with the holdest of equity there of the Company and manufacturity entitled to dividend in School 15 of the face value per annum. The above mile provenible into Class A Beguity States as per the executs and conditions attend below:

L	Conversion event*	Convention ratio
Ŀ	Nitreteersh anniversary of the transmit of the Class A performe shore	
2	The date on which the Ansar Investments (tables of the aforestentioned CCPS) owns fewer than 6,630,000 Class A equity states.	
	The economics of a Qualified Jamis Public Offer or the last start by which at convenities recording in the Company should be convened into equip shares in bardes for the Qualified Institute Offer to be permitted under lead in Law.	Our Chia A equity three for every 466,954 Chias A quelennice disses
1	parties are converted to detail its in the Computer should be converted into Equity. Shares in order feet the 12'D which is not a Quilified 3PO so be permitted uniter applicable law.	Each Class A prefer new share shall convers into the lower of (f) One Class A equipy three; or (f) The following number of Class A equipy shares = { [9932 * N/Y] = N /466,954 Where X = Total number of equity shares gamed by the holder of the Class A CCPS immediately before Doublewish Y = Actual IPO Price

*CCFS is classified as expirity as the Company expects to issue fixed manifes of equity assets as the occurrence of convention around the number of which in controlled by the Company

Sobsequent or the year-end, owing to the shates split commercial in rote \$8.4() and (i), the aforementioned conversion event and convention ratio has been updated and subulted below.

	Conversion evens	Conversion ratio
- 1	Nincicends amine trang of the insurance of the Clerk A preference abuse	
2	The date on which the Anane Invertible is folder of the Hotementioned CCPS) owns fewer than 33,150,000 reprint shares.	
	The occurrence of a Qualified hand Public Offer or the has date by which all convenible actumizes as the Company should be convened into equity states in arriver for the Qualified Initial Public Offer to be permissed under Indian Law.	Tive equity shares of Ra. 2 each for every 466,950 Glass A CCPS
	which all convertible Socializes in the Company should be convented into Equity Starce in order for the EPO which is not a Qualified IPO to be permitted under apply table law	Each Class A Professore Singre shall convert into the lower of (D Five equity shares of Ra. 2 cach to a (B) The following number of equity shares of Rs. 2 cach at ([(186.40°N)/73 - N)/ 306.954 Where X = Toush number of equity shares of Rs. 2 cach owned by the holder of the Class A professore share immediately before convention X = Toush number of Professore

iv Reconcilionon of number of CCPS outstanding at the beginning and at the end of the year

	As at 51 Murch 2021		At si H Moreh 2020	
	Nomber	Amount (f to lakhe)	Number	Amaunt (7 in lakha)
Balance at the beginning and at the end of the year	466,954	3,250:00	465,954	3,250.00
Details of shareholder holding more than \$% of CCPS				
Name of the shareholder	Number	*	Number	V 4
Asset Inventors	466,954	100 60%	166,951	100.09%
			A1 6; 31 Morch 2021	As 51 31 March 2020
Note - 19		·	(l'intology)	(f in lakha)
Other equity				(the rains by
gestructure biologicum			48,702.31	47,000.87
Status department contribution of excession			3,232.43	4,843.45
Hatamash cananga			88,199.R7	82,223.43
Скрай кенте			20.00	30.00
Nature and engineer of other services			140,154.69	134,067,75

ईरम्मा (१२४ प्रस्टामध्य

Securities premium is used to record the premium on issue of threes. This betwee con be utilized in accordance with provisions of the Acc.

Share options outstanding account

This account is need to recognise the grant date fair value of the options usued to employees under the Company's employee stock against plan-

Restined comings

Retained carnings is weed to second befance of interment of profit and loss and other enging asignstments

Capital reserve

Capital reserve represents difference between these expited of transferovernity and these capital insued to secrebilly restribile these holders of transferovernity.





Note - 28	As we 31 March 2021 (8 in lakhe)	As qu 31 March 2020 (* in lahfu)
Ranourige - non-cunent Secured form		
Yelvele lugge		
from bosecut insummen (refer note (e) helan)		
Least cutorae manifolies of langue on Borrowings	96.33	140.62
·	[48.62]	(43.69)
	17,70	(43.69) 96.33
Deterred payment labilities (refer note (b) below)		
Loss; Concent manurages of deferred payment liabilities	2,251.45	3,241.05
1,	(364.63)	(53042)
	F,886.62	1,7(1.5)
	1,934,32	1,807,54
Renament terms (factor)		1100

- Repayment terms (including current maturities) and accurity details for term from banks:

 (a) The Company has volated from of 3.21.75 lable from Dainter Financial Services India Provide Limited which exerce an interest at 10.75% year anomal, required by view of hypothecistics on vehicle produces vide the end form. The base is epayable to 48 monthly interferent and repayment his commenced from \$4 hlay 2018
- (b) This expresent balancy for medical equipment principated on defected payment to time to be repaid between April 2021 to May 2025.

Particulain			(Cin lakha)	
	Non-current bonowings*	Finance coulf	T _{Gt0} 1	
EApril 2019 Cath Uses:	1,745.46			
	1,142,40	•	1,745.46	
- Interest capeano				
New cells adjustments	37.10	110.20	110.25	
- Paymeine made 3i March 2020	0.63250	(37 10) (83.10)		
Cash Bawp	140.02	[03.70]	(1.715.64)	
- Interest expense		•	140.02	
- Payments made		54.67		
34 March 2021	(43.67)	(54.67)	54.67	
* Discoolid	96.35		(98.34) 96.35	
* This includes chircuit insputities of non-current borrowings.			30.77	
a) Opening and closing frainness represent interest accreed feachading interest accrued on defented just	yardes (abildics) openanding at i	the remeative very-end		-
Note - 21	•	,		
Leave liabilities - non-current				
Erner babdines (refer sinte #1)				
,		17,290.99	19,439.64	
		17,290.99	19,439.64	•
Lease diphilities - current			47447704	
cente programa (teles arose 41)				
•	_	3,135.00	3,363.36	
	-	3,135.00	3,282.36	
The changes in the Company's lease liabilities arising from his penny activities can be classified at fedior	_			
a ministratio	orij:		(₹ in tekhs)	
Lease l'abilives os as l'April 2019 (current and non-current)			Aniouni#	
24/10/16/448			20,059,16	
Interest on leuse dubalities			4,063-36	
frances of lesse lidadities			2,915.16	
3J March 2020			(3,815.66)	
Change on account of lease modifications			22,722.02	
Delotions on account of early termination			(45.12)	
totenest on lease tabilities			(735.60)	
System of lase handnes			2,258.43	
Cent Concessions from Issue			(3,586.56)	
ease Uabitides as at 31 March 2021 (current and non-current)			(136.8%)	
		 	20,445,99	
· · · · · · · · · · · · · · · · · · ·				
V6(4 - 27)		MAY A 744 MAY 1		
CONTROLL VADA-CUATAR				
teoretion for employee hone for:				
Sensony feefer near 42; Compensors alvences		2,601.23	25454"	
AND THE PROPERTY OF THE PROPER		1,129.99	3,240,69	
	*****	4,031.22	1,784,84 3,527.55	
Povisions - quiaent	<u> </u>		0,041.83	
reserves for employee bracker				
Grammy fector note 43)				
Compensated absonces		\$ A (3.0C	574 87	
HISTOR for contragencies!! (teles aute () below)		352.13	293 39	
		1,373.65	081.44	
		4 005 54		
Novement of provision for contingenties		2,205.84	1,552,70	

CEL II 559.21 1,273.65

684.44 684.44 Note:

(4) The provision for contingencies pension to the estimate of the present probable obligation of cash outloor towards stelly in completion of the under construction facility per agreement.





		At al 31 hEptch 2021	At #1 31 Morety 2020
	Note - 25	(† id lakba)	(K in fakha)
٨	Other non-current habibiges		
	Seletated government krame.	- 40	
	• •	1,771.55	1,886 47
	* Deferred government grans	1,771.55	1,666.47
	Opening before	2.241 99	2,665.75
	Grants regard during the year	1,083.72	4,005.75 1,149.63
	Less - Referred to remember of professor loss	(1,355,92)	(1,551,44)
	Classified into	2,211.79	2,283.99
	Non-entitie tito		· · · · · · · · · · · · · · · · · · ·
	Custon portion	1,771.55	1,885.47
	A	440 25	397.52
		2,211,80	7,283.99
Ð	Other current l'obidities		
	Psychile to transfery authorities	1,334.76	
	Advance from conomerc	2,403.93	1,309.55
	Deferred government grants	440.25	2,071.25
	Others limbulated	135.35	101.28
	Note - 24	4,3(4.31	3,593.60
	rvoie - 24 Trade payablea		
	riest Inlymes		
٨	Testal constanding clace of micro enterprises and small enterprises.		
		5,313.37	1,640,35
		2,313.37	1,643,35
1Di	clearase under the Micro, Small and Medium Enterprises Development Ace, 2006 ("MSMED Act, 2006") as at 31 Moseb 2021 and	11 24405 7030	
-	Particulare	3t March 2021	31 March 2020
N	the principal amount and the interest due chargon remaining unpuid to any supplier as it the end of each accounting year;	(€ die fateke)	(E in lakke)
1 79 1	the amount of inferent paid by the buyer in second of section 16, slowe with the amounts of the parameter of	2,313.57	3,643.33
1 !	with the ability of the second	. 1	,
141)	the amount of enterer the and parable for the period of delay in militing payment (which have been paid but beyond the		
1 4	There was a ground the year one manner and the interest specified about the VINVEST Was	1	` }
IVI I	the amount of success account and remaining supplied at the end of each accounting year, and	5.84	59,41
"	the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest third as		
	shows are acquilly grid to the small enterprise, for the purpose of disallowance as a deductible expenditure under section 23.		1
L		<u></u>	
25	Letal orinandrals gries referedators either dare wisto cutedbases may mary eulerbeises		
	Due to relixed parties (refer note 18)	814 62	_
	Que to others	317.85 8,389.94	310.34
	•	8,607,79	9,949.89
			10,160,23
	Note - 25		
	Other financial linbitries - current		
	Lutrest Mikhanies of Jong-term bourounings Lutrem matarities of the ferred payment hebilides	18.62	43.69
	Nation Activides of the learning between Alphanes	364.65	230.41
	Inital Cadillon	129.92	185.11
	ectainy deposits recorded	451.67	643.89
	imployee relined payables	2.50	5.50
1	timburns payable so retained party (to be some 18)	5,070.75	1,085.05
C,	Other labelines	1.73	12.92
	•	151.82 6,224.64	Lancar.
	-	0,224.04	3,506.60





	For the year ended 33 Musch 2021 (8 in takha)	For the year ended 31 March 2020
Note - 20	(at the sale)	(f in lakise)
Revenue from operations		
Uncome from healthears services		
lis patient Ous patient	100,664.48	117,078.44
	19,532.55	26,214,27
Income from sale of pharmacy products to out-patients Sale of pharmacy products	•	-0/412/41
Other operating revenue	1,004.30	
Government grants income		
Chinaral research income	1,355.91	1,551.44
Other operating revenue	129.01	166.82
, grand	53.56	177.65
	122,739.81	147,208.62
Note - 27	•	
Other income		
Insertest income on bank deposits		
Interest metarie un other financial acrots incamient ai amortised cost	1.342.64	Q\$69.41
Interest meaning on refound of accompanies	44.61	17.60
Всина проме	229.64	•
Profit on disposal of property, plant and equipment (not)	77,89	136.33
Coreign exclusives + Bom (Dei)	86.30	
Spenioriship income		85.75
Revenue share from food court	103.45	73.5.55
Sevenue share from pharmacy	1 2.46	258.92
Sain on de recognition of lease liabilities and right of use assets!	194.63	76 8.61
Reut concersions from tessors	85.15	•
Missell interns invoine	126.89	
	412.63	181.72
as account of enrist emphasiza of base	2,834.86	4,353.89
, , , , , , , , , , , , , , , , , , , ,	· · · · · · · · · · · · · · · · · · ·	
Note • 28		
Cost of materials consumed		
izanizcy, medical and inhornery consumables related to harpations services		
Opening stock		
Add: Porchases (includes government assistance of TNB (3) March 2020; T 27.85 lakhi))	3,033.07	2,212.31
Less: Closing stock	28,618.63	32,192.73
derials consumed	(2,540,88)	(3,033.07)
name of the state	29,110,22	31,371.97
chersi stores		
Opening stock		
Add: Parchasis	192.55	116,65
Len: Closing stock	489.96	624,59
Altials Consumed	(286.17)	(192.55)
Provide Consumer	396.34	548.69
SERVICE and medical concumpling valued to a local		
tarmacy and medical consumables related to sale of pharmacy products to out-patients. Opening stock		
Addi Purchases		,
Less Cloning stock	1,608.68	
	(3-(1.83)	
nferials consumed	GGG.8\$	
T .	36,173.41	31,920.66
C. C. C. Agrico		11+4444
iployed benefits expense		
*	39,653.38	49,213.36
maduusen in provident sail other lunds If welfare expenses	1,554.51	1,926.86
AN ANDRIN POLICIAN	3.76	132.94
		956.97
	378.88	
	378.88 41,590.53	52.230.13
oltryce aliane diased papraent expense	41,590.53	52,230.13
altryce where based papment expense	41,590.53	52,230.13
linger share hased papment expense	41,590.53	52,230.13
iltyses share hased payment expense	41,590.53	52,230,13
iltyser share hased payment expense The surfactor salety expense of employees weeking for research and development amounting to ₹ 78,35 likins (31 historia 2020); ₹ 57 - 30 The costs	41,590.53	52,230.13
altisec share based parment expense p-includes salsry expense of employees working for research and development amounting to ₹ 78,35 likibs (31 blarch 2020; ई ॰	41,590.53	52,236.13
player share based payment expense 10 includes salery expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 18 - 30 19 - 30 2010 Exercises Salery expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 18 - 30 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and development amounting to ₹ 78.35 takins (31 hterefi 2020): ₹ 4 20 and taking expense of employees working for research and taking expense of employees working expense of employees worki	41,500.53 99.29 in dip)	\$2,236,13 \$2,236,13
physicalisms based payment expense on includes salary expense of employees working for research and development amounting to ₹ 78.36 likibs (31 hlarch 2020; ₹ 4) le - 36 ance consignated likibs Zeit accretions replied lower— The consignation replied lower representation represents the consignation represents the	41,500,55 99,29 inklij)	52,230.13
national states based payment expense in includes salary expense of employees working for research and development amounting to ₹ 78.35 likibs (31 hterefi 2020; ₹ 18 to 30 interesting to \$ 78.35 likibs (31 hterefi 2020; ₹ 18 hterefi	41,500,55 99.29 inklm)	52,230,13 92,83
instructions where expense of employees working for research and development amounting to ₹ 78.35 lakes (31 blanch 2020); ₹ 4 per - 30 per	41,500.53 99.29 inklin) 11,74 12,94 2,256.43	52,230.13 92.83 17.37 2,415.16
nature share based payment expense in uncludes salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 interview of the salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 interview of the salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 interview of the salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 interview of the salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 interview of the salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 interview of the salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 interview of the salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 interview of the salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 interview of the salary expense of the salary ex	41,500.55 99.29 Inklij) 11.74 12.94 2.256.43 153.60	52,230,13 72,83 17,37 2,415.16 185.66
in includes salary expense of employees working for research and development amounting to ₹ 78.35 lakins (31 hiereh 2020): ₹ % pie + 36 includes easiery expense of employees working for research and development amounting to ₹ 78.35 lakins (31 hiereh 2020): ₹ % pie + 36 includes easier eas	41,500.55 99.29 inkin) 11.74 12.94 2.256.43 155.69 5.84	52,230,13 92,83 17,37 2,415.16 185.66 51.41
instructures salary expense of employees working for research and development amounting to ₹ 78.36 labbs (31 blanch 2020) ₹ 10 step = 30	41,500.55 99.29 Inklij) 11.74 12.94 2.256.43 153.60	52,230,13 72,83 17,37 2,415.16 185.66
instructure salary expense of employees working for research and development amounting to ₹ 78.35 labbs (31 hterefi 2020); ₹ 4 pie + 30 pi	41,500.55 99.29 inkin) 11.74 12.94 2.256.43 155.69 5.84	52,230,13 92,83 17,37 2,415.16 185.66 51.41
philyses share based payment expense in includes salary expense of employees working for research and development amointing to ₹ 78.35 lakins (31 hterefi 2020): ₹ 4 ie - 30 ance costs	41,500.55 99.29 inkin) 11.74 12.94 2.256.43 153.69 5.84 2.472.55	72.83 72.83 17.37 2.415.16 185.66 51.41 2,765.45
player share based payment expense in includes salary expents of employees working for research and development amounting to ₹ 78.35 likins (31 htereb 2020); ₹ 4 ie - 30 ance costs rest on testing rapinal logger rest on leave liabilities rest on leave liabilities rest on leave liabilities re borrowing rests rest on a frequent payment labilities re borrowing rests e - 31 rectation and amornisation expense rectation and amornisation expense rectation and property, plant and equipment rectation a night of use savets	41,500.55 99.29 inkin) 11.74 12.94 2.256.43 155.69 5.64 2,472.55	72.83 72.83 17.37 2.415.16 185.66 51.41 2,765.45
player share based payment expense in includes salary expents of employees working for research and development amounting to ₹ 78.35 likins (31 htereb 2020); ₹ 4 ie - 30 ance costs rest on testing rapinal logger rest on leave liabilities rest on leave liabilities rest on leave liabilities re borrowing rests rest on a frequent payment labilities re borrowing rests e - 31 rectation and amornisation expense rectation and amornisation expense rectation and property, plant and equipment rectation a night of use savets	41,500,55 99,29 inkin) 1174 12,94 2,256,43 153,60 5,84 2,472,55 7,169,31 1,472,99	52,230,13 92,83 17,37 2,415.16 185.66 53.44 2,765.45
phlyser share based payment expense in includes salery expense of employees working for research and development amointing to ₹ 78.35 likins (31 htereh 2020) ₹ 4 ie + 30 ance corsts were acceptable to the sale of the s	41,500.55 29.29 inklin) 41,500.55 41,500.55 41,500.55 42,55 7,169.31 1,472.59 101.92	52,230,13 92,83 17.37 2,413.16 183.68 51.41 2,785.45 b,262.73 1,199.52 94.57
naturely salary experts of employees working for research and development amounting to ₹ 78.35 likibs (31 htereh 2020) ₹ 1 life > 30 unce costs excitoring replied lower— rest on vehicle four, rest on leave labilities rest on deferred payment fabilities	41,500,55 99,29 inkin) 1174 12,94 2,256,43 153,60 5,84 2,472,55 7,169,31 1,472,99	52,230,13 92,83 17,37 2,415.16 185.66 53.44 2,765.45



Global Realth Limites (formerly known as Global Health Private Limited)

Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

•	For the year ended 31 March 2021	For the year ended 31 hinrels 2020
Note - 32	(t in lukles)	(t in lakhe)
		•
Impairment insecs on financial assets		
Experied credit less on tende receivables	525.21	1,111.0
Expected credit has on other receivables	95.79	
Mar. 22	621,60	1,111.6
Note • 33		
Other expenses Proves and high		
Exact rent.	2,742.61	3,410.5
1 ^t romises		
Vehicles	82.65	88.4
Equipments	44.35	43.6
Reports and manifestance.	3.037.62	3,781,3
Equipment		,
Office	3,728.30	3,877.3
Building	357,04	385.45
Rates and taxes	164.50	218.81
	963.76	1,137.00
Вослиноски ехрепкез Виможее	161.91	185.8-
	185.05	155.5
Traveling and conveyance	232.47	¢08.5
Communication expenses	227.09	275.0
Auditor's remuneration		*
Standary with fees (including taxes)	45.84	54.28
Reinforcement of expenses (including taxes)	2.07	2.24
Patry expenses	1,338.28	1,522.13
Laundry expenses	3(5.9)	343,6
Security expenses	657.54	947.81
Facility management expenses	5,610.33	4,144.66
Advensement stid saler promonon	161,84	329,45
Research and development expense	2.72	1.23
Outsourced survices	698.64	963.60
Retainer and compliant fee - medical	9,327.58	10,213.99
Facilitation fee	876.35	3,083,96
Legal and professional fee	2.131.51	2,776.31
Printing and stationary	391.28	564.53
Saliteription and membership charges	104.28	116.68
Commente rocial responsibility expenses (refer note (i) below)	394.54	224.86
Discusses sining deep	12.98	1,18
Bank charges .	447.54	488.29
Penergy exchange - loss (nel)	. 21.09	40E.XX
Assets written all	125.76	-
are on dispersi of property plant and equipment (net)	123.10	E +1
leavel, boarding and other related expenses for conferences	£23.23	9.65
describilities under export frenchi scheme westen off	302:35	587.49
Miscellaneous expenses	293.76	
•	33,511.0F	303.53 40,584.50

(i) Corporate social responsibility expenses:
Gross amount sequited to be spent by the Company during the year is \$ 194.54 takhs (3) March 2020: \$ 167.15 takhs).
Amount approved by the Doord of Directors to be spent during the year is \$ 400.00 takhs.

Amount spent during the year on corporate toold exponsibility: 7 42.75 liklis (31 March 2020; 7 224.88 blds).

The Company has spent 7 42.73 liklis on 'ongoing project' during the year from Company's bank account.

The Company has revealed provisions of 7 131.81 hider which in the company has been company.

	-				
	D11				
i	Particulars	Year		Yet to be paid in cash	Total
	Construction/acquisition of any asset	31 March 2021	,	•	
	4	31 diarch 2028	,	***************************************	
	On purposes other than above	31 March 2021	12.73		42.73
		31 March 2020	224,88	·····	22.73





Global Health Limited (formerly known as Global Health Private Limited)

Standalone summery of significant accounting policies and other explanatory information for the year ended 31 March 2021

(C in lakis)	For the year ended 31 March 7620 (7 in lakks)
5,677.20	4,975.63
72.53	
2,713.78	(2,154.15) 2,812.68
	(€ in lakšis) 3,677.20 72.53

During the previous year, the Company had elected to exercise the option permitted under section 115BAA of the Income-test Act, 1961 as introduced by the Taismon Laws (Amendment) Ordinance, 2019. Accordingly, the Company had recognized provision for income-test for the previous year ended 31 March 2020 and re-measured in deferred tax assent/inhibiting trains the case presented in the aforesaid rection.

The major components of the reconciliation of expected tax expense lined on the domestic effective tax rate of the Company at 25.168% and the reported tax expense in the statement of profit and loss are as follows:

Accounting profit before income tax At standary meaning tax rate of 25.168% (3) black 2020: 25.168%)	8,442.28 2,124.75	13,693.34 3,295.33
Tax effect of amounts which are not deductible (taxable) in calculating taxable incomes: Tax impact of statutory deduction allowed as per Income tax Act, 1961 under the head income from 'Florise Property' Tax impact of expense which well never be allowed under Income tax Act, 1961 Tax impact on unpairment in value of investments Tax impact on account of change in income tax case Tax impact in respect of eather years Others Tax expense	(22,75) 406,46 72,53 139,19 2,713,78	(89.98) 242.55 210.58 (904.85) 64.55 2.817.6H

Note - 35

Earninge per etrace (BPS)

farmings per share (EDS) is determined based on the nei profit attabatable to the chareholders. Base comings per share is computed using the weighted average number of shares observations and dilutive common equivalent shares curvantling during the year, except where the result would be annidative.

except where the retail words be anti-delutive	and the comment of the vicing bullet	constanting ander the year.
Profit attributable to equity shareholders for hasic and diluted EPS	5,728.50	10,275.66
Weighted average number of equity shares for basic BFS*3 Effect of dilution - weightage average number of potential equity shares on account of employee stock aptions*2 Weighted average number of equity shares adjusted for the effect of dilution	251,408,094 647,391 252,036,385	250,255,[11 1,304,785 251,559,894
Carnings per equity there		
Basic Diluted	2.28	4.11
123044.0	2.27	1.09

^{&#}x27;The Company had issued computsority convertible preference shares which are experted to be converted into equity shares and the same has been duly considered in calculation of basic earning per share, considering maximum number of equity shares to be issued upon conversion.

⁵ Subsequent to the year-and, the Board of Directors of the Company has approved thate split of Class A equity shares from ₹ 10 per share to ₹ 2 per share and the same has subsequently been duly approved by the shareholders of the Company. As presented under Ind AS 53, 'Barnings per Share', the Company has presented basic and diluted earnings per share on considering the afterencement of the current as well as previous year.



(This space has been intentionally left blank)



[&]quot;Shace options (universical under the ISOP Plan 2014 and ESOP Plan 2016 are considered to be potential equity shares. They have been included in the determination of distinct examings per

Global Realth Limited (formerly known as Global Health Private Limited)

Standalone summary of eignificant accounded policies and other explanatory information for the year ended 31 March 2021

Note - 36

Fair value disclosures

(f) Fair value biererchy

The following explains the judgements and entomates made in determining the Crie values of the financial instruments that are recognized and monated at fair value. To provide an indication whene the echatility of the inputs used in determining face value, the Company has classified its financial instruments into the three levels prevented under the accounting standard. The following explains the judgements and enumine made in determin

Level Is quoted prices (unadjusted) in active markets for financial instruments

Exect 2: imputs other than quoted prices included within Level 1 that are observable for the asset of hability, either directly or indirectly

Level 3: unobservable inputs for the asser or habitey

Valuation techniques used to determine fair value

valuation techniques used to increment star value. The fact of the financial users and liabilities are included at the amount that would be received to tell an asset and posit to transfer a liability in an orderly tensistion between market participants. The following methods were used so estimate the fast values:

- Trade executables, eath and each convenients, other bank balances, toxis, other curent financial as vers, reade payables and other curent financial liabilities deproximate their carrying accounts largely due to the short-term matteness of these instruments.

Bearousings taken by the Company are as per the Company's credit and liquidity risk assessment and there is no comparable instrument having the similar terms and conditions with related security being plunged and hence the earlying value of the borrowings represents the best estimate of fair value.

(ii) Fair value of assets and liabilities which are measured at amortised cost for which fair value are disclosed

Particulars	As at 3t Iderch 2021		As at 31 March 2020		
	Carrying value	Pair value			
Pinencial assets	1	T-941 VBINE	Carrying value	Fair value	
Loans					
Prade receivables	650.69	450.69	605.93	605.93	
Cash and eath econostonis	12,983,69	12,985.69	14,842.08	14,842.08	
Other bank hidness	4,530.65	4,530.68	13,155,36	13,155.30	
	20,946.76	20,946.76	8,721.39	8,721.30	
Other funnial assers	4,341.24	4,341.24	4,677,57		
Total financial accets	43,453.03	43,451.03	42,002.33	4,677.57	
Borrowings (hishading current manufacts of long-term borrowings)	2,347.78	2,347.78		42,002.33	
Trade payables			2,381,97	3,381.97	
Other linancial liabilities (excluding current maturities of long-term borrowings)	10,921,16	10,921.16	11,803.58	11,805.58	
Total financial liabilities	5,810.78	5,810.78	4,932.48	4,932.48	
	19,079.73	19,079,73	19,118.03	19,118,03	

Note + 37

Pinancial risk management (i) Pinancial instruments by estegory#

Particulare	Pairv	alue *	Amortised cost	
	Az at 31 March 2021	As at 31 March 2020	As at 31 March 2021	1 4- at 31 bears 2000
Financial accets			14 110 11021	THE ME DE PROPERT 2020
lovertments	5.00			
Lower	ν.LQ	٠ :		
Trode occouplilis	,		650,69	405.93
Cash and cash equivalence			12,783.69	14,842.08
Other bank bytances		,	4,530.65	13,155.36
Other financial assets	,	٠	20,946.76	8,721,39
Notal fignwolst orsets	· · · · · · · · · · · · · · · · · · ·		4.341.24	4,677,57
Visoncial Rabibbles	5.00	-	43,453.05	42,002.33
Horrowings fincluding current maturities of turn-current borrowings)			***************************************	
Lasto lightines	i .		2,347.78	2,381.97
Trade payables	,	•	20,446.00	22,722,02
		,	10,921.16	11,803.58
Other financial hobitises (excluding carrent maturities of non-corrent horrowings) Total financial liabilities			5,810.78	4,932,48
This investment is measured at fast value through other comprehensive income and is categorised as		-	39,525,72	41,840.05

This investment is measured at fair value through other comprehensive income and is categorised as level J in fair value hierarchy.

(ii) Rick managemen

The Company's artificities expose a to market risk (foreign exchange and interest risk), liquidity tisk and execut risk. The Company's board of characters has overall responsibility for the establishment and nevertight of the Company's risk management fearnework. This note explains the exerces of risk which the entity is exposed to and how the courty manages the risk and the related impact in the

 financial alakements.	······	, a province to the critical	countries the time and the trasted impact to the
Risk	Exposure arising from	Messurement	Management
	Loans, trade receivables, each and each equivalents, other bank liabures and other financial assets measured at amortised our	Ageing analysis	Diversification of bank deposits and credit limits and regular monitoring and follow ups
	Boscowings, made payables and other financial hisbilities		Availability of communed credit lines and Brorrowing facilities
	Puture commercial transactions, recognised financial assects and liabilities not destominated in Indian repres	Cash flow forecasting sometimes analysis	Forward foreign exchange contracts
 Market rish - imercisi tale	Long-term hutrowings at variable rates	Sensitivity analysis	Diversitioners of batterwines

...(z)..Credit risk.

Code iish isongemen

Credit ask is the risk of financial loss to the Company if a customer or constrainty to a financial asset fair to meet its contentual obligations. The Company's exposure to credit eak is influenced mainly by the ordividual characteristics of each financial asset. The currying amounts of financial assets represent the maximum credit risk exposure.

A default on a financial asset is when the counterpany fails to make contractual payments as per agreed terms. This default is determined by remaidering the business environment in which entary operanes and other nacto-economic factors.

The Company has a credit ask management policy in place to limit credit losses due to non-performance of counterpanies. The Company monitors its exposure to credit risk on an ongoing losse. Assets are written off when there is no restanable expectation of recovery. Where loans and recovables one written off, the Company continues to copage in enforcement activity to attempt to recover





filmestments in subsidiation and joint venture is inquired or cost as per Ind AS 27 Separate Financial Statements'.

Pente example.

The Company closely monutars the credit-worthness of the receivables through internal systems that are configured to define credit family of customers, thereby, limiting the credit sisk to pre-calculated amounts. The Company uses a susplifted approach diffetine expected ends four modely for the purpose of computation of expected credit loss for trade reconsibles. Expected ends for the purpose of computation of expected credit loss for trade reconsibles. Expected ends for the purpose of computation of expected credit loss for trade reconsibles. Expected ends for the purpose of computation of expected credit loss for trade reconsibles.

Category	Input for measurement of expected credit	Assumptions
Сенциничи	Same in half lasts	Trade receivables outstanding for more than two years are considered inecoverable. Allow each for expected cress fors on receivables outstanding for terr than two years is recognised trated on expected deductions by government agencies.
New-gave-tuneat		· · · · · · · · · · · · · · · · · · ·
\$ndividuati	topos ribs	Tesde receivables outstanding for more than two years are considered irrecoverable. Other secondales are considered good due to ongoing communication with customers.
Congression	Collection against outstanding acceluables in pase	Trend of collections made by the Company over a netled of six years preceding balance sheet date and considering default to have occurred if receivables are not collected for more than two years.
These party attenness actions of insurance companies	(****	Trade receivables outstanding for more than two years are considered inecoverable. Allowance for expected credit loss on receivables outstanding for loss than two years is recognised based on expected deductions by their party administrators.
Odurs	Customer wise trade receivables and information obtained through sales occurrent follow ups	Specific allowance is made by researing pany wise outeranding receivables based on communication between sales team and contoniers.

Good and said equinstant and other land butteres

Credit risk related to eash and each equivalents and bank deposite is managed by only investing in deposite with highly exted banks and financial institutions and diversifying bank deposite and accounts on different banks. Credit risk is considered for Decase the Company deals with highly rated banks and financial institution.

Lantes and other financial attitle

Loans and other framewal arrest measured at amortized cost includes receiving deposits and other receivables. Credit risk related to these thranged at severe is managed by monitoring the recoverability of uch amounts arrest incomes as anisotroc our incomes account agreement and once executation. Oreall task resident defined limits. Credit are immaged by monatoring the recoverability of uch at the large of security defined limits. Credit are the large of monatoring the recoverability of postession of the underlying asset (in one of security deposit) or as per trade expedience in case of unbilled executation and other recovablet from recome sharing advantagements. Further, the Company creates provinced by assessing individual financial asset for expectation of any credit loss basis 12 month expected credit loss model.

(b) Credit risk exposure

i) Experted steeds has for trade exceesibles under simplified approach i.e. pseuvision smarts approach using historical trends.

As at 31 March 2021 Particulars	Government			Noa-government	·····	(č is lakbs)
	1	Individuals	Corpurates	Third party administrators of	Others	Total .
Gross categing value	16,879.31	1,128.8)	1,348.73	inturance companies	···	
Less: Expected credit loss (imparement)	3,223.53	757.01	1,169.46	4,390.50 932.77	826.94 489.85	19,576.31 6,592.62
Carrying amount free of impairment) * Inter also, including outstanding balance from parties not of a	# 8,655.E1	371.80 af sim4st econom	159.26	3.457.73	339.09	12,963.69

(CG145) amounts to \$ 3,392.68 lables and Ex-remitentan Contributory Health Schome (ECHS) amounts to \$1,477.96 labbs.

As 21 3(Majob 2020 Particulars	Government*	140mgovernment				
		iudividuats	Corporates	Third party administrators of insurance companies	Others	Tolz}
Gross carying value Less: Expected credit loss (impairment) Carrying amount first of intestimism)	12,625.69 3,667.15 9,558.74	993.14 641.01 352.13	1,713.77 794.48 910.20	4,237.64 777.60	1,539.66 786.08 	20,909.50 6,067.42

Internity, including outstanding behaves from parties act of expected credit loss of similar economic characteristics i.e., Central Government Health Scheme (CGHS) amounts to ₹ 3,496.24 likely.

As at 31 March 2021	and 3 bloom board out times meaning assets (racounted at an annual equal to 12 months especial credit losses)						
Particulars							
127CC01315	Estimated gross	Expected credit	Corrying amount not of impairment				
	carning amount at default	tosses	provision				
Loues	650.69						
Cash and each equivalents	4,539.65	l	450.69				
Other bank balances	20.9 46.76	<u>'</u>	4,530.61				
Other imaneriti ussets	4,573.62	' I	26,946.76				
	*,777.1.02	332.39	4.341.24				

	Pardouter	····		(\$ io lakhs)	-
	FORMULANT	catiding atooner or gelonit Engmated 5.012	Expected creati	Carrying amount uct of impairment provision	
i	Loans	605.93	+	605.93	
	Caste and testi equivateurs Other bank tratances	13,155.36	•	13,155.36	
	Other financial actets	8,731.39 5,669.68	***************************************	8,721.39	
			136.60	4037.48	

ь и)	Recognition of expected credit loss for other financials associand trade receivables		(E in lakhs)
		Other financial essets	Trede seccivables
	Loss allowance on 1 April 2019		
	Allowance for expected credit (tr)	136.60	4,955,81
	1-oss allowance on 31 Masch 2020		1,111.61
	Allowance for expected credit loss	136.60	6,667.42
	Loss allowance on 31 March 2022	232,39	525.20
		1 404-07	6.592.62





Global Health Limited (formerly known as Global Health Private Limited)

Standaloue cummany of eignificant accoming politics and other explanatory information for the year ended if hisrch 2023

(b) Liquidity fits

Legating risk is the mik that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering each or another financial arees. The Company's approach to managing figurity is to ensure as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due.

The Company maintains theribility in funding by maintaining availability under committee credit lines. Althougement maintain the Company's Equidity position (companing the undrawn borrowing facilities below) and cash and cash equivilents on the basis of expected each flows.

The Company takes and account the liquidity of the attakes in which the entity operates.

Manufilles of Anapolal habilities

The following are the committing contracted materials of featured labilities at the reporting date. The amounts are gross and undiscounted, and include contracted interest payments and exetute the

As at 31 March 2021				(Ť in lakha)
Non-derivatives	Less than I year	1 - 3 years	More than 3 years	
Borcovings				
Leare habilities	413.26	1,632:07	416.70	2,482.03
Texte opposite	3,542.55	6,166.62	350,584.25	260,293,43
Other financial liabilities	10,931.16			10,921.16
Total	5,810.78		. 1	5,810.7a
1014	20,687.75	7,818.69	251,000.95	
			200,000,93	279,507.39

As at 31 March 2020 Non-derivatives	Less than I year	l-Syeure	More than 3 years	(7 (n takhs) Torat
Borrowings Loss Litaburg Trade psychle Other funnical habitures Trade	342 60 3,815,44 31,803,58 4,932,48 28,893,50	890.52 7,310.28	917.3 <u>2</u> 254,065.46	2,149,84 265,189.18 11,203.58 4,932.48 284,075.08

The Company also has access to the following uniterwa boscowing from banks at the end of the reporting period.

Particulate		(Vin lakin)
	As 44 31 March 2821	As at 31 March 2020
Undrawn bettering facilities	9,316,49	

(c) Market risk (i) Poteign exchange risk

The Company has international transactions and is exposed to foreign exchange tisk uniting from foreign currency transactions (imports and exposs). Possign exchange tisk utities from future commercial transactions and recognised assets and liabilities denominated in a currency that is not the Company's functional currency. The Company has not hedged its foreign exchange receivables and payables as at 33 Narch 2021.

A GLESS CONTENTS WERE CX DOCKFORT	Foreign	currency rish exposure:
-----------------------------------	---------	-------------------------

Particulars	Az 21 31 N	fareli 2021	A) at 31 M	(erch 2020
fast La	Forciga currency	INIt (¶ in takha)	Foreign currency	JNR (7 io lalda)
Fadic (Occordibles (gross) Liabilities	QSD	267,27 267,27	USD	086.9
Defend paymen liabilitie; Lorde payables Praile payables Drule payables	EURO EURO USD GBP	665.88 0.16 0.01	USD EURO USD	686.5 19.5 19.5
	100	62.74 728,79	GHP	232.3 268.5

1 is this like the same of the					
The remaining of profit 21 1815 to changes we the exchange rates arises from force Particulars	St. Coursell governin				([?] in lakhe
		3f Mare		31 Marc	
Assets	Съггевсу	Exchange care increase by 3%	Exchange rase decrease by 3%	Exchange rate Increase by 6%	Exchange rate decrease by 6%
Trade topovables (gener)	ยรเว	8.62	(8.62)	+1.21	(41.31
Libhlities					,
Deferred payment to tolones Trade payables	EURO	19.98	(19.98)		
Trade payables Trade payables	บรอ	9.00 6.00	(0.00) (0.00)	1.17	(1.17)
	GBP	6,80	(1.86)	(3.94)	(13.94)



(this space has been interiorally life block)



Clobal Health Limited (formerly known as Global Health Private Limited)

Standalone summary of significant accoming policies and other explanatory information for the year ended 31 March 2021

Note - 38

Related party transactions

the accordance with the requirements of find AS 24, Related party disclosures, the names of the related parties, transactions and year-end balances with them as identified and certified by the management are given below:

i) Butilies where control exists

34 March 2021

Subsidiary companies

- (i) Global Health Patliputes Powate Limited
- (i) Medanta Holdings Private Limited

31 March 2020

Subsidiary companies

- (i) Global Health Padiputta Private Limited
- (i) Medama Holdings Private Limited

Joint venture

(i) Medania Duke Research Institute Private Limited (refer note below)

The Board of Directors (the Board) of Medania Duke Research Institute Private Limited (a joint venture) in its meeting held on 19 June 2019 had resolved to invitate the process of winding up of the aferensentioned emity and subsequently, they have initiated the process of voluntary liquidation of the said entity in accordance with the provisions of the Insulvency and Bankruptey Gode, 2016 read with Insulvency and Bankruptey (Voluntary Liquidation Process) Regulations, 2017. This has also been affirmed by the shareholders in the August General Meeting (AGM) of Medania Duke Research Insulted Private Limited field on 24 September 2019. During the year, on 25 February 2021, the official liquidator has submitted fant application for liquidation/winding up of the said entity with National Company Law Tribunal (NCLT). However, the final order from the NCLT is awaited.

ii) Individual who exercise control over the Company

- 1	The second secon	
- 1	31 Murch 2021	*************************************
		31 3 C DATO
		31 March 2020
- 1		Da Standa Trading
٠,	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	Dr. Najesh Trelian
	Besis the rights modifiable as wer Articles of Assemblan Dr. Nameh Technology and Assembland	
	Will the tight thinging it her Atting at A Cheffing I'm Same h Tochan arranges and a facility of	

ili) Key management personnel (KMP)

31 March 2021	31 March 2020
(i) Dr. Naresh Techan - Chairman and Managing Director (ii) Mr. Shoul Sachideva (iii) Mr. Havi Kant Jaipuna (iv) Mr. Neeraj Bharadwa) (iv) Mr. Neeraj Bharadwa) (iv) Mr. Pankaj Sahna (ivi) Mr. Pankaj Sahna (ivi) Mr. Udhiram Tilah Koattiath (from 05 Junis 2020 upto 21 February 2021) (ivii) Mr. Udhiram Tilah Bharia (from 23 March 2021) (ivii) Mr. Pravcen Mahajam (from 25 January 2021) (iv) Mr. Verkaresh Rajnayama (from 25 January 2021) (iv) Mr. Pravcen Mahajam (from 10 July 2030)	(i) Dr. Naresii Frehan - Chairman and Managing Director (ii) Mr. Sunit Sachdeva (iii) Mr. Ravi Kant Japuria (iv) Mr. Rohit Sipahimalani (upto 26 September 2019) (v) Mr. Neenij Blaraduaj (va) Mr. Stenij Blaraduaj (va) Mr. Sanjuev Kumar (viii) Mr. Pankaj Sahni

iv) Relatives of KMP;

31 March 2021 and 31 March 2020

31 March 2021 20th 31 M12/CH 2020		
 Name of Relatives Mr. R.L. Sachdevs	Relationship with KMP	
	Mother of Mr. Sunil Sachdeys	-
May Sheel Traine	Daughter of Dr. Neresh Trehan Daughter of Dr. Naresh Trehan	
	Wife of Dr. Naresh Trehan	
DICTORY LICENS	Brother of Dr. Nacesh Trehan	

v) Enterprises under the control/joint control of KMPs and their relatives or where the individual exercising control over the Company is exercising significant influence or is a KMP, with whom transactions have been undertaken or whose balances are outstanding:

31 March 2021	31 March 2020
(Oil AN Citobat India Private Limited	OlFAN Global India Private Limited
(th) Tar Chamber of Kapur & Frehau	100 Lay Chimber of Kapur & Treban
(iii)Raksliz TPA Private Limited	(oi) Raksha TPA Private Limited
(iv)Stratak Healtheare Private Limited	(iv)Sharak Healtheare Peryate Lanuted
(c)Language Architecture Body (LAB)	(v)Language Architecture Body (LAB)
(vi) Vidyanta Skill Institute Private Limited	(vi) Vidyama Skill Justinue Povace Limited
(va)Medanta Institute of Education & Research (Paist)	(vis)Medanta Institute of Education & Research (l'enst)
(viii)RJ Corp Linsted	(via)R) Cary Limited
(m)Desyam International Limited	1
(a)Diagno Labs Private Limited	(ix)Devyani International Limited
(xi)N.A.S Infotech Private Limited	(x)Diagno Labr Private Limited
(sa) Vanu Beronges Lamed	(xi)S.A.S Inforects Povate Limited
Card - west ne coulds & that the	(mi)Varua Beverages Lamined

New Delhi

Stebus (kastis Linuised (filment) immun as Clabal Hamish Briture Litulad) Standalante aurumany of aigri immu procurating politics published (kalantana arbumania kasta)

·	Stevenstein vortei Mehrert Debt Riverich hausen Debrik Loopie		Pade ti duals using the received concretion of the Concrete	Manufaction and American	Related peoples Juiet rentuce	Kay manageriona prisonnel and shell relatives	Emissiphies under the Consol of NATE and their relatives as asper	i I
·	dicertos en porto						KMPs are common	1
·	A DESCRIPTION OF THE PARTY OF T				L			1
·	Medical Liche Research Base-in Patrick Lympted	31 [460] (202)			ļ			
Ţ-		115 link 2000			401			J
Ĩ.,	Medical Indian of Education & Research (Tours)	31 Missty 3021			101	·-·	50.17	
	Records their from food rown	36 Minch 1926					10.17	
	Organ handword oracl	Di Mercia 2021			f forestern			
		31 March 200		···			11246	1124
·	Reschidenma capeage						248.52	234.9
	IFAN Coplat India Private Lange	31 Mauh 3021					*5.45	
I.	Rem expenses	31 NEARN 1070					118.00	
	Stedarce Date Restaute lossing Private Linkord	31 13sech 1031						1
;!		11 14spt 2030		·	693			
·	Professional designs							<u></u>
ш.	l	31 March 2024 31 March 2000	····		····		30.64	26.8
İ	Affertrate Matterge Mirate Laures	34 Magely 2026	····				31 15	34.1
2"*	Tisteing expenses	31 N (et h 2020		* }-	******			
	Veryama \$1.8% Impacts: Pacific artiful	31 \$1 arch 2021						
- 1		31 March 2020					14517	149.5
	Turcham of progent, plens and excipance.	1	i				121 40	81.4
Ě	Stedents Chale Restautt Instaure Private Landed	Ji Marta See				***********	·	
: "f	Sale of property, plant and compenses to establing secret	31 Marsh 2020						57.8
I.								77.3
7	Medical Indiago Prose Land	\$1 March 3054 \$1 March 2030		1145				
{:	Show Here! Partients Partie Lindas	31 Hanh 2030	*************	6.94		**************		33.77
i.		21 March 2021	71100 10 0000 - 4: 61:44	7859				6.W
	havence from prisons one red poore assure	33 Mart. 2020						10.2
ď	Reballs The Cores larges	Manb Still					M = 0-00	
1:	Book Herskein beren Linies	H March 2025			·		56532	7,0%3.11
- 1		38 Merch 2021		**************************************		*****	(443)	(,344.5)
i ti	Kiederfog of husblaner repriess	31 March 2020					614	924
- 1	K & Sorlder	13 Minh 7025						<u></u>
1.	Mrs. Szieni Szcielyy	3(Heed, 2020				1,62		1.47
ľ	Tita. Saidin Saidayay	31 34sek 2021				316		3.86
Į.	O Conf Lengs	21 Alark 2020 21 Flack 2021	**************************************			630		4.10
ļ.		51 hlarch 2020					141	1.61
ľ	Notice Privatages Looding	31 March 2021						0.43
17	Despeta lade perhaps a lacuned	JI March 2000					D 45	0 85
- 1	i	\$1 fd (m) 70 }1					6.11	
F	trice Selah	31 bleach 2025					162	C.35
1	The same property of the same	31 March 2020			—— 	0.74	·····	C.96
- 1	A & Interests Private Banace	11 57 at the 2021					53.10	0.03 12. N
K	Ardner Haldings Florar Limited	31 Man (2020 31 Man (2021					505	9.61
		31 Meg/1 7000		10.93				\$1.29
-14	Control of the left of				···			(0.91
ľ	was our on het de let Let By Profits	31 March 2021		16,030.00		}	·	10,400, pg
i.	Admiel leitings Payor Livered	11 March 2030		4,200.00				700.00
- 1		31 March 2010 34 March 2000	·	2,560,60 10,530,69				1,3430,000
- 2	Againmed it topicer Again Labs frince Lamord			10,7,044		·-··		10,360.60
''	and the child	31 Men's 2021			****			268.60
	sprease puls on tedals of	3) Manta 3020					19.6	327.45
i i	Rabel Blester, Pothernes Proper Latered	21 Morth 5021						
1-	AS Interest Prints Louise	31 Moreta 2000 E						14
	}	21 March 2021 21 March 2030				· 	38.5	1,00
M	feduras Hestings Francis Leaving	51 March 2030		(Ca 12			311 96	243,25 137,94
				103 72				
-6	as disfused at source past on behalf of loke the on Subgene Private Control							
	ŀ	31 Mirch 2021		135			····	7.33
11.	the of chief their tabild (requested territors bitterious)			11.45				11.11
. J				1	1			
1.	rite Situs	St Macch 2024			·····	7580	,	
7	exemples grices an achell of sublidiery company to third	31 Ment 2020	777777777777777777777777777777777777777		•	1020		11-25
-	male Construction of the Holles & Cons brud to Unity					· · · · · · · · · · · · · · · · · · ·	····	35.83
	relacts [Beldings Presse Laught]	21 Marsh 2021		اــيبيدا				
بيراد		21 Strate 2020		tja bi				1346
-104	transmir a cining tire (including 4: 32)		·		······································			Pin.se
1"	and her by Haridar	34 Elizak 2021		-	····			
[Ki	Live Copy, State,	JI Museu Mass					A-18-11-	5.41
	. i	31 March 2027 31 March 2027 31 March 2020	••••• • • • • • • • • • • • • • • • •			76		236
1	- Day Division	The state of the second second				1		
1	eperine Cardina	31 https:// 5030		Marketter Mark IV		1.11		
	1-	31 March (63)		Di Contracto de la Contracto d				
1	Boot and caker beredita	31 March 10/0						138
1	North Unback	51 STurch \$275						
1	I						[. 7
115	}	31 14 - 14 50 50	1,613.65					-, war
141 123 141	rus Komië	31 March 5050 10 March 5011	1,033,05			646.81		ale a
141 123 141	}	51 March 2020 51 March 2021 55 March 2020 53 March 2020 53 March 2020	16.75					170.04 170.04 213.21

G. These are no post employees to be the compression employee beselfet and these based payment populated Da, Kindah Technol. B. Herse are no share break growers payoble to Sunjan James.



	Course share capital the Newski Technic possity with idea Madita Technic	You	Individuals who exectings women as so the Conferna	\$Christing	faire symbol	Reg Russingers mi	Merapolies water the	Tolet
	County chair depited the Bounds Porton county with idea Medica Treken	1		tempera.		przeminal oad ibeit teitlitas	Sheered of RMPs and sheer columns to refuge EddPs are continued	
		31 Nanh 2021				64021		
- 1	De Nasset-Teslus	31 March 2020	1,600 60			49.21		649.3 649.3
- 1	bie bone berhaten bentj mat hing Somen Spriefere	21 March 3026 24 March 3421	1,02.00					0.000,0 0.00 0, 0
	My Enter I agreed	I & Minock, Side	***************************************			e4010	2000	480.0 490.0
-	Pente Salva	34 March 2024 34 March 2020 31 March 2021			* ** ** ***	- 670	100.00	100,0 200,6
-5-4	Tridi payables	1) Hart 2021				946		<u> </u>
	De Nierah Tielini	JI Mark 2011	36.51					363
	Sand Safely of	31 March 2014 31 March 2021	3034			36.00		50.1
ŀ	FAN Chibal India Person Lanua d	24 March 2024				50 54		70.1 70.1
	te- Charles of Kayes & Techan	31 Mart ir 2020 31 March 2021					(4.1.5)	(L)
- 1.	Lidy are \$1.1 fight or there's Landed	51 March 2029					€ <u>1.</u> 01	(L) (.) (.)
- 1	Jargang And Street Bort	21 March 2077 21 March 2017					28.84 12.34	11.4
ı,		13 March 2021 14 March 2020		~			h11	0.1
- 1	Drogod Labe Freeds Lawred	31 M(14) (20) 31 M(14) (202)	***************************************				11 61	8.1 013.9
ľ	Reserve Head age From Secure	11 March 3074 11 March 3020		476			124-61	120 e
. J	Other recupatives Redouglossors of Education to Massack (Fairly			(.3i				4.5
	Degree les magazil Lentes	16 kines, 8001 34 Nigels 8000					7,27 7,73	V.9
i.		Ja New B 2021 Ja Morch 1000					150.57	7.7 236.§
- 1.	. 53 Secure & Pro ale Secured	DE Minels NOZE 22 Minels 2000					150 ac 141.50	I NJ.S
	Stationa Hostings from Lange	\$1 Miny'n SC23		153.65			105 44	174.9
- 1	2013 H. Cit Catigoria Princip Library	95 Mirch 3070 1408 Amilk 36		6,56 87.95				¥7/6
	Peda eschialdes	Di Mireli 2020	/*************************************			***********		
I.	Obaha TPA Parisar Located	11 March 2021					180.72	234.9
- 1	disease Landon see Consent Larrated	51 March 2021 21 March 2020					233.13	2,11,5
F	Costs furnes	11 Marie 3011					01)	0.01
V	of the Mesterges Books of	31 Mars 5 2020 31 Mars 5 2021					11.16	J3-j0
j,	hay are less constraint langer	31 Man k 2920 31 Man 1, 2011					037	0.51
š	A S. P. Lattels Process Sanded	31 March 2011					6.53 6.63	9.67
į,	holacis Helbory Person Largers	31 March 2009 14 March 2011					280>	1,0
	Ober pysica	31 Blank 35/4	TOTAL CONTRACTOR OF THE STREET					\$3.41
i di	Seal Hisbit Balgadia Physic Landred	H Mrack 2021		1.11 1241				11.13
<u> </u>	rantee era in point brother	14 Mars k \$050	***************************************	152				0.07
	Industr Date Research Compact Priests Limited	31 Much 2021	4					
	matterest in ordered any or appeared	31 Numb 2034						
I.,	Education age from Local	31 March 2000		(1,100 to 1,100 to				19,700 00 9,700 50
		JI March 3931		47,1710				42,410,00
175	mercule Press on hithelf of subsidiery companies to third						·	+0,130,00
	Lond Section Congress Princete Consend	31 Abril 2031		1,0040				1,600,00
Ä	c'usallatings force too and	37 March 50 1	441-dia (5 (4).50 1,901.03				(000) 861(6)

This is the necurrence on the company has received improvement for artist behave in author sector



Global Health Limited (formerly known as Global Health Private Limited)

Standalone summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

Note + 39

Capital management

The Company's objectives when managing capital ace:

To consuce Company's ability to commune as a going concern, and

- To maintain optimum equital structure and to reduce cost of capital

Management assesses the capital requirements in order to maintrin an efficient overall furniting stancture. The Company manages the capital structure and makes adjustments to it in the light of changes in antengentian assessed the copin requirements in material material and entering superiories are company arranged and copined substance and material and the material and the material and the material and the material and the material and the material and antenges in the company is not subject to exercisely supposed capital requirements. The Company manages are capital requirements by averaging the gearing ratio:

Particulars		
	As at 31 March 2021	(3 in lakha)
1 oth politicalist (excluding interest octored)		As at 31 March 2020
Total equity	2,347.78	1,831,54
Net debt to equity seria	1-8,363.18	142,272.25
	1.58%	

Note - 40

Contingent liabilities and commitments

А	Contingent liabilities	
	Particulars	(f in lakha)
	totome-pay matters As as 31 March 2021	As at 31 March 2020
	Other cases (select parts (si) below)	
	208.7%	
	20030	

(i) It is not practicable for the Company to estimate the notings of each outflows, if any, is corpect of the above penting resolution of the respective proceedings.

(ii) The amounts disclosed show represent the best possible estimates served at on the basis of available information and do not metude any penalty payable

- (iii) The Company is contesting employee schieft cases in various forums. Based on the intensit analysis, the Company is of the view that the likelihood of any outflow of the resources is remote except, as
- (w) The Company is contesting various medical related legal cases in various forums. Based on the legal opinion from external consultant and internal analysis, the Company is of the view that the likelihood of
- 8 Commitment

(i) Capital commitment Particulars (f in lakin) As at 31 March 2021 Property, plant and equipment As at 31 March 2020 977.63 495.36

(ii) Other commitment Particulars As at 31 March 2021 Bank guarantee As at 31 March 2020 Performance bank guarantee S 226.50 ₹69,53 Consource guarante@ 1,500.00 1,500,000

This includes bank guarantees given for capital goods imported under the Export Promotion Capital Goods, of the Government of India, at concessional rates of duty on an undertaking to fulfill quantified expons within stipulated period of time.

5 The Company has natural a performance bank guarantee of \$ 1,500.00 laklus to Government of Bilize on behalf of Global Health Parliquites Private Limited (a wholly owned subsidiary).

@ The Company has resulted corporate guarantee of \$ 2,741.58 lakhs to Deputy Commissioner of Customs, New Delhi on behalf of Medants Holdings Private Limited (a wholly owned subsidiary) for

(iii) During the year ended 31 March 2020, the Company has issued letter of support to Global Health Pathiputes Private Limited (a subsidiary) for providing operational and financial support if it fails to fulfill Doing the year claims of the contract and the fetter of support was valid till June 2020. Further, the out-patient services has attently became operational in the month of September 2020 and the Company expects to complete the first plaste of project as soon as the second wave of Covid-19 normalise and in this reference, the subsidiary has an outrawn borrowing facility of \$ 20,570 labels.

Additionally, the Company less also given an undertaking in favour of the RBL Bank Limited for Global Health Pathquist Private Limited (a wholly owned subsidiary) for additional infusion through equity or unsecuted borrowing in case of shouldlin secricing al debt facilities by the said subsidiary.

(This open has been intentionally left blank)



Global Health Limited (formerly known as Global Health Private Limited)

Standalone summary of significant accounting policies and other explanatory information for the year ended M Murch 2021

Note - 45

(i) Leuse related disclosures as lessee

The Company has leaves for had, buildings, equipments and relatives. With the exception of short-term leaves and leaves of low-value underlying assets, each leave is reflected on the balance sheer as eight-of-use asset and a leave haddling. Variable leave payments which do not depend on an index or a rate are excluded from the building measurement of the leave haddling and right of one assets. The

Each lease generally imposes a restriction that, unless there is a contractual right for the Company to subtract the asset to another party, the right-of-use asset can only be used by the Company. Some feases contain an opinion to extend the teate for a further term. The Company is prohibited from selling or pledging the underlying leased assets as security. For teases over buildings required to pay maintenance fees in accordance with the lease contracts.

A Louse payments not included in measurement of lease liability

The expense relating to payments not included in the measurement of the lease habitay is as follows:

Particulars			(Cin laktu)
Shan-term leases	<u></u>	31 March 2021	33 March 2020
Taract screen screen		3 164 63	
	,	3,404.03	3,913.32

- B As at 31 March 2021, the Company was committed to short-teen leases and the total commitment as at that date was \$ 50.02 lakhs (\$) Africa 2020; \$ 113.95 lakhs).
- C. Total cash outflow for traves for the year ended M March 2021 is \$ 3,586.55 lakks (3) March 2030 : \$ 3,815.66 lakks).

D Total expense recognised during the year

Paniculars		(Lin Jalche)
Interest on lease habilities	31 March 2021	31 March 2020
Degree about in poly of me and	2,258.43	2.415.16
	1,472.59	1 400 52

E Maturity of teate liabilities .

The lease labilities are recured by the related underlying assets. Future minimum lease payments were as follows:

31 March 2021			Minimum leas	e payments due	(₹ in lekhi)
Lexic payments	Less than Lyene	1-2 years	2-3 years	More than 3 years	Total
Interest exponse	3,542.55	3,446.02	2,720.68	250,584.25	260,293,42
Net mescut values	387.54	404.72	399.56	238,655.61	239,847,43
	3,155.01	3,041.30		11,928.64	20.445.00

31 March 2020		· · · · · · · · · · · · · · · · · · ·	Minimum less	e payments due	(₹ in lakhs)
Ежяге рауптения	Less than 1 year - 3.815.44	1-2 years 3,688.91	2-3 years	More than 3 years	Total
Interest expense	533.06	557.09	3,621.37- 581.66	254,063.46 240,795,35	265;189:18* 242.467.16
Net present values	3,282.38	3,131.82	3,039.71	13,268,11	22,722.02

F	Bissecation of lease liabilities at the end of the year in current and non-corrent		
	Particulars in district and non-correct		(C in Takine)
	a) Correst liability (amount due within one year)	31 March 2021	31 March 2020
	b) Non-current liability (amount due over one year)	3,155.60	3,282,38
	Total texte liabilities at the end of the year	17,290.99	19,439,64
	The state of the year	20,445.99	22,722,62

The someone works and the	enormon control		***************************************		·	
Right of use assets	Number of leuses	Range of remaining term (in years)	Average remaining lease term (in yews)	Number of leases with extension option	Number of leases with purchase option	Number of leases with termination option
Building premises	43	1.25 to 20.26	8.5	E .		
Other plant and equipment	1	20	20			4.5
Vehicles		0.14 to 1.78	0.31	4		
व्यस	i	86	86	-	·····	


23 As per the accounting policy, the Company has applied for practical expedient to all rene concessions and recognised \$ 126.89 laklys in statement of profit and fore.

(ii) ... Lease related disclosures as lessor.

The Company has entered at to operating leases for the parking. The leases have terms of 3 years.

l'suure minimum rentals receivable uniter non-cancellable operating leaves are na follows:

Particulars		(Vin laktis)
12004	31 March 2021	31 March 2020
Later than one year but not later than five years	102.00	102.00
Later than five years	. 34.00	136.00
	<u> </u>	





Note - 42

Employee benefits obligations

À	Defined	contribution	ptan

Particulars	····	
	For the year ended J1 Match 2021	For the year ended
Employer's contribution to provident fund charged to statement of profit and loss.		31 March 2020
Contribution to Employee state insurance scheme charged to statement of profit and lust	1,383.67	1,734.98
Contribution to labour welfare found charged to statement of profit and loss	1+7,04	169.02
Total	23.61	22.86
Contributions are made to recognised provident fund administered by the government of India for employees at the case of 12% of two	1,554.52	1,740,00

to the amount contributed and it has no further contractual or constructive obligation.

B Gratuity

The Company provides for granuly for employees in India as per the Payment of Gravity Act, 1923. Employees who are in continuous service for a period of 5 years are eligible for granuity. The amount of gravity payable on collection and fermionalism is the employees last drown basic salary per month computed proportionately for 15 days salary multiplied for the number of years of service

(i)	Amounts recognized in the balance wheet		
	Perticulars		(7 in faklis)
	Present value of the obligation	As at 31 March 2021	As at 31 March 2020
	Unfunded Exhibity/provision in belance slicer	3,181,29	2,815.56
		(5,181.29)	(2315.56)

(ii) Annual recognized in other comprehensive income		
Particulars		(fin lakla)
	Par the year ended	For the year ended
Actuanal loss	31 Mnich 2021	31 March 2020
Changes in demographic assumptions		
-Changes in fission assumptions	(46.34)	(1.62)
Changes in experience adjustment	301.27	177.11
Actuarial loss recognized in other comprehensive income	(200.77)	- 55.87
	54.16	234.29

(iii)	Expenses recognized in statement of profit and loss		
	Portionlase		(f in laking)
	-	For the year ended	For the year ended
	Cuttent service cost	31 March 2021	31 March 2020
	Interest cos	452.12	440.25
	Expense recognized during the year	(93.43	183.16
	X	645.55	622.41

(iv)	Mayement in the liability recognized in the balance theet is so under:		
	Particulars	~~	(\bigce{\chi}\) in lakha)
	Present value of defined benefit obligation at the beginning of the year	As at 31 Merch 2021	A6 at 31 March 2020
	Correct service cost	2,815.56	
	Interest coer	452.12	44(623)
	Actuarial loss	193.43	103.70
	Benefits from	54.16	0.01.271
	Present value of defined benefit obligation at the end of the year	(333,97)	(1) 22,227
		3,181,30	2.814.56

(v)	For determination of the highlity of the Company the following actuarial assumptions were used:		300103-2010
- 1	Discount rate	As as 31 March 2021	At at 31 March 2020
	Solary excatation rate	6.75%	6.87%
- le	Representage (pars)	6.00%	S.Rn% _e
į,	Average print service	60 345518	60 years
- 1	A verage age	3.74	3.40
1.	Average temporary working the	31.91 years	THE PROPERTY.
į,	per temelolibidi	28.02 years	28.47 years
ŀ	Up to 30 years	1 1	
- 1	From 31 to 44 years	13.40%	4.00%
	160c-147513	3.60%	3.00%
	durishing rates includive of provising for displainty (1906 of 1818/ 72012 - 14)	0.40%	2.00%

Year 31 March 2021	Year 31 March 2020		(č in lakita)
April 2021 - March 2012	April 2020: Murch 2023	As at 35 March 2021	As at 31 Merch 2020
April 2023- March 2023	April 2021 - March 2022	599.1	5 589.06
April 2023 - March 2024	April 2022 March 2023	140.2	6 115.63
April 2024: March 2025	April 2023 - March 2024	240.0	0 183.16
April 2025 - March 2026	April 2024- March 2025	125.1	162.63
April 2026 - March 2027	April 2025 - March 2026	171.3	
April 2027 onwards	April 2026 onwards	142.3	
Gross Total	Viluti sosti quinatak	9,193.6	
C17033 1043		5.573.5	2,102





Globs! Health Limited (formetly known as Global Health Psicale Limited)

Standaloue summary of significant accounting policies and other explanatory information for the year ended 31 March 2021

vit,	Sentitivity analysis for gracuity		
	Posticulose		(₹ in laklıs)
	a) Impact of the change in discount cate	Ji March 2021	31 March 2020
	Present value of obligation of the end of the year		
	Impect due su mesesso af 0.50 %	3,181.29	2,815.56
	Impact the to decrease of 4.50 %	(145.55)	(117.54)
		158.67	127.90
- 3	b) Impact of the change in salary increase	1	
	Present value of obligation at the end of the year	İ	
	Impact due to increase of 0.50 %	3,181.29	2,815.56
	Impact the to therease of 0.50 %	159.07	129.64
	Sensitivation due to mortality and withdrawels are not material blenge, impact of classic as not calculated above.	(347.21)	1120,000

Sensitivities as to case of inflation, rate of interase of pensions in payment, rate of increase of pensions before retirement and life expectancy are not applicable being a lump aum benefit on retirement

The above sensitivity analysis are based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in annual the assumptions may be correlated. When calculating the sensitivity of defined benefit obligation to significant actuarial assumptions the same method (present value of defined benefit obligations calculated with the projected unit method at the end of the reporting period) has been applied as when calculating the defined benefit fishility (congruent in the battere sheet.

(viii) Rick

Salary increases	Actual sub-representation incremental and the sub-relative for
Discount rate	Actual subspire increases will increase the plan's liability. Increase in seasy increase rate assumption on future valuations will also increase the liability.
	The state of the production of
A Later Communication of the C	for the many training the property of higher than assumed in the reference of the property of
WRITERWEIS	Actual withdrawals proving higher or lower than assumed withdrawals and change of withdrawal rates at subsequent valuations can impact plan's liability.
	and charge of whiteleast sales at bublequeur valuations can impact glan's liability.
·	

Note - 43

Share based payments

GHPL ESOP Plan 2014

GHPL ESOP Plan 2014

The Company vide General Meeting resolution dated 25 September 2014 approved "Global Health Employee Stock Option Scheme 2014" for genting employee stock options in the form of equity shares finished on the companion of a minimum period of continued employment to the eligible employees of the Company. The plan was modified on 11 May 2016 where in the Company increased the number of available upitous from 740,628 to 852,973 to eligible employees and the vesting period was revised from 5 years from the date of great to graded vesting of 25% each year starting with effect from 30 April 16. The Company had granted 740,628 options to eligible employees on 25 September 2014. The eligible employees, including directors, for the purpose of this scheme will be determined by the flemaneration Committee from time to time. Each stock options entitle the eligible employee to avail one share at the end of the vesting period. The vested options can be exercised within a period of 3 manufactors the date of outline.

Movement in number of cottons:

Particulars		
Become bytess	As at 31 March 2021	As at 31 March 2020
Exercised during the year	260,648	354,123
Lapsed during the year	85,565	93,475
Closing balance	19,839	·
	\$\$\$.244	350 540

Particulars Outstanding options (unvested and vested but not exercised) as at 31 March	Grant I	Grant II	Grant HI	Grant IV
2023 Ourstanding options (ouvested and vested but not exercised) as at 31 March	50,244	-		105,000
2020 Grant dase	40,972	26,451	19,838	173,387
Vestag penud	25 September 2014 Graded coming (25%	Graded vesting 195%	Gradest marine (256)	10 December 201
	options to year every year from the date of gram)	Commission of the control of the	year every year from the date of	dest and, host from the date of transfer activities (50% obtains)
Exercise Inice	10.00	10.00		
Espiry date Fait value of Option on the date of graen!	29 April 2022 691.95	10.00	08 November 2023	10.0x 09 December 202
Remaining contractive life (weighted months) as at 31 March 2021 Remaining contractive life (weighted months) as at 31 March 2020	15.13		755.29	755.24 32.77
	25.10	39.93	43.96	1-1.93

"The fair value of the apassis has been determined using the Black Scholes model, as certified by an independent values with the following assumptions:

	**************************************			O - 1144 - 144 1 1 1 1 1 1 1 1 1 1 1 1 1	
	Particulars				
	Weighted average three page (i),)	Grant I	Grant II	Grapa III	
	Weighted average share pince (its.)	698.65			Grant IV
	Exercise price (ils)		749.78	762.95	762.05
	a management bearing the second of the secon	10.00	10.00	\$20.00	
-	- portor square, (19)	100	The state of the s	10.00	10.00
•	Experied life of the gation beauty	3/70	37%	37%	36%
			TO THE PARTY 127		3079
	Risk-free interest rate	8.70%		1-1	
	Weighted average fair value as on the grant date (Rs.)	***************************************	7.16%	6.67%	6.51%
•	The Late (A.S.)	691.95	742.28	***	
				755 20	755.24
	Clibi Péchalle acce				

GHP1. ESOP Plan 2016

The Company vide General Meeting resolution dated 13 July 2016 approved "Global Health Employee Stock Option Scheme 2016" for granting employee stock options in the form of equity shares linked to the competition of a minimum period of continued employment to the eligible employees of the Company. The eligible employees, including directors, for the purpose of this scheme will be determined by the Remonteration Commutee from time to time. Each stock options emitte the eligible employee to avail one share at the end of the vesting period. The authorized state capital of the Company was also increased by creation of 1,025,000 Class A equity theres on 13 July 2016 with a view to allot the alternated the ESOP Plan 2016. Each stock options entitle the eligible employee to avail one share at the end of the vesting period. The vested options can be exercised within a period of 3 years from the date of vesting.

	Movement in number of options:			
	Particulars			
	Opcome balance	······································	As at 33 March 2021	As at 31 March 2020
	Exercised dynamicale year		561,500	771,250
	Faparel duning the year	•	155,250	116,750
	Closing balance	······································	55,009	10811/ 91,00m
2.7	(1.1	// / / / / / / / / / / / / / / / / / /	351,250	\$61,500
Ţ,	1 1		/ የ	
À	~ -2.6		(-⊡	(New Delhi) E
. 10.	N Z07	·	l O	1

Particulara	Grant I	Grant []	Grant III	Grant IV	
Outstanding options funcested and vested but not exercised) as as 31 March 2021	116,250		17,000	17,000	Grant V 176,000
Outstanding uptions (intrested and rested but not exercised) as at \$1 March 2020	157,300	#0,000	50,000	50,000	224,090
Grant dasc	10 December 2016		17 April 2018	Of a Japane	
Vertingaction	Graded vesting (25% options to vest every year from the date of grant)	Graded vesting (23%)	Genderi vesteng (13,33% opious to vest every year from the date of grant)	25 April 2018 Gradult verting (33.33% options to vert every year from the due of geson)	Graded vesting (20% notions of
Exercise price	10.00	10.00	10.00		
expire date fair other value of opion on the date of	09 December 2023	19 March 2025	16 April 2024	19.00 24 April 2024	13 July 2020
dent,	755.24	626.01	626.01	624,14	626.17
Remaining contractual life (weighted) neutlis) as at 31 March 2021	32.77	48.30	37.07	37,33	64.33
termining contractual life (weighted norths) as at \$1 March 2000	44.93	60.47	49.23	49.50	76.50

The fact value of the options has been determined using the black Scholes model, as certified by an independent values with the following assumptions

Particulars	Grani I	Grent H	Grant III	Gross IV	
Weighted average share price (fls.)	762,95	632.44	633,34	633.44	Grant V
Exercise price (Rs.) Expected volatility (%)	10.00	10.00	10.00	10.00	633,44
Expected life of the upnon (years)	36%	37%	37.60%	37,76%	37.33%
Risk-free interest rate	1.7	1-7	1.6	1.0	1.8
Weighted average his value as on the grant	6.51% 755.24	7.44%		7.82%	8.22%
[date (Rs.)	133.21	636.01	626,03	626.16	636.17
·				· 	

During the year ended on 31 March 2021 and 35 March 2020, the Company has recorded an employee stock compensation expense of ₹ 378.88 bkhs and ₹ 956.97 bkhs respectively.

During the year ended on 31 March 2021, the total number of optionanested but not exercised is \$28,002 (\$1 March 2020: 392,195). The weighted average share price on the date of exercise is \$ 574.02 (\$1 March 2020: \$ 505.88)

Note - 44

The chief operating decision maker (CODM) examines the Company's performance from a service perspective and his identified the Healthrane services as single business segment. The Company is operating in India which constitutes a single geographical segment. The CODM reviews internal management reports to assess the performance of the segment Healthrane terrices.

The recember from extremal customers attributed to an individual is not material and there are no transactions with a single external customer which would amount to on percent or more of the Company's executes.

Mote - 45

Research and development expenditure includes consultant's and specialist honoracium amounting to ₹ 2.72 laklis (\$1 March 2020: ₹ 1.23 laklis) and salaries of employees amounting to ₹ 79.36 laklis (\$7 March 2020: ₹ 1.23 laklis).

Nose - 46

Revenue related disclosures

1 Dienggregotion of sprenue

For the year ended For the year ended 31 March 2021 31 March 2020	Description		(₹ in ini
(A) Operating revenue			
In patient	(A) Operating revenue	31 March 2021	31 March 2020
In patient	income from healthease services	ļ .	
Cot parient 19,532.55 28,2	· · · · · · · · · · · · · · · · · · ·		
(B) Income from sale of planmacy products to out-patient Sile of pharmacy, products Sile of pharmacy, products Sile of pharmacy, products (C) Other operating revenue Clinical tesearch income Other operating revenue Sub-total (C) Sub-total (C) Sub-total (C) Sub-total (C)	Out patient	, -1	
(B) Income front sale of pharmacy products to out-patient Sale of pharmacy products Sub-total (II) (C) Other operating revenue Chief operating revenue Other operating revenue Sub-total (C) Sub-total (C)	Sub-total (A)		28,21
Sale of phormasy products 1,004.30		120,397.03	145,29
Sale of pharmacy products 1,004,30	(B) Income from sale of pharmacy products to out-patient	1	
CO Other operating revenue	Safe of pharmacy products		
(C) Other operating revenue Glinical research income Other operating revenue Sub-total (C) 53.56 17			
Clinical research income 120,01 HE		737/707//2004/20	
Other operating sevenue 129,01 HE 53.56 17			
Sub-total (C)	Glinical research income	120.01	
3H9-10HH (C)	Other operating revenue	, , , , , , , , , , , , , , , , , , ,	
	Sub-total (C)		

A) Operating revenue	For the year ended 31 March 2021	(f in tak) Por the year anded It Morch 2020
lucture from healthcare services		
Government		
Non-government	12,019.36	16,677.
oral operating revenue	108,177.67	128,615
	120,197.03	145,292
-MJ = -N N	/~	
- 627 AZA	<i>f</i> 10	<i>II</i> \3

Global Health Limited (formerly known as Global Mealth Private Limited)

Standalone summary of significant accounting policies and other explanatory information for the year ended M Morch 2021.

M. Comraci balances

The following table provides information about acceivables and contract liabilities from contract with customers:

Particulars Contract Liabilities	As at 31 March 2021	(t in takiss) As at 31 March 2028
Advance from customers		
Total contract tiabilities	2,403.95	2,091.25
	2,403.95	2,091.25
Contract 86606		
Unbilled recenue	1	
Total contract neces	1,350.94	598,00
	1,350.94	598 60

Contract asset is the fight to consideration in exchange for goods or acrivees transferred to the customer. Contract liability is the entity's obligation to transfer goods or services to a customer for which are entity has received consideration from the customer in advance. Contract search (unbilled receivables) are transferred to receivables when the performance obligation is satisfied.

111 Significant changes in the contract isobilities balances during the year are as follows: Contract liabilities - Advance from enstomers (t in iakha) As at 31 March 2021 Opening balance of Contract liabilities - Advance from customers As at 31 March 2020 2,091.25 Add: Addition flaming the year 1.609.61 120,509.73 145,77435 Less: Amount of revenue recognised during the yest (120,197.03) Closing balance of Contract liabilities - Advance from customess (145,292.71) 2,403.95 2,091.25

TV The aggregate amount of transaction price allocated to the performance obligations (yet to complete) as at 31 March 2021 is ₹ 2,403.95 laklis (31 March 2020 : ₹ 2,093.25 laklis). This balance represents the advance received from customers (goost) against healthcare services. The strangement expects to forther bill and collect the centaining balance of total consideration in the coming periods. These balances will be exceptional as teverine in subsequent period as per the policy of the Company.

V Reconcilation of recense:

Particulate		(₹ în lakha)
	For the year ended 31 March 2021	For the year ended
Resease		31 March 2020
Adjustment for:	125,691.69	150,894.05
Discounts and zebotes		
Income from healthcuse survices and sale of about and all all and all and all and all all and all and all and all all and all all and all all and all all all all all all all all all al	(4,490.37)	(5,601.34)
	121,201,32	145,292.71

Note - 47

Change is accounting policy on government grants

- 1 During the year, the Company has changed voluntarily its accounting policy related to government grants whereby, grants relating to capital assets are recognised as deterred income on infinit recognition of the statement of profit and loss on a straight line basis over the expected useful life of the related asset and presented within 'other operating income' from its enabling policy of retting Company will ecopying in the statement of profit and loss over the life of a depreciable asset as a reduced depreciation expense. The application of the revised accounting policy adopted by the insured statement. The impact of adoption of the expital assets and reflect the gross amount of depreciation in its books of accounts and thereby provide more referred nor the users of proceeding period and also does not materially impact the balance sheet as at the beginning of preceding period.
- 11. Below are the impacts on each financial statements line item as at and for the year coded 31 March 2021;

Λ	Particulars	(₹ in lakks)	
	<u> </u>	Ass	1
	Balance slicet	31 March 2021	}
:	Interesse in property, plant and equipment (see block)		}
==	Sectoric Microsoft and Microsoft Industries	339.92	-
	barrense in order conserve listable as	261.72	<u> </u>
	The state of the s	18/10	

В	Particulars	
		has the year ended
	Increase an other operating revenue	
	discussive in depreciation and appendianton expense	20.14
	The state of the s	2612

C. There is no impact on basic and diluted extrings per share for the respective years.

Note - 48

Previous period/yearshouldness faces been reproduced/exclassified wherever considered receisary.			
Bulaico elico	Ji March 2020	Adjustment	31 March 2020
Lipbilines	(Reported)		(iteclossified)
Non-current provisions	4,211.97	(GH4.14)	3,527,53
Assets	868.26		1,552.70
Other current financial assets Other current assets	2,981.83	23.63	3,003.46
C	640.77	(23,63)	617.14

Statement of profit and loss	For the year ended	Adjustments	
	3J March 2020	volue meute	Lot site hear crided
		!	31 March 2020
13	(Neparted)	i !	(Reclussified)
Reverse Level appearations	145,657.18	1,551.44	
Other income	5,905,33		147,3(66.62
	7.703.33	(1.554.4.5)	(A) 11 L \ J1(1 2n

(Dies space has been ententionally left blank)



Global Mealth Limited (furnishly known as Global Health Private Limited)

Standaloue sommary of eignificant accounting policies and other explanatory information for the year ended 37 March 2021

Note - 49

Raman Sharma (Complainter) filed a Piess Information Report (FIR) dated 6 June 2020 against, inter also, the Company and certain directors and other office braners, under various provisions of the Indian Penal Code, the Prevention of Money Laundering Act, 2002 and the Prevention of Cormption Act, 1988. The Complitiums has alleged that the Banana Urban Development Authority (FIUDA) India Poil Code, the Presention of Modey Laundering Act, 2002 and the Presention of Coruption Net, 1986. The Computation has ranged this the execution of Modey Laundering According to the Coruption of the Computation of th emiliaging me suove Cancentron resport, vice us once entred at aircen 2021, the Court accepted the Chief the Court accepted the Universal of Court accepted th secrived any further communication from the Enforcement Directorise in this matter.

Note - 50

in the board meeting direct 25 January 2021, the Board of Directors of the Company have approved capital raising comprising of feeth issue and offer for eals of equity states by the existing shareholders through an Initial Public Offening (IPO). Further, authrequent to the year-end, the Company has alterted 652,075 Class A equity shares to De. Navesti Tratises at face value of \$10 each at a premium of \$565 per share on preferential alteration basis as per provisions of the Articles of Association (AOA) of the Company and the shareholders agreement dated 12 January 2015.

Note - 51

The unde receivables as at 34 Alarch 2021 intendio include receivables in foreign currency which have been constanting appropriation to \$ 287.27 lands (31 March 2020. \$ 680.80 lakes) beyond the simulate stopolated by the applicable provisions of Reserve Bank of India read with foreign exchange management regulations. The Company has filed necessary applications with the appropriate authority in this regard as per regulations. The management does not envisage any additional financial impact of the same at this stage.

The Code on Social Security, 2020 ("the Code") relating to employee benefits during employment and purst-employment received Presidential assent in September 2020. Subsequently, the Ministey of Labour and Employment had released the draft roles on the aforementioned Code. However, the same is yet to be notified. The Company will evaluate the impact and make necessary adjustments to the linearisal materiories in the period when the Code will be notified and will come into effect.

The outbreak of Coronavieus Disease 2010 (CCVID-19), declared as a pandemic by the World Bealth Organization, severely impacted the businesses and economic activities account the world including India. During the year ended 31 Merch 2021, both Coursel and State Government of India land imposed lock down and other emergency restrictions which had led to the disruption of all regular dusiness operations. Further, the recent second wave of COVID-19 has again resulted in partial lockdown/restrictions in various states. The Company is closely monitoring the impact of the aforementioned partifemic and has made a detailed assessment and considered possible effects, if any, on its liquidity position, including recoverability of its assess as at the balance sheet date and currently believes that these will not be any adverse impact on the long term operations, furnish position and performance of the Company.

This is the standardne summary of significant accounting policies and other explanatory information referred to in our report of even date.

EMED ACCO

For Walker Chandick & Co LLP

Chargered Accountages

Firm's Registration No.: 001076N/N500013

Rajni Mundra

Paciner

Membership No.: 058644

Place: Gorogram

Date: 12 September 202

For and on behalf of the Board of Directors

Chairman and Managing Director

[DIN:00012148]

Ploce: Gurugram

Date: 19 Semeniaer 2021

Sanjeev Kunter Group Chief Financial Officer

Place: Guragions

Date: 17 September 2021

Place: Goorgrans

aj Sahni

Chief Executive Officer

Company Secretary Place: Garagram

Date: 17 September 2021

Certified True Copy